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The studies in this thesis evaluate the clinical and laboratory risk factors for hip fractures in men 
with special emphasis on bone mineral density and androgen status and assess its outcome in 
terms of both its morbidity and mortality. 
PATIENTS AND METHODS 
100 men aged 50 years and over, living in Cornwall, presenting consecutively with minimal 
trauma hip fracture were recruited prospectively over 14 months (December 1995-January 
1997). 100 age-matched community controls were drawn from a general practice register within 
the catchment area. Similar data were collected from all cases and controls. Interviewer assisted 
questioimaires were used to obtain socio-demographic information and assess potential risk 
factors for fracture, quality of life and concurrent diseases and drugs. Early morning blood and 
urine samples were collected for biochemical measurements; in the fracture cases they were 
collected before gam within 48 hours of admission. All controls and 62 cases had bone mineral 
density measurements (BMD) at the lumbar spine and proximal femur using dual energy X-ray 
Absorptiometry (Hologic 1000). In fracture cases measurements were within one week of 
admission. Both cases and controls were followed-up at 6,12 and 24 months. 
RESULTS 
Demographic: The mean age of the fracture cases was 80 years (range 54-97) compared to 75 
years (range 50-96) in controls. All were Caucasian except for one Chinese. 55 fractures were 
cervical and 45 intertrochanteric. There was no side predilection, one patient had spontaneous 
bilateral fracture. Most (67%) fractures occurred indoors. 
Co-Morbidity. General Health And Lifestyle: Fracture cases had more co-morbidities, especially 
previous falls, strokes, impaired vision, restricted mobility, dementia and Parkinson's (p<0.001). 
Mean weight and BMI in fracture cases (67.8kg and 23.4) were significantly lower than in 
controls (77.7kg and 26.7; p<0.001 by t-tests). 
Laboratory: Routine laboratory results showed normal acute phase responses following fractures. 
However, 25-hvdrox vitamin D was significantly lower in fracture cases than controls at the time 
of the fracture (mean 9.7 ng/ml Vs 18.3ng/ml respectively, p<0.0001) and, this difference 
persisted for 6 months. Vitamin D deficiency was present in 65% cases compared to 14% 
controls. Total testosterone and free androgen index, though they declined with age in both 
groups, were significantly lower in fracture cases (P<0.001 by t-test) compared with controls 
initially and remained low at 6 and 12 months. Mean sex-hormone binding globulin, FSH. LH 
thyroxine, TSH and parathyroid hormone were similar in cases and controls. Hip fracture cases 
exhibited features of impaired bone turnover (uncoupling): serum osteocalcin was reduced while 
urinary deoxypyridinoline was raised, compared to controls. 
BMD: Cases had significantly lower BMD at all sites compared to controls: lumbar spine 
(0.92g/em2 Vs 1.08g/em2; p<0.05) and the femoral neck (0.61 g/cm2 Vs 0.76 g/cm2; p<0.05). 
Using the WHO criteria cases were 7 times more likely to have osteoporosis at the femoral neck 
and 10 fold more likely to have osteoporosis at the lumbar spine compared to controls. 
SF36: Quality of life, assessed by the SF36 at the time of admission, showed a significantly 
worse pre-morbid health status in the fracture group compared to controls in all domains 
(p<0.001) except pain. This continued on prospective assessment upto 24 months (p<0.001). 
Mortality: At a mean follow-up of 661 days (1.8 years), mortality was 60% in the hip fracture 
population against 10% amongst controls. Cause of death was similar in the two groups: chest 
infections and heart disease being the commonest. Many survivors in the fracture group 
continued to require institutionalized care 24 months after the fracture. 
CONCLUSIONS 
The main risk factors for minimal trauma hip fracture in men arc low BMD, testosterone 
deficiency, vitamin D deficiency along with poor general health. Presence of co-morbidities like 
poor vision, Parkinson's, strokes, poor mobility increase their likelihood for falling and hence 
fracture. All of these are potentially preventable. The mortality accompanying hip fracture is 
high; the causes of death are not related to fracture but to poor general ill health. Survivors are 
left with significant morbidity that requires long-term care. 
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1.1.1 Historical Perspective 
Osteoporosis was first clearly described and the term coined by the Strasbourg pathologist, 
Jean Georges Lobstein the younger (1777-1835) in the early 1820's (Schapira and Schapira, 
1992). It is derived from the Greek words "osteon" (bone) and "poros", (little hole)-literally 
porous bone. The term was first used as a pathological description and applied to any 
disorder resulting in a reduction in bone quantity, though it was subsequently distinguished 
from osteomalacia by Pommer in 1885 (Schapira and Schapira, 1992). 
Evidence of age related bone loss or osteoporosis has been found in paleopathological 
specimens from early antiquity (Perzigian, 1973). One of the earliest representations of 
clinical osteoporosis, however, is present in pictorial art, in a painting by Vittorio Carpaccio 
(1465) who, in "the arrival of the English ambassadors' depicts an ageing governess with a 
dowagers hump and a walking aid (Dequeker, 1994). 
In 1842, Astley Cooper noted that fractures might result from an age-related reduction in 
bone fragility. However detailed study of the relationship between bone fragility and 
fractures was to wait for over 100 years 
Osteoporosis went unrecognized in almost all English and American textbooks until well 
into the 20'h century - and was then attributed mainly to old age. In middle-aged and 
younger people it remained unexplained or "idiopathic" until Fuller Albright et al, 
recognized oestrogen deficiency as its commonest cause in 1940 (Albright et al, 1941), and 
noted a promising response to oestradiol, first isolated only 4 years earlier. 
Since then, and particularly during the last two decades, there have been major advances in 
both our understanding of the pathogenesis, and our ability to measure and quantify 
osteoporosis as a result of more and more sophisticated methods of investigation and novel 
forms of treatment. Hip fracture however, remains one of the classic hallmarks of 
osteoporosis. 
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1.1.2 Definition and Classification of Osteoporosis 
Osteoporosis has been defined as, "... a systemic skeletal disease characterised by low bone 
mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone 
fragility and susceptibility to fracture" (Consensus Development Conference, 1993). 
Although widely accepted this definition lacks the detailed classification criteria required to 
separate individuals into those with and without the disorder. The difficulties arise because 
the definition is phrased both in terms of a clinical outcome (fracture) and a risk factor (bone 
fragility), and their relative importance is not specified. 
Some advocate classification on the basis of a reduction in bone mass (the major 
determinant of bone fragility) (Nordin, 1987), however there are difficulties with such an 
approach as there is no clearly defined threshold value above which fracture risk increases 
(Cummings et al, 1990). Others have suggested restricting classification to individuals who 
have already sustained an age-related fracture, however such a classification is of limited 
clinical relevance as it excludes those who are at high risk because of a low bone mass, and 
in whom preventive measures may be effectively targeted. 
A WHO working party recently proposed a classification which incorporates both the 
notions of reduction in bone mass and fracture (Kanis et al, 1994). In this classification, 
osteoporosis is present when an individual bone mineral content or bone mineral density is 
less than 2.5 standard deviations below the young normal adult mean value. Such a 
threshold identifies approximately 30% of postmenopausal women as having osteoporosis- a 
figure comparable to the lifetime risk of the major osteoporotic fractures at age 50 
(Cummings et al, 1995; Melton et al, 1992). Individuals with evidence of frailty fracture are 
classified as having severe or established osteoporosis. 
The classification includes a separate category (low bone mass) which allows identification 
of individuals who are at moderately increased risk of fracture, and in whom preventive 
measures might be considered (about 15% of perimenopausal women, [WHO, 1994]). 
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Table 1.1 Classification of Osteoporosis (WHO, 1994) 
Category 
I Normal 
II Low bone mass (osteopenia) 
III Osteoporosis 
Criteria 
BMD or BMC not more than 1 SD below young adult mean 
BMD or BMC between 1-2.5 SD below young adult mean 
BMD or BMC >2.5 SD below young, adult mean 
IV Established osteoporosis (severe) BMD or BMC >2.5 SD below young adult mean plus one 
or more fragility fractures 
BMD=Bone Mineral Density; BMC=Bone Mineral Content; SD=Standard Deviation 
1.1.3 Clinical Manifestation 
Low bone mass by itself causes, few, if any symptoms. Except for the possibility of tooth 
loss (Krall et al, 1994) the clinical manifestations of osteoporosis relate exclusively to its 
associated fractures. It is traditional to link fractures of the proximal femur (hip), vertebrae 
(spine), and distal forearm (wrist) with osteoporosis; however, because bone is lost 
throughout the skeleton, almost all types of fractures in the elderly are due in part to low 
bone density. These include fractures of the distal femur, rib, pelvis, humerus, finger and toe. 
Osteoporosis-related fractures can be uncomplicated and followed by full recovery, or they 
can lead to chronic pain, disability, increased dependence on others for some or all of the 
activities of daily living (ADLs), deformity to total collapse of the spine, need for nursing 
home care and death. 
The probabilities of the various types of fractures over time have been calculated for an 
average-risk white women (Cummings et al, 1989; Melton et al, 1992). For example, the 
probability that a 50-year-old average-risk white women will have a hip fracture some time 
in the rest of her life is about 14%. The probabilities are different for African-American 
women and for men. The lifetime risk of hip fracture has been estimated at 5-6% in white 
men from age 50 and older (Cummings et al, 1989; Melton et a!, 1992), while lifetime risk 
for hip fracture for African-American women is about 6% and is 3% for men (Cummings et 
al, 1989). Unfortunately, there is insufficient data on the probabilities of various types of 
fracture by age for men. 
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1.1.4 Current Management 
Many interventions have been considered for osteoporosis. They ranke from general public 
health recommendations-such as diet (calcium), vitamins (vitamin D), exercise, and tobacco 
cessation- to the use of specific drugs, such as hormone replacement therapy (HRT), 
calcitonin, fluoride, or one of the bisphosphonates. Some interventions, such as HRT, have 
multiple effects, while others are specific to osteoporosis. 
Contrary to the wealth of information about women, therapy of osteoporotic disorders in 
men is virtually unexplored and there are no approved pharmacological therapies for 
osteoporosis in men. There have been very few trials of osteoporosis therapies performed 
specifically in male populations, although some men with osteoporosis have been included in 
mixed populations treated with a variety of agents. In general it is very difficult to assess 
independently the success of these approaches in the male subjects. 
Very little information is available on the efficacy of calcitonin in men with osteoporosis. In 
a small randomised study in men with osteoporosis, calcitonin therapy for 2 years produced 
a decrease in vertebral fracture incidence compared with calcium or multivitamin (Agrawal 
et al, 1981). Men have been included in several trials of calcitonin, but the results in men are 
not separable from those in women (Burckhardt et al, 1993; McDermott and Kidd, 1987). 
Men have comprised the majority of subjects in some series of patients receiving steroids 
who responded to calcitonin (Montemurro et al, 1991). Although there are few data in men, 
theoretically calcitonin should be effective in reducing osteoblastic activity in patients with 
osteoporosis. There have been no trials of any bisphosphonate performed exclusively in 
men. Male patients have been included in mixed patient populations and seem to have a 
benefit on bone mineral density during treatment with pamidronate (Valkema et al, 1989), 
etidronate (Orme et al, 1994) and alendronate (Saag et cal, 1998). Although specific data are 
lacking, there is no theoretical reason that bisphosphonates would not be effective in 
reducing osteoclastic work in men as in women (Papapoulos et al, 1992). Slovik et al 
reported that in a small group of men with idiopathic osteoporosis, combined parathyroid 
hormone and 1,25 dihydroxyvitamin D administration increased spinal bone mass (Slovik et 
al, 1986). Although the role of parathyroid hormone administration in the treatment of 
osteoporosis remains unclear, its potential appears similar in men and women. As with 
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previous therapies, there have been no specific trials of flrrorrde administration in men. In 
some trials, men have been included in the treatment groups (Mamelle et al, 1988; Jowsey et 
at, 1972; Riggs et al, 1980) but it is difficult to ascertain whether responses were in any way 
sex-specific. 
There have been several reports of small increases in bone mineral density with androgen 
replacement in hypogonadal (Behre et a!, 1997; Devogelear et al, 1992; Diamond et al, 
1991; Finkelstein et at, 1989) and eugonadal men with osteoporosis (Anderson et cal, 1996). 
However, there is a lack of studies showing the effect of long-term androgens in men with 
osteoporosis. In general, the response of BMD to androgen replacement therapy has been 
modest. Essentially all evaluations of the effectiveness of androgen replacement therapy in 
hypogonadal men have examined the use of parenteral testosterone or the restoration of 
endogenous testicular function after treatment of reversible causes. Research still needs to 
look into the most appropriate route of administration and the specific androgen to be used. 
The potential risks of androgen replacement, particularly in the elderly, are uncertain in 
relation to the possible skeletal benefits to be gained. There is essentially no experience with 
other treatments in therapy of hypogonadal bone loss in men. The character of hypogonadal 
bone loss in men suggests it is similar to that in women (an early phase of resorption 
followed by lower turnover), so approaches that have been effective in postmenopausal 
women (bisphosphonates, calcitonin) may be useful in men. Treatment of osteoporosis in 
men remains unclear as there is a lack of randomised controlled studies with fracture as the 
end point assessing the different options. The UK Consensus Group for the management of 
male osteoporosis recommended the use of bisphosphonates and the consideration of 
sodium fluoride and anabolic steroids in the case of treatment failure (Eastell et at, 1998). 
In conclusion, despite the wealth of information on women there is dearth of data on lifetime 
risk of osteoporotic fractures and their management in men. Future studies are needed 
exclusively addressing these issues in men. 
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1.2 EPIDEMIOLOGY OF HIP FRACTURES 
1.2.1 Introduction 
Fracture is the clinical manifestation of osteoporosis that leads to its health, social and 
economic impact. Our knowledge of the occurrence of fractures is an important starting 
point in assessing the social and economic impact of osteoporosis. Of all osteoporotic 
fractures, hip fracture is the commonest and the major cause of mortality and disability in the 
elderly. With increasing numbers of elderly people, the burden on health care will become a 
critical issue for public health in many developed and developing countries. However, there 
is remarkable variability in the incident rates of hip fracture in various geographic regions. 
The epidemiology of hip fractures has been extensively studied in women using available 
data from countries and projections made for the future. However, data on men is scarce. 
1.2.2 Incident rates for hip fracture world-wide 
The incident rates for hip fracture in men and women aged 50 years and over in different 
countries throughout the world over a 30 years period (between 1960 -1990) have been 
reviewed by Maggi et al (1991). Incidence rates increased with age over the 30-year period 
in all geographic areas and ethnic groups, in both sexes. A significant difference in incidence 
was seen between sexes and age groups in all countries studied. The highest annual 
incidence of hip fracture was seen in Norway, Sweden, Denmark, New Zealand and US 
(>350/100,000); intermediate rates (150-349/100,000) in the UK and Finland and lower 
rates (149/100,000 or less) in Singapore and Hong Kong. There is dearth of data from Asian 
countries, which failed to derive any conclusions. Possible explanations to account for these 
differences in incident rates were the degree of industrialisation and hours of sunlight 
exposure 
The comparisons made in the above study were based on incidence of hip fracture from 
limited geographic regions within a country. The same group (Bacon et al), in 1996 re- 
addressed this issue looking at national hospital discharge data for a specified time interval 
(1988-89) in nine countries (Canada, Chile, Finland, Hong Kong, Scotland, Sweden, 
Switzerland, USA and Venezuela) using more stringent criteria. Due to potential problems 
in definition of "discharge", data from each country was compared to US data that had been 
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adjusted to account for differences. From each country number of patients with a diagnosis 
of femoral neck fracture based on the International Classification of Diseases, Ninth 
Revision code 820 was obtained. Simultaneously, population by sex and age groups for 
1988 and 1989 were obtained. The groups were 50-59 years, 5 year age groups from 60-84 
years, and 85 years and older. To minimise multiple counting of the same fracture case, 
countries were asked to send data excluding transfers from or to other hospitals. This study 
confirmed the previous findings that hip fracture rates increased with age and varied across 
nations. However, hip fracture rates in north European and North American countries 
appeared to be more similar than previously thought. 
The Mediterranean Osteoporosis Study (MEDOS) group (Johnell et al, 1992) in 
collaboration with the WHO and the European Foundation for Osteoporosis addressed the 
incidence of hip fractures in 17 European countries (representing 46% of the European 
population with a potential catchment of 83 million). The group looked at number of hip 
fractures by age and sex between the years 1983-1985. Population data if not obtained from 
the country concerned was obtained from the United Nations demographic yearbook. 
Incidence rates were standardised to the population of Sweden using 10-year intervals. In 
seven countries 100% of the known cases of hip fracture were obtained, whereas in others it 
was an estimate based on a sample ranging from 10-85% of the population. In some 
countries data was available only from selected geographic areas. 
Their data also confirmed the marked differences in the incidence of hip fracture between 
sexes, by age and by country of origin. Also, an increase in incidence with age in both sexes 
and in all countries was noted. However, larger differences in incidence between countries 
were reported with 11-fold variation amongst women and 7 fold amongst men. Like 
previous researchers, the highest incidence was found in the northern Europe, slightly less in 
Central Europe, with the exception of Poland, and low in southern European countries. The 
incidence rate for hip fracture in men aged 50 years and over in England was interpolated as 
114 per 100,000 with a sex ratio of 2.9. 
A more recent cross-national study of hip fracture incident rates was carried out in five 
geographical areas- China, Hungary, Hong Kong, Brazil and Iceland over a2 year period 
(Schwartz et al, 1999). Cases were identified using hospital discharge data. Estimated 
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incidence rates varied widely, with Beijing reporting the lowest and Iceland the highest. 
Similar to previous reports, this study concluded that the differences amongst countries 
reflect genuine variation in hip fracture incident rates 
The only prospective-population based study aimed at defining incidence of hip fractures in 
different countries using same sampling techniques in contrast to previous studies based on 
national registers was the second part of the MEDOS study (Elffors et al, 1994). Hip 
fractures were recorded prospectively in defined catchment areas over a 1-year interval 
(1988-89) in 6 southern European countries (14 European centres). A total of 3629 men 
and women over the age of 50 years with a hip fracture were identified from a catchment of 
3 million. In all communities fracture rate increased exponentially with age. Lowest rates 
were observed in Turkey and the highest in Spain and Portugal. There were large and 
significant differences between centres in the doubling time of hip fracture risk with age and 
in crude and age-standardised rates. Similar to the conclusion of the first part of the study, 
the authors showed marked and sizeable differences in incidence rates of hip fracture 
amongst Mediterranean European countries and related them to lifestyle and genetic 
differences. 
1.2.3 Influence of Age, Sex, and Ethnicity 
All studies stated earlier (Maggi et al, 1991; Bacon et al, 1996; Johnell et al, 1992; Elffors 
et al, 1994; Schwartz et al 1999) have consistently shown that majority of hip fractures in 
any country occur in the elderly and that the incidence increases with age and in both sexes 
in all countries where data is available. The proportion of hip fractures found in women over 
age 80 years ranged between 37-66% (Johnell et al, 1992) across all countries, with the 
exception of Turkey and Yugoslavia where only one quarter of fractures were aged 80 and 
older. 
Most studies have found an exponential rise in the incidence of hip fractures with age, 
particularly after the age of 45 years. The exponential rise was more marked in women, so 
that the female to male ratio for the MEDOS study rose from 1.1 between age 50-54 years 
to >2.0 over age 70 years (Elffors et al, 1994). On similar lines, using the regression model 
on the prospective data collected from southern Europe (Johnell et at, 1992) researchers 
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calculated the doubling time of hip fracture between 5-7 years in women and 6-10 years in 
men. However, significant differences were noted in doubling time amongst females, males 
and also between sexes in each country studied. In Europe, the highest doubling time was in 
Yugoslavia, the lowest in Iceland and Malta (Johnell et al, 1992). 
The MEDOS study has also shown a significant positive correlation (r=0.85) between life 
expectancy and risk of hip fracture. Highest rates were observed in Sweden and Iceland 
where life expectancy at age 70 years is among the highest in the continent (over 14 years) 
(Johnell et al, 1992). 
There was a marked difference in the incidence of hip fracture between sexes by age and 
country of origin within the European countries (Johnell et al 1992; Elffors et al, 1994). The 
number of hip fractures were significantly greater amongst women than men except in 
Turkey and Yugoslavia where it was equally common (Johnell et al, 1992) and in China 
where rates for men were higher (Schwartz et al, 1999). There was a 3-fold range between 
countries in the female to male sex ratio; varying from 1.3 (Yugoslavia) to 4.2 (Iceland) see 
Table 1.2. There was an 11-fold range in the apparent incidence among women and a 7-fold 
range amongst men between countries (Johnell et al, 1992). However, this variation in 
incidence between sexes was less than differences between regions. There was a significant 
positive correlation between age-standardised incidence rates reported in men from each 
country and that in women. 
The risk of having a fracture at the age of 80 is significantly greater in women than in men 
and ranges between 3% to 19%. In the MEDOS study the risk of hip fracture at age 80 
years in England was 7% for females and 3% for males (Johnell et al, 1992). In contrast the 
figures for Sweden were 19% and 13% and for Malta 3% and 2% respectively. 
Age and sex-adjusted hip fracture rates are generally higher in Caucasians than in Asian and 
Black populations (Maggi et al, 1991; Bacon et al, 1996). The female to male ratio is 
greater than 1 in the white population with the exception of Chilean and Finnish males aged 
50-59 years (Maggi et al, 1991; Bacon et al, 1996). The rates were higher in females than 
males in Hispanics also. However, the number of cases studied were not enough. The ratio 
is reversed for blacks, Asians (Maggi et al, 1991; Bacon et al, 1996) and Chinese (Schwartz 
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et al, 1999). However, more recent surveys from Asians and blacks living in the west have 
shown that the male to female ratio is similar to those in the white population with rates 
higher in women than in men. These differences in sex ratio between studies carried out in 
the developing world versus those in the West seems to further support an effect of 
environmental factors in the aetiology of hip fractures. The more recent study by Gullberg 
and colleagues (Gullberg et al, 1997) also showed a good correlation between sexes within 
a community. 
1.2.4 Burden of hip fractures in men compared to women 
There were an estimated 1.66 million hip fractures worldwide in 1990. According to 
epidemiological projections, the total number will rise to 3.94 million (1.16M men) in 2025 
and 6.26 million (1.79M men) by 2050. This rise will be in great part due to the huge 
increase in the elderly population of the world. In 1990,28% of these hip fractures occurred 
in men (Cooper et al, 1992). All over the world the age-adjusted and age-specific hip 
fracture incidences were about two times higher in women than in men (Kanis 1993; Melton 
1993). 
The lifetime risk of hip fracture is 5-6% in white men, 2.8% in black men, 16-18% in white 
women and 6% in black women (Cummings et al, 1989). A recent life time risk estimate 
taking into account the projected life expectancy in the male population, came to slightly 
higher estimates: 11.1% in men versus 22.7% in women at age 50 years; 10.1% in men 
versus 20% in women at age 80 years (Oden et al, 1998). Lower age-specific incidence and 
shorter life expectancy in men explain the difference in lifetime risk. Hip fracture incidence 
in men reaches the same level as in women, at an about 5-6 year older age. For example, 80 
year old males have the same hip fracture risk as 75 year old females (De Leat 1997). 
The incidence of hip fracture in many Western countries has increased considerably over the 
past 30 years. This is due to an increase in age-specific rates as well as an increase in age of 
the population. In the UK, Boyce and Vessey compared the incidence of hip fracture in 
Oxford in 1954-58 and in 1983 (Boyce and Vessey, 1985). They found that over this 28- 
year period the age-specific incidence had doubled in both men and women. However, 
studies looking at secular trends have reported the increase in age-adjusted hip fracture 
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incidence to be greater in men (80%) than in women (51%) (Parkkari et al, 1994). The 
recent study in Wessex showed a rise in the annual mean number of hip fractures from 330 
men and 1496 women in 1978-81 to 568.5 men and 2405.5 women in 1993-5 (McColl et al, 
1998). This represented an overall increase of 18.8% for men and 15.2% increase for 
women. 
The importance of hip fracture in the UK was reviewed by the Royal College of Physicians 
in 1989 (Hoffenberg et at, 1989). The report concluded that in England, hip fracture 
patients occupy one-fifth of all orthopaedic beds and the direct hospital costs were estimated 
at 160 million pound per year using 1987/8 prices. More recent estimates suggested the cost 
at £198 million per year (Kanis, 1993). Hip fractures have an overall mortality of 15-30% 
(Browner et at, 1996) with one year mortality following hip fracture of around 30% in men 
and 20% in women (Johnell et al, 1993). The excess mortality is of a smaller magnitude and 
shorter duration among women compared to men (Melton et at, 1998). Compared to similar 
populations of the same age and sex without fracture the excess mortality is 12-20% (Miller, 
1978). This excess mortality is mainly in the first year after fracture. Hip fractures are also 
associated with considerable morbidity, necessitating hospital admissions for an average of 
20-30 days (Johnell et al, 1992). There have been reports of higher rates of hospitalisation 
and institutionalisation following fracture in men compared to women (Reginster et al, 
1999). 
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1.2.5 Future Projections 
In 1990, Cooper et al used epidemiological literature on hip fracture incidence in various 
regions of the world and demographic projections obtained from the US Bureau of the 
Census International Database to estimate the number of hip fractures in different parts of 
the world. They used this data to make future projections for the years 2025 and 2050. In 
1990, there were 1.66 million hip fractures over the world among people aged 35 years and 
over; with Europe and N America accounting for about half of all hip fractures. The authors 
projected an increase to 3.94 million (1.16 million men and 6.26 million women) by the year 
2025 and 6.26 million (1.79 M men and 4.47 M women) by the year 2050. Their data clearly 
showed that as a result of these demographic changes there will be a dramatic increase in 
proportion of all hip fractures in Asia and Latin America with corresponding reduction to 
around a quarter in Europe and N America. The increase in men would be far greater than 
the increase in women. 
A more recent study (Gullberg et al 1997) projected figures along similar lines. According 
to the authors, in the year 2025 the number of hip fractures will be 2.6 million with 30% in 
men assuming no change in age-and sex- specific incidence worldwide. The figures would 
be 3.6 million assuming a conservative 1% increase. A 1% increase in fracture rate per year 
predicts a further 42% increase in frequency in 2025 and 82% increase in 2050. This is an 
increase of 135% in men and 100% in women. The more marked increase in men was 
attributed to improving life expectancy. 
Clearly, both studies helped characterise the health burden posed by hip fractures on a global 
scale. They emphasised that hip fractures represent a global problem, rather than a regional 
issue and warrant a degree of urgency on international health care agenda. Preventative 
strategies will have to be tailored to the needs and resources of the region. 
1.2.6 Conclusion 
With the constraints of imperfect data capture, all studies conclude that there are marked 
differences in the incidence of hip fracture by age, country of origin and gender. Although 
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hip fracture is well recognised to be more frequent in women than men, it is of particular 
interest that the range in sex ratio between countries was less than the range in incidence 
rates within each sex from the various communities. Although, no conclusions regarding 
aetiology of hip fractures can be made from this, most authors have suggested differences in 
genetic and environmental factors of greater importance than differences between sexes. If 
true, identification of these may be relevant for future prevention. Despite the marked 
differences it is clear that hip fracture is common and represents a major health care problem 
in all countries. 
The frequency of hip fracture appears to be increasing in many countries. The reason for this 
is two folds. Firstly, life expectancy over the age of 50 years has increased and will continue 
to do so. This means progressively more of the population will be elderly, and at risk of 
fracture. Secondly, there appears to be an increase in age-and sex-specific rates in many 
countries that will affect future projections. Estimates of lifetime risks of hip fracture appear 
to vary markedly from country to country and even within countries. Within Europe the 
range is approximately 11 fold but may be higher throughout the world. Currently, the risk 
is lower in the developing countries but there is evidence that the incidence is rising and 
approaching figures in the Western countries. Projections based on population figures 
clearly show that the proportion of cases with hip fracture will steeply increase in Asia 
suggesting that osteoporosis will truly become a global problem in the not too distant future. 
Reasons for the apparent differences in incidence between countries are conjectural. They 
may be artefacts due to non-standardized methods of data capture or a reflection of genetic 
and environmental factors. Comprehensive studies with special emphasis on the burden of 
osteoporosis in men need to be performed. 
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1.3 RISK FACTORS (NON BMD) FOR OSTEOPOROTIC HIP FRACTURE 
1.3.1 Background 
Low bone mass is an most important risk factor for hip fracture. However, there have 
recently been several large, well-conducted studies examining the risk of having a hip 
fracture independent of low bone mineral density. These factors probably operate 
through the effects on the risk of trauma and or on skeletal strength. 
The following section summarises the methodologies used by the various investigators. 
There have been two case-control (Poor et al, 1995; Grisso et al, 1997) and a number of 
prospective studies focusing on either one (Kiel et al, 1996; Langlois et al, 1998) or 
multiple risk factors (Hemenway et al, 1994; Nguyen et al, 1996; Mussolino et al, 
1998). 
Poor used a population-based nested case-control study design and addressed the role of 
a number of risk factors for hip fracture exclusively in men. His cohort comprised of 232 
men aged more than 35 years with a moderate trauma hip fracture and an equal number 
of aged matched controls from the general population. Data on potential risk factors was 
obtained from medical records. The Hip Fracture Study Group (Grisso et al, 1997) also 
used a case-control study design and enrolled 356 men aged 45 years and older with first 
hip fracture between 1991-93 along with 402 community controls. Information on 
potential risk factors was obtained through personal interviews at a median duration of 
6.5 weeks from hip fracture occurrence. 
A longitudinal epidemiological study assessed risk factors in 820 elderly men (aged 60 
years or more) in the city of Dubbo, Australia (Nguyen et a, 1996). Subjects were 
followed for over 5 years during which 31 men with hip fractures were identified. Similar 
prospective population-based study design was used by Mussolino et al to assess 
predictors of hip fracture risk in men participating in the NHANES survey. The authors 
identified a cohort of 2879 men aged 45-74 years at entry (1971-75) and identified 71 
hip fractures over a 22-year period. Another prospective study (1-lemenway et al, 1994) 
examined risk factors in approximately 50,000 health professionals (49,895 men) who 
were between the ages of 40 and 75 years in 1986 and identified 67 hip fractures by 
1992. 
Most of the above mentioned studies addressed the role of anthropometry (height, 
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weight, body mass index), lifestyle factors such as activity, smoking, alcohol, co-morbid 
diseases and medications as risk factors for hip fracture exclusively in men. The 
Framingham study (Kiel et al, 1996) exclusively addressed the issue of smoking at 
different life stages on BMD. They used a population - based cohort study design and 
collected data prospectively over a 40-year period. Similarly, the more recent cohort 
study by Langlois (Langlois et al, 1998) exclusively investigated the effects of change in 
body weight on risk of hip fracture. The workers used data from the Established 
Populations for Epidemiologic Studies of the Elderly (EPESE) comprising a cohort of 
2413 men who were followed for over 8 years during which time 72 hip fractures were 
noted. Change in body weight from age 50 years to old age was recorded and its role as 
risk factor for hip fracture was analysed. 
From the above it is quite clear that compared to the extensive literature available for 
women, data in men are limited in the number of hip fractures studied. The following 
section aims to draw useful conclusions from the evidence that exists in literature on the 
role of various factors other than BMD that influence the risk of hip fracture in men. 
1.3.2 Genetic contribution 
Maternal history of osteoporosis and or fracture is a well-recognised risk factor for 
osteoporosis in women. There is dearth of literature for men. The Rancho Bernado 
Study (Soroko et al, 1994) looked at the association between family history of 
osteoporosis and BMD in a cohort of 1477 white elderly non-institutionalised 
ambulatory subjects that included 600 men. Their study showed a significant relationship 
between maternal history of osteoporosis and lower BMD at the hip in men. 
A recent study has confirmed that polymorphism of an Spl binding site of the Collal 
gene is significantly associated with osteoporotic vertebral fracture in men and the effect 
on fracture risk is partly independent of BMD (Langdahl et al, 1998). There is no study 
to date addressing the role of any candidate genes as risk factors for hip fracture in men. 
1.3.3 Anthropometry: height, weight and body mass index 
The relationship of height to risk of fracture has been studied by a number of workers 
(Meyer et al, 1993 & 1995; Hemenway et al, 1994; Poor et al, 1995; Nguyen et al, 
1996; Grisso et al, 1997). Most studies have suggested taller height to be an independent 
risk factor for hip fracture (Meyer et al, 1993 ; Hemenway et al, 1994; Poor et al, 1995) 
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with an odds ratio of 1.6 per 6 cm increase in height (Grisso et al, 1997). One possible 
explanation for this is the strong association of height with hip axis length, itself a risk 
factor for hip fracture. In contrast, Nguyen and co-workers (Nguyen et al, 1996) found 
men with both hip and vertebral fractures to be about 6 cm shorter than non-fracture 
controls. After adjusting for femoral neck BNM, shorter (current) height was a 
significant risk factor for fracture. Since height decreases with advancing age it has been 
suggested that measurement of current height may not be as reliable as peak height in 
assessing the fracture risk of an individual. 
The relationship between weight and risk of hip fracture has been studied using "current 
weight", "weight gain" and "weight loss" over defined periods and linking these to risk 
of hip fracture. All studies confirm low weight to be a risk factor (Nguyen et al, 1996; 
Langlois et al, 1998; Mussolino et al, 1998). The longitudinal study by Nguyen and co- 
workers in Dubbo, Australia involving 820 men aged over 60 years showed higher 
weight was protective against fracture risk but was not independent of BMD (Nguyen et 
al, 1996). The more recent Established Populations for Epidemiologic Studies of the 
Elderly (Langlois et al, 1998) assessed the risk of hip fracture associated with weight 
change between middle (50 years) and old age in men. The study confirmed extreme 
weight loss (>=10%) beginning at age 50 associated with a near 2-fold increased risk of 
hip fracture (RR 1.8). Similarly, weight gain of 10% or more provided borderline 
protection (RR 0.4). Similar results were obtained from another prospective study even 
after adjustments were made for the presence of co-morbid conditions (Mussolino et al, 
1998). A weight loss of 10% or more from maximum was associated with a two fold risk 
of hip fracture (OR=2.3 1). One limitation of this study was the very small number of hip 
fractures (n=71). However, on comparison of those with BMI less than to more or equal 
to 25.7, amongst those who lost 10% or more weight; fracture risk was higher in the 
"thinner" than "heavier" men (Mussolino et al, 1998). 
Although low BMI is a significant predictor of hip fracture risk in women it has not been 
consistently related to hip fracture risk in men. One possible explanation comes from the 
Framingham data (Felson et al, 1993) which suggests that body weight has less 
influence on BMD in men than in women and that past body weight is not as strongly 
related to bone density as current weight. Thus relationship between BMI and hip 
fracture risk might be more difficult to detect when based on measurements made many 
years prior to the fracture. Body weight was related to hip fracture risk in men based on 
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measurements made within 6 weeks to 5 years of duration but BMI did not differ 
between men with and without hip fracture in a study with 14 years follow-up 
(Mussolino et al, 1998). Similarly, no relationship was found between BMI and risk of 
hip fracture in 51,529 male health professionals in the US aged 40 through 75 years 
(Hemenway et al, 1994). On the contrary, in a case control study using current 
anthropometric measurements (Grisso et al, 1997) men in the lowest quintile of body 
mass were at increased risk of hip fracture compared with men in the heaviest quintile 
(OR 3.8). Similarly, low BMI was confirmed to be a risk factor for hip fracture in middle 
-aged Norwegian men (Meyer et al, 1993) and older white men (Langlois et al, 1998). 
Both these were longitudinal studies of 12 and 8 years duration respectively. Baseline 
BMI had a strong and statistically significant trend of decreasing rate of bone loss with 
increasing BMI over a2 year period in the Rotterdam study (Burger et al, 1998). 
1.3.4 Hip axis length 
Recent studies have suggested that geometric characteristics of the proximal femur may 
be additional important determinants of fracture risk (Faulkner et al, 1993; Boonen et al, 
1995; Peacock et al, 1995; Karlsson et al, 1996). In women, an increase in hip axis 
length (the linear distance from the base of the greater trochanter to the inner pelvic rim 
along the line through the mid point of the femoral neck) has been linked with hip 
fracture risk in several studies (Faulkner et al, 1993; Duboeuf et al, 1997). A one 
standard deviation increase in hip axis length (HAL) is associated with a 1.8 fold 
increase in hip fracture risk (Faulkner et al, 1993) with the effect being independent of 
bone mass. There are, however, no data concerning the influence of HAL on risk of hip 
fracture in men. Two previous studies suggested no difference in femoral neck axis 
length (one of the component parameters of HAL) among fracture cases than controls 
Peacock et al, 1995), however, the link between FNAL and hip fracture risk is less clear 
(Karlsson et al, 1996; Center et al, 1998). 
The mechanism by which an increase in HAL confers an increase in susceptibility to 
fracture in women is unknown. Studies suggest that the risk persists after adjustment for 
body height and weight indicating it is not a surrogate for body size (itself linked with an 
increased risk of hip fracture) (Faulkner et al, 1993). It has been suggested that HAL is a 
marker for the ability of the femur or pelvis to absorb or avoid the impact of a fall 
(Faulkner et al, 1995). There are important gender differences in both the shape of the 
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proximal femur and pelvis including the pelvic brim (Beck et al, 1992; Wahner et al, 
1994) which may influence bone strength or resistance to fracture. In females, the 
acetabular diameter is usually less than that in males, not only because it is absolutely 
smaller but also because the anterolateral wall of the cavity is comparatively and 
absolutely wider. It is possible that one or more of these shape parameters interact with a 
long hip axis length to increase susceptibility to hip fracture, and explain the discordance 
in fracture risk in men and women. 
1.3.5 Previous history of a fracture at any site 
Most but not all studies confirm past history of fracture as risk factor for future 
fractures. Using a case control study design, history of fracture within 5 years 
significantly increased fracture risk among elderly men (Nguyen et al, 1996). This was 
true even after adjusting for BMD at the femoral neck. Similar findings were reported 
using case control (Poor et al, 1995), longitudinal (Hannan et al, 1992) and 
observational study designs (Jonsson et al, 1993). Results of the NHANES 
Epidemiological study (Mussolino et al, 1998) on the contrary did not support this 
observation. These differences may be a explained on the way previous fracture was 
defined "5 years" versus "anytime" increasing the likelihood of the former to be related 
to osteoporosis and hence significant. 
1.3.6 Age 
Increasing age has been found to be a risk factor for hip fracture in a number of studies 
(Hemenway et al, 1994; Nguyen et al, 1996; Langlois et at, 1998; Mussolino et al, 
1998). A population based prospective study of middle aged adults in 3 Norwegian 
counties (including 27,015 men) over a 12 year period showed that age is a significant 
risk factor for hip fracture with a relative risk of 1.67 for every 5 year increase in age 
(Meyer et al, 1993. This is supported by the findings of the longitudinal population based 
study in Rotterdam that assessed the effect of age on rate of bone loss over a median 1.8 
year period (Burger et al, 1998). The study showed statistically significant acceleration 
of bone loss with increasing age up-to 80 years, most clearly in men. 
1.3.7 Smoking 
The effect of smoking is less clear. Most studies that have looked at the relationship 
between smoking, risk of hip fracture and BMD have confirmed an increased risk of hip 
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fracture along with lower BMD in smokers (Meyer et al, 1993; May et al, 1994; Egger 
et al, 1996; Grisso et al, 1997; Mussolino et al, 1998). However, in case controls studies 
(Grisso et al, 1991; Poor et al, 1995) and in the prospective study of 50,000 male health 
professionals in the US (Hemenway et al, 1994) no significant relationship was observed 
between smoking and risk of hip fracture. The latter may be a biased sample of healthy 
individuals. In the Leisure World Study (Paganini-Hill et al, 1991) current cigarette 
smoking increased hip fracture risk in men (OR 2.2) compared with never-smoking, but 
the risk for past smokers was not different from that of lifetime non-smokers. The 
association between smoking and hip fracture may partly reflect the lower body weight 
of smokers. After allowing for body weight, the association persisted in most studies but 
not in some. Both current and past smoking, including pipes but not cigars increased the 
risk of hip fracture (OR range 1.4-3.2) independent of body mass and no reduction in 
risk was detected with increased duration of quitting (Grisso et al, 1997). Results of 
prospective studies (Nguyen et al, 1996; Mussolino et al, 1998) again suggested an 
increased risk of fracture amongst current smokers although the risk did not reach 
statistical significance. Excess smoking (equal or more than 15 cigarettes/day) was found 
to be a risk factor in the prospective study involving middle aged Norwegians (Meyer et 
al, 1993). In the Rotterdam study (Burger et al, 1998) cigarette smoking was 
accompanied by a substantially higher rate of bone loss at the femur in both men and 
women. The Framingham Study exclusively addressed the effect of smoking at different 
life stages on BMD in elderly men (Kiel et al, 1996). The study showed smoking at all 
stages to have an adverse effect on the skeleton. This was independent of weight, 
alcohol or caffeine use, implying other mechanisms for its effect on bone. A recent meta- 
analysis of cigarette smoking, BMD and risk of hip fracture (Law and Hackshaw, 1997) 
suggested a similar effect on BMD and risk of hip fractures in the two sexes. The 
authors concluded that the data for smoking in men is limited and the variation in mean 
age between studies is too narrow to permit regression analysis on age. 
1.3.8 Alcohol 
Results for alcohol have been varied somewhat in previous prospective studies in men. 
Moderate alcohol consumption has been suggested to be associated with an increase in 
BMD (Holbrook et al, 1993; Glynn et at, 1995). Nevertheless, alcohol abuse is 
associated with osteoporosis, and in particular with an increased fracture risk (Saville 
1965; Seeman et at, 1983; Felson et al, 1988; Slemenda et al, 1992). Nguyen et at found 
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a decrease in rate of bone loss over a 2-year period in self reported alcohol drinkers but 
found no relationship to fracture risk after adjusting for bone density (Nguyen et al, 
1996). Similarly, no relationship between hip fracture risk and alcohol use was noted in a 
longitudinal study of 2879 men followed for 22 years (Mussolino et al, 1998). The two 
case-control studies similarly did not find an association between current or past alcohol 
intake and risk of fracture despite a relatively high prevalence of heavy use (Grisso et (Il, 
1991; Poor et al, 1995). Similarly, in the Rotterdam study no convincing relationship 
between alcohol consumption and bone loss at the proximal femur over 2 years was 
noted (Burger et al, 1998). On the contrary, a variable relationship with heavy alcohol 
usage according to age group was found in the Framingham cohort. Heavy current 
alcohol consumption was associated with a modestly increased risk of hip fracture for 
men (RR=1.3) after adjusting for age (Felson et al, 1988). Differing results for alcohol 
use may be due to differences in the way in which these variables are measured. 
1.3.9 Calcium 
A recent meta-analysis of prospective studies in women concluded that increased 
calcium intake is associated with a small reduction in fracture risk (Cummings et al, 
1997). Results from prospective studies on hip fracture that have included men have 
been mixed. The NHANES epidemiological follow-up study (Mussolino et al, 1998) 
over 22 years addressing this issue in men showed that although not statistically 
significant, men with higher calcium (and protein) intakes had lower risk of hip fracture 
even after adjusting for energy intake. Similarly, in the Rotterdam study (Burger et al, 
1998) a significant trend of lower rates of bone loss with increasing dietary calcium 
intake was demonstrated. A more recent publication by the Dubbo Epidemiology Study 
group showed a positive correlation between dietary calcium intake and BMD at both 
the lumbar spine and proximal femur in men (Nguyen et al, 2000). By contrast, there 
have been reports showing no correlation between dietary calcium intake and BMD in 
men (Glynn et al, 1995). 
1.3.10 Exercise and activity 
The role of life-style factors as determinants of BMD and hence fracture risk has 
received considerable attention. Higher physical activity has been shown to be protective 
against fracture risk (Cooper et al, 1988; Lau et al, 1988; Mussolino et al, 1998; 
Nguyen et al, 1996) with odds ratio of 0.2 for activities equal to or more than 7 hours 
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per week (Grisso et al, 1997). The Leisure World Study similarly showed a strong and 
negative association between active exercise and hip fracture risk with an odds ratio of 
0.5 in men for 1 or more hours of exercise per day compared with less than half hour of 
exercise (Paganini-Hill et al, 1991). The degree of protection conferred has been shown 
to be irrespective of type of activity (Grisso et al, 1997). Similarly, lower limb 
dysfunction and use of ambulatory aids (Grisso et al, 1997) has been shown to be 
associated with an increased risk of hip fracture. The Rotterdam study (Burger et al, 
1998) similarly demonstrated higher rates of bone loss with lower limb disability, 
probably through its association with reduced physical activity. In addition the presence 
of upper limb dysfunction and difficulty with one or more instrumental activities of daily 
living has also been shown to be associated with increased risk of fracture (Grisso et al, 
1997). 
1.3.11 Medications 
Few studies have addressed specifically the correlation between medicinal intake and hip 
fracture risk in men. There is lack of consistency in the drugs implicated. Despite the 
rather common use of diuretics (22% of controls) no significant association was been 
found between the use of thiazides diuretics and hip fracture risk (Poor et at, 1995; 
Grisso et al, 1997; Langlois et al, 1998). In contrast, use of psychotropic drugs were 
shown to double the risk of hip fracture (Grisso et al, 1997). Similar strong associations 
have been reported between risk of fracture and cimetidine use (Grisso et al, 1997). 
Using a case-control study design, Poor and colleagues did not demonstrate a 
deleterious effect of corticosteroids and anticonvulsants on hip fractures in men (Poor et 
at, 1995). In contrast, using the same study design oral steroids and anticonvulsants 
were both associated with a significantly increased risk of vertebral fracture in men (OR 
6.1) (Scane et al, 1999) 
1.3.12 Co-morbid diseases 
Almost all studies confirm the presence of co-morbid diseases as risk factors for hip 
fracture (Mussolino et al, 1998). Using a case-control study design Poor and colleagues 
demonstrated significantly increased risk of hip fracture in association with hemiplegia 
(OR 2.6), Parkinson's (OR 8.0), dementia (OR 5.3), blindness (OR 5.5), vertigo (OR 
6.0) or anaemia around the time of fracture (OR 2.6) (Poor et al, 1995). More 
prominent risk factors included a history of thyroidectomy (OR 5.0), gastric resection 
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(OR 2.6), pernicious anaemia (OR 3.8) and chronic bronchitis (OR 2.3). Similar results 
were obtained in another case-control study (Grisso et al, 1997). The authors 
demonstrated specific chronic illnesses (stroke, Parkinson's disease) as well as having 
two or more chronic illnesses to be associated with increased risk of fracture. An 
explanation for the association is the probable link between these disorders and 
secondary causes of osteoporosis or an increased likelihood of falling. 
1.3.13 Synopsis 
Many risk factors for fractures are comparable between the sexes, such as low body 
mass index, inactivity, low diet calcium, excess alcohol intake, heavy smoking and 
presence of co-morbid condition. Risk factor analysis may be helpful in designing 
strategies for preventing hip fractures. Some risk factors act at least partly through 
effects on bone density, whereas others act by influencing the risks of falls. Many of 
these factors can be eliminated or modified. Even those that cannot be modified are 
important for identifying at-risk patients, who may benefit most from therapies that alter 
other risk factors. However, risk factor assessments are not a substitute for BMD 
measurements and cannot be recommended as screening tools in their own right due to 
variable results. They may however, provide valuable information to a BMD scan, 
particularly for risk of falls. Knowledge of risk factors may also contribute to the clinical 
treatment of individual patients. Information about risk factors helps in the understanding 
of disease causation. Clearly, large prospective studies encompassing all risk factors are 
warranted in men. 
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1.4 BONE MINERAL DENSITY AS RISK FACTOR FOR HIP FRACTURE 
The ultimate determinants of fracture are bone strength and trauma. Bone strength is 
related to quality of bone, its architecture and its mass. These characteristics cannot 
easily be assessed in-vivo, but correlate closely with bone mineral density (BMD). BMD 
can be measured safely, accurately and precisely by a number of methods. The most 
widely available of these is dual-energy X-ray absorptiometry (DXA). The clinical value 
of bone densitometry depends on its ability to estimate the risk of fracture. This section 
describes the developments in measurement techniques, determinants of peak bone mass 
in men and reviews the little evidence available in literature of BMD as a risk factor for 
hip fracture in men. 
1.4.1 Measurement techniques 
There are a number of techniques available for measuring BNM and these are 
summarised below. 
1.4.1.1 Single Photon Absorptiometry (SPA) 
Cameron and Sorenson first described SPA in 1963 (Cameron and Sorenson, 1963). 
Instruments based on this knowledge were commercially available through the 1970s and 
1980s. An essential part of our knowledge of bone mineral content of the peripheral 
skeleton was obtained with these instruments. In SPA, instrument source and detector 
are coupled in parallel opposed geometry and are motor driven in a direction exactly 
transverse to the longitudinal axis of the bone. As the beam scans across the bone the 
integrated attenuation of the photon beam is compared to the beam intensity of the 
adjacent tissue. The requirement for a uniform tissue absorber of constant thickness 
surrounding bone makes SPA unsuitable for bone mineral measurements in spine, hip or 
other parts of the trunk, where bone is surrounded by tissues of different composition 
and thickness. SPA is restricted to quantification of bone mineral in appendicular bones, 
most frequently the radius. Measurements of the bone mineral content (BMC) on long 
bones correlates highly with total skeletal bone mineral and with total body calcium. As a 
test for the clinical diagnosis of osteoporosis, SPA has been disappointing. Several 
studies have shown that 30% or more of the patients with vertebral crush fracture have 
normal BMC. This limited usefulness is true for measurements on the ultradistal radius 
as well as the calcaneous. 
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While SPA measurements on the radius and the calcaneous are still useful for 
epidemiological studies of bone mass or perhaps in screening large populations, in 
clinical practice, SPA has been replaced by DXA measurements of bone mineral on the 
axial skeleton. 
1.4.1.2 Dual X ray Absorptiometry (DEXA) 
This is the most widely available technique and performs measurements at the lumbar 
spine, proximal femur, forearm and whole body. In this technique attenuation profiles are 
recorded in two different energies. By multiplying the soft tissue attenuation at one 
energy by a constant the difference between the two profiles becomes zero over soft 
tissue areas. 
The first equipment for measuring bone mineral in the spine was based on a dual energy 
isotope source in the late 1960s. The technique was referred to as dual energy photon 
absorptiometry (DPA). However, these instruments had several practical drawbacks 
mainly imposed by the use of radioactive isotopes as photon sources. Precision errors 
were 2-4% for spine measurements and the decreasing source strength due to isotope 
decay required complicated correction and quality control procedures. 
DXA was introduced in 1987 and overcome most of these shortcomings. In DXA, dual 
energy X-rays are generated by an energy switching system (Hologic) or by rare earth 
filtered X ray sources (Lunar, Norland). Each system has its own limitation, which are 
however, of little practical importance when the instruments are used within their 
specifications. 
By both systems the human body is considered a two compartments system: soft tissue 
(calculated as a uniform absorber by averaging soft tissue values for each pixel) and 
bone. Of all soft tissues in the body, fat more than other tissues, affects the calculated 
(average) consistency of this soft tissue compartment that surrounds bone. It is also 
assumed that soft tissue above and below the bone, where it cannot be separated from 
bone, is equal to that on both sides of the bone. Furthermore, it is assumed that this 
calculated soft tissue represents bone marrow. These assumptions are not strictly true 
when patients are measured, but they set the limits within which the measurements have 
to be performed. For DXA measurements on the spine, if the amount of fat overlying the 
spinal column is greater than on either side of the lumbar spine, BMD will be 
41 
underestimated. A mean fat thickness of 2 cms results in bone mineral error of 9-10%. A 
change in bone marrow fat of 50% will change BMD by 5- 6% (Sorenson 1990). More 
recent studies of DXA measurement accuracy found similar errors for BMC as well as 
area measurements, but smaller errors for BND. Short term DXA precision error in-vivo 
of the lumbar spine, femoral neck, Wards' triangle and trochanter region is about 0.9, 
1.2,2.7 and 2.4% respectively. Normative databases are generally created from cross- 
sectional studies. With old age, cross sectional studies show an increase in the 
population variance and a decrease or cessation of the age related bone loss. This 
probably reflects both local degenerative changes in the lumbar spine and selective 
mortality of more frail individuals. 
The DXA technique is also applicable to bone mineral measurements in peripheral bones. 
These measurements can be made using the instruments commonly used for the spine 
and hip scans. A special device to position the forearm is supplied. At the distal radius 
the scans give comparable accuracy and precision as those with SPA. 
The advantage of this technique is the higher beam intensity and more rapid scan, 
improved spatial resolution with easier identification of vertebrae, and better precision. 
Recent developments in the technology includes scanning of the lumbar spine in the 
lateral position, which has the advantage of eliminating the posterior arch and the spines 
of the vertebral bodies, as well as aortic calcification, from the measurements. In addition 
the technique can be modified to assess vertebral heights, so that vertebral deformity can 
be quantified as part of the analysis of the scan. The precision of these recent additions 
remains uncertain. 
Absorptiometric methods of bone density measurements can be reported in a variety of 
ways. The scan itself assesses the bone mineral content (BMC) and the area of the bone 
projected on the scan. Bone mineral density (BMD) is calculated as BMC/area. Finally, it 
is possible to estimate volumetric bone density (BMAD) using a mathematical algorithm. 
All these parameters are associated with the risk of fracture, but BMD is the variable 
with the closest association (Cummings et al, 1994) 
1.4.1.3 Quantitative Computerised Tomography (QCT) 
Quantitative computed tomography can be performed on the lumbar spine with most 
commercial instruments and with dedicated instruments on peripheral bones, generally 
42 
radius. It is the only method for assessing trabecular and cortical bone separately. The 
measurement unit is apparent density. 
For measurements at the lumbar spine, a software package and calibration phantom to be 
added to the CT scanner are available. Several authors have reported marginally lower 
rates of bone loss with dual energy QCT, which corrects for the error due to fat. Bone 
density (QCT) shows a greater difference between normal and osteoporotic subject than 
areal bone density (DXA). Because of the greater normal population variance seen with 
bone density (QCT) meaningful comparisons between QCT and DXA should be based 
on Z scores. Of interest is also a comparison of the discriminatory ability of QCT and 
DXA to distinguish normal from osteoporosis. Expressed as percentage difference, the 
average difference was -20% (QCT) versus -11% (DXA). When expressed as Z scores, 
however, this was -0.7 versus -0.6 standard deviations. 
1.4.2 Determinants of BMD in normal men 
Although comparatively little attention has been paid over the years to the determinants 
of peak bone mass in men, race, genetic factors (Krall and Dawson-Hughes, 1993), 
hormonal factors, diet (Kelly et al, 1990) and exercise (Snow-Harter et al, 1992) have 
all been shown to have an influence. As in women, genetic factors account for a 
substantial amount of the variation in peak bone mass, but the precise genes remain to be 
elucidated. 
The most obvious influence on peak bone mass is hormonal, and this is accounted for by 
the differences in pubertal development in males and females. Women exhibit a dramatic 
increase in bone mass during puberty, which is almost complete when puberty ends. 
Similar changes occur in men, but at a later time corresponding to the later onset of 
puberty, and peak bone mass is consequently achieved at a later age. The greater peak 
bone mass in men is largely related to body size rather than to BMID (Orwoll and Klein, 
1995) except at certain sites such as the radius (Kelly et al, 1990). The age of pubertal 
onset may be important in determining peak bone mass. It has been shown that males 
with constitutional delay of puberty have substantially lower spine and forearm BMD 
than those with a normal onset of puberty, despite matching the two groups for length of 
post pubertal exposure to testosterone (Finkelstein et al, 1992). After reaching peak 
bone mass men maintain a stable bone density during middle age but then loose bone at 
an accelerating rate into old age (Tobin et al, 1993). 
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1.4.3 Age related bone loss in normal men 
Bone loss occurs with ageing in men as in women, and longitudinal studies suggest that 
this loss may reach 5-10% per decade (Orwoll et al, 1990). This is greater than that 
estimated from cross sectional studies (Hannan et al, 1992). The change in bone density 
with age in men is of a similar order using single photon absorptiometry (Christian et al, 
1989), dual photon absorptiometry (Mazess et al 1990), and by dual energy X-ray 
absorptiometry (Wishart et al, 1995; Burger et al, 1994; Mazess et al, 1990). Overall 
loss of peak bone mass from 20 years to advanced old age may reach 5-15 % for cortical 
bone and 15-45% for trabecular bone (Francis et al, 1989; Mazess et al, 1990). The rate 
of change of bone density with age varies at different sites. Most workers have found no 
significant change in bone density with age at the lumbar spine and trochanter (Mazes et 
al, 1990; Burger et al, 1994; Nguyen et al, 1994; Wishart et al, 1995). On the contrary, 
highly significant falls with age in femoral neck and Ward triangle BMD have been 
observed. A more recent study (Wishart et al, 1995) showed minimal loss of bone in 
men before age of 50 after which it appears to accelerate associated with a decline in 
markers of bone turnover. This bone loss is associated with histomorphometric evidence 
of decreased bone formation with decreased osteoid seam width and trabecular width 
(Aaron et al, 1987; Francis et al, 1989). Trabecular number may also be decreased and 
trabecular connectivity reduced (Mosekilde 1989), while bone turnover may be increased 
in elderly men (Orwoll and Deftos, 1990). 
Up to 40% of men with severe osteoporosis have no identifiable medical condition or 
risk factor associated with bone loss (Francis et at, 1989; Baillie et al, 1992) and in such 
men with primary osteoporosis the pathogenesis of age-related bone loss is far from 
clear. Although genetic factors partly determine peak bone mass, they do not appear to 
be important in age-related bone loss in men (Christian et at, 1989). There have been 
some reports that men with osteoporotic fractures have hypercalciuria (Zerwekh et at, 
1992; Kelepouris et al, 1995), but it is unclear whether this is due to increased bone 
resorption or renal leakage of calcium. It has been suggested that a combination of 
declining renal function and vitamin D deficiency during normal ageing may produce 
secondary hyperparathyroidism and consequent loss of bone (Orwoll et at, 1986). 
Increasing levels of serum parathyroid hormone with age have been implicated in age- 
related bone loss in men (Orwoll et al, 1986), as have decreasing serum growth hormone 
levels (Johansson et at, 1994). 
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A variety of other factors may influence age-related bone loss, including low vitamin D 
levels (Orwoll et al, 1986), low serum testosterone levels (Kelly et al, 1990; Kelepouris 
et al, 1995; Murphy et al, 1993), and low calcium intake (Kelly et al, 1990) and 
absorption (Francis et al, 1989). Other studies however, have shown little if any 
correlation between BMD at various sites and free testosterone levels (Drinka et (Il, 
1993) or dietary calcium intake (Francis et al, 1992). A longitudinal study on healthy 
male twins addressed the issue of genetic and environmental factors in determining rate 
of bone loss in men over a 16 year period (Slemenda et al, 1992). The study showed 
both cigarette smoking and alcohol consumption to be the independent predictors of 
bone loss. Intense physical activity was also associated with slightly reduced bone loss. 
Rates of bone loss were similar within twin pairs, apparently because of shared 
environment, making it difficult to separate genetic from environmental effects on rate of 
bone loss. 
1.4.4 BMD as risk factor for hip fracture 
Bone mineral density (BMD) is highly correlated with bone strength (Mazess et at, 
1982), accounting for 75-85% of the variance in ultimate strength of the bone tissue 
(Melton et at, 1988). Studies in women indicate that for each standard deviation 
reduction in bone mass the risk of hip fracture increases by a factor of 1.5-3.0 (Marshall 
et at, 1996). Less is known about the influence of BMD in determining fracture risk in 
men. Several observational studies suggest that BMD is lower among men who have 
sustained a hip fracture than those without, though in most of these the number of 
individuals studied have been relatively small (Karlsson et at, 1993; Greenspan et at, 
1994; Greenspan et al, 1998; Nguyen et at, 1996; Boonen et at, 1997; Nyquist et at, 
1998; Melton et al, 1998; De Laet et al, 1998). 
Bone mineral density diminishes with ageing in the femoral neck, falling an estimated 
39% in men between the ages of 20 and 90 years, while BMD of the intertrochanteric 
region of the proximal femur declines 35% (Riggs et al, 1982). Age-related bone loss in 
the shafts of the limbs is partially compensated for, biomechanically, by remodelling of 
these bones to increase the diameter, and thus increase resistance to bending and torsion. 
This process is less marked at the ends of these bones where the fractures occur that are 
typically associated with osteoporosis. There is little compensatory increase in diameter 
of the proximal femur to offset cortical bone loss with ageing (Melton et al, 1988). 
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Consequently, the age-related reductions in bone mass leads to a corresponding decline 
in strength of the proximal femur, which is greater in women than men. 
Since bone strength is a determinant of fracture susceptibility, it follows that BMD is 
also correlated with fracture risk. There is now ample evidence that bone mass 
measurements can stratify patients on the basis of fracture risk. Recently published 
studies have demonstrated that measuring bone mass at the radius (Hui et al, 1988) or 
calcaneum (Wasnich et al, 1987) will predict the risk of fracture in the future. In contrast 
to extensive studies in women, few studies have related BMD in men to the risk of hip 
fracture. Studies have shown that there is a gradient of increasing hip fracture risk as 
bone mass falls. In a group of 654 men in Malmo in whom BMD was assessed by 
single-photon absorptiometry, those in the lowest quintile of BMD had a 6-13 fold 
increase in risk of fracture over the following 11 years (Gardsell et al, 1990). A later 
study from the same centre using a case control design compared BMD using DEXA 
within 10 days of hip fracture to controls (Karlsson et al, 1993). Of their 93 hip fracture 
cases, 26 were men with mean age of 75 years. They found significantly lower BMD at 
both the lumbar spine and the proximal femur in the hip fracture patients compared to 
age and sex matched controls. A 66% reduction in risk of hip fracture (n=31) per SD 
increase in BMD at the femoral neck was reported on prospective follow-up of 820 men, 
aged 60 or more, residents of DUBBO city (Australia), over a2 year period (Nguyen et 
al, 1996). This finding is in agreement with previous studies in women (Cummings et al, 
1990) and supported by reports of a3 fold increase in risk of fracture per SD decrease in 
BMD in men (De Laet et al, 1998). Measurement at the proximal femur was a more 
powerful predictor of fracture risk than the lumbar spine site consistent with findings of 
some (Cummings et al, 1993) but not all researchers (Melton et al, 1993). In the elderly, 
femoral BMD is more sensitive than lumbar spine. Another prospective population - 
based study assessing predictors of hip fracture risk in white men (NHANES) aged 45- 
74 years showed that phalangeal bone density was inversely related to hip fracture risk. 
In both the age- and risk-adjusted models, fracture risk increased by 70% for each 1 SD 
decrease in bone density (Mussolino et al, 1998). The drawback of this study was the 
determination of BMD from a baseline X-ray of the left hand using radiographic 
absorptiometry (RA) and in the small number of fracture cases (n=71 hip fractures). The 
authors concluded that the relative risks for phalangeal BMD and hip fracture risk in 
their study was similar to those seen for other appendicular sites using a variety of bone 
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densitometry techniques. A recent prospective population - based study was carried out 
on a cohort of 242 men, aged 50-80 years who were followed for a period of 7 years 
with a total of 9 hip fractures during the study period (Nyquist et al, 1998). This study 
concluded that using SPA, a1 SD decrease in forearm BMD is associated with a relative 
risk of osteoporotic fracture 1.75 95%CI (1.08-2.83); and relative risk of hip fracture 
3.88 95%CI (1.3-11.57). The only prospective study addressing this issue in elderly 
nursing home residents, including 7 men with a hip fracture, similarly showed 
significantly lower femoral BMD in subjects who fell and fractured compared to those 
who fell but did not sustain a fracture (Greenspan et al, 1998). The same authors in an 
earlier study assessed site - specific BMD in 112 elderly hip fracture patients including 
27 men and concluded that a relatively lower trochanteric or a high femoral neck BMD 
was associated with trochanteric hip fractures (Greenspan et al, 1994). This led to 
suggestions of site specific measurements for assessment of fracture risk. Clearly 
therefore, using a range of measurement techniques and different study designs BMD 
seems to be an independent risk factor for fracture in men. This appears to be true for all 
types of fractures. These findings parallel those in women. However, contrary to the 
wealth of literature in women, studies in men are limited by the very small sample size, in 
particular number of hip fractures. 
The WHO criteria for diagnosis of osteoporosis relate specifically to Caucasian women. 
The reference ranges currently used for men are those supplied by the instrument 
manufacturers, and often relate to smaller study population than those obtained for 
women. This may lead to inaccuracy in the reference ranges for men highlighting the 
urgent need to establish appropriate reference ranges for BMID in men. 
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1.5 SEX HORMONES AS RISK FACTORS FOR HIP FRACTURE 
1.5.1 Background 
This chapter outlines the patho-physiology of sex hormone production, changes in hormonal 
milieu with age, mechanism of action of sex steroids on target tissues with special emphasis 
on bone and finally provides evidence on the role of sex steroids, in maintaining skeletal 
health in men. 
1.5.2 Brief review of the control of sex hormone production 
1.5.2.1 In health 
The control of testicular function begins with the pulsatile release of gonadotrophin- 
releasing hormone (GnRH) from the hypothalamus. GnRH is transported by the 
hypothalamic-pituitary-portal system to the anterior pituitary, where it effects the release of 
luteinizing hormone (LH) and follicular stimulating hormone (FSH). The frequency of 
GnRH pulses seen by the pituitary along with the negative feedback signals is the 
determinant of the relative amounts of LH or FSH that are released from the pituitary. At a 
GnRH pulse frequency of 3.8 pulses every six-hour, optimal amounts of both LH and FSH 
are released for normal testicular function. If the pulse rate of GnRH slows, then FSH is 
preferentially released, while more rapid GnRH pulse frequency results in a more prominent 
release of LH. Following release from the pituitary gland, LH is transported via systemic 
circulation to the testes, where it specifically binds to the Leydig cells to initiate testosterone 
production and secretion. FSH after release into the systemic circulation binds specifically to 
the Sertoli cells in the testes and stimulates the secretion of a number of proteins. One of 
these is inhibin, which, along with testosterone from the Leydig cell, induces and maintains 
spermatogenesis. The secretion of FSH and LH is regulated by the negative feedback of 
testosterone and inhibin at the level of both the pituitary and the hypothalamus. Testosterone 
can inhibit the secretion of both LH and FSH, while inhibin inhibits primarily the secretion of 
FSH. 
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1.5.2.2 In disease states 
Primary hypogonadism is the result of a testicular defect involving either the Leydig cell 
production of testosterone, seminiferous tubule production of sperm, or both compartments. 
Secondary hypogonadotrophic hypogonadism is suspected when the end products, 
testosterone or sperm are low and there is no increase in LH or FSH 
Combined primary and secondary hypogonadism: Decline in gonadal function with age is 
multifactorial. It includes an increased negative feedback capacity of testosterone on LH 
secretion, decreased gonadotrophin response to GnRH, and decreased testicular response to 
human chorionic gonadotrophin (HCG). Recent studies examining frequent samples of 
testosterone throughout the day have shown that there is a significant decline in total 
testosterone because with age, in addition to the declining testosterone secretory capacity of 
the testes, there is also an age related increase in sex hormone-binding globulin (SHBG). 
Overall, associated with the decrease in testosterone with age there is an increase in LH and 
FSH suggesting that a primary testicular defect is predominant. 
Severe stress or injury rapidly lowers serum testosterone and gonadotrophin levels. Even if 
the serum binding protein for testosterone is decreased, free levels of serum testosterone 
remain low. This effect appears to be due to an effect on gonadotrophin secretion with a 
decrease in immunoreactive LH as well as an even greater decrease in biologically active 
serum LH. Immediately following the onset of hospitalisation for an acute severe illness, 
there may be a period of hypogonadotrophic hypogonadism. 
Isolated deficiency of LH is known and termed as the fertile eunuch syndrome. These men 
are androgen deficient but have enough FSH secretion to maintain fertility. One group that 
may fit this syndrome are older men who have fathered children and maintained 
spermatogenesis but have a lower than normal testosterone levels without an increase in LH. 
These men most likely fall on the curve of normal ageing. 
Isolated FSH deficiency has also been reported. They have normal androgens but have 
decreased or absent sperms without concomitant increases in FSH. 
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1.5.3 Endocrine evaluation of testicular function 
1.5.3.1 Testosterone 
The laboratory diagnosis of hypogonadism begins with the finding of testosterone 
deficiency. The daily production of testosterone in adult men is approximately 6 mg, and the 
testosterone content of the adult testis is 15-25 ug, indicating that the testis is continuously 
synthesising and releasing testosterone into the circulation. 
Testosterone is secreted in bursts at a frequency of approximately one pulse per hour. 
Testosterone varies in peripheral blood from 50-200 ng/dl but these variations do not 
correlate with the secretory bursts, partly because of the rapid frequency and the delayed 
disappearance of testosterone from peripheral blood because of binding to SHBG. Single 
measurements of testosterone levels in the morning reliably predict the annual mean level. 
There is a diurnal rhythm in the circulating testosterone levels in adult men, however, with 
highest levels in the morning, followed by a progressive fall throughout the day, reaching the 
lowest levels in the evening during the first few hours of sleep. Peak and nadir differ by 
approximately 30%. This diurnal rhythm is blunted with ageing and in testicular failure. 
Commercial kits for direct assay of testosterone in unextracted serum use an I125-labelled 
tracer which is simple to use and accurate for most purposes. In some assays the results may 
be artifactually overestimated with low SHBG levels and underestimated with high SHBG 
levels because of SHBG differences between levels in the standards and samples. In 
addition, direct assays tend to overestimate the true values of testosterone at very low 
concentrations. To control for effects of SHBG concentrations and to discriminate among 
low levels accurately, immunoassays using organic solvent extraction and chromatographic 
separation may be needed. 
1.5.3.2 Sex Hormone-Binding Globulin 
Of the circulating testosterone in normal men, less than 4% is free (not protein bound), 1- 
2% is bound to cortisol-binding globulin, approximately 40% is loosely bound to albumin, 
and the remainder is bound with high affinity to sex hormone-binding globulin (SHBG). 
SHBG is synthesised in the liver and released in circulation. The function of SHBG is partly 




for SHBG in tissues (testis, prostate, epididymis and others) suggests that they could also 
play a direct role in androgen action. 
SHBG is measured indirectly using radioligand-binding assays based on the specific binding 
of 3H-testosterone or by direct immunoassay of the protein. A number of disorders are 
associated with an increase or decrease of SHBG levels and must be borne in mind. 
1.5.3.3 Free / Bioavailable Testosterone 
When testosterone is measured by immunoassay, the total testosterone is determined. 
Abnormal SHBG levels, however, can cause an increase or decrease in the measured serum 
total testosterone concentrations. One approach to correct the total testosterone for the 
variation in SHBG is to determine a free testosterone index. It is calculated as the ratio of 
total testosterone/SHBG, or total testosterone times SHBG divided by the mean normal 
SHBG levels. 
The level of free (non-protein bound) testosterone is independent of SHBG concentration. 
This is determined from the diffusion across a semipermeable membrane of tracer amounts 
of 3H-testosterone added to the sample. The free testosterone is calculated from the product 
of the total testosterone level and the percentage free testosterone. This method is complex, 
time consuming and expensive. Another approach is a solid phase free testosterone 
radioimmunoassay (RIA) kit that uses a 125I-labelled testosterone analogue as the tracer. 
This has a strong positive correlation with free testosterone measured by equilibrium dialysis 
but produces substantially (75%) lower values making comparison with published data 
difficult. 
Bioavailable or non -SHBG bound testosterone is the one that is bound loosely with albumin 
and is readily available to target tissues as is free testosterone. The most widely used 
technique to measure non-SHBG bound testosterone involves the precipitation of tracer 
amounts of 3H-testosterone bound to SHBG using ammonium sulphate. The bioavailable 
testosterone is calculated by subtracting the SHBG-bound from the total testosterone level. 
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1.5.3.4 Gonadotrophins 
The major regulator of testosterone production is LH, which is secreted in adult men in 
pulses in response to bursts of gonadotrophin-releasing hormone (GnRH) released from the 
hypothalamic neurones into the hypothalamic portal blood. Because of the robust pulsatile 
pattern of LH concentration in peripheral blood, a single blood sample may not provide an 
accurate estimate of mean concentrations. Pooled assay of 3 samples drawn at 20-minute 
intervals may give a better estimate of the mean. Although follicular-stimulating hormone 
(FSH) as well as LH secretion is stimulated by GnRH, serum FSH levels are more constant 
in peripheral blood, presumably because FSH responses to GnRH are delayed, of lower 
magnitude, and because the clearance of FSH from blood is slow compared to LH. 
If serum LH and FSH concentrations are increased, the diagnosis is primary testicular 
failure. They may have normal total testosterone although the bioavailable testosterone is 
usually low. The rise in LH levels reflects reduced testosterone negative feedback, whereas 
elevated FSH results from deficient secretion of inhibin as well as sex steroid. In some men 
LH and testosterone levels are normal, but FSH levels are elevated. This is believed to occur 
because seminiferous tubules are more sensitive to damage than are Leydig cells. A 
monotropic increase in serum LH is rarely seen. When testosterone deficiency is caused by 
impaired gonadotrophin secretion LH may be low or low normal. The overlap in serum LH 
levels between normal and hypogonadal men may be partly explained by the incomplete 
analysis of LH secretion that follows single blood sample, changes in LH bioactivity and by 
assay insensitivity at lower values. The diagnosis of gonadotrophin deficiency has been 
facilitated by the development of sensitive and specific two-site immunoassays. Even though 
LH levels measured by two-site immunoassays are generally low in hypogonadal men with 
hypothalamic or pituitary disease, the diagnosis of gonadotrophin deficiency should not be 
made by measuring the serum LH level alone, but a low serum testosterone level should also 
be documented. 
1.5.3.5 Oestrogen's 
Most of the oestrogen in the circulation in men are derived from the bioconversion of 
testosterone or androstenedione to oestradiol or estrone, respectively, by aromatase enzyme 
complex in fat, muscle, kidney and liver. Thus circulating oestradiol levels in men are 
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proportional to the production of these substrates and to the aromatase activity in tissues. 
Most of the oestradiol is loosely bound to albumin or unbound, and a small proportion is 
bound to SHBG. However, the affinity of SHBG for oestradiol is less than for testosterone, 
hence, changes in SHBG have lesser effect on total oestradiol compared to testosterone 
levels. Serum oestradiol levels are relatively constant throughout the day and unlike 
testosterone are maintained with ageing. Commercial kits for direct assay of oestradiol are 
available but are optimised for high values. At the low values characteristic of male plasma, 
these assays are imprecise and inaccurate and generally overestimate the true values. 
Determination in male plasma requires extraction with organic solvents before 
immunoassay. 
1.5.4 Sex steroid changes with age in men 
1.5.4.1 Testosterone 
Both cross-sectional (Vermeulen 1991) and longitudinal studies (Morley et at, 1997) 
involving large groups have clearly provided evidence that the ageing process in man is 
accompanied by changes in the hypothalamic-pituitary-gonadal axis which results in notable 
decline in serum levels of androgens. Serum testosterone levels decrease by 30% between 
age 25 and 75 years. A recent meta-analysis of 88 published studies showed a significant 
inverse relationship between age and total testosterone (Gray et at, 1991). However, reports 
of age related declines in free testosterone are few and show an estimated annual decline of 
1.2% in free testosterone and 1% in albumin bound testosterone with age. The steeper 
decline of free than total testosterone is explained by an age-associated increase in SHBG 
(Vermeulen et at, 1972). The only prospective population based study (Rancho-Bernado) 
involving 810 men over the age of 24-90 years showed a weaker association of total 
testosterone (r=-0.13) than bio-available testosterone (r=-0.52) with age (Greendale et at, 
1997). This dramatic decrease was independent of body size, health behaviour and chronic 
disease. In view of the expanding role of androgens in bone remodelling, these changes 
might be involved in the determination of fractures in older men. 
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1.5.4.2 Oestradiol 
Studies relating oestradiol and ageing in men are few and have produced mixed results. 
Some report no age association with oestradiol (Tenover et at, 1987) while others have 
reported reduced levels with age (Khosla et at, 1998). In the Rancho Bernado Study, mean 
total oestradiol declined but not significantly with age. In contrast, a strong negative 
association (r=-0.28) of bioavailable oestradiol with age was seen and was explained by 
decreasing levels of testosterone, the primary substrate for male oestradiol, coupled with a 
higher SHBG in older adults (Ferrini and Barrett-Connor, 1998). 
1.5.4.3 Dehydroepiandrosterone (DHEA) 
Dehydroepiandrosterone has drawn recent attention as a bio- marker of ageing. Shortly after 
birth DHEA production drops to unmeasurable levels within months. It remains low until 
the age of 5-6 years followed by a surge preceding puberty. It peaks at puberty then 
gradually declines throughout life at the rate of approximately 0.10-0.18 umol/l per decade 
reaching unmeasurable values after the age of 70 in many individuals. 
1.5.5 Mechanism of action 
1. S. S. 1 General 
Steroids enter the cell by diffusion. Inside the cell, testosterone is converted to more active 
metabolites by two enzymes: 5 alpha reductase and aromatase. 5 alpha reductase irreversibly 
converts testosterone to dihydrotestosterone (DHT) which is then converted to 5 alpha 
androstane -3 alpha, 17 beta-diol. Aromatase irreversibly converts testosterone into 
estrogenic molecules. Metabolism of testosterone to oestrogen compounds results in action 
via estrogenic receptors and conversion to DHT greatly increases binding affinity to 
androgen receptors. Testosterone and DHT bind to the same high affinity androgen receptor 
protein. This hormone receptor complex interacts with acceptor sites in the nuclei to effect a 
biological response. The result of the interaction within the chromosomes is increased 
transcription of specific target genes and subsequent appearance of new mRNA and protein 
in the cytoplasm. 
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1.5.5.2 On bone 
Published studies have confirmed the presence of androgen receptors in bone cells and the 
ability of these cells to respond to androgens (Colvard et al, 1989). Effect on maintaining 
bone mass are thought to be both direct through action on osteoblast and chondrocytes and 
indirect through maintaining muscle mass and therefore loading on bone. Normal human 
osteoblast-like cells have been shown to express functional androgen and oestrogen 
receptors (Colvard et al, 1989). This is consistent with the fact that men have both 
hormones in circulation. It is postulated that oestrogen is a possible intracellular receptor in 
men (Nawata et al, 1995). Androgens increase osteoblast transforming growth factor-beta 
(TGF-ß) production, elevate levels of insulin growth factor-II (IGF-II) receptors and 
increase sensitivity to fibroblast growth factor. They also increase osteoblast differentiation 
based on alkaline phosphatase and collagen production. In addition, there is evidence that 
androgens act on osteoblast to produce autocrine/paracrine factors such as growth 
hormone, IGF-I or decrease production of interleukines (IL-1 & IL-6). These would 
increase bone mass via stimulating bone formation or resorption or both. 
1.5.6 Role of testosterone in influencing bone density 
Animal studies have mostly been performed in orchidectomised male rats. There is 
reservation about the appropriateness of this model because rat skeleton, unlike humans, 
grows throughout life. Therapy with testosterone or 5 alpha DHT has shown to increase 
bone mass, though it remains lower than in control rats (Coxam et al, 1996). 
A number of studies in men have addressed the relationship between androgen status and 
bone density. Most studies carried out on healthy men living in community have shown a 
positive correlation between androgen levels and BMD. Rudman and co-workers (Rudman 
et al, 1994) compared the relationship between testosterone and BMD in healthy men living 
freely versus living in care. Testosterone was the most important predictor of BMD in free 
living men even after multivariate analysis including age. In contrast, amongst men living in 
care, although testosterone correlated to BMD at the femoral neck it failed to reach 
significance after age was entered into the equation. Similarly, a cross sectional study 
comparing young (age 20-40 years) versus older (age 60-90 years) healthy men reported a 
positive correlation between BMD (percent cortical area at II phalanx) and testosterone 
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(Foresta et al, 1984). Another cross sectional study of 90 healthy men over a wide age 
range (20-80 years) supported this observation by confirming a significant positive 
correlation between free testosterone and BMD at all sites (Ongphiphadhanakul et al, 
1995). The relationship persisted even after adjusting for age. In contrast, another cross 
sectional study on ambulatory elderly men including some with diseases (Drinka ei al 1993) 
failed to show an association between free testosterone and BNM. 
Studies addressing the effect of androgen deficiency in early life to attainment of peak bone 
mass have shown consistent results. Compared to normal, significantly lower spinal and 
radial BMD have been reported in men with history of delayed puberty (Finkelstein et al, 
1996). Prospective follow-up after 2 years confirmed permanent decreased peak BMD in 
these men despite evidence of normal bone turnover. Similar findings of low BMD in men 
with established hypogonadism have been confirmed by other researchers (Francis et al, 
1986; Arisaka et al, 1995). Significant increase in BMD following therapy with androgens in 
both hypogonadal (Francis et al, 1986) and eugonadal (Anderson et al, 1996) men also 
point towards the role of androgens as important determinants of bone health. Furthermore, 
clinical studies have shown that castration results in enhanced incidence of osteoporosis in 
men and treatment with androgens prevents its occurrence. Twelve men who underwent 
judicial castration for sexual delinquency showed significant decline in lumbar spine BMD 
with the most rapid loss occurring in the first five years after castration (Stepan et al, 1989). 
The role of hypogonadism in the causation of osteoporotic fractures in men is still unclear. 
Biochemical evidence of hypogonadism has been reported in about 20% of men with 
vertebral fractures (Baillie et al, 1992) and upto 50% of men with hip fractures (Stanley et 
al, 1991; Jackson et al, 1992). However, these studies are limited by small numbers, 
heterogeneity in timing of sample collection (Jackson et al, 1992), selection of control 
population (Stanley et al, 1991) and absence of BMD measurement (Stanley, et al, 1991; 
Jackson et al, 1992; Abbasi et al, 1995). Assessment of hypogonadism based on chart 
reviews with their inherent problems of accuracy and completeness furthermore cast doubt 
on the authenticity of the results (Stanley et al, 1991; Abbasi et al, 1995). The recent case- 
control study reporting hypogonadism in men with an osteoporotic hip fracture (Boonen et 
al, 1997) is limited in controlling for the effects of trauma due to proximity in sample 
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collection to fracture event and its cross sectional design. In addition, the authors restricted 
BMD measurements to the proximal femur. The only prospective population- based study 
addressing this issue in men failed to show a correlation between testosterone and BN D 
(Nyquist et al, 1998). The main limitations of this study was the very low number of 
fractures, especially hip fractures (n=10), in addition to use of SPA for BMD measurements 
at the forearm. 
This combination of clinical and experimental evidence has led to the current view that 
gonadal androgens are the principal bone-active steroid hormones in men and androgen 
deficiency is thought to play an important role in many cases of male osteoporosis. Although 
decreased androgen levels have been linked to lower bone density in men, there is no 
definite proof that there is a link between lower androgen levels and the increased incidence 
of hip fractures. 
1.5.7 Role of oestradiol in influencing bone density 
Oestrogen deficiency is an important pathogenic factor in female osteoporosis. It is also 
known that androgens have a strong anabolic effect on bone (Orwoll 1996), on human 
osteoblastic cells in vitro (Kasperk et al, 1997), as well as in hypogonadal (Greenspan et al, 
1986) and eugonadal men in vivo (Anderson et al, 1997). This effect has been suggested to 
be partly due to aromatisation of androgens into oestrogens. Androgen receptors and 5 
alpha reductase are found in osteoblasts at densities consistent with other androgen - 
sensitive tissues, with similar binding affinities (Orwoll et al, 1991; Benz et al, 1991; 
Vanderschueren and Bouillon, 1995). Oestrogen receptors are equally abundant in cultures 
of these cell lines (Colvard et al, 1989; Benz et al, 1991) and osteoblasts respond 
metabolically to oestrogen in vitro (Purohit et al, 1992) and in fresh biopsy samples of male 
bone (Barfis et al, 1996). Aromatase activity is present in cultured osteoblast cell lines 
(Purohit et al, 1992) demonstrating that these cells have the capacity to convert testosterone 
to oestradiol. In orchidectomised rats oestradiol prevents bone loss more effectively than 
progestogen or 5 alpha-DHT, although the combination is more effective than any single 
agent (Coxam et al, 1996). 
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In humans, skeletal oestrogen dependency is supported by a number of small studies and key 
case reports. A number of studies on groups of healthy men have shown that bone densities 
at the lumbar spine, femoral neck, trochanter and radius are positively correlated to serum 
oestradiol concentrations. A significant positive correlation between estrone and percentage 
cortical area measured at the second phalanx was demonstrated in a cross sectional study of 
healthy young and older men (Foresta et al, 1984). On similar lines, another cross sectional 
study involving 37 healthy men found that BMD at both lumbar spine and hip correlated 
more closely with oestradiol levels (r=0.38) than with testosterone (r=0.24) (Anderson et al, 
1998). A prospective study of 93 healthy men aged over 65 years revealed serum oestradiol 
levels to be closely related to initial BMD values at all sites and predictive of significantly 
lower rates of bone loss at hip and radius over a2 year period (Slemenda et al, 1997). 
Further, in two recent studies (Greendale et al, 1997; Khosla et al, 1998) it has been shown 
that oestrogen/SHBG ratio is an independent predictor of BMD in healthy men. 
There is dearth of literature on the role of oestradiol in men with osteoporotic fracture. 
Using a case-control study design, lower oestradiol levels were found in men with a 
vertebral fracture compared to controls (Francis et al, 1989). The small size of the study 
implied that differences observed did not attain statistical significance. A similar case-control 
study showed men with idiopathic osteoporosis (n=12) to have significantly lower serum 
levels of oestradiol and oestradiol/ SHBG ratio compared to aged matched controls 
(Gillberg et al, 1999). The authors also showed femoral neck BMD to bear a significant and 
positive correlation with ratio oestradiol/ SHBG (r=0.67). In a therapeutic trial of 
testosterone supplementation in men with osteoporotic vertebral fracture, pharmacological 
doses of testosterone were associated with rises in oestradiol levels. The increase in lumbar 
spine BNM noted correlated more closely with changes in oestradiol levels than serum 
testosterone (Anderson et al, 1997). The only published study evaluating oestradiol in men 
with hip fracture did not show any differences in oestradiol levels between fracture cases 
and healthy controls (Boonen et al, 1997). 
In case reports describing genetic mutations, men with defective aromatase activity 
(Morishima et al, 1995; Carani et al, 1997) and non functional oestrogen receptors (Smith 
et al, 1994) showed markedly reduced BMD despite normal or raised testosterone levels 
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and normal androgen receptors. Perhaps the most convincing evidence is the case of a 28 
year old man with an inactivating mutation of his aromatase gene who presented with 
infertility, eunuchoid habitus, non closure of epiphyses, below average BMD and bone age 
of 15 years. Treatment with testosterone replacement produced no benefit but treatment 
with oestradiol resulted in skeletal maturation, rapid increase in lumbar spine BMD and 
epiphyseal closure (Carani et al, 1997). 
1.5.8 Role of DHEA in influencing bone density 
Recently there has been considerable interest in the role of DHEA and its sulphate in the 
prevention of age related diseases such as osteoporosis. Human osteoblasts have been 
shown to convert DHEA into estrone (Nawata et al, 1995), which is a precursor for both 
testosterone and oestradiol. DHEA itself is known to act directly on androgen receptors of 
osteoblasts to stimulate proliferation and differentiation (Kasperk et al, 1997). The role of 
DHEA in the maintenance of male bone mass has received limited investigation. The Rancho 
Bernado Study involving 534 men (and women) failed to establish a correlation between 
DHEA and BMD at any site in men (Greendale et al, 1997). Two previous studies similarly 
failed to show an association (Murphy et al, 1993; Barrett-Connor et al, 1993). 
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1.6 VITAMIN D, PARATHYROID HORMONE AND CALCIUM AS RISK 
FACTORS FOR HIP FRACTURE 
1.6.1 Background 
Many factors contribute to the bone loss that characterises the syndrome of osteoporosis. 
This section focuses on the evidence in literature supporting the potential involvement of the 
two major calcium-regulating hormones, parathyroid hormone (PTH) and vitamin D, in the 
development of osteoporosis. 
Among the many functions that parathyroid hormone and Vitamin D perform, the most 
important is maintenance of normal bone remodelling. Osteoporosis is an intrinsic outcome 
of the ageing process. Also, intrinsic to the ageing process is the synthesis, metabolism, and 
responsiveness of vitamin D and parathyroid hormone. It is possible that age related changes 
in vitamin D and parathyroid hormones are causally related to the age-associated changes in 
bone mass. The following section discusses the various mechanisms that may be responsible 
for derangement of the normal calciotropic hormonal environment with age. 
1.6.2 Overview of calciotropic hormones in the pathogenesis of osteoporosis 
Subclinical deficiency of vitamin D has long been recognised to be a factor in the 
development of osteoporosis. Most studies report a fall in circulating concentrations of the 
active form of vitamin D (1-25 dihydroxyvitamin D) with advancing age. Osteoporotic 
individuals have circulating 1-25 dihydroxyvitamin D levels that are even lower. Possible 
abnormalities include vitamin D deficiency, abnormal production of 25-OH D or 1-25 
dihydroxy-vitamin D, altered sensitivity / number of intestinal vitamin D receptor or 
acquired resistance to vitamin D. 
Inadequate supply of vitamin D from its two major sources, diet and sunlight, can lead to 
the disorder. Vitamin D is derived from dietary sources and via supplementation in milk in 
some countries. In addition to low dietary intake it is known that absorption of vitamin D 
from the gastrointestinal tract is reduced upto 40% with advancing age. Whether there is a 
gender difference in dietary vitamin D absorption rate is not known. Also, whether the 
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absorption rates vary between subjects who develop osteoporosis and their age/ sex 
matched controls is not known. 
The other source of vitamin D is the skin, where Ultraviolet B energy of 290-315 nm 
converts 7-dehydrocholesterol to previtamin D. 7-dehydrocholesterol levels in the skin fall 
approximately 50% between 20-80 years of age. It is not known whether the reduced 
quantity of skin substrate is exaggerated in those who develop the disease. Studies have 
shown a seasonal variation in levels of 25 OH D. In winter months at northern latitudes, 
decreased exposure of skin to UV light of correct wavelength can lead to vitamin D 
insufficiency. Recent studies have shown that no synthesis of pre-vitamin D occurs in the 
skin during late fall and winter months at northern latitudes resulting in subclinical vitamin D 
deficiency. In parallel, bone density has been observed to decline during these months, rising 
again in summer. The rise in bone density has been seen to be associated with a resolution of 
the accompanying secondary hyperparathyroidism. 
Subclinical vitamin D deficiency has been seen in sub-population of osteoporotic patients. 
These subjects do not exhibit symptoms of vitamin D deficiency. On investigation, they are 
found to have low mean bone mineral density, low serum calcium and phosphorus, higher 
parathyroid hormone and urinary calcium excretion than vitamin D replete subjects. 
Secondary hyperparathyroidism induced by vitamin D deficiency is seen as the major factor 
leading to low bone density. Studies attempting to implicate subclinical vitamin D deficiency 
in the development of osteoporosis have assayed levels of 25-OH D levels. These are 
believed to be an accurate representation of the storage form of the vitamin and hence useful 
in clinical practice. 
There is no evidence in literature that the liver looses its capacity to convert vitamin D to 
25- hydroxyvitamin D with ageing and in osteoporosis. On the contrary, a decline in the 
ability of the kidney to form 1-25 dihydroxyvitamin D occurs with age. The age-related 
decline in renal 1 alpha-hydroxylase activity has been proposed as a mechanism of age- 
related osteoporosis. The decline in renal hydroxylation capacity associated with advancing 
age could be due to the ageing process per se or to the decline in renal function seen in the 
elderly. Halloran and his colleagues studied 70 men with normal renal function and 
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demonstrated normal ability of the kidney to convert 25-OH D to 1-25 dihydroxyvitamin D. 
They concluded that the impaired responsiveness is due exclusively to a decline in renal 
function with age (Halloran et al, 1990). Studies comparing 1-alpha-hydroxylation capacity 
between normal and osteoporotic subjects have not been able to show any difference. 
Another possible role of vitamin D in the pathogenesis of osteoporosis may be reduced 
sensitivity to 1-25 dihydroxyvitamin D in the small intestine. Intestinal resistance to 1-25 
dihydroxyvitamin D is proposed as a primary alteration. Alterations in binding of 1-25 
dihydroxyvitamin D to its receptors in the small intestine and/or reduction in intestinal 
sensitivity to 1-25 dihydroxyvitamin D due to age related reduction in vitamin D receptor 
concentrations are proposed mechanisms resulting in osteoporosis. 
Genetic polymorphism of the vitamin D receptor has been proposed as a determining factor 
for the development of osteoporosis. Although initial studies were very favourable, later 
research has not been conclusive. Whether these allelic variants are markers for other more 
relevant genetic factors is yet unknown. 
The importance of the various mechanisms by which alterations in vitamin D system can 
lead to osteoporosis is yet unclear. Any or all the above mentioned mechanism may play a 
part contributing to bone loss with ageing. Impaired calcium absorption from the 
gastrointestinal tract due to abnormalities at any point in the synthesis, metabolism and 
responsiveness to vitamin D, underlie the potential role of vitamin D in the development of 
osteoporosis. These result in calcium deficiency resulting in an imbalance between bone 
formation and resorption manifesting as osteoporosis. 
The current consensus redefining vit D deficiency in relation to its bone effects is as follows: 
Amount (ng/ml) (nmol/1) Vitamin D status 
0-5 0-12 Severe deficiency 
6-10 13-25 Mild deficiency 
11-20 26-50 Sub-optimal supply (insufficiency) 
21-100 51-250 Optimal supply 
101-150 251-375 Highest levels obtained after long-time UV light exposure 
>150 >375 Intoxication 
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1.6.3 Vitamin D in normal elderly men 
Vitamin D status was assessed in an adult urban French population of 1569 subjects 
including 765 men aged 45-65 years (Chapuy et al, 1992). Vitamin D insufficiency (<12 
ng/ml) was found in 14% of this healthy population. 74% of the men had serum 25-OH D 
levels lower than 31 ng/ml, the threshold at which secondary hyperparathyroidism sets in. 
This study concluded a very high prevalence of vitamin D insufficiency in the general adult 
population of France. The researchers did not find an age or sex effect on 25-OH D values 
between 35-65 years. Vitamin D levels related to latitude of residence and hours of 
sunshine. Similar results were reported in another study among Swiss adults (Burnand et al, 
1992). The authors found that 34-95% had a relatively low concentration of vitamin D (i. e. 
< 38 ng/ml or < 95 nmol/1) and 6% of the population was vitamin D deficient (< 20 nmoUl). 
Contrary to continental Europe, in North American men a very low prevalence (0.43%) of 
low 25-OH D (<12 ng/ml) was reported (Gallagher et al, 1998). This difference could be 
explained on the basis of better sunlight exposure and supplementation of dairy produce in 
the US. 
These studies conclude that vitamin D insufficiency with resultant sub-optimal calcium 
absorption and secondary mild hyperparathyroidism is very common in elderly people 
(including men) particularly in Europe where dairy products are not fortified with vitamin D. 
1.6.4 Effect of age and sex on Vitamin D status 
Most (Agnusdei et al, 1998; Diamond et al, 1998; Rudman et al, 1989) but not all 
(Gallagher et al, 1998) studies addressing this issue have shown a decline in serum levels of 
vitamin D with age in men. 
Using a cross sectional design age related changes in serum 1-25 dihydroxyvitamin D, PTH 
levels, intestinal calcium absorption and bone mass were studied in 70 normal men aged 17- 
91 years (Agnusdei et al, 1998). The study demonstrated that in normal males, after age 
40years, both intestinal calcium absorption and levels of 1-25 dihydroxyvitamin D exhibit an 
age-related linear and progressive decrease. In parallel, an age-related increase in PTH 
(confirming hyperparathyroidism developing with ageing) was also noted. Similar decline of 
25-OH D levels with age in men have been shown by other workers (Rudman et al, 1989). 
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Similar negative correlation's between age and serum 25-OH D levels (r =-0.29) have been 
seen using a case-control study design (Diamond et al, 1998) 
In contrast, in a cohort of 273 men and 814 women, aged 65-87 years, in different 
geographic sites in North America no relation of 25-OH D and serum PTH with age in men 
(r = 0.003) or women (r =-0.03) was observed (Gallagher et al, 1998). The covariates 
predictive of 25-OH D were gender, season, calcium intake and weight. Similarly for PTH 
the covariates were 25-OH D, age, calcium intake and weight. Overall comparison by 
gender showed mean serum 25-OH D was significantly higher in men compared to women 
with a significant decrease in mean serum PTH in men compared to women. Serum PTH in 
men was inversely correlated with serum 25-OH D (r =-0.25) and calcium intake (r =- 
0.15). 
1.6.5 Relationship between Vitamin D and BMD in men 
Results of published literature so far are inconsistent and raise the need of large prospective 
studies exclusively addressing this problem in men. In a cross sectional study of 70 normal 
males, a decrease in vertebral and forearm BMD with advancing age after the age of 50 
years, was reported (Agnusdei et al, 1998). The study also showed age-related linear 
reduction in vitamin D levels and intestinal calcium absorption. The study concluded that 
bone loss accelerates in men after 50 years of age and among other factors vitamin D levels 
play a role. On similar lines, Gallagher et al in the study mentioned earlier, showed that in 
men spinal BMD was positively correlated with serum 25-OH D (r=0.20), but not with 
serum PTH (Gallagher et al, 1998). In contrast, BMD at the femoral neck was not 
correlated with serum PTH or 25-OH D. Sherman and colleagues studied a highly motivated 
healthy cohort of 192 men and 120 women and evaluated the relationship between 25-OH 
D, 1-25 dihydroxyvitamin D, PTH and BMD in the radius, spine and femur. There was no 
significant associations between BMD at any site and serum concentrations of any 
parameters except in older men where lower radial BMD was significantly correlated with 
higher PTH and lower 25-OH D (Sherman et al, 1992). Factors that determine BMD at 
axial and appendicular sites were studied in 48 healthy men aged 21-79 years (Kelly et at, 
1990). Dietary calcium intake was a significant independent predictor of BMD of axial 
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bones, explaining 24-42% of the variance at the lumbar spine and femoral neck respectively. 
Vitamin D levels were not measured. 
Results from supplementation studies are more consistent and give some evidence of a 
positive correlation between vitamin D- calcium and BMD. The effects of 3 years of diet 
supplementation with calcium and vitamin D on bone mineral density, biochemical measures 
of bone metabolism and incidence of non vertebral fractures was studied in 176 men and 213 
women, 65 years of age and older, living at home (Dawson- Hughes et al, 1997). The study 
subjects received 500-mg calcium (calcium citrate malate) plus 700 IU of vitamin D3 per day 
or placebo. BMD was measured by DXA; blood and urine analysed every 6 months and 
non-vertebral fractures recorded. Differences in BMD were found between the calcium- 
vitamin D and placebo groups at all sites after one year, but were only significant for total 
body BMD in second and third years. Serum osteocalcin concentrations were 9% lower in 
men and 14% lower in women than at baseline, indicating that supplementation led to a 
sustained reduction in the rate of bone remodelling. In addition there were significantly 
reduced number of fractures in the calcium-vitamin D group. The study concluded that 
dietary supplementation of calcium-vitamin D moderately reduced bone loss over a 3-year 
period and reduced the number of non-vertebral fractures among community dwelling 
elderly. 
On the contrary, an earlier study using a similar regime in men did not reveal any benefits on 
BMD (Orwoll et al, 1990). It may be that subjects in this study were younger (aged 30-87 
years) and had a higher mean calcium intake than those in the study by Dawson Hughes and 
co-workers (1159 vs. about 700 mg per day). 
The magnitude of the reduction in number of fractures observed in the study by Dawson 
Hughes (Dawson- Hughes et al, 1997) is similar to that reported in a study of 3270 elderly 
French women treated with 1200 mg calcium plus 800 IU of vitamin D or placebo (Chapuy 
et al, 1992). In contrast, in a study of 2600 elderly Dutch men and women, given 400 IU 
vitamin D daily (without calcium) as compared to placebo, no reduction in incidence of 
fractures was noted (Lips et al, 1996). This may raise the question about the individual 
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effects of calcium and vitamin D on BMD and fracture prevention and the therapeutic dose 
required in relation to latitude of residence. 
1.6.6 Vitamin D as a risk factor for hip fracture in men 
A number of cross sectional studies have in the recent past determined the role of vitamin D 
deficiency as a risk factor for hip fracture in elderly men. Most have consistently shown low 
vitamin D status in men with hip fracture compared to controls. Two researchers (Diamond 
et al, 1998; Boonen et al, 1997) have exclusively addressed this issue in men using small 
numbers (n = 41 and 40 respectively). 
Vitamin D status was assessed in 41 Australian men consecutively presenting with a hip 
fracture and comparisons made with an equal number of two control groups: in-patient and 
out-patient (Diamond et al, 1998). Men with hip fracture had significantly lower 25-OH D 
levels than both control groups. Subclinical vitamin D deficiency (< 50 nmol/l) was present 
in 63% of fracture cases compared to 25% of the controls. In multiple regression analysis, 
subclinical vitamin D deficiency was the strongest predictor of hip fracture in their group of 
elderly men. Secondary hyperparathyroidism (>8.5) was seen in 17% of men with hip 
fractures compared with only 4.2% of controls. Their study concluded that subclinical 
vitamin D deficiency might contribute to the development of hip fracture through the effects 
of secondary hyperparathyroidism. 
Similar results were seen in a cross sectional study involving 40 Swedish men, mean age 73 
years, with a hip fracture (Boonen et al, 1997). Vitamin D levels were significantly lower in 
hip fracture cases compared to controls. Serum PTH was markedly increased in fracture 
cases. The study concluded that hypovitaminosis D may predispose to bone resorption in 
elderly men and increase risk of hip fracture. 
Another group compared serum 25-OH D and parathyroid hormone in hip fracture cases (n 
= 179; men = 43) versus matched controls (Thiebaud D et al, 1997). In their group of 43 
men with hip fracture, 25-OH D were significantly lower (-19%) than matched controls. 
49% men with hip fracture had 25-OH D<4.3 (lower limit of normal range). BMD was low 
in fracture cases, PTH correlated weakly with BMD (neck: r=-0.19). 
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Similar results of low vitamin D status in hip fracture patients have been reported by other 
workers that have included men in their study although in small numbers (Harju et al, 1985; 
Lau et al, 1989; Ng et al, 1994). 
There is only one randomised, placebo controlled clinical trial looking at effects on hip 
fractures and other peripheral fractures following vitamin D supplementation (400 IU/day) 
in a significant number of men (n=662) (Lips et al, 1996). Amongst 2578 Danish subjects 
(662 men) aged 70 years and above, over a period of 3.5 years, no difference in the 
incidence of hip or other peripheral fractures were noted between the two groups. It may be 
that the mean dietary calcium intake in the group was high. More studies of this nature are 
clearly needed. 
1.6.7 Parathyroid function in the elderly 
The cumulative response of a deficit in calcium intake (Chapuy et al 1987) and an age 
related decline in calcium absorption (Agnusdei et al, 1998), which is partially accounted for 
by 1-25 dihydroxyvitamin D deficiency (Recker, 1993), is a negative calcium balance 
stimulating PTH secretion (Hegarty et al, 1994). In addition, ageing is associated with a 
shift in basal calcium-regulated PTH secretion (Quesada et al 1992; Ledger et al 1994). The 
increase in PTH with age is not associated with an altered sensitivity of the parathyroid 
glands to extracellular calcium. Rather ageing is associated with higher basal and maximally 
stimulated PTH levels, similar to those described for patients with secondary 
hyperparathyroidism associated with renal insufficiency, and consistent with an increased 
number of parathyroid cells. In view of the fact that elderly women have normal 
responsiveness to 1-25 dihydroxyvitamin D suppression of PTH secretion (Quesada et al 
1992; Ledger et al 1994), these parathyroid abnormalities do not seem to be related to 
parathyroid gland resistance to 1-25 dihydroxyvitamin D. More likely, the impairment of 
calcium balance with ageing provides a chronic stimulus to the parathyroid glands. This 
would result in age-related increase in circulating PTH. 
Serum PTH has been reported to show a significant age related increase (Quesada et al 
1992; Ledger et al 1994) although mean values remain within the normal range. This age 
related increase in intact PTH is partially determined by progressive decline in 1-25 
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dihydroxyvitamin D status, suggesting that age is associated with mild secondary 
hyperparathyroidism necessary to maintain normal serum 1-25 dihydroxyvitamin D 
concentrations. In addition the ability of PTH to increase renal 1-alpha-hydroxylase activity 
diminishes with age and may contribute to the age associated increase in PTH. Depending 
on the 25-OH D status and renal function, final 1-25 dihydroxyvitamin D will or will not be 
normal. Consistent with this some studies have not reported lower serum 1-25 
dihydroxyvitamin D levels in elderly whereas others have. 
1.6.8 Calcium 
The concentration of calcium in plasma is maintained within a very narrow range, despite 
the large movements of calcium across gut, bone, kidney and other tissues. The major 
hormones involved in calcium homeostasis are 1-25 dihydroxyvitamin D and parathyroid 
hormone. These hormones regulate the ionised fraction of plasma calcium by modulating 
calcium fluxes to and from the extracellular fluid. The principle effects of 1-25 
dihydroxyvitamin D on calcium metabolism are to increase intestinal absorption of calcium 
and phosphate. Because of the age-related decrease in calcium absorption and in renal 
calcium conservation, elderly people have an increased requirement of dietary calcium. On 
the contrary, evidence from studies, suggests that the proportion of elderly people ingesting 
less than two-thirds of the recommended daily allowance (RDA) of calcium is in the range 
of 19-40% for males and from 35-43% for elderly females. Thus, current calcium intake is 
inadequate in a large number of the older population- the groups at most risk of 
osteoporosis. When the amount of calcium absorbed from the diet is insufficient, calcium 
must be withdrawn from the bone, which contains 99% of total body stores of calcium. 
However, most elderly subjects fail to increase their calcium intake to offset this age related 
increase in calcium requirement. 
The evidence relating dietary calcium to osteoporosis is conflicting (Cumming et al, 1990). 
Most research has focused on the relationship of calcium intake to bone density rather than 
fracture. Only a weak relationship has been observed between self reported calcium intake 
and bone mass or bone loss in cross sectional studies (Cummings et al, 1990; Nordin and 
Heaney, 1990). In epidemiological studies including 48 healthy men aged 21-79 years, 
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dietary calcium intake was a significant independent predictor of BMD of axial bones (Kelly 
et al, 1990). Diet calcium explained 24-42% of the variance at the lumbar spine and femoral 
neck BMD, respectively. In contrast, BMD at the forearm was not predicted by diet 
calcium. A more consistent relationship has emerged from calcium supplementation trials, 
which generally have shown a small, but positive effect of calcium on bone (Dawson Hughes 
et al, 1997). 
Fewer studies have examined the relationship between dietary calcium and hip fracture risk 
and these have also produced conflicting results. Most of the studies have been case-control 
designs. In a case control study including 300 elderly men and women with hip fracture and 
600 matched controls, a decrease in hip fracture risk in men with a calcium intake above 1g 
was observed (Cooper et al, 1988). The 5 prospective trials looking at the role of calcium in 
hip fracture risk have not ended the confusion. A subsequent cohort study by the same 
group with, 15 year follow up of 1688 British elderly people including 720 men aged 65 and 
over, to determine whether dietary calcium intake was a risk factor for hip fracture, did not 
reveal any relationship between the two in either sex (Wickham et al, 1989). Some 
prospective studies (Holbrook et al, 1988; Looker et al, 1993) found a protective effect of 
calcium on hip fracture, while others (Wickham et al, 1989; Paganini-Hill et al, 1991; Meyer 
et al, 1997; Owusu et al, 1997) found no effect between calcium and hip fracture in men. A 
calcium intake of more than 765 mg per day was associated with a 60% lower rate of hip 
fracture in men (and women) compared to those with an intake below 470 mg (Holbrook et 
al, 1988). In contrast, low dietary calcium intake was not a risk factor for hip fracture in 
another study (Wickham et al, 1989). Differences may have stemmed from the way the 
dietary calcium intake was collected, i. e. the abbreviated food frequency questionnaire using 
six foods to assess calcium intake (Paganini-Hill et al, 1991), single 24 hour recall 
(Holbrook et al, 1988; Looker et al, 1993; Meyer et al, 1997) and the 7 day food record 
(Wickham et al, 1989). Some of the studies were not powered (Holbrook et al, 1988; 
Wickham et al, 1989) with small number of fractures (n=33 and 44 respectively). The other 
two studies (Paganini-Hill et al, 1991; Meyers et at, 1997) were better powered with 418 
and 213 hip fracture cases respectively. However, they failed to show any protective effect 
of calcium on hip fracture. This could be accounted for by the very low calcium intake from 
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food in their samples: median and upper tertile were 371 and > 501 mg/day respectively. 
Large variation in the quantity of calcium intake from food in the various studies may also 
explain discordance between study results. The most recent study exclusively addressing this 
issue in men is the Health Professionals Follow-up Study (Owusu et al, 1997). Among 
43,063 men aged 40-75 years followed for 8 years, 56 hip fractures were recorded. After 
controlling for age, smoking, BMI, physical activity, alcohol consumption and total energy 
intake the relative risk for hip fracture for men in the highest quintile of calcium intake 
compared to the lowest quintile was 1.19; similarly relative risk for consuming >600 ml milk 
per day compared with 240 ml or less per week was 0.97. This large study of healthy men 




Osteoporosis is a disease characterised by a low bone mass and by microarchitectural 
deterioration of bone tissue related to abnormalities of bone turnover. Bone turnover is 
characterised by two opposite activities; the formation of new bone by osteoblasts and the 
resorption of old bone by osteoclasts. Both the activities are tightly coupled in a sequence of 
events. Bone mass depends on a balance between the two within a remodelling unit and on 
the number of remodelling units that are activated within a given period of time in a defined 
area of bone. Osteoporosis is characterised by both an imbalance between the two processes 
within a remodelling unit, and by an increased activation frequency, the latter being 
responsible for increased bone turnover after menopause. 
Invasive procedures for measuring bone turnover have provided useful information but have 
limitations. They are less accurate for assessing bone resorption although they provide 
unique information on the rate of formation at both the cell and the tissue levels and allow 
estimation of activation frequency of remodelling units. Calcium kinetic studies and the use 
of labelled bisphosphonates have not proven to be sensitive. These limitations, in addition to 
the need for non-invasive techniques that can be applied more widely and repeated several 
times in an individual, explain the development of markers of bone turnover to be measured 
in blood and urine. 
Osteoporosis is a condition where subtle modifications of the bone-remodelling unit can lead 
to a substantial loss of bone turnover over time. This explains why results with most 
conventional markers are normal despite established osteoporosis in the individual. This 
explains the continued efforts to develop more sensitive biochemical markers of bone 
turnover. 
The rate of bone formation and resorption can be studied either by measuring an enzymatic 
activity of the bone forming or resorbing cells or by measuring the bone matrix components 
released into the circulation during formation and resorption. Although grouped into 
markers of bone formation and those of resorption, in disease states where both events are 
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coupled and occur in the same direction, any markers will reflect the overall rate of bone 
turnover. They cannot discriminate between turnover at cortical versus cancellous bone sites 
but reflect whole body net changes 
The markers are of unequal specificity and sensitivity, which implies that estimating the net 
excess of one over the other, will result in wrong conclusions. These markers are also 
influenced by factors other than bone turnover, such as their metabolic clearance. Hence, 
validation of each marker in specific disease states is important before concluding its clinical 
utility. 
1.7.2 Biochemical markers of bone formation 
Bone formation markers include total (TALP) and bone specific alkaline phosphatase 
(BALP), osteocalcin (OC) and carboxyterminal (PICP) and aminoterminal propeptide 
(PINP) of type I procollagen. 
Alkaline phosphatase: Bone specific alkaline phosphatase appears to be more sensitive than 
TALP for clinical purposes. A significant increase in BALP after menopause is noted, 
significantly higher than TALP and decrease following treatment with bisphosphonate is 
larger for BALP than for TALP (Adachi et al, 1996) 
Osteocalcin: Osteocalcin is a vitamin D dependent protein that has been estimated to 
represent upto 20% of all non-collagenous protein in bone. It is only found in bone tissue 
and dentin. A proportion of newly synthesised OC is released into circulation, where it can 
be measured by immunoassay. Thus, the serum level of osteocalcin is a very specific marker 
for the rate of bone formation. When resorption and formation are coupled, serum 
osteocalcin levels reflect bone turnover. 
Procollagen type I extension peptides: More than 90% of the organic matrix of bone 
consists of type I collagen with the non-collagenous proteins comprising the remaining 10%. 
Type I collagen is synthesized as procollagen precursor molecules. Before inserting into the 
extracellular matrix, the terminal propeptide extensions are proteolytically removed. Thus 
both the PICP and PINP propeptide of typel procollagen are released into circulation. There 
is evidence that both PICP and PIMP assays are measures of bone formation. 
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1.7.3 Biochemical markers of bone resorption 
Fasting hydroxyproline and urine calcium corrected for creatinine are measures of bone 
resorption that have been employed for many years. Newer resorption markers include 
tartrate-resistant acid phosphatase, galactosyl hydroxylysine, urinary pyridinoline (Pyr), 
deoxypyridinoline (Dpyr), N telopeptide of type I collagen (NTx) and carboxyterminal 
telopeptide of type I collagen (ICTP) and urinary cross-laps. 
Plasma tartrate-resistant acid phosphatase: Osteoclast contain a tartrate -resistant acid 
phosphatase that is released into circulation. The lack of specificity of plasma tartrate- 
resistant acid phosphatase, its instability in frozen samples, and the presence of enzyme 
inhibitors in serum limits its clinical usefulness. 
Galactosyl hydroxylysine: Hydroxylysine is an amino acid that is involved in collagen 
metabolism. Galactosyl hydroxylysine is five or six-fold more concentrated in typel bone 
collagen than in skin collagen. At present, it is not suitable for routine measurements 
because it is a technically complex and demanding assay. 
Pyridinoline and Deoxypyridinoline: Pyr and Dpyr are two nonreducible trivalent cross- 
links that stabilise the typel collagen chains and are released during the degradation of 
mature collagen fibrils. Pyr is abundant in bone and cartilage, whereas Dpyr is largely, 
although not entirely, confined to bone. It is possible to measure only free fractions of Pyr. 
During bone resorption, only about 40% of the crosslinks are released in free form. The 
remaining 60% remain peptide bound. 
N and C carboxyterminal telopeptides of typel collagen: It has been established that typel 
collagen has two cross-link-forming sites: one in the amino terminal peptide region and one 
in the carboxyterminal region of the molecules. Two immunoassays to detect NTx and ICTP 
have been described. 
Crosslaps: Urinary excretion of cross-laps is determined by an immunoassay that recognises 
a small aminoacid sequence of ICTP. It correlates closely with total excretion of Pyr 
measured by high-pressure liquid chromatography (HPLC). The cross laps assay do not 
cross react with either free Pyr or free Dpyr. 
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Urinary hydroxyproline: Hydroxyproline results from the degradation of various forms of 
collagen. Because only half the collagen in the human body is found in the bone, urinary 
hydroxyproline is in part dependent on other sources and diet. After active liver metabolism, 
free and peptide bound urinary hydroxyproline represents only a fraction of total collagen 
catabolism and correlate poorly with histomorphometry. 
1.7.4 Bone markers in men 
There have been important developments in the field of bone markers in women in the last 
few years looking at their usefulness in daily clinical practice. Researchers have addressed 
effects of treatment (hormones, bisphosphonates) on bone markers (Prestwood et al, 1994), 
whether determination of biochemical markers of bone turnover is useful to monitor skeletal 
effects of hormone replacement therapy (Riis et al, 1995), whether they would be useful to 
predict future bone mass (Hansen et al, 1991) and changes in bone markers in patients with 
vertebral osteoporosis (Delmas et al, 1993) and following hip fracture (Akesson et al, 1993, 
1995). In summary, studies have demonstrated excellent correlation between predicted and 
measured bone mass measurements for groups of patients: however their predictive value in 
individuals is not as good. Most studies conclude that biochemical markers of bone turnover 
are beneficial as early indicators of response to therapy. Establishing a relationship between 
bone markers and fracture prediction is still in its infancy. 
Whereas in women several potentially important factors have been identified, the pathology 
of age-related bone loss in men is not known. It still remains unclear if similar age related 
changes in bone metabolism as in women occur in males. The usefulness of bone markers in 
men is less well studied. 
1.7.5 Effect of age and sex 
Almost all studies have shown a good correlation between the markers (r=0.35 to 0.77) 
(Gallagher et al, 1998; Kenny et al, 1998). Only one study has examined differences in bone 
markers between the genders (Gallagher et al, 1998). The study demonstrated that both 
mean osteocalcin and mean 24 hour urine N telopeptide were significantly lower (13 & 30% 
respectively) in men compared to women. However, the effect of age on bone resorption 
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and bone formation in men is still controversial. Some studies report a decrease in bone 
formation (Wishart et al, 1995; Clarke et al, 1996) and bone resorption (Wishart et al, 
1995), some an increase in bone formation (Orwoll et al, 1990) and bone resorption (Clarke 
et at, 1996) while others no relationship of bone turnover with age (Resch et al, 1994). 
Discrepancies between results in literature can be explained in part by different 
radioimmunosystems or differences in the populations studied as shown below. 
The influence of sex and age on bone markers was studied in 155 healthy subjects including 
64 men (Resch et al, 1994). The study suggested different age-related alterations in bone 
metabolism in males and females. Contrary to evidence of increased bone turnover in 
females, bone markers remained unchanged in healthy males above or below the age of 
50years, indicating no relationship between bone turnover and age. Another study looked at 
bone turnover along with bone mineral density and sex hormones in a group of healthy 
community living men (n=35) but aged over 75 years (Kenny et al, 1998). 
Deoxypyridinoline levels were above the normal range for premenopausal women in 23% 
men. This was in line with the observations in a subset of 11 men over the age of 70 by 
Wishart and colleagues (1995). Both N telopeptide and C telopeptide were within the 
normal range while mean bone specific alkaline phosphatase was below the normal range for 
men. Similar age - related changes in osteocalcin and urine N telopeptide have been studied 
in 735 normal elderly Caucasians that included 235 men (Gallagher et al, 1998). Significant 
correlation's between age and serum osteocalcin (r=0.15) and 24 hour urine N telopeptide 
(r=0.23) were reported in their subset of men. An earlier study, in contrast, on a population 
highly selected for their health, failed to demonstrate any associations between age and bone 
markers (Sherman et al, 1992). A more recent study determined the effects of ageing on 
bone turnover in 178 healthy Caucasian men over a wider age range (20-79 years). The 
study showed that bone turnover is highest in the third decade, lowest in the fifth and sixth 
decade, with a small increase in some markers in the eighth decade (Fatayerji and Eastell, 
1999). 
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1.7.6 Relationship between bone turnover and BMD 
A variety of biochemical indicators have been related to bone loss in healthy men, including 
increases in urinary calcium, osteocalcin, serum parathyroid hormone and vitamin D levels 
(Sherman et al, 1992). In men with osteoporosis, urinary calcium and hydroxyproline 
excretion and serum alkaline phosphatase levels are increased, indicating increased bone 
turnover (Resch et al, 1992). Serum osteocalcin levels are also increased and vitamin D 
levels reduced, indicating increased bone formation (Demiaux et al, 1992). 
A cross sectional analysis addressing the associations between bone turnover markers 
(osteocalcin and N telopeptide cross links), bone density and age was carried out in a group 
of 1087 healthy adults including 273 men aged 65-87 years (Krall et al, 1997). Serum 
osteocalcin and urinary NTx levels were each inversely related to BMD in men; however, 
the associations with spine BMD tended to be consistently weaker than with other skeletal 
sites. Subsequently, another study addressed the same relationship but exclusively in men 
over age 75 years (Kenny et al, 1998). This study showed that bone resorption markers 
correlated inversely with BMD of the whole body, femur and spine. However, markers of 
bone formation did not significantly correlate with bone density with the exception of an 
inverse correlation between osteocalcin and femoral neck BMD. This supported an earlier 
study showing a significant relationship between lower femoral neck BNM and higher serum 
osteocalcin levels in men (Sherman et al, 1992). This study also showed an inverse 
relationship between urine calcium/ creatinine and femoral neck BMD. Others (Kelly et al, 
1990; Wishart et al, 1995) have not shown an association between bone markers, BMD and 
age. The only consistent finding in various studies seems to be the inverse relationship 
between serum osteocalcin and BMD. The strength of the inverse relationship between the 
two is similar (Krall et al, 1997; Sherman et al, 1992). It has therefore been suggested that 
serum osteocalcin may be an indicator of bone status at most skeletal sites (Krall et al, 
1997). An explanation for the associations between markers and BMD to be weaker at the 
spine than other skeletal sites supports the assumption that non-bone, calcified soft tissue is 
detected in spine scans resulting in erroneous results. 
Krall et al further analysed the relationship between bone markers and BMD at all sites 
They showed the differences in mean femoral neck BMD between men with osteocalcin 
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values in the lowest quartile and those in the highest quartile was 8%. The corresponding 
differences between quartiles of NTx distribution were 7%. When examined by joint 
contributions of both markers (NTx and OC), the differences in femoral BMD between low 
and high groups increased tol 1%. Differences in BMD at the other regions of the hip, whole 
body and spine between extreme categories of both markers were also within the range of 8- 
16% (Krall et al, 1997). In summary, in most studies bone resorption markers along with 
serum osteocalcin bear an inverse relationship to BMD most consistently at the femur. 
1.7.7 Correlation of bone markers to fracture risk 
There is growing evidence that subjects with high levels of bone turnover are at greater risk 
for developing osteoporotic fractures. This suggests that biochemical markers of bone 
metabolism could be of value in risk assessment and clinical management of osteoporosis. 
However, clinical usefulness may be limited if there is marked variation within individuals 
over time, preventing reliable classification into high or low bone turnover states. 
Bone resorption marker (NTx) was longitudinally evaluated over a 2-year period in a cohort 
of community dwelling elderly subjects aged over 60years (Bollen et al, 1997). This 
included 57 men. The study showed a relatively stable excretion of NTx over 2 years, good 
reproducibility and supported the use of markers in stratifying subjects according to level of 
bone resorption. This would help identify subjects with high turnover who may be at greater 
risk of fracture. However, there still remains the need to establish the actual level associated 
with increased risk of fracture. 
Retrospective studies comparing bone marker levels in patients who had sustained an 
osteoporotic fracture and in controls are inadequate to assess the relationship between bone 
turnover and fracture. Indeed, bone turnover can change after fracture because of 
immobilisation, because of the callus formation and / or because of a frequent regional 
activation of bone turnover. Relating bone marker levels measured before fracture to 
subsequent risk of fracture is the only valid methodology to assess their clinical utility. Due 
to the heterogeneity in the pathogenesis and, potentially, in underlying bone turnover 
abnormalities, the predictive value of bone markers should be analysed separately for all 
types of osteoporotic fractures. 
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Bone turnover has been studied after hip fracture in a large group of females. The study 
showed increased urinary cross-links excretion and decreased serum osteocalcin levels 
compared to age-matched healthy elderly controls (Akesson et al, 1993). The authors 
suggested this increased bone resorption and decreased bone formation might be important 
determinants of low bone mass that characterise patients with hip fracture. Despite the 
importance of hip fracture in men as a major health problem, there are no published studies 
exclusively addressing this issue in men. 
1.7.8 Bone markers to monitor therapy 
Unlike studies in women examining whether determination of biochemical markers of bone 
turnover may be useful in monitoring skeletal effects of hormone replacement therapy, there 
is little published literature available looking at the effects of bone markers following 
treatment with bisphosphonates or testosterone replacement therapy. An uncontrolled study 
of testosterone treatment in 21 eugonadal men with vertebral osteoporosis showed a 
significant increase in spine bone density of 5% in six months, although no change in hip 
bone density was seen (Anderson et al, 1997). Subsequent analysis of the markers of bone 
turnover showed a reduction in bone resorption with testosterone. 
Because of the small change in BMD (as compared to its long-term precision error) in 
patients treated with anti-resorptive drugs, monitoring treatment efficacy with only a bone 
mass measurement could at the earliest be performed 1 year-preferably 2 years- after 
therapy. Conversely, placebo controlled studies in women have shown a rapid decrease in 
levels of bone markers with treatment. This short-term decrease has been shown to correlate 
with long term increase in bone mass. Although bone markers cannot predict the absolute 
bone mass gain, measurement of markers before and after therapy is likely to provide similar 
but earlier evidence of drug effectiveness than bone mass measurement. The responsiveness 
of bone markers to treatment offers the possibility of early monitoring of drug efficacy in 
osteoporosis. 
There are a number of limitations with the use of bone markers and explain to some extent 
the limited number of studies in men. Circulating and urinary bone markers reflect the 
overall level of bone turnover of the entire skeleton and do not allow discrimination between 
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trabecular and cortical bone. Different markers perhaps reflect different events of bone 
metabolism, and using a panel of markers is likely to provide more information on the 
complex aspects of bone formation and resorption. Since the abnormalities leading to bone 
loss is quite subtle in osteoporosis conventional markers are insensitive to change. Some of 
the newer markers still need to be further characterised, especially in terms of clearance and 
metabolism. 
For clinical purposes, in patients with clearly low bone mass, the biochemical variables may 
not be that useful as risk predictors since it would generally be advised to treat these 
individuals regardless of their projected bone loss rates. In contrast, combinations of 
biochemical variables might be more useful in a group of patients with intermediate bone 
mass values in whom treatment decisions might be affected by knowledge that the rate of 
bone loss would be relatively high over the upcoming years. Furthermore, responsiveness of 
bone markers to therapy offers the possibility of early monitoring of the drug efficacy. The 
cost of a battery of markers, however, must be compared with the cost of serial bone 
densitometry. In clinical practice, combinations of biochemical indices can only partially, but 
not completely, replace serial bone density measurements. 
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1.8 Outcome: Mortality And Morbidity 
1.8.1 Background 
Fractures of the proximal femur (hip) represent the most serious complication of 
osteoporosis in terms of morbidity, mortality, disability and medical costs (Melton et al, 
1993). The consequences are often calculated on economic costs. However, the human 
costs of osteoporosis include diminution in functional status, health status, and 
independence. From the individuals' perspective, quality of life is threatened by these 
declines; from a societal point of view, loss of functional independence is a major 
determinant of the need for home assistance and for permanent institutionalisation. 
In 1990, about 30% of 1.66 million hip fractures world-wide occurred in men (Cooper et al, 
1992). Due to the exponential rise in the number of hip fractures with age, the projected 
increase in the year 2025 will be 3.94 million (1.16 million men and 6.26 million women) 
increasing further by the year 2050 to 6.26 million (1.79 M men and 4.47 M women). 
Despite their growing importance, there is little published data addressing mortality 
following hip fracture in men and factors that may influence the outcome. 
Contrary to the wealth of information on women with this problem there are only two 
studies assessing mortality and its determinants in men with hip fractures. Both studies 
(Poor et al, 1995; Diamond et al, 1997) are population based retrospective chart reviews 
from medical records and include 131 and 51 men respectively. The former (Poor et al, 
1995) used data collected from medical records of all men aged 35 years and over in 
Rochester Minnesota who presented with a hip fracture between 1978-89. The authors 
assessed mortality at 30 days, 1 year, 5 years and 10 years and analysed determinants of 
reduced survival. The latter (Diamond et al, 1997) was a retrospective audit from medical 
notes of all men aged 60 years and over who presented with a hip fracture between 1 
January and 31 December 1995 to St. George Hospital, Sydney. The authors assessed 
prognostic factors and outcome at 6 and 12 months post fracture. In addition, they 
compared the results to an equal number of women (n = 51) of similar age with the 
condition. 
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Most of the published work on mortality following hip fracture have either included very 
few men (Thorngren et al, 1993; Stavrou et al, 1997) or despite substantial numbers of men 
with hip fracture (> 100 men) have failed to analyse mortality and risk factors for poor 
survival by gender (Beals et al, 1972; Colbort and 0' Muircheartaigh 1976; Jensen et al, 
1979; Jensen et al, 1984; Magaziner et al, 1989; Parker et al, 1991; Nettleman et al, 1996; 
Wolinsky et al, 1997). The only studies with substantial numbers of men with hip fracture 
that have analysed mortality rates separately by sex (Myers et al, 1991; Sernbo et al, 1993; 
Aharonoff et al, 1997; Forsen et al, 1999) have again failed to analyse potential risk factors 
by gender. A common limitation of most studies is that they do not differentiate the 
mortality experience of individuals residing in nursing homes or other long -term care 
institutions at the time of fracture from that of community dwelling patients. Some restrict 
studies to select population groups who are ambulatory, home dwelling and cognitively 
intact (Aharonoffet al, 1997). Numerous studies include hip fracture cases younger than 55 
years (Beals et al, 1972; Jensen et al, 1984; Poor et al, 1995) for whom the cause of 
fracture is severe trauma and for whom the prognosis of recovery is generally excellent. 
Moreover, except for the study by Poor and colleagues (Poor et al, 1995) most studies have 
restricted their analysis to studying the effects of some but not all risk factors in their patient 
cohort. Differences in age, sex, race, residence, ambulatory status and degree of co- 
morbidities makes comparisons across studies difficult. With these constraints in mind, from 
the existing literature, the following conclusions can be drawn. 
1.8.2 Mortality rate 
Reported rates of mortality in men with hip fracture vary from 11% (Lu-Yao et al, 1994) to 
71% (Poor et al, 1995). A good deal of this variance can be explained by differences in 
method of case selection and characteristics of the study population - age, health status, 
cognitive status, ambulatory status, institutionalised patients or from a general population 
mix of the elderly, influence of major trauma, coexisting illnesses, variation in length of 
hospitalisation and most importantly time of assessment (early versus late mortality). A 
number of study designs have been used. Mortality in hip fracture patients has been 
compared with mortality in sex and age matched controls (Jensen et al, 1979; Poor et al, 
1995; Browner et al, 1996), and with expected mortality in the general population 
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(Magaziner et al, 1989; Fisher et al, 1991, Pitto 1994; Cooper et al, 1997; Katelaris et al, 
1996; Forsen et al, 1999). The following section summarises mortality rates following hip 
fracture at various time intervals. Where data by sex was available the mortality figures for 
men have been cited separately. 
In hospital mortality rate: 2.0% - Ceder et al, 1980; 4.3% - Magaziner et al, 1989; 5.8% 
Jensen et al, 1979 
30 day mortality: 6.3% - Fisher et al, 1991; Men 11% Women - 6% Lu-Yao et al, 1994); 
Men 14% Women 6% - Diamond et al, 1997; 18.5% - Riska et al, 1970 
3 month mortality: 8.2% - Magaziner et al, 1989; 13% - Lu-Yao et al, 1994; 12.5% - Fisher 
et al, 1991; Men 21.5% Women 15.2% - Jensen et al, 1979; 
6 month mortality: 11.1% - Jensen et al, 1979; 12.6% - Magaziner et al, 1989; 18% - 
Marottoli et al, 1994; 20% - Kreutzfeldt et al, 1984; Men 20% - Diamond et al, 1997; Men 
25% Women 20% - Jensen et al, 1979 
12 month mortality: Men 16% Women 14% - Kenzora et at, 1984; 17.4% - Magaziner et 
al, 1989; 20% - Wolinsky et al, 1997; Men 20.7% Women 10.7% - Aharonoff et al, 1997; 
23.7% - Fisher et al, 1991; 24% - Lu-Yao et al, 1994; Men 37.1% - Parker et al, 1991; 
Men 35% Women 21% - Schurch et al, 1996; Men 34% - Sernbo et al, 1993; Men 42% - 
Poor et al, 1995; Men 51.4% Women 33% - Gordon et al, 1971; Men 37% Women 23% - 
Miller et at, 1978; 50% - Beals et al, 1972; 27% - Jensen et al, 1979 
2 years: Men 51.4% Women 37.3% - Gordon et al, 1971 
3 years: 35% - Jensen et al, 1982; 43% - Jensen et al, 1979 
S years: 56% - Jensen et al, 1979; 84% - Beals et al, 1972; Men 60% - Poor et al, 1995 
10 years: 90% - Beals et al, 1992; Men 71% - Poor et al, 1995 
An attempt has been made to quantify the excess mortality, though the data for men with hip 
fracture is scarce. Most studies have consistently shown the excess mortality to persist for 
the first 4-6 months post fracture, although the precise figures vary. Excess mortality was 
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most apparent in the first 4 months following fracture, but persisted for at least 8 months 
(Miller et al, 1978). This was similar to the findings by Gordon and colleagues in 1971 who 
noted the period of greatest mortality within 12 weeks of fracture (Gordon et al, 1971). In 
contrast, Jensen and co-workers found that the survival rate did not parallel the expected 
rate until 1.6 years after the fracture (Jensen et al, 1979). Others (Evans et al, 1979) found 
in addition to an early period of high risk of death, a secondary rise occurring after 4-6 
weeks. The only study comparing the excess mortality by sex (Forsen et al, 1999) concluded 
that the excess mortality is short term (up-to 3 months) in women and longer (up-to 1 year 
after the hip fracture) in men. 
The most detailed analysis of mortality amongst men with hip fractures comes from the 
recent population-based, prospective, matched-pair, cohort study in the county of Nord- 
Trondelag (Forsen et al, 1999). The study comprises of 1338 women and 487 men with a 
hip fracture along with 11086 women and 8141 men as controls. The study showed that 
men have a higher mortality than women irrespective of age after a hip fracture. The excess 
mortality is seen up-to 3 months in women but longer (up-to 1 year after fracture) in men. 
Amongst younger patients (<75 years) in the first 3 months after hip fracture men had a9 
fold increased risk of dying compared to a5 fold increased risk in women. This risk changed 
to 5-fold in men and 6-fold in women in the age group 75-84. Among cases 85 years or 
older the excess mortality in the first 3 months was 6 fold in men and 4 fold in women. 
1.8.3 Factors associated with mortality 
In women, factors that have been shown to influence mortality after hip fracture include type 
of fracture, age and sex of the patient, presence of co-morbidity, cognitive state, place of 
residence, peri-operative factors and post operative complications. Contrary to the wealth of 
literature available addressing the outcome following a hip fracture in women and factors 
that determine it, there are only two studies exclusively addressing this issue in men (Poor et 
al, 1995; Diamond et al, 1997). Poor and colleagues using a population based cohort study 
design involving 131 men and an equal number of age-matched controls from the 
community addressed the issue of determinants of reduced survival following hip fracture in 
men. Risk factors for early death were age, male sex, post-operative deterioration in mental 
status, nursing home residence prior to fracture, functional limitation before fracture and 
83 
presence of co-morbid diseases. Type of fracture and nature of surgery were not risk 
factors. On similar lines, Diamond and co-workers retrospectively audited medical records 
of all men and women (n=51 each) aged 60 years and over a one year period. They analysed 
mortality and risk factors for death in men and compared the results to those found in 
women. Compared to women, men in their study had a higher prevalence of excess alcohol 
consumption, pre-existing medical illness and fracture related complications. Despite this, in 
men, age, smoking history, alcohol intake, pre-existing medical illness, pre-fracture Barthel 
index score and length of hospitalisation did not contribute to fracture related mortality. 
Most of the published work addressing outcome and determinants of survival after hip 
fracture have predominantly included women and have generalised the results to either sex. 
Studies with significant number of men have either not performed separate analysis by 
gender (Aharonoff et al, 1997; Myers et al, 1991) have limited their observations in men to 
one or more risk factor only [Jacobsen et al, 1992 (race and sex); Forsen et al, 1999 (age 
and sex)] or addressed factors associated with short term (in-hospital) but not long term 
mortality (Myers et al, 1991). 
The following section summarises the current data on potential risk factors for mortality 
following fracture. Most of the results come from studies in which the predominant 
population studied is women. Where separate analysis for men was available the data has 
been cited. 
Age: Most studies have found that advancing age is associated with increased mortality after 
hip fracture (Gordon et al, 1971; Beals et al, 1972; Miller et al, 1978; Dahl et al, 1980; 
Magaziner et al, 1990; Myers et al, 1991; Fisher et al, 1991; Sernbo et al, 1993; Poor et al, 
1995; Schurch et al, 1996; Stavrou et al, 1997; Aharonoff et al, 1997). Some have found no 
relation between age and mortality (Kenzora et al, 1984; Mossey et al, 1989; Diamond et 
al, 1997). The only two studies that have addressed this issue in men provide conflicting 
results: no association (Diamond et al, 1997) versus a 1.4 fold increase in death associated 
per decade increase in age (Poor el al, 1995). The small sample size of the former with few 
deaths may be one explanation for the conflicting results. 
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Sex: The relationship between gender and risk of death after hip fracture remains 
controversial. Gender was not predictive of increased mortality in some (Kenzora et al, 
1984; Jensen et al, 1984; Aharonoff et al, 1997) but a risk factor for death in other studies 
(Gordon et al, 1971; Miller et al, 1978; Jensen et al, 1979; Dahl et al, 1980; Magaziner et 
al, 1989; Kellie et al, 1990; Myers et al, 1991; Fisher et al, 1991; Jacobsen et al, 1992; 
Sernbo et al, 1993; Poor et al, 1995; Schurch et al, 1996; Forsen et al, 1999). The number 
of studies addressing this issue are limited in the number of men included. The few studies 
with substantial numbers (Myers et al, 1991; Jacobsen et al, 1992; Sernbo et al, 1993; 
Forsen et at, 1999) consistently show male sex associated with higher mortality than 
women. A comparative study addressing both race and gender in over 712027 subjects with 
hip fracture has shown that irrespective of race men have the highest mortality after hip 
fracture (Jacobsen et al, 1992). In a more recent study (Forsen et al, 1999) male hip fracture 
patients had higher mortality than women the first year after the injury, irrespective of age, 
both in absolute terms (31% and 17% respectively) and relative to age-matched controls). 
The study by Poor and colleagues also showed male sex as a risk factor for hip fracture. 
Race: Most workers agree that Black race is associated with higher mortality following hip 
fracture. The earliest report (Myers et al, 1991) showed little differences in mortality by race 
(RR 1.1 for Whites versus Blacks). The large study (Jacobsen et al, 1992) specifically 
addressing this issue in 712027 hip fracture covered by the Medicare programme over 3 
years reported that Blacks have a higher mortality after hip fracture compared to Whites. A 
more recent publication (Lu-Yao et al, 1994) similarly confirmed that Whites had the lowest 
overall post-fracture mortality of the racial groups studied. No differences were found in 
mortality between the races during the first 90 days post fracture; subsequent mortality was 
higher in Blacks RR = 1.2 (Lu-Yao et al, 1994). These finding were independent of type of 
fracture and treatment. A possible explanation for this observed difference was the lower 
socio-economic status and limited access to health care by the Black community. 
Fracture type: There is considerable variation between reports evaluating mortality rates 
for extra and intracapsular fractures. This is probably caused by variation in types of patients 
treated, variable exclusion of some patients from the studies (example those with 
pathological or multiple fractures) and exclusion of younger patients. 
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Some early studies (Gordon et al, 1971; Beals et al, 1972) have noted a higher mortality 
rate for subjects with an intertrochanteric fracture, although more recent studies do not note 
any difference, particularly when accounting for age (Kenzora et al, 1984; White et al, 
1987; Jensen et al, 1979; Dahl et al, 1980). Type of fracture was not predictive of increased 
mortality after hip fracture (Myers et al, 1991; Sernbo et al, 1993; Aharonoff et al, 1997; 
Koval et al, 1998). Using multiple logistic regression presence of cervical fracture increased 
the odds of death by 9.06 with fracture at femoral neck compared to that at the 
intertrochanteric site (Marottolli et al, 1994). The only study specifically addressing this 
issue in men (Poor et al, 1995) concludes that the type of fracture is not predictive of 
increased mortality after hip fracture. 
Nature of operation: Some (Rodriguez et al, 1987; Broos et al, 1988; Skinner et al, 1989; 
Lu-Yao et al, 1994) but not all (Kenzora et al, 1984) studies have shown better survival 
following internal fixation compared to arthroplasty. These differences can be due to 
selection of healthier patients for internal fixation (Miller et al, 1978) with no significant 
relationship between duration of anaesthesia, blood loss, choice of fixative devise and 
outcome one year after hip fracture. 
Co-morbidity: Hip fracture patients are almost all elderly and many are frail. Poor 
controlled systemic illnesses, such as cardiac failure, diabetes, chronic airway disease have 
all been shown to increase mortality rate after hip fracture. Most investigators have found 
co-morbidities as significant predictors of increased mortality after hip fracture (Kenzora et 
al, 1984; Magaziner et al, 1989; Fisher et al, 1991; Myers et al, 1991; Marottolli et al, 
1994; Poor et al, 1995; Nettleman et al, 1996; Aharonoff et al, 1997; Stavrou et al, 1997). 
A diagnosis of CHF or angina was an independent predictor of 30-day mortality after hip 
fracture (Nettleman et al, 1996). This is consistent with other studies (Myers et al, 1991; 
Kenzora et al, 1984). 
There were inconsistencies in the two studies addressing this in men. Pre-existing medical 
illness did not contribute significantly to the fracture related mortality within 6 months of 
fracture (Diamond et al, 1997). However, one has to remember that the study was limited 
with a small sample size (n=51 men). In the study by Poor and colleagues, the effect of 
individual co-morbid components was not significant in the multivariate model, but the 
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overall influence of co-morbidity remained significant among patients with hip fracture after 
adjusting for other predictors of death (hazards ratio 4.4). Overall, patients with hip fracture 
had a higher mean co-morbidity score (2.8) and among the components of the score 
significantly more dementia (38%) (Poor et al, 1995). 
The cause of death of these patients also reflects the co-morbidities. In their cohort of 131 
men with hip fracture, Poor and colleagues found the cause of death at 1 year were more 
likely to be gastrointestinal disease (SMR 3.8); malignancies (SMR 2.6); stroke (SMR 2.6) 
and coronary artery disease (SMR 1.7) (Poor et al, 1995). These findings were corroborated 
by Nettleman and co-workers a year later where the cause of death in their men were similar 
(Nettleman et al, 1996). 
Residence: Relatively few studies have looked at the effect of pre-fracture residence on 
outcome. Living in nursing home increased the odds of death both in the short term (90 
days-OR 1.39) and long term (up-to 3 years-OR 1.54) (Lu-Yao et al, 1994). Nursing home 
residence prior to fracture increased risk of mortality at 1 year especially in the younger age 
group (Fisher et al, 1991). Patients coming from institutions had a 3-4 times higher 
mortality rate than those coming from home (Holmberg et al, 1986). Of the two studies in 
men only the study by Poor addressed residence as a risk factor. Discharge to a nursing 
home predicted death in univariate analysis but pre-fracture residence in nursing home did 
not alter 30 day mortality (Poor et al, 1995. This may partly be due to the relatively small 
number of deaths. 
Mental status: Cognitive disorders are good predictors of mortality. The role of pre- 
fracture mental status using formal assessment tools on outcome has not been studied to a 
large extent. Poor baseline mental status with more than four errors on the short portable 
mental status questionnaire was significantly associated with death after hip fracture (OR 
6.92) (Marottolli et al, 1994). Some workers have studied presence of dementia on 
admission as a risk factor for poor outcome. Some (Magaziner et al, 1989) did not but 
others have found dementia or presence of organic brain syndrome highly predictive of 
death within one year of hip fracture (Beals et al, 1972; Miller et al, 1978). Differences may 
be explained by differences in inclusion of patients from extended care facilities with more 
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advanced dementia. Deterioration of mental status during hospitalisation was shown to be a 
risk factor by Poor with a hazards ratio of 9.2 (Poor et al, 1995). Similarly, cases with an 
ASA operative risk rating of 3 or 4 were more likely to die in the first year after hip fracture 
(Aharonoff et al, 1997). 
Pre-fracture physical function: Very few studies have examined the role of pre-fracture 
functional status to mortality in men. Most studies in women have identified physical 
function before fracture as an important determinant of outcome. Subjects who were 
relatively immobilised "dependent" owing to illness prior to fracture were more likely to die 
at 1 year than those "independent" (Gordon et al, 1971). Similarly, pre-fracture dependency 
in basic activities of daily living (BADLs) predicted increased mortality one year post 
fracture (Aharonoff et al, 1997). Walking ability before fracture was an important factor in 
discriminating those who were going to die within 1 year and those who were able to return 
to their own homes 1 year after the fracture (Sernbo et al, 1993). 
The results in the two studies in men are conflicting. Poor found activity status at the time of 
fracture a predictor of survival. Survival was worse among patients with hip fracture and 
controls who were inactive before the index date in the nested case-control study. 
Compared with men who were active patients with hip fracture who had limited activity or 
who were more or less confined to bed had hazards ratio of 2.1 and 5.6 respectively (Poor 
et al, 1995). On the contrary, Diamond and co-workers did not find pre-fracture Barthel 
index contributing to mortality at 6 months (Diamond et al, 1997). 
Postoperative complications: Mortality is increased by specific post-operative 
complications, including sepsis, dislocation or other failure of the prosthesis. Aharonoff 
reported a strong correlation between mortality at one year and the presence of one or more 
in-hospital postoperative complication. (Aharonoff et al, 1997). The only study addressing 
this in men found post operative confusion to be a risk factor (RR 8.1) for early mortality 
(Poor et al, 1995). 
1.8.4 Morbidity 
Functional competence in basic and intermediate activities of daily living and physical 
functioning is markedly diminished after hip fracture. Subjects who fracture their hips tend 
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to have other diseases and functional limitations prior to the occurrence of the fracture. 
Thus, the hip fracture is often not the sole factor leading to functional decline; rather it is 
probably the cumulative effect of the hip fracture in the setting of other co-morbidities and 
limitations that leads to a profound decrease in functional capability. Factors that predict 
better recovery after hip fracture in women are consistent with the concept that outcome of 
hip fracture depends largely on the prior condition of individuals who suffer the fractures. 
Recovery of pre-fracture health status and or return to living at home is more common 
amongst patients who are younger, in better general health, and not demented. There is very 
little information along these lines in men. There is no data on quality of life following 
fracture in men. 
The two studies that have addressed morbidity in men (Poor et al, 1995; Diamond et al, 
1997) are descriptive in nature. At 1 year, of the 76 Rochester patients that were alive, 
functional outcome at 1 year revealed recovery to pre-fracture level of functioning in 41%: 
68.4% needed an aid to walk, 29% were bedfast or chair or bedridden and only 19.7% could 
walk independently. At 1 year 45% resided in a nursing home, 8% were in intermediate care 
facilities, 26% were at home requiring help with only 21% living independently in their own 
homes. No relationship was noticed between functional outcome parameters or nursing 
home placement and type of surgery, age, co-morbidity, presence of dementia or 
deterioration of mental status, attendance at nursing home or duration of physical medicine 
and rehabilitation (Poor et al, 1995). Functional outcome after 1 year was not studied. In 
the study by Diamond, of the 41 men who were contactable for assessment of outcomes at 6 
and 12 months 50% were institutionalised and a significant (17%) decline in Barthel index 
score was observed amongst the survivors compared to pre-fracture scores. More detailed 
assessment was limited due to the small sample size. 
1.8.5 Functional outcome and factors influencing it 
A number of studies have looked at factors prior to fracture that may influence functional 
outcome in women. No such studies are available for men. The key predictors of functional 
outcome in studies in women are listed below. 
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Age: Advancing age (more than 85 years) has been shown to predict failure to recover basic 
activities of daily living after fracture (Koval et al, 1998; Magaziner et al, 1990; Mossey et 
al, 1989). Miller et al, 1978 also found that the probability of non-ambulation at one year 
after fracture increased markedly with age after the age of 60 years. 
Sex: Patients gender had not been shown to be a significant predictor of functional outcome 
(Koval et al, 1998) nor have an effect on ambulatory status at 1 year (Miller et al, 1978). 
Fracture Type: The role of fracture type in functional outcome rarely has been studied. 
Fracture type was not a predictor of functional recovery (Magaziner et al, 1990; Koval et al, 
1998). 
Pre-fracture functional status: A good score on basic activities of daily living (ADL) 
before fracture was strongly predictive of recovery post fracture at all assessment intervals 
(Koval et al, 1998) 
Co-morbidity: Presence of one or more co-morbid condition was a predictor of failure to 
recover pre-fracture basic activities of ADL at 3 and 6 months (Koval et al, 1998), but not 
12 months after fracture (Magaziner et al, 1990; Koval et al, 1998). This suggests that 
functional recovery is delayed in the presence of co-morbidities. The severity of co- 
morbidities was not a predictor of recovery of basic ADL. 
Pre-fracture residence: Living alone before sustaining a fracture was a significant predictor 
of failure to recover basic ADL status at 3 months (Koval et al, 1998). This confirms earlier 
findings that social circumstances influence recovery (Cummings et al, 1988). Lack of social 
support at baseline has been reported to be an important predictor of institutionalisation 
(Ceder et al, 1980; Fitzgerald et al, 1988). Similarly, being married and a good pre-fracture 
mental status were protective against institutionalisation (Marottolli et al, 1994). 
Despite the critical importance of hip fracture and the comprehensive literature available for 
women, to date, the current knowledge in relation to men remains inadequate. The lacuna 
lies in there being no prospective studies, limitations in using hospital discharge data taken 
from medical records including incompleteness and inaccuracy, no national studies, 
comparisons with inappropriate groups and most reports being descriptive as they have not 
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involved multivariate analysis. The need therefore is a comprehensive prospective study 
primarily targeted at assessing outcome following hip fracture in men with the aim of 
identifying treatable / modifiable factors associated with poor outcome. It must be 
remembered that neither acute nor long-term mortality rates after hip fracture are 
attributable solely to hip fracture, since they represent all-cause mortality estimates. 
Hip fractures represent a significant source of morbidity and mortality for the elderly 
population. The number of hip fractures treated is rising throughout the world; nonetheless, 
outcome results remain poor. Comprehensive prospective studies are needed to guide 
surgeons to optimise patient survival and postoperative functional recovery. Many 
determinants of outcome are independent of the level of care given and are dependent on 
pre-fracture status. In today's cost cutting environment, caution must be taken to prevent 
short-term cost saving measures from compromising long-term outcome for elderly hip 
fracture patients. Particular attention is needed addressing the relationship between pre- 
fracture status and outcome. 
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2. SUBJECTS AND METHODS 
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2.1 Summary 
This chapter describes the various methodologies used in this study. These include details 
about the method of recruitment, calculation of sample size, identification of the two study 
populations, questionnaires administered, laboratory tests, bone mineral density 
measurement and process involved in follow-up which implied contact with the vital 
registration system. 
2.2 Study Setting 
The study was undertaken at the Royal Cornwall Hospital in Truro. This is only centre for 
acute orthopaedic care in Cornwall and serves 80% of the total population (the other 20% 
of the population are seen in Plymouth and other hospitals in Devon). This provides a 
population base of 384,000 people (including 65,858 men aged over 50 years). 
2.3 Study Design 
This was a case control study. Both cases and controls were recruited simultaneously over 
a 14 month duration (December 1995-January 1997). The initial aim of the study was to 
assess the role of hypogonadism as a risk factor for low trauma hip fracture in elderly men. 
However, it was soon clear that it would be vital to re-assess hormone levels following 
fracture in addition to studying the role of many other potential risk factors. It was then 
decided to capitalise on the follow-up visits and address outcome following hip fracture both 
in terms of mortality and morbidity. As a result, both groups were prospectively followed 
for a mean of 661 days (1.8 years) (range 2-1128 days). 
2.4 Sample Size 
The sample size calculation was based on estimates of the prevalence of low testosterone (< 
9.0 mg/dl) in a population with the age distribution for male low impact hip fractures. 
However, there are no published data on the prevalence of low testosterone in the normal 
elderly population although it is believed that testosterone levels decline with increasing age. 
The estimates used were a low estimate of prevalence of 15% and a high estimate of 25%. 
For the low estimate a sample size of 97 in each arm of the study would be needed to detect 
a relative risk associated with low testosterone of 2.75 ((x= . 
05; 1-0 = . 
90). A sample size 
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of 92 would detect a relative risk of 2.5 (a= . 
05; 1-ß = . 
90) using the high estimate. Given 
these figures, it was decided that a sample size of 100 in each arm would give the study 
adequate power if low testosterone was to prove an important risk factor for low impact hip 
fracture. In the event, the relative risk associated with low testosterone in the study was 
3.07 and the observed power of the study was. 9859. 
As part of the decision to extend the study to assess the sequelae of male hip fracture, the 
power of the sample to detect any associated risk of mortality was considered. Using 
Cornish age specific mortality figures for 1995 (ONS data) the "expected" one- (7.41%) and 
two- year (15.02%) mortality was estimated for the control group. Using those figures, the 
study would have been powered to detect (a= . 05; 1-0 = . 
92) a relative risk of mortality of 
3 in the year following fracture and a relative risk of 2.5 over the two years following 
fracture (a= 




Men aged 50 years or more, presenting with a low-trauma hip fracture and not having any 
malignancy requiring active treatment were eligible as cases. "Low - trauma" was defined as 
fall from standing height or less. 100 men consecutively presenting to the Royal Cornwall 
Hospital fulfilling these eligibility criteria were identified by checking the admissions register 
of the two orthopaedic wards on a daily basis. 
2.5.2 Controls 
Controls were recruited from the community. A local general practice surgery was identified 
as the representative of the catchment population. A list was drawn of subjects fulfilling the 
following entry criteria: males aged 50 years and over with no history of hip fracture. A past 
history of other fractures did not qualify as exclusion criteria. Using this criteria, 2000 men 
were eligible as controls. When a case was admitted to the hospital, in parallel an age- 
matched control was invited to take part from this list. The recruitment of controls was 
random and simultaneous to identification of a hip fracture case. To finally recruit 100 
controls, 185 subjects were invited to take part from this list of eligible men giving a 
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participation rate of 54%. No subjects withdrew from the study after giving informed 
written consent. 
2.6 Clinical Assessment 
2.6.1.1 General Physical Examination 
A standardised clinical assessment was carried in both groups at baseline, 6 months and 1 
year. This included a detailed history and physical examination. Difficulty in getting fracture 
patients onto the scales in the immediate post-operative period meant that it was only 
possible to measure height (n=51) and weight (n=53) in just over half the cases within 7 
days of the fracture. An attempt was made to measure the maximum possible number of 
subjects. This increased the final numbers where anthropometric measurements were 
possible within the first 3 months of the fracture to 74 and 85 respectively. Three controls 
could not have their heights and weights measured; one was a diabetic amputee. 
2.6.1.2 Questionnaires 
A single interviewer administered all questionnaires during the time of the first visit in the 
controls and within 48 hours in men with a hip fracture. All the questionnaires used in this 
study are attached in Appendix 2. It was not possible to gather complete information in 
some subjects due to their very ill health in the immediate post fracture period, hearing and 
visual impairment, poor mental status and co-morbid diseases. Missing data in these 
individuals were collected from the next of kin or carer. If there was a doubt on the 
credibility of the information being provided or where no close relative was identified the 
subject was excluded from that particular analysis. In subjects living in institutional care 
information obtained from the subject especially in relation to recent events, medications and 
co-morbid conditions was checked from their carer and or medical notes to ensure accuracy. 
Standardised questionnaires were used. They were based on those used in the European 
Vertebral Osteoporosis Study (EVOS) and the Mediterranean Osteoporosis Study 
(MEDOS). The quality of life was assessed using the generic Short Form 36 (SF-36). 
The socio-demographic questionnaire (Appendix 2.1) was based on the EVOS 
questionnaire. It was administered to collect personal details, socio-demographic data, 
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mental score using the mini-mental test, lifestyle data on risk factors for development of 
osteoporosis and fracture, past and / or family history of osteoporosis and minimal trauma 
fractures. In cases, two additional sections captured details of current fracture and 
circumstances around the incident event. 
The medical questionnaire (Appendix 2.2) collected data on frequency and risk factors for 
falls, concomitant diseases and medications that may be risk factors for development of 
osteoporosis along with intake of bone protective medications 
The standardised Short form 36 (Appendix 2.3) was used as the "generic" health assessment 
questionnaire. In addition, a section of the MEDOS questionnaire was used to assess 
"specific" effects of hip fracture on daily functional abilities. Both these questionnaires 
ascertained health status 4 weeks prior to assessment date (which in cases was prior to 
fracture). This enabled us to collect information on the individuals' pre morbid general health 
status and specific functional limitations. Similarly, baseline pain assessment in cases implied 
levels of pain in the 4 weeks prior to the onset of their hip fracture. 
2.7 Laboratory Assessment 
2.7.1.1 Timing of samples 
Baseline samples were collected at the time of the first visit in controls and within 48 hours 
of admission in men with a hip fracture. Subsequent samples were collected as per protocol 
at 6 and 12 months in both groups. All blood samples were collected early morning after an 
overnight fast to avoid potential diurnal variation. All urine specimens were 2 hour second 
morning urine samples following an overnight fast. 
2.7.1.2 Handling and storage of samples 
Blood and urine samples for routine tests were sent off for analysis immediately after 
collection and results were available in the majority within 48 hours. Blood samples for 
osteocalcin, 25-hydroxy-vitamin D, parathyroid hormone and free testosterone were 
centrifuged at 200g for 8 minutes to separate the serum. Serum thus obtained and urine for 
assay of deoxypyridinoline was split into 250 ul aliquots, snap frozen and stored at -70° C 
until assay. A strict cold chain was maintained during transportation of the samples between 
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storage site and laboratory to prevent thawing of the samples at a later date. All stored sera 
were analysed in one laboratory (Clinical Biochemistry, King's College, London) by trained 
staff The assays were run in one analytical batch. 
2.7.1.3 Details of tests 
Routine haematological and biochemical tests were carried out in the Clinical Haematology 
and Biochemistry departments based at the Royal Cornwall Hospital. The aim of these was 
to exclude secondary causes for hip fracture. The assays were performed as per standard 
protocol. 
Routine haematological and biochemical tests included full blood count (FBC), C reactive 
protein (CRP), plasma viscosity (PV), serum protein electrophoresis, bone profile (corrected 
calcium, alkaline phosphatase, total protein, albumin, globulin), renal function tests (B urea, 
S creatinine), thyroid function tests (TSH, thyroxin), prostate specific antigen and urine 
calcium creatinine ratio. Androgen status in both groups was evaluated using 3 assays: 
serum testosterone, free androgen index (FAI) which controls for sex hormone binding 
globulin (SHBG) and free testosterone. Levels of the two gonadotrophins, follicular 
stimulating hormone (FSH) and luteinising hormone (LH), were additionally analysed to 
fully characterise the androgen profile. 
Tests carried out for research purpose: 
Free testosterone radioimmunoassay: Free testosterone was measured using the DSL-4900 
ACTIVE Tm free testosterone coated-tube radioimmunoassay kit in accordance with the 
manufacturer's instructions for the standard method. This utilises an 1 125 labelled 
testosterone analogue, which has low affinity for SHBG and albumin. The analogue 
competes with the unbound testosterone in the test sample for binding to specific anti- 
testosterone polyclonal antibodies that have been immobilised on the assay tube. This 
competitive binding format allows direct estimation of unlabelled free testosterone levels in 
unextracted samples. The procedure follows the basic principle of RIA where there is a 
competition between a radioactive and a non-radioactive antigen for a fixed number of 
antibody binding sites. The amount of I 125 labelled testosterone analogue bound to the 
antibody is inversely proportional to the concentration of the free testosterone present. The 
detection limit of this assay is 0.18 pg/ml. The mean intra-assay (n=10) CV over the range 
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of 1.87-28.53 pg/ml is 5.2-6.2%. The inter-assay (n=14) CV over the range of 3.7-34.02 
pg/ml is 7.3 -9.7%. The assay cross-reactivity with dihydrotestosterone is <0.1% 
Oestradiol immunoassay: The Bayer Immunol system was used. This is a competitive 
immunoassay, where test samples are incubated with an antibody reagent to which an 
enzyme conjugate reagent is then added. The enzyme conjugate competes for binding sites 
with the oestradiol in the sample. The next step is the addition of the magnetic particle 
reagent to allow separation of the antigen-antibody complex. Excess reagent is then washed 
away and the enzyme substrate is added. The indicator reaction is the conversion of p- 
Nitrophenyl phosphate and water to p-Nitrophenoxide and phosphate that is catalysed by 
the alkaline phosphatase which forms part of the enzyme conjugate. This reaction is 
monitored at 405 nm. A sample having no oestradiol will have maximum label bound, while 
samples containing higher oestradiol concentrations will have less labelled bound. Hence the 
dose/response curve is inversely proportional to the concentration of oestradiol in the 
sample. The analytical range for this method extends from the minimum detectable 
concentration of oestradiol (10 pg/ml [36.7 pmol/l]) to 3600 pg/ml [13212 pmol/l]. The 
reference range for an adult male is <170 pmol/l. At this range between batch CV is 8.4% 
and within batch CV 1.8%. Cross reactivity with other naturally occurring steroids changed 
the oestradiol concentrations by <0.1%. 
25-hydroxyvitamin D radioimmunoassay: Quantitative determination of 25- 
hydroxyvitamin D was performed using a two-step assay. The first involved rapid extraction 
of 25-OH-D from the serum with acetonitrile. Following extraction the treated sample was 
then assayed using an equilibrium RIA procedure. The RIA method is based on an antibody 
with specificity to 25-OH-D. The sample, antibody and tracer are incubated for 90 minutes 
at 20-25 T. Phase separation is accomplished after a 20-minute incubation at 20-25 °C with 
a second antibody-precipitating complex. The sensitivity of this assay is<3ng/ml. The 
coefficient of variation is less than 10%. The cross reactivity with Vitamin D2 and D3 is 
0.8%. 
Intact PTH immunoradiometric assay (IRMA): Quantitative determination of intact 
parathyroid hormone in the serum was performed using Nichols Institute Diagnostics intact 
PTH immunoassay with a sensitivity of 1 pg/ml. This is highly specific for only biologically 
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active and intact PTH molecules. The intact PTH immunoassay is a two-site 
immunoradiometric assay (IRMA). Two different goat polyclonal antibodies to human PTH 
have been purified by affinity chromatography to be specific for well defined regions on the 
PTH molecule. One antibody is prepared to bind only the mid-region and C-terminal PTH 
38-84 and is immobilised onto plastic beads. The other antibody is prepared to bind only the 
N-terminal PTH 1-34 and this antibody is radiolabeled for detection. The inter and intra 
assay (n=20) CVs over the range 38-277 pg/ml were <6.1 and <3.4 % respectively. Cross 
reactivity and interference with other PTH fragments is zero. 
Patients' sample is incubated simultaneously with an antibody-coated bead and the 125 I 
labelled antibody. Intact PTH present in the sample is bound by both the immobilised and 
the labelled antibodies to form a "sandwich" complex: bead anti-PTH (39-84)- Intact PTH 
(1-84)- 125 1 anti-PTH (1-34) 
Although mid-region and C-terminal fragments are bound by the antibody coated bead, only 
the intact PTH 1-84 forms the sandwich complex. The bead is washed to remove the 
unbound components and the radioactivity bound to the solid phase is measured in a gamma 
counter-the radioactivity of the bead bound complex is directly proportional to the amount 
of intact PTH in the sample. A dose response curve of radioactivity vs. concentration is 
generated using results obtained from standards that are assayed concurrently with the 
unknowns. Concentrations of intact PTH are determined directly from this curve. 
Osteocalcin immunoassay: Intact osteocalcin in serum was assayed using NovoCalcin TM 
kit as per manufacturer guidelines. The assay uses human osteocalcin coated strips and 
bovine- antiosteocalcin antibody with a high homology to human osteocalcin. There is 100% 
cross-reactivity recognising only intact osteocalcin, as it is "conformationally dependent". 
An anti-mouse alkaline phosphatase conjugate and anti-human parc nitro-phenol phosphate 
(pNPP) substrate are used to quantify osteocalcin. The assay has a minimum detection limit 
of 0.45 ng/ml. The intra assay (n=22) and inter assay (n=3 in 3 runs) CVs over the range 
6.2-16.5 ng/ml were <10 and <9.8% respectively. 
Deoxypyridinoline immunoassay: Deoxypyridinoline cross-links were measured in the 
second morning void urine using the Pyrilinks-D immunoassay by Metra Biosystems. It is a 
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competitive enzyme immunoassay utilising a monoclonal anti-Dpd antibody coated on the 
microtitre strip wells. Dpd in the sample competes with conjugated Dpd-alkaline 
phosphatase for the antibody and the reaction is detected with pNPP substrate. Pyrilinks-D 
results are corrected for variations in the urine concentration by dividing the Dpd value 
(nmol/1) by the creatinine value (mmol/1) of each sample (creatinine mg/dl x 0.088 = 
mmol/1). The final results are expressed as nmol Dpd/mmol creatinine. The normal reference 
values of the assay for males aged 25 - 55 years is mean (SD) 3.8 (1.0); range 2.3 - 5.4. The 
within subject longitudinal variation of the assay is 15.5%. The monoclonal anti-Dpd 
antibody is selective and has a high affinity for free Dpd and negligible binding to Dpd 
peptides. The assay is sensitive to detect a minimum value of 1.1 nmol/l. The within and 
between-run CV of the assay at the range < 5.4 Dpd values is 8.4% and 4.8% respectively. 
2.7.1.4 Algorithm for work-up of hypogonadism 
Further investigation of individuals with abnormal endocrine results (low testosterone and or 
free androgen index) followed an algorithm that was designed to establish the type and 
nature of the hypogonadism: primary versus secondary. Dynamic pituitary function tests 
were not considered appropriate in these subjects because of their age. Patients with 
laboratory values consistently showing either normal testosterone (>9 nglml) and / or free 
androgen index (>30 IU/1) or a primary hypogonadal pattern (low testosterone (<9 ng/ml) / 
free androgen index (<30 IU/1) with raised LH (>10 IU/1) and or F SH (>10 IU/1)) did not 
have any further assessments. Subjects with low testosterone and low gonadotrophins (FSH 
& LH <10 IU/1) suggestive of secondary hypogonadism both at baseline and at 6 months 
were further investigated with measurement of thyroxin, cortisol and prolactin using serum 
stored from the two visits to identify the cause. Free thyroxin was performed only if total T4 
was less than 70 nmol/l on both occasions. MRI / CT Scan of the pituitary was requested if 
prolactin values were over 2500 mIU/1 on at least 2 occasions after excluding diseases or 
medications that may be responsible for these results. 
2.8 Bone Mineral Density and Hip Axis Length Assessment 
Bone mineral density (BMD) measurements were performed at the lumbar spine and 
proximal femur on all subjects capable of lying still in a specified position on the scanner for 
at least 10 minutes. BMD was measured by dual energy X-ray absorptiometry (DXA) using 
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Hologic QDR 1000. In the fracture cases, measurements were performed within 7 days of 
admission. The controls had proximal femur measurements made at the right hip, while in 
fracture cases the non-fractured side was assessed. Hip axis length (HAL) was recorded 
using the automated software provided with the scanner. The DXA unit is calibrated daily 
using the spine phantom provided by the manufacturer. The coefficient of variation in 
assessment of HAL and BMD in our unit is 0.4%. No significant change in the phantom's 
BMD value was noted during the study period. BMD was measured in all of the controls 
and 62 cases. The reasons for non-scanning among the cases include early death, extreme 
frailty and concurrent co-morbid diseases (36) and, refusal (2). In a further 4 cases 
measurements were not made at the proximal femur, because of prosthesis (2), frailty (1) or 
extreme obesity (1). 
2.9 Ethics Approval 
A patient information sheet was created outlining the objectives of the study, study duration 
and the proposed protocol. The hospitals' ethics committee approved this. This information 
sheet was provided to all eligible subjects at the time of recruitment into the study. Each 
study participant gave informed written consent before being enrolled into the study. For 
subjects with visual impairment the information sheet was read aloud. Similarly, for patients 
who were confused on admission consent was taken from the closest relative or carer. 
2.10 Follow-up Assessment 
Study subjects (cases and controls) were reviewed at 6 months, 12 months and 24 months 
(Table 2.1). In the majority, follow-up assessments were carried out in the hospital setting. 
In subjects who were in institutional care, very frail or had problems with transport follow- 
up visits were arranged at their place of residence. 
General physical examination: This was carried out either in the hospital or in the subjects' 
own place of residence. An attempt to measure height and weight was restricted to the first 
3 months following recruitment into the study. 
Generic Quality of Life assessment: The SF-36 questionnaire was administered to both 
groups at the time of the follow-up visits at 6,12 and 24 months. An additional "follow-up 
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questionnaire" (Appendix 2.4 & 2.6) captured data on current residence, outcome of 
surgery (in cases), current medications, occurrence of further fractures and degree and 
nature (i. e. family/ social/ paid help) of help needed to perform activities of daily living. 
Specific Quality of Life assessment: The section of the MEDOS questionnaire (Appendix 
2.3) was used at follow-up visits to assess the specific functional limitations of an individual 
in normal daily activities. 
Laboratory assessment: Laboratory assessments were carried out using the same guidelines 
in both groups at 6 months and 1 year. The protocol is outlined in Table 2.1. 
2.11 Outcome-Mortality and Cause of Death 
Vital status of all study participants was collected at each assessment interval by direct 
contact with the patient, relative or carer. The cause of death was confirmed using death 
certificates or post-mortem reports obtained using the vital registration system from the 
registrar general office. 
2.12 Statistical Analysis 
The raw data was entered as a spreadsheet in EXCEL -97. The data was then transferred to 
SPSS version 7.5.1 and STATA 4.0 depending on the need for a particular statistical 
analysis. Details of the various statistical tests employed are described under the "methods" 
section of the individual "results" section. 
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Table 2.1 Schedule of patient visit and observations 
Activity Baseline 6M 12M 24M 
Signed informed consent X 
Clinical Assessments 
Physical Examination X X X X 
Height, Weight, BMI X 
Demographic data X 
Risk factors for OP X 
Risk factors for falls X 
Co-morbidity data X X X X 
Concomitant drugs X X X X 
Circumstances around current X 
fracture 
Details of fracture X 
Functional status Assessments 
SF - 36 Questionnaire X X X X 




Routine haematology X X X 
Routine chemistry screen 2 X X 
Extended blood chemistry 3 X X 
Androgen status X X X 
Oestradiol assay X X 
25-hydroxy-vitamin D assay X X 
Parathyroid assay X X 
Osteocalcin X X 
Pituitary function tests 5 X X 
Urine: 
Urine electrophoresis X 
Urine Ca/Cr ratio X X 
Urine deoxypyridinoline X X 
Radiological Assessments 
X ray pelvis with both hips X 
Femoral neck & lumbar spine X 
BMD using DXA 
Others 
Residential status X X X X 
Record of adverse events X X X X 
Other co-morbidities X X X X 
Additional fractures X X X X 
Health service utilisation X X X X 
Mortality X X X X 
Routine haematology': Haemoglobin. Full blood count, Plasma Viscosity, C Reactive protein, 
Routine chemistry 2: Liver functions (serum protein, albumin, globulin, alkaline phosphatase, alanine 
transaminase), renal functions (blood urea, s creatinine), bone profile (calcium, corrected calcium, and 
phosphorus) 
Extended blood chemistry 3: Serum electrophoresis, Thyroid, prostate specific antigen 
Androgen status 4: testosterone, free androgen index, free testosterone, sex hormone binding globulin, 
follicular stimulating hormone, and leutinising hormone 
Pituitary function tests 5: Free thyroxin, cortisol, prolactin, and MRI scan of the pituitary fossa 
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The aims of this chapter are to describe the characteristics of low trauma hip fracture in 
elderly men, to outline their associated sociodemographic and life style features and to 
identify variables that increase fracture risk 
100 men aged 50 years and over with a low trauma hip fracture were recruited prospectively 
over 14 months. Simultaneously 100 aged matched controls were randomly enrolled from 
the community. Interviewer assisted questionnaires collected data in both groups, in cases 
these were administered within 48 hours of fracture. Anthropometric measurements (height, 
weight) were carried out in both groups at baseline. 
The mean age of men with a low trauma hip fracture was 79.9 years. Fifty-five fractures 
were cervical, 45 intertrochanteric with the majority (67) occurring indoors. Ninety-three 
fractures followed a fall, in 70 of whom the fall was on the same level. Ninety-five had 
surgical intervention of which the commonest procedure was a Dynamic Hip Screw or 
Thompson's hemiarthroplasty. Fracture cases were older, had lower BMI, poor mental 
scores, multiple co-morbid disorders such as Parkinson's disease, dementia, poor vision, 
stroke, restricted mobility, poor dietary milk intake in childhood and frequent falls. They 
were frequently single, living alone or in care. 
Risk of hip fracture is greatest in the seventh and eighth decade of life. Presence of co- 
morbid diseases and some dietary and lifestyle characteristics further the risk of hip fracture 
in this group of elderly men. Early identification of those at "high risk", namely single men, 
living alone or in care, with multiple co-morbid conditions who are restricted in mobility and 
have a tendency to frequent falls would help target preventive measures. This may 
subsequently reduce the number of low trauma hip fractures in elderly men. Measures such 
as adequate calcium intake in childhood, regular physical activity throughout adult life and 
improvement of general health should reduce the burden of the problem. 
The study is limited in evaluating age and race as risk factors for hip fracture in men 
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3.2 BACKGROUND 
This study was performed at The Royal Cornwall Hospital. This is the only referral centre 
for acute orthopaedic care to the local population, which is geographically well defined, 
relatively stable and socially homogeneous. It serves an estimated 80% of the population of 
384,000 people that includes 65,858 men aged 50 years and over. 
All patients following hip fracture require hospitalisation. The study capitalised on the ability 
to capture consecutive admissions from a geographically defined population over a defined 
period of time. To ensure homogeneity only those resident in Cornwall were included in the 
study. Only men aged 50 years and over were included in this study to allow comparison 
with the published literature. No upper age limit was set to avoid selection bias. 
Controls were randomly drawn from the community to ensure similar exposure to potential 
risk factors. A single large general practice, representing the catchment population, was 
identified to help provide controls. Cases and controls were recruited simultaneously over a 
14-month period. This avoids bias due to seasonal variation. 
This chapter explores the demographic and lifestyle risk factors for low trauma hip fracture 
in this elderly male population. The results of the analysis are presented as follows 
i) Descriptive characteristics of the fracture population which includes sociodemographic 
profile, circumstances in which they fracture, operative interventions performed and 
differences between those who sustain a cervical fracture compared to an intertrochanteric 
fracture 
ii) Comparison of demographic and lifestyle factors between hip fracture cases and age- 
matched community controls, and finally 
iii) Calculation of age-adjusted odds ratios for risk of low trauma hip fracture associated 




3.3.1 Study Design And Subjects 
100 consecutive male admissions to the Royal Cornwall Hospital with a "low trauma" hip 
fracture aged 50 years and over were recruited as cases. "Low trauma" was defined as a 
fracture following a fall from standing height or less. Hip fractures following major trauma, 
those not residents in Cornwall and with active malignancy were excluded. Simultaneously, 
100 age-matched controls were randomly recruited from a local general practice register. 
Data in both groups was collected over a 14-month period. Details are given in chapter 2. 
3.3.2 Questionnaires 
Interviewer assisted questionnaires were administered within 48 hours to fracture cases and 
at the time of the first visit to controls. Details of these are given in chapter 2 and the 
questionnaires themselves are attached in appendices 2. Questionnaires captured personal 
details, sociodemographic data, mental score, lifestyle risk factors for osteoporosis, family 
history of osteoporosis, risk factors for falls and list of concomitant diseases and 
medications. In cases, details of current fracture and circumstances around the incident 
event were also ascertained. Where questionnaires were incomplete due to lack of 
information from patient or carer, data was excluded from the analysis. 
3.3.3 Analysis 
All data was entered in EXCEL, then transferred to SPSS and STATA for statistical 
analysis. For categorical variables, percentages were calculated and significance estimated 
using Pearson chi -square. Due to significant difference in age between cases and controls, 
adjustment for age was made in calculating odds ratios using STATA. 
3.4 RESULTS 
100 cases (99 Caucasians and 1 Chinese) were seen over 14 months giving an annual 
incidence of 140/100,000/year for first low trauma hip fracture in males over 50 years. All 
100 community controls were Caucasian. 
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3.4.1 Fracture Details 
There was no side predilection: of the 100 fractures - 51 involved the right hip, 48 the left 
and one patient had bilateral hip fracture. Fifty-five involved the neck of femur (including 
subcapital) and 45 the intertrochanteric region. The majority (67%) fractured their hip 
indoor see Table 3.1. 
Table 3.1 Fracture details 
Details Number 
Type of fracture Cervical 55 
Intertrochanteric 45 
Side of fracture Right 51 
Left 48 
Bilateral 1 
Site of fracture Outdoors 31 
Indoors 67 
Unknown 2 
Many of the fractures occurred in the morning 40 (41.2%); only 11 (11.3%) occurred 
during the night. Ninety-three (93.9%) fractures followed a fall, in 70 (73.7%) the fall was 
on the same level (Table 3.2). The commonest cause for the fall was tripping 46 (48.9%) 
with change of posture during transfers next 36 (38.2%); most frequently from a chair 7 
(7.4%). However, many could not give a clear history of the fall, and the circumstances of 
the fracture remained uncertain in 5%. Eighty-five (91.4%) cases testified to good light 
conditions at the time of the fall. Seven cases sustained concomitant fractures at other sites 
at the time of the incident hip fracture. 
Ninety-five cases had surgery. The two most common operative procedures performed to 
stabilise the fractured were Dynamic Hip Screw and Thompson's hemiarthroplasty. These 
accounted for 85% of the operations performed (Table 3.3). Five cases were not considered 
fit for surgery and died within the week following hospitalisation. 
A significant number of fractures occurred in the winter months (Nov-Feb) despite lack of 
environmental factors locally that may predispose to them i. e. ice or snow (Figure 3.1). 
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Time of fracture 97 Morning 26 (26.8) 
Midday 14 (14.4) 
Afternoon 23 (23.7) 
Evening 23 (23.7) 
Night 11 (11.3) 
Light conditions 93 Light 85 (91.4) 
Dark 8 (8.6) 
Following a fall 93 on same level 70 (73.7) 
different level 23 (23.4) 
Number* = number of cases in whom data was available 
Table 3.3 Operative procedures 
Nature of operation (n=95) No (%) 
Dynamic Hip Screw 43 (44.1) 
Thompson's hemiarthroplasty 39 (41.9) 
Bipolar hemiarthroplasty 4 (4.3) 
Nailing 1 (1.1) 
Screws 8 (8.6) 
Twenty-nine (29%) cases were living alone in their homes when the incident took place. 
Twenty-five (25%) were living in care (residential and nursing home) see Table 3.5. No 
significant differences were found in respect of age, body mass index, residence, level of 
physical activity, nature and site of fall when comparisons were made between cases with 
cervical fracture against those with an intertrochanteric hip fracture (data not shown). 
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Figure 3.1 Seasonal variation in fracture occurrence 











Table 3.4 Characteristics of hip fracture cases and controls 
Variable No. Hip Fracture No. Controls Significance 
Mean (SD) Mean (SD) 
Age (yrs) 100 79.9 (9.4) 100 75.1 (9.6) <. 01 
Height (cms) 74 170.6 (8.4) 97 170.6 (7.7) NS 
Weight (kg) 85 67.8 (11.2) 97 77.7 (16.3) <. 01 
Body mass index (kg/m2) 72 23.4 (3.3) 97 26.7 (5.5) <. 01 
3.4.2 Age, Height, Weight And Body Mass Index In Cases And Controls 
Cases were significantly older compared to controls (p<0.01) Table 3.4. These differences 
principally resulted from the difficulty faced in getting healthy elderly controls living in 
community to volunteer. However, the mean age per decade between cases and community 
controls was similar (data not shown). 
Height and weight were recorded in 97 controls, and at or within 3 months of admission in 
74 and 85 of the fracture cases respectively. Missing observations were a result of frailty, 
co- morbid conditions, death or difficulty in getting fracture patients onto the scale. Men 
with hip fracture were lighter (cases: mean 67.8 kg, SD 11.2; controls mean 77.7 kg, SD 
Ä ti w 
º; 
özÄ ti 
Month of admission (Dec95-Jan97) 
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16.3 p<0.01) and had lower body mass index (23.4 kg/mz Vs 26.7 kg/m2 respectively) 
compared to controls. There was no difference in height. 
3.4.3 Demographic Characteristics In Cases And Controls 
Significant differences were noted in the marital and residential status between cases and 
controls. Cases more often lived in care or alone at home and were single 12 (12%) or 
widowed 30 (30%) at time of fracture compared to married controls 79 (79%) who were 
living with family in their own home Table 3.5. There was no significant difference in the 
type of area of residence (rural Vs. urban) either in childhood (rural 44.9% Vs 39%; urban 
55.1% Vs 61%); adult life (rural 35.7% Vs 29%; urban 64.3% Vs 71%) or recent past (rural 
45.9% Vs 33%; urban 54.1% Vs 67%) between cases and controls. 
Table 3.5 Demographic details in cases and controls 
Variable No Cases Controls Significance 
Marital status 100 Single 12 3 x2=15.7 
Married 55 79 d f--4 
Divorced 2 - p<0.003 
Separated 1 - 
Widowed 30 18 
Residence 100 Own home 66 92 x2=24.5 
Others home 4 4 d5 
Residential H 14 2 p<0.0002 
Nursing H 11 2 
Hospital 4 - 
Others 1 - 
Living status 100 Alone 29 16 x2=15.7 
With family 52 78 d2 
With others 19 6 p<0.0004 
Significantly more cases were fair complexioned than controls [91(93.8%) cases Vs 
72(72.7%) controls, x=15.6, df--1, p<0.001] and tended to less often have brown or black 2 
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iris compared to controls [16(16.5%) cases Vs 30(30%) controls, x2=5.5, dgl, p<0.03). 
However, no difference in hair colour was noted 
Sixteen (16.3%) cases had difficulty in reading the newspaper which was explained by 
6(6.1%) of the cases being blind and 10(10.2%) suffering from dementia or other conditions 
resulting in this handicap. None of the controls found this to be a problem and this 
difference was statistically significant xz =17.8, df 1, p<0.0001 Interestingly, all except 3- 
4% of subjects in both groups required the use of a visual aid/ spectacle. 
3.4.4 Life Style Characteristics In Cases And Controls 
There were significant differences in the main occupations of the two groups. The majority 
of cases (57/96,58.4%) had been involved in manual work especially mining or agriculture. 
By contrast the majority of controls (53/100,53%) had been office workers. This difference 
was highly significant (x, 2=15.6, df=4, p<0.004) as shown in Table 3.6. 
Significant differences were also noted in the level of physical activity carried out by both 
groups during childhood and recent past. The majority of cases (52/91,51.7%) had led a 
sedentary life in childhood compared to (32/100,32%) controls (x2=13.6, df=3, p<0.004). 
Almost half 45(49.5%) the cases confirmed spending none to less than half an hour walking 
every day prior to fracture compared to less than a third 30(30%) controls (x2=11.8, df3, 
p<0.008) However, there was no difference in the duration of previous prolonged 
immobilisation (defined as confinement to bed for a period of greater than 2 months) 
between the two groups. 
Milk consumption in childhood, based on recall memory, was significant lower in cases 
compared to controls. "Adequate" milk was defined as intake of 1 pint per day or its 
equivalent. Milk intake in childhood was inadequate in (43/86,50%) cases compared to 
(21/100,21%) controls (x2=18.1, df-3 p<0.0004). In contrast, milk intake in adult life and 
in the recent past was similar in both groups. No differences were found in current dietary 
calcium intake between the two groups. 
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Table 3.6 Various lifestyle data: comparison between cases and controls 
Variable Cases (%) Controls Significance 
Past occupation N=96 N=100 
Agriculture 21 (21.9) 7.0 x2=15.6 
Mining 36 (37.5) 30 df--4 
Office work 32 (33.3) 53 p<0.004 
Domestic 3 (3.1) 1 
others 4 (4.2) 9 
Activity as child N=91 N=100 
Sedentary 52 (57.1) 32.0 x2=13.6 
Light 29 (31.9) 55.0 d3 
Heavy 10 (11.0) 12.0 P<0.004 
Very Heavy - 1.0 
Current walking N=91 N=100 
None 24 (26.4) 9 x2=11.8 
Less than '/2 hr 21 (23.1) 21 df--3 
12 to 1 hr 22 (24.2) 29 P<0.008 
>1 hr 24 (26.4) 41 
Milk as a child N=86 N=100 
>3 glasses id 7 (8.1) 14 x2=18.1 
1-2 glasses /d 36 (41.9) 65 d3 
Every week 17 (19.8) 11 p<0.0004 
Less than once /wk 26 (30.2) 10 
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No differences in smoking habits were seen. Sixty nine (74.2%) cases and 70 (70%) controls 
had smoked sometime in life with 15 (16.1%) cases and 15 (15%) controls being current 
smokers (x2 =1.2, d2, p=NS). In both groups more than 60% had been heavy smokers 
defined as having consumed more than 10 cigarettes per day at some time in their life. 
Alcohol consumption was similar in the two groups. Twenty percent [18(19.6%) cases & 
20(20%) controls] in both groups denied ever having alcohol with over 80% of "ever" 
drinkers denying history of "excess" intake (defined as intake of more than 21 units of 
alcohol per week). Approximately 60% [57(62%) cases and 60(60%) controls] of subjects 
in both groups were currently consuming alcohol in an acceptable amount. 
3.4.5 Mental Status In Cases And Controls 
Mini mental score examination in cases within 48 hours of fracture and in controls at first 
visit showed significant difference (p<0.001) between the two groups. Forty eight (52.7%) 
cases versus 84 (84%) controls scored 10 (x2=20.4; df=l, p<0.01); 15 (16.5%) versus 3 
(3%) respectively scored less than or equal to 5. Mental status could not be assessed in 9 
cases due to severe dementia. 
3.4.6 Past And Family History Of Fracture In Cases And Controls 
History of any fracture following trivial trauma after the age of 40 years was recorded in 
order to see whether the subjects were accident-prone or showed signs of osteoporosis. 
History of previous fractures or family history of osteoporosis was not significantly different 
between the two groups (Table 3.7). Seventeen (17 %) cases and 12 (12%) controls gave a 
past history of a spontaneous fracture or following minor trauma (x2=2.7, d2, p=NS). 
Three (3%) cases but none of the control had a documented vertebral fracture in the past. 
Family history of fracture spontaneously or following minor trauma after age 40 years was 
seen in 5(5%) cases and 10(10%) controls. The most common relative to be affected was 
the mother and in the majority it involved the hip (Table 3.8). 
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Table 3.7 Past history of fracture after age 40 years following minimal trauma 
Level of No Site of fracture 
trauma 
Cases spontaneous 3 
minor 14 
Controls spontaneous 0 
minor 12 




Table 3.8 Family history of fractures after age 40 years following minimal trauma 
Level of No Relative with fracture Site of fracture 
trauma 
Mother Sister Father Several Hip Wrist Others 
Relatives 
Cases spontaneous 111 
minor 43131 
Controls spontaneous 111 
minor 96111513 
3.4.7 Co-Morbid Diseases In Cases And Controls 
Co-morbid diseases were present in the majority of cases and controls [79(82.3%) cases and 
54(57.4%) controls; x2=13.8; df=1, p<0.001]. Forty-seven (49%) cases had more than 2 
pre-existing co-morbid conditions compared to only 18(19.1%) controls (x2=29.7, df=7, 
p<0.0001). Cerebrovascular accidents, dementia, diseases affecting mobility like Parkinson's 
and poorer vision were significantly commoner in cases compared to controls (p<0.001). 
The most striking difference was in the number of subjects with dementia and Parkinson's; 
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26 and 14 versus 2 and 1 respectively in cases and controls. History of falls was significantly 
more frequent in cases compared to controls [35(36.5%) cases Vs 8 (8.4%) controls 
(x2=21.5, df=1, p<0.001)]. This could be explained by presence of co- morbid conditions 
like Parkinson's, poor vision, stroke, dementia and reduced mobility all of which were 
significantly commoner in the fracture cases than controls (Table 3.9). There was no 
significant difference in the frequency of heart disease (present in about 40% in both 
groups), thyroid disease, diabetes, osteoarthritis, malabsorption, gastro intestinal surgery, 
and dizzy spells between the two groups (data not shown). 
Table 3.9 Co-morbid risk factors: Odds ratios (adjusted for age) 
Co- morbid condition Cases Controls Odds ratio (95%CI) 
No (%) No (%) Adjusted for age 
Poor Vision 21 (21.9) 7 (7.4) 2.26 (0.86,5.93) 
Parkinson's 14 (14.6) 1 (l. 1) 14.76 (1.89,115.64) 
Dementia 26 (27.1) 2(2.1) 13.29 (3.01,58.70) 
Reduced mobility 25 (26.0) 4 (4.2) 8.36 (2.73,25.60) 
Falls 35 (36.5) 8 (8.4) 5.31 (2.27,12.42) 
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3.4.8 Concomitant Medications In Cases And Controls 
Use of medications was common in both groups. The most frequently used drugs were 
diuretics [29(30.2%) cases and 15(15.8%) controls; 2=5.6, df 1, p<0.02)] and hypnotics 
[10(10.4%) cases and 4(4.2%) controls; x2=2.7 df=1, p=NS)]. No significant differences 
were found in the frequency of intake of any particular medication that may be causally 
linked to the development of osteoporosis. 
3.4.9 Age-Adjusted Odds Ratios For Demographic And Lifestyle Risk Factors 
Odd ratios for risk of fracture associated with variables found significantly different between 
cases and controls were analysed using STATA. Correction for age difference between the 
groups was carried out using linear regression with age in the equation. Presence of co- 
morbid conditions increased the risk of hip fracture many fold: poor vision (OR 2.26; 
95%CI 0.86,5.93); reduced mobility (OR 8.36,95%CI 2.73,25.60) and dementia (OR 
13.29; 95%CI 3.01,58.7) Table 3.9. 
With married as referent marital status, being single increased the risk of hip fracture almost 
seven fold (OR 6.83; 95%CI 1.76,26.47) Table 3.10. Similarly, compared to living alone 
subjects living in care were at increased risk of hip fracture (OR 1.37; 95% CI 0.44,4.25) 
With no walking as referent a protective effect was noticed with increasing duration of 
walking: less than 30 minutes, 30-60 minutes and over 1 hour. The odds ratio were 0.37, 
0.31,0.26 respectively, with 95%CI ranging from 0.21 to 29.42. Similarly, milk intake in 
childhood and adult life was protective. With 3 glasses per day as referent the risk increased 
with reducing intake from 1-2 glasses per day to every week to less than once a week. The 
odds ratio were 1.94,2.12 and 2.62 respectively with 95% CI ranging from 0.33 to 14.60. 
Compared to never smokers, past versus current smokers were at increased risk of hip 
fracture (OR 1.35; 95%CI 0.54,3.38 and OR1.77 95%CI 0.58,5.45 respectively). 
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Table 3.10 Lifestyle risk factors: Odds Ratios (adjusted for age) 
Variable Categories Odds ratio (age adjusted) 
Marital status Married 1.0 
Single 6.83 (1.76,26.47) 
Divorced - 
Separated - 
Widowed 1.72 (0.84,3.51) 
Living Alone 1.0 
With relatives 0.38 (0.18,0.78) 
With others 1.37 (0.44,4.25) 
Residence on admission Home 1.0 
Others home 1.11 (0.26,4.80) 
Residential Home 7.56 (1.63,34.98) 
Nursing Home 5.56 (1.16,26.61) 
Hospital - 
Milk in childhood 3 glasses per day 1.0 
1-2 glasses per day 1.07 (0.3 9,2.93) 
Every week 2.54 (0.76,8.52) 
Less than weekly 4.3 (1.31,14.12) 
Walking in recent past None 1.0 
Less than 30 mins 0.37 (0.14,1.01) 
30-60 mins 0.31 (0.12,0.82) 
More than 1 hour 0.26 (0.10,0.66) 
Smoking Never 1.0 
In the past 1.35 (0.54,3.38) 
Current 1.77 (0.58,5.45) 
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3.5 CONCLUSION 
Low trauma hip fracture in elderly males is common with an incidence of 140/100,000/year 
in Cornwall, which exceeds the only pre-existing UK incidence data on male hip fractures 
(114/100,000/year) from a 1985 study of 22 males in Oxford (Boyce and Vessey, 1985). 
The highest risk of hip fracture is in the seventh and eighth decade of life. They are 
commoner in the winter months, most occurring indoors after minor falls during change of 
posture or a result of tripping. 
A number of sociodemographic and lifestyle variables are implicated in increasing fracture 
risk. These are being single (OR=6.8), living in care (nursing home OR=5.6; residential 
home OR=7.6), having low BMI (OR=4.2), along with multiple co-morbid conditions 
namely Parkinson's (OR=14.8), dementia (OR=13.3), reduced mobility (OR=8.4) and 
history of falls (OR=5.3). Regular walking (OR=0.26) and adequate intake of milk in 
childhood reduce the risk. 
The study has limitations. Cause-effect relationship between variables identified and risk of 
hip fracture cannot be established due to the cross sectional design of the study. Matching 
the two groups for age prevented studying age as a risk factor for hip fracture. The 
geographic location of the study prevented evaluation of race as a risk factor. 
Despite the above constraints and that the study was not strictly age matched it seems 
reasonable to conclude that simple measures like ensuring adequate calcium to children, 
encouraging regular walking in adult life, preventing falls and overall general improvement 
of health in the elderly men may reduce the burden of low trauma hip fractures. Preventive 
measures targeting the "high risk" individual namely single men, living alone or in care with 
low BMI, multiple co-morbid diseases and history of falls may reduce the number of hip 
fractures in this age group. 
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4. BONE MINERAL DENSITY: A RISK FACTOR FOR LOW 
TRAUMA HIP FRACTURE IN MEN 
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4.1 SUMMARY 
This chapter explores bone mineral density (BMD) and its determinants in a community 
population of elderly men, compares these results with a matched hip fracture population 
and examines the role of BMD as a risk factor for low trauma hip fracture in men. 
The populations studied (hip fracture cases and community controls) are those detailed in 
chapter 2. Sixty-two (62%) cases and all 100 controls underwent BMD measurement, at the 
lumbar spine and the proximal femur. BMD was measured by dual energy x-ray 
absorptiometry (DEXA). In fracture cases this was within one week of fracture and in 
controls at the time of their first visit. Interviewer assisted questionnaire collected data on 
lifestyle variables (appendices 2). Laboratory parameters were assessed as outlined in 
chapter 2. 
A good correlation was seen between BMD at different sites in the control population. 
Mean BMD in community living men was 0.75g/cm2 at the femoral neck and 1.08g/cm2 at 
the lumbar spine. 39% of men aged over 50 years fulfilled the WHO criteria of osteoporosis 
at the femoral neck and 5% at the lumbar spine. BMD at the lumbar spine increased with 
advancing age; perhaps an effect of degenerative spiral disease. No significant age related 
changes were observed at the proximal femur. A significant positive relationship was seen 
between body mass index (BMI) and BMD at all sites; rs =0.42; p<0.01 for lumbar spine and 
r, =0.24; p<0.05 for femoral neck. Weight, physical activity like regular walking, past and 
family history of fracture together explained 20% of the variance in femoral neck BMD. 
Cases had significantly lower BMD at all sites compared to controls: femoral neck 
(0.61g/cm2 Vs 0.76g/cm2 p<0.001) and lumbar spine (0.92g/cm2 Vs 1.08g/cm2 p<0.001). 
Cases were 7 times more likely to have osteoporosis at the femoral neck (OR 7.2,95%CI 
3.3,15.9) and 10 fold more likely at the lumbar spine (OR 9.7,95%CI 3.4,27.8) compared 
to controls using WHO criteria. Using this definition low BMD increased the risk of hip 
fracture over 6 fold (Odds ratio (OR) 6.2-27.9 dependant upon the site measured). 
This study shows that femoral neck BMD in the elderly men is influenced by BMI, physical 
activity, past and family history of fractures and levels of testosterone, oestrogen and urinary 
cross links but not significantly by age and calciotropic hormones. Low BMD is an 
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important risk factor for low trauma hip fracture in these elderly men. After adjusting for 
age, height and weight the risk of hip fracture is substantial per 0.1mg/cm2 decrease in bone 
mass: lumbar spine - OR=1.2,95% CI 1.0,1.6, femoral neck - OR=2.0,95% CI 1.3,3.1. 
4.2 BACKGROUND 
The importance of low BMD as a risk factor for hip fracture is well established in women 
(Marshall et al, 1996). Each standard deviation reduction in bone mass increases the risk of 
hip fracture by a factor of 1.5-3 fold in women with the diseases (Marshall et al, 1996). Data 
for BMD in male hip fractures is sparse, yet one third of all hip fractures worldwide (Melton 
et at, 1998) occur in men. The data that does exists comprises of three small case-control 
(Karlsson et at, 1993; Greenspan et at, 1998; Boonen et al, 1997) and one population-based 
cohort study (Nguyen et at, 1996) of 820 men that included 31 hip fractures only. All found 
low BMD in hip fracture cases. 
These studies have imitations. They include small numbers (ranging between 7 and 40 
fractures), BMD measurements not contemporary to fracture and selection bias with 
exclusion of the very elderly and those in institutions. A study designed at capturing 
consecutive male hip fractures from a defined population and comparing data with controls 
randomly selected from the representative community would overcome these limitations. 
With this background this case control study measured BMD within one week of fracture 
and imposed no restrictions on age and place of residence. 
This chapter explores BMD as a risk factor for low trauma hip fracture in men. In addition it 
analyses lifestyle and hormonal variables that may influence / determine BMD in men. The 
results of the analysis are presented as follows: 
i) BMID and its determinants in community dwelling elderly men 
ii) Comparison of BMD in men with a hip fracture versus men living in community 
iii) BMD as a risk factor for low trauma hip fracture in men 
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4.3 PATIENTS AND METHODS 
4.3.1 Study Design 
100 consecutive men with low trauma hip fracture over a 14-month period were identified 
as cases. Simultaneously, an equal number of community living men were randomly 
recruited as controls. Details of study design, exclusion and inclusion criteria are given in 
chapter 2. 
4.3.2 Bone Mineral Density Measurements 
BNID was measured at both the lumbar spine and proximal femur by dual energy x-ray 
absorptiometry (DXA) using Hologic QDR 1000 on all subjects capable of lying still in a 
specified position on the scanner for at least 10 minutes. In cases this was within 7 days of 
the hip fracture and in controls at the time of their first visit. Controls had their right hip 
scanned; cases the non-fractured hip. The coefficient of variation in BMD in our unit is 
0.40% calibrated daily using the spine phantom. 
BMD was measured in all (100) controls and only 62 (62%) cases. In 4 of these 62 cases 
BMD measurements were possible at the lumbar spine but not at the femur. This was due to 
metal prosthesis in the non fractured hip following arthroplasty for osteoarthritis in 2 cases, 
inability to lie still on the scanner due to extreme frailty in 1 and difficulty in positioning due 
to extreme obesity requiring use of a hoist in 1 case. Early death, severe co-morbidity's, 
uncontrolled Parkinson's and extreme frailty explain why measurements were not performed 
in 36 cases. 2 patients refused scanning. 
4.3.3 Anthropometry 
Height and weight was measured in 97 controls at the time of their first visit. 2 controls 
were diabetic amputees and 1 very frail making measurements difficult. Height and weight 
was recorded at the time of admission or within subsequent 3 months in 74 and 85 fracture 
cases respectively. Missing observations were due to early death, extreme frailty and co- 
morbid conditions. 
4.3.4 Endocrine Status And Bone Markers 
Samples for assessing the endocrine status (androgen, oestrogen, vitamin D, parathyroid 
hormone) and bone markers (osteocalcin, urinary free deoxypyridinoline) were collected at 
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first visit and at 6 months in both groups. Details of the measurements performed, assays 
used and timing of the assays are presented in chapter 2. To explore the relationship 
between these laboratory parameters and B1VID, baseline results amongst controls were used 
as they were contemporary to BMD measurements and not altered by the acute phase 
response following the fracture. 
4.3.5 Lifestyle Questionnaire 
Data on lifestyle variables was collected using an interviewer assisted questionnaire based on 
the EVOS (European Vertebral Osteoporosis Study) study forms which was administered at 
the time of initial assessment to both groups. The questionnaire is attached in appendix 2. 
4.3.6 Analysis 
All data was entered in EXCEL, then transferred to SPSS and STATA for statistical 
analysis. For categorical variables, percentages were calculated and significance tested using 
Pearson chi-square. Age adjustments were made in calculating odds ratios using STATA. 
4.4 RESULTS 
4.4.1 BMD In Community Controls 
BMD was measured in all 100 controls. The mean age was 75.1 years (range 50-97); mean 
weight 77.7 kg (range 46.1-176.4) and mean body mass index 26.7 (range 18.5-66.2). 
Mean BMD at the femoral neck was 0.76g/cm2 and at the lumbar spine it was 1.08 g/cm2 
(Table 4.1). Using the WHO definition of osteoporosis (T score less than 2.5 SD of normal 
mean) 39% fulfilled the criteria of osteoporosis at the femoral neck and 5% at the lumbar 
spine. Twenty-nine of the 39 (74.3%) with WHO defined osteoporosis were over 70 years 
of age. 
BMD at all sites correlated well with each other; Spearman's correlation (r) ranging 
between 0.50-0.83. Correlation between the lumbar spine and femoral neck was r, = 0.50; 
p<0.01, n= 100. 
4.4.1.1 Influence of age and BMI on bone density in community men: 
Age showed no significant correlation with BMD at any site (Figure 4.1). A trend towards 
increasing BMD at the lumbar spine with advancing age was noted (rs = 0.15; p= NS). This 
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may be explained by coexisting degenerative spinal disease in the elderly. Age explained only 
0.2% of the variance in femoral neck BNID (r2 = 0.002) and 2% of lumbar spine BMD 
(r2=0.02) using linear regression with the dependant variable being site specific BMD and 
independent variable age. 
BMD correlated with BMI at both the lumbar spine (rs=0.42; p<0.01) and the femoral neck 
(rs =0.24; p<0.05). 
Table 4.1 Subject characteristics and BMD (g/cm2) in community controls 
Variable No Mean (SD) 
Age (yrs) 100 75.1 (9.6) 
Weight (kg) 97 77.7 (16.3) 
Body mass index (kg/m2) 97 26.7 (5.5) 
Lumbar spine (g/cm2) 100 1.08 (0.20) 
Femoral neck BMD (g/cm2) 100 0.76 (0.13) 
Intertrochanteric BMD (g/cm2) 100 1.06 (0.16) 
Trochanteric BMD (g/cm2) 100 0.75 (0.13) 
Wards Triangle BMD (g/cm2) 100 0.52 (0.14) 
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4.4.1.2 Influence of androgens, oestrogens, calciotropic hormones and bone markers: 
BMD showed positive correlation with both sex hormones, testosterone and oestrogens. 
Androgens (testosterone, free androgen index, free testosterone) had a significant positive 
correlation with BMD at the femoral neck (r, =0.25, n=97, p<0.01) but not at the lumbar 
spine. By contrast, oestrogen showed a significant correlation with BMD at both sites: 
femoral neck (r, =0.25, n=98, p<0.01) and the lumbar spine (r, =0.24, n=98, p<0.01). Using 
linear regression with dependant variable being site specific BMD and independent variable 
sex hormones (free androgen index and oestrogen) oestrogen seemed the more powerful 
determinant of BMD at either site. Individually they explained 6% (r2=0.057) and 12% 
(r2=0.12) of the variance in femoral neck BMD respectively. Multiple regression analysis 
was carried out with site specific BMD as the dependent variable and both free androgen 
index and oestrogen as predictors in the model. The analysis showed that both sex hormones 
played a role in determining BMD at the femoral neck but not at the lumbar spine (Table 
4.2). In combination they explained 17% of the variance in femoral neck BMD (r2=0.17). 
Oestrogen alone accounted for only 0.6% (r2=-0.006) variance in BMD at the lumbar spine. 
Vitamin D and parathyroid hormone did not bear any relation to BMD at any site. Amongst 
the bone markers urinary free deoxypyridinoline exhibited a significant negative correlation 
with BMD at the femoral neck (rs =-0.21, n=96, p<0.05) but not at the lumbar spine. Bone 
formation marker, osteocalcin, did not show any relation to BMD at any site. 
Table 4.2 Multiple regression: Sex hormones as predictors of femoral neck BMD 
Model B SE B Beta Sig 
Constant 0.609 0.036 0.000 
Oestradiol 0.0007 0.000 0.317 0.002 
Free androgen index 0.001 0.001 0.194 0.05 
4.4.1.3 Influence of anthropometric & lifestyle factors on bone density: 
Variables known to influence BMD in women such as current height and body mass index, 
tobacco and alcohol intake, current dietary calcium, current walking, history of 
immobilisation, past and family history of fractures were initially considered for formulating 
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a regression model at each skeletal site. The variables included in the final model of BMD 
prediction was based on the results of a regression using backward elimination with the 
probability of "F" to eliminate set at >0.1 and "T" to include set at p<0.05. The regression 
analysis showed current weight, walking, past and family history of fracture as significant 
predictors of BMD at the femoral neck (Table 4.3). Together they explained about 20% of 
the variance in BMD at this site (r2=0.19). 
Predictors of BMD at the lumbar spine were different with the combination of BMI and 
calcium intake explaining 17% of the variance (r2=0.174) see Table 4.4. 
Table 4.3 Multiple regression: Predictors of femoral neck BMD 
Model B SE B Beta Sig 
Constant 0.56 0.08 0.0001 
Current Weight 0.002 0.001 0.23 0.02 
Walking 0.07 0.03 0.26 0.009 
Past H of Fracture -0.07 0.03 -0.25 0.01 
Family H of Fracture -0.07 0.04 -0.18 0.07 
Table 4.4 Multiple regression: Predictors of lumbar spine BMD 
Model B SE B Beta Sig 
Constant 0.58 0.14 0.0001 
Body mass index 0.02 0.005 0.332 0.001 
Calcium 0.09 0.04 0.214 0.03 
4.4.2 BMD In Fracture Cases 
BIVID was measured in 62 cases within one week of fracture. Early death, extreme frailty 
and co-morbid conditions like Parkinson's explain the missing observations in 36 cases. 2 
cases refused scanning. Four of the 62 where BMD was measured could not have their hip 
scanned due to metal prosthesis in the non-fractured side in 2 cases, extreme frailty in 1 and 
obesity in 1 case. 
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Cases who could not be scanned (n=38) were significantly older (mean age 82.63 95% CI 
80.34,84.91) than those where measurements were performed (mean age 78.0 95%CI 
75.41,80.59; p<0.01). There was no significant difference in height, weight and body mass 
index between the two groups (data not shown). 
The mean age of the 62 cases was 78.4 years (range 53.7-97); mean weight 67.6 kg (range 
50.8-93.2) and mean body mass index 23.4 kg/m2 (range 16.4-33.4). BNID at the femoral 
neck was 0.61gm/cm2 (95% CI 0.59,0.64); at the lumbar spine it was 0.92 gm/cm2 (0.87, 
0.97) see Table 4.5. Using the WHO definition of osteoporosis (T scores <-2.5), 83% 
(48/58) fracture cases had osteoporosis at the femoral neck and 36% (22/62) at the lumbar 
spine (Table 4.6). Thirty-eight of the 48 (79.1%) cases with osteoporosis were 70 years of 
age or older. 
Table 4.5 BMD in fracture cases 
Site BMD Osteoporosis (T<-2.5) 
No Mean SD No % 
Femoral neck (g/cm2) 58 0.61 0.11 48 82.8 
Trochanteric (g/cm2) 58 0.58 0.13 22 37.9 
Inter-trochanteric (g/cm2) 58 0.82 0.14 35 60.3 
Ward's triangle (g/cm2) 58 0.38 0.11 52 91.2 
Lumbar spine (g/cm2) 62 0.92 0.20 22 36.1 
Table 4.6 Percentage of cases & controls with osteoporosis at different sites: 
Using WHO definition T<-2.5 
Site Osteoporosis (T<-2.5) 
Cases Controls 
no(%) no(%) 
Femoral neck 48/58 82.8 39/100 39.0 
Trochanteric 22/58 37.9 2/100 2.0 
Inter-trochanteric 35/58 60.3 11/100 11.0 
Ward's triangle 52/58 91.2 61/100 61.0 
Lumbar spine 22/62 36.1 5/100 5.0 
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Relationship between BMD and age was analysed using linear regression with the dependant 
variable - site specific BMD and independent variable age. 12.8% of the variance in femoral 
neck BMD (r2=0.128) and only 1.6% (r2=0.16) of the variance in lumbar spine BMD could 
be accounted for by age. Since, all anthropometric recordings were not contemporary to 
BMD measurement, role of BMI in determining BMD in fracture cases was not explored. 
Similarly, role of androgens, oestrogens, bone markers and calciotropic hormones in 
determining BMD in the fracture population was not analysed. Due to changes expected in 
the hormonal environment following a fracture, baseline samples were not considered 
appropriate to reflect the individuals' normal physiological state. 
4.4.3 Comparison Of BMD Between Fracture Cases And Community Controls 
BMD was measured at both the lumbar spine and proximal femur in 62 cases and all 100 
controls. Bone mineral density was significantly lower in fracture cases than controls at all 
four sites of the proximal femur and at the lumbar spine - see Fig 4.2. At the femoral neck 
BNID was 0.61gm/cm2 (95% CI 0.59,0.64) in the fracture cases and 0.76 gm/cm2 (0.73, 
0.78) in the controls p<0.001. At the lumbar spine it was 0.92 gm/cm2 (0.87,0.97) and 1.08 
gm/cm2 (1.04,1.12) respectively; p<0.001. These differences persisted after adjusting for 
age and body mass index (Table 4.7). 
Figure 4.2 BMD in cases and controls 
Q Cases ® Controls 
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Table 4.7 BMD (g/cm2) in cases and controls (mean, SD are shown) 
Site Cases n =62 Controls n =100 
Mean SD Mean SD t test * 
Femoral neck (g/cm2) 0.61 0.11 0.76 0.13 <0.01 
Trochanteric (g/cm2) 0.58 0.13 0.75 0.13 <0.01 
Inter-trochanteric (g/cm2) 0.82 0.14 1.06 0.16 <0.01 
Ward's triangle (g/cm2) 0.38 0.11 0.52 0.14 <0.01 
Lumbar spine (g/cm2) 0.92 0.20 1.08 0.20 <0.01 
* significance level after adjusting for age, body mass index 
Using the WHO definition of osteoporosis (T scores <-2.5), 83% (48/58) fracture cases had 
osteoporosis at the femoral neck compared with 39% (39/100) controls. At the lumbar spine 
36% (22/62) cases had osteoporosis compared with 5% (5/100) controls. Thirty-eight of the 
48 (79.1%) cases with osteoporosis were 70 years of age or older (Table 4.6). 
Relationship between BMD and age was analysed using linear regression. The dependent 
variable was site specific BMD and the independent variable age. This showed that 12.8% of the 
variance in femoral neck BMD (r2=0.128) in fracture cases but only 0.2% of the variance in 
controls was explained on the basis of age. Relationship between age and lumbar spine BMD in 
both groups was similar 1.6% (r2=0.16) in cases and 2% (r2=0.02) in controls. 
4.4.4 BMD As A Risk Factor For Low Trauma Hip Fracture In Men 
Bone density at the lumbar spine and all sites of the proximal femur was significantly lower 
in the fracture cases than in the controls. After adjusting for age, height and weight the risk 
of hip fracture increased substantially per 0.1mg/cm2 decrease in bone mass: lumbar spine - 
OR=1.2,95% CI 1.0,1.6; femoral neck - OR=2.0,95% CI 1.3,3.1. Similarly, after 
adjusting for age, height and weight, the risk of hip fracture increased for each standard 
deviation reduction in bone mass at all sites measured: lumbar spine (OR=1.8), femoral neck 
(OR=3.1), trochanter (OR=3.9), inter-trochanteric area (OR=4.0) and wards triangle 
(OR=3.7) see Table 4.8. 
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Table 4.8 BMD in hip fracture cases and controls 




Sig^ Odds Ratio/ 1 SD change$ 
Mean (SD) Mean (SD) OR* (95% CI) OR+ (95%CI) 
Lumbar Spine 0.92 (0.2) 1.08 (0.2) <0.01 2.4 (1.6,3.5) 1.8 (1.2,2.9) 
Femoral Neck 0.61 (0.1) 0.76 (0.1) <0.01 4.2 (2.5,7.1) 3.1 (1.8,5.3) 
Trochanteric 0.58 (0.13) 0.75 (0.13) <0.01 4.1 (2.5,6.6) 3.9 (2.2,6.9) 
Inter-trochanteric 0.82 (0.14) 1.06 (0.16) <0.01 4.9 (2.9,8.3) 4.0 (2.3,7.1) 
Ward's triangle 0.38 (0.11) 0.52 (0.14) <0.01 4.5 (2.6,8.0) 3.7 (2.0,6.8) 
4 significance level; * adjusting for age; + adjusting for age, height, weight; 
$ For BNID - per 1 standard deviation decrease in measurement 
Using WHO definition (T score less than 2.5 SD of normal) the presence of osteoporosis at 
the femoral neck or the lumbar spine increased the risk of hip fracture 7-28 fold depending 
on the site measured (Table 4.9). 
Table 4.9 Bone mineral density as risk factor for fracture 
Site Abnormal T score Odds Ratio 
Lumbar spine <2.5 9.2 (3.2,26.4) 
Femoral neck <2.5 6.9 (3.1,15.3) 
Trochanteric <2.5 27.9 (6.1,126.9) 
Intertrochanteric <2.5 13.2 (5.5,31.5) 
Ward's triangle <2.5 6.2 (2.3,16.9) 
All odds ratios are adjusted for age. 95% confidence intervals are shown. 
Among the 62 hip fracture cases with BMD measurements, there were 31 men with a 
cervical and 31 with an inter-trochanteric fracture. Compared to those with an inter- 
trochanteric fracture, those with a cervical fracture were slightly older (79.0 years Vs 77.0 
years), taller (172 cms Vs 170.4 cms) and lighter (67.5kg Vs 67.8 kg) however, none of 
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these differences were statistically significant. Those with an inter-trochanteric fracture had 
lower BMD at all sites, though this was significant for the trochanteric region only, see 
Table 4.10. After adjusting for age, height and weight, the risk of inter-trochanteric 
(compared to cervical) fracture increased per standard deviation reduction in bone mass at 
the trochanteric region (OR=2.5; 95%CI 1.2,5.4), see Table 4.10 
Table 4.10 BMD in individuals with cervical and intertrochanteric fractures 




Odds Ratio/ 1 SD change$ 
Mean (SD) Mean (SD) OR* (95%CI) OR+ (95%CI) 
Lumbar Spine 0.96 (0.20) 0.88 (0.19) 1.7 (1.0,2.9) 1.5 (0.8,3.1) 
Femoral Neck 0.63 (0.11) 0.60 (0.11) 1.6 (0.8,3.3) 1.7 (0.8,3.7) 
Trochanteric 0.63 (0.14) 0.53 (0.10) 4. 2.9 (1.4,5.9) 2.5 (1.2,5.4) 
Inter-trochanteric 0.85 (0.14) 0.79 (0.14) 1.8 (0.9,3.5) 1.6 (0.8,3.2) 
Ward's triangle 0.38 (0.10) 0.37 (0.11) 1.1 (0.6,2.3) 1.4 (0.7,3.2) 
4 significant p<0.01; * adjusting for age; + adjusting for age, height, weight; 
$ Inter-trochanteric Vs cervical fracture; For BNM - per 1 standard deviation decrease in 
measurement 
4.5 CONCLUSION 
There is no existing criterion for diagnosing osteoporosis in men. Using the WHO definition 
for women, 39% of men living in community aged 50 years and over suffer with 
osteoporosis. Majority (74%) of these are very elderly (aged 70 years and over). Different 
lifestyle and laboratory variables influence BMD at various sites. While physical activity like 
regular walking, past and family history of fractures influences BMD at the femoral neck, 
calcium intake is important for lumbar spine bone density. BMI influences BMD at both 
sites. By contrast age has no correlation with BMD at any site in elderly men. Similarly, 
amongst the laboratory parameters androgens, oestrogens and bone resorption marker 
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urinary cross-links predict BMD at the femoral neck but not at the lumbar spine. The 
contribution of oestrogen is higher (12%) compared to testosterone (6%). Together they 
account for 17% of the variance in bone density at the femoral neck. In contrast, the role of 
bone formation marker osteocalcin and, calciotropic hormones vitamin D and parathyroid, in 
influencing BMD at any site is marginal/ insignificant. 
Men with hip fracture are 7-10 times more likely to fulfil the WHO criteria for osteoporosis 
at any site compared to men living in community. This study was not designed to evaluate 
relationship between BMD and risk of hip fracture in men. The study has however shown 
that a reduction in BMD is associated with an increased risk of hip fracture in men. The 
associations are stronger for measurements at the proximal femur than the lumbar spine. 
The magnitude of the risk of hip fracture associated with femoral neck BMD has been 
reported in several studies. Nguyen reported a 66% reduction in risk of hip fracture (n=3 1) 
per SD increase in BMD at the femoral neck (Nguyen et al, 1996), while De Laet (De Laet 
et al, 1998) reported a3 fold increase in risk of fracture (n=23) associated per SD decrease 
in BMD. These data are similar to the findings of this study of a 3.1 fold increase in risk per 
SD decrease in femoral neck BMID. 
The strength of the association between bone mass and fracture risk was greater for the 
measurements at the hip than those at the spine. This may be in part due to the presence of 
concurrent degenerative disease which leads to an artifactual increase in spinal bone density 
(Masud et al, 1993; Jones et al, 1996). 
Bone mass, at all sites was lower in those with an inter-trochanteric compared to those with 
a cervical fractures, though the difference was significant for the trochanteric measurement 
site only. Similar findings have been reported using the Singh Index in men (Sernbo et al, 
1989) and DEXA in women (Karlsson et al, 1993; Greenspan et al, 1994). 
The study has limitations. It is using a cross sectional design to study the effects of age and 
other variables on BMD. Relationship between BMD and risk of fracture is explored 
applying the "WHO criteria for women" in "men", in the setting of a case control design. 
Recall bias cannot be excluded in collecting data on lifestyle variables dating back to 
childhood despite using standardised questionnaires in this elderly population. Also, the 
numbers of variables studied are large which may affect the power of the study to analyse 
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their individual effects on BMD and fracture risk. The constraints of using an anterior 
posterior view in measuring BMD at the lumbar spine using Hologic QDR1000 affecting 
measurements in the elderly due to degenerative spinal disease must not be forgotten. 
Furthermore, fracture cases were recruited consecutively, and none invited declined to 
participate. Controls were recruited from a local general practice and a proportion (46%) 
declined. If this was because they were less healthy and therefore likely to have lower bone 
mass than those who took part, the observed differences in BMD between fracture cases 
and controls may have been overestimated. 
The frailty and poor mobility of cases immediately after the hip fracture caused difficulties in 
obtaining data concerning bone mass in a significant proportion (38%). Individuals in whom 
BMID was not assessed were older and greater proportion had co-morbidities than those 
who were assessed-factors again likely to be linked with lower BMD. The effect of such a 
selection bias would be to underestimate the strength of the relationship between hip 
fracture and BMD. 
In conclusion, a significant percentage (39%) of men living in community suffer with 
osteoporosis. Most of this is undiagnosed. Modification of lifestyle variables that influence 
bone density may help reduce the burden of the problem. Within the constraints of the study 
design low BMD is a significant risk factor for hip fracture in men. Studies are needed to 
establish a criterion for diagnosing osteoporosis in men and to quantify the risk of fracture 
associated. This will help in our understanding of this neglected problem in men and help 
plan measures to reduce the absolute number of hip fractures worldwide. 
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5. HIP AXIS LENGTH 
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5.1 SUMMARY 
This chapter explores whether hip axis length (HAL) is a risk factor for low trauma hip fracture 
in elderly men. 
Data on hip axis length was collected from the same subjects recruited in the case control study 
(described in chapter 2). Hip axis length was measured in all 100 controls and 58 of the 100 
fracture cases. Hip axis length, defined as the linear distance from the base of the greater 
trochanter to the inner pelvic brim was measured using software provided with the scanner 
(Hologic QDR 1000). Measurements were performed at the same time as the bone mineral 
density estimates of the proximal femur. Controls had their right hip measured, cases the non- 
fractured hip. In cases this was within one week of the fracture and in controls at the time of their 
visit. Missing observations were a result of frailty, early death or co-morbid diseases making 
measurements impossible. 
Men with hip fracture were older and had significantly lower body mass index. This was due to 
low weight rather than height. No differences were seen in hip axis length between the two 
groups (12 cms Vs 12.1 cms). HAL correlated with height (r, =0.56, p<0.05) but not age. There 
was no relationship between HAL and the risk of hip fracture (Odds ratio [OR]=0.9 (95% CI 
0.6,1.3); this remained true after adjusting for height (OR=0.9 (95% CI 0.5,1.5). 
Results from this study suggest that assessment of hip axis length does not help predict risk of hip 
fracture in elderly Caucasian men. This study is limited by its cross sectional design. Prospective 
data are required to confirm these findings. 
5.2 BACKGROUND 
In the UK there are 70,000 low trauma hip fractures annually (Mc Coll et al, 1998) which cost 
the NHS 942 million pounds per year (Mc Coll et al, 1998). One third occur in men (Cooper et 
al, 1992). Identification of those at high risk of hip fracture would help target preventive therapy 
and reduce the health burden associated with these fractures. To date, bone mineral density is one 
of the best predictors of the risk of hip fracture in women and men (Marshall et al, 1996). The 
previous chapter (chapter 4) confirms low BMD to be a risk factor for hip fracture in our elderly 
community population. 
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Recent studies of risk factors for hip fractures in Caucasian women have suggested that 
factors other than BNM may be important in hip fracture prediction (Faulkner et al, 1993). 
Two measures of structural geometry of the proximal femur, namely hip axis length (HAL) 
and femoral neck axis length (FNAL), have recently drawn much attention (Peacock et al, 
1995). In women, a1 SD increase in hip axis length (HAL) - the distance from the base of the 
greater trochanter to the inner pelvic rim along the femoral axis, is associated with a 1.8 fold 
increase in hip fracture risk (Faulkner et al, 1993). Femoral neck axis length (FNAL) where 
measurements exclude the acetabulum however, has not been shown to confer risk in either 
sex (Peacock et al, 1995), but the data in men is scanty (Center et al, 1998). There is no 
data on HAL in men. 
The study capitalised on the ability to measure hip axis length using the automated method 
by use of a software specifically designed and compatible with the scanner simultaneous to 
BMD measurements of the proximal femur. All cases and controls that underwent BMD 
measurements at the proximal femur also had their hip axis length measured at the same 
time. 
With this background, this chapter explores HAL as a risk factor for low trauma hip fracture 
in men in a case control setting. 
5.3 METHOD 
5.3.1 Study Design 
This study used a case-control design with prospective and simultaneous recruitment of 
subjects in both groups over 14 months. They are the same subjects that are detailed in 
chapter 2. 
5.3.2 Cases And Controls 
100 consecutive male admissions to the Royal Cornwall Hospital with a "low trauma" hip 
fracture aged 50 years and over were recruited as cases. Simultaneously, 100 closest age- 
matched controls were randomly recruited from a local GP register. Full details are given in 
chapter 2. All subjects capable of lying still with their hip joint internally rotated and 
strapped in a specified position on the scanner (Hologic QDR1000) for at least 10 minutes 
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were consented for measurement of the HAL. This was performed simultaneous to BMD 
measurement at the proximal femur. Measurements were carried out within one week of the 
fracture in cases and at the time of the first visit in controls. 42 (42%) fracture cases could 
not have HAL measured. This was a result of extreme frailty, co-morbid conditions such as 
Parkinson's or death. 
5.3.3 Hip Axis length Measurement 
A software with the scanner (Hologic QDR 1000) specifically designed for this purpose was used 
to calculate the distance between the base of the greater trochanter and inner pelvic brim in 
centimeters (cms). The coefficient of variation of the scanner was 0.4%. Controls had their right 
hip measured, cases the non -fractured side. Measurements as mentioned earlier were within one 
week in fracture cases and at the time of the first visit in controls. 
5.3.4 Analysis 
Data was entered on EXCEL and descriptive analysis and intergroup comparisons using Mann 
Whiney U test carried out using SPSS version 7.5. Logistic regression was performed using 
STATA version 4.0. 
5.4 RESULTS 
5.4.1 Hip Axis Length In Community Controls 
The mean age of the 100 community controls that had HAL measured was 75.1 years. The mean 
hip axis length was 12.1 cms, SD 0.8 cms and the range was 10.1-13.8 cms. HAL correlated 
with height (r, =0.56; p<0.05) but not with age. There was no relation between HAL and 
BMD at any site. 
5.4.2 Hip Axis Length In Men With Hip Fracture 
Mean HAL, in the 58 cases where measurements were made was 12.0 cms, SD 0.8 cms, and 
range 9.5-13.4 cms. Death, extreme frailty and co-morbid diseases explained the missing 
observations in 42 (42%). Amongst fracture cases, men who could have HAL measured (n=58) 
were younger (mean age (SD) 78.0 (10.1) Vs 82.6 (7.6); p<0.01) than those where 
measurements were not performed (n=42); there was no significant difference in height, weight 
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and body mass index. Comparing HAL between the two types of hip fracture there was no 
significant difference between cases with cervical (n=28) and trochanteric (n=30) hip fracture 
(mean (SD) 12.1(0.6) Vs mean (SD) 11.8 (0.8); p=NS). Also, comparing the anthropometric 
characteristics between these two groups there was no significant difference in age, height, 
weight or body mass index. There was no correlation of HAL with BNM at any site. 
5.4.3 Comparison Between Cases And Controls 
HAL was measured in 58 (58%) cases and 100 (100%) controls. Compared to controls, 
men with hip fracture were older and had significantly lower body mass index due to lower 
weight (Table 5.1). Differences in height were not significant. Hip axis length was similar in 
both groups (12 cros Vs 12.1 cms) and correlated with height (r=0.56, p<O. 05) but not age. 
Table 5.1 Characteristics of hip fracture cases and controls 
Variable Hip Fracture Controls 
n=58 n=100 
Mean (SD) Mean (SD) Significance 
Age (yrs) 78.0 (10.1) 75.1 (9.6) NS 
Height (ems) 171.2 (8.7) 170.6 (7.7) NS 
Weight (kg) 67.1 (10.6) 77.7 (16.3) . 
01 
Body mass index (kg/m2) 23.2 (3.3) 26.7 (5.5) . 
01 
Hip axis length (cm) 12.0 (0.8) 12.1 (0.8) NS 
5.4.4 Hip Axis Length As Risk Factor For Hip Fracture 
Using logistic regression there was no association between HAL and risk of hip fracture (Odds 
ratio [OR]=0.9 (95% Cl 0.6,1.3); this remained true after adjusting for height (OR=0.9 (95% Cl 
0.5,1 . 5). 
5.5 CONCLUSION 
Results from this study indicate no association between HAL and risk of hip fracture in men. The 
mechanism by which HAL results in an increase in risk of hip fracture in women is unknown. 
Previous studies suggest that the risk persists after adjustment for body height and weight 
indicating it is not a surrogate for body size (itself linked with an increased risk of hip fracture). It 
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has been suggested that HAL is a marker for the ability of the femur or pelvis to absorb or avoid 
the impact of a fall. There are important gender differences in both the shape of the proximal 
femur and pelvis including the pelvic brim which may influence bone strength or resistance to 
fracture. It is possible that one or more of these shape parameters interact with HAL, and explain 
the discrepant findings in relation to fracture risk in men and women. 
Osteoarthritis (OA) reduces HAL by reduction in hip joint space as a result of degenerative 
changes of the articular cartilage. OA is also associated with a reduced risk of hip fracture. 
These factors may confound the association between HAL and fracture risk. In our study 
there was no significant difference in the number of subjects with known OA between the 
two groups (chapter 3). 
Height has recently been shown in several large prospective studies in men and women to be 
related to the risk of hip fracture. This may reflect longer hip axis length and increased 
mechanical impact. In our study there was a significant correlation between HAL and height 
consistent with earlier studies but there was no significant difference in height between our 
fracture cases and controls. Obesity is associated with a decreased risk of fracture. Weight 
and BMI were significantly different in our study but there was no correlation of HAL to 
BMI. 
Results in this chapter suggest that assessment of hip axis length does not help predict hip 
fracture in men. Consequently, it should not be included in risk evaluation. It also highlights the 
need for caution in extrapolating the predictive risk of HAL observed in female Caucasians, to 
other populations. This study is limited by its cross sectional design; prospective data are required 
to confirm these findings. 
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6. ANDROGEN STATUS 
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6.1 SUMMARY 
This chapter evaluates the male sex-hormone profile in a community population of elderly 
men, compares these with a matched hip fracture population, studies the effects of hip 
fracture on levels of androgens over 12 months and examines the relationships between 
androgen levels, bone density and risk of hip fracture. 
In controls androgen levels declined modestly with age (r, =-0.64, p<0.01). In parallel, there 
was an increase in the levels of gonadotrophins and binding globulins. Depending on the 
definition used 11 - 40% of the controls satisfied the criteria for diagnosis of hypogonadism 
(testosterone <9nmol/l or Free Al <30IU/l respectively). In the majority, primary testicular 
failure was the cause of the low androgens. Androgens also showed a significant positive 
correlation with BMD at all sites of the proximal femur (r, =0.25, p<0.05) but not at the 
lumbar spine (r, =O. 19, p=NS). An inverse correlation was seen with bone markers (urinary 
cross links r, =-0.27, p<0.01; osteocalcin r, =-0.30, p<0.01). 
Androgen levels were consistently lower in cases compared to controls from the time of 
fracture up-to 1-year. Hypogonadotrophic hypogonadism was the predominant cause. 
Chronic ill health reported earlier in the cases might be responsible for the 
hypogonadotrophic hypogonadism seen in fracture subjects. Hypogonadism (defined as Free 
Al <30IU/1) increased the risk for low trauma hip fracture 6 fold (odds ratio 6.34; 95%CI 
2.32,17.30)). 
Androgens, gonadotrophins and sex hormone binding globulin showed a significant increase 
in levels between the time of fracture and 6 months with no further change at 1 year. Down- 
regulation of androgens around the time of the fracture secondary to the acute phase 
response may explain this finding. 
The study has limitations. The two study groups were not perfectly age matched. Significant 
changes were noted in androgen levels between time of the fracture and 6 months. 
However, the combination of a case control design with longitudinal follow-up undoubtedly 
confirms low androgens as risk factors for hip fracture in men. 
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6.2 BACKGROUND 
The importance of age, bone mineral density, and sex hormones on fracture risk in females is 
well established. Their role in men is not clear. Although, oestrogen deficiency is an 
established risk factor for fracture in women (Cummings et al, 1996), there is paucity of 
information on the role of androgens in hip fracture in men (Boonen et al, 1997). There is 
some evidence that gonadal hormones play a part in bone integrity of men (Rudman et al, 
1994) analogous to their role in women. Young males with hypogonadism are known to 
develop osteoporosis (Finkelstein et al, 1996) which improves with testosterone 
replacement therapy (Francis et al, 1986). However, the impact of androgen deficiency on 
bones of older men is noted in only a few studies with very little data on its association with 
hip fractures (Boonen et al, 1997; Nyquist et al, 1998)). 
Biochemical evidence of hypogonadism has been reported in up to 50% of men with hip 
fractures (Jackson et al, 1992, Stanley et al, 1991, Boonen et al, 1997). These 3 case 
control studies have limitations. They include small numbers (19-40 men only), cross 
sectional design, heterogeneity in timing of the samples (2 days to 18 months post fracture), 
incomplete hormonal work-up (no measurement of SHBG and gonadotrophins) and failing 
to control for physiological diurnal variation in hormone levels. The single longitudinal study 
by Nyquist and colleagues failed to find low testosterone as a risk factor for hip fracture. 
However, it looked at 10 hip fractures only and hence needs to be interpreted with caution. 
A number of measures exist to assess androgen status in an individual. There is not much 
literature on levels of male sex hormones in the elderly. All laboratory reference ranges are 
derived from data in men aged 20-50 years. As a result it was considered appropriate to 
assess sex hormone status using a number of assays. Of the circulating testosterone in 
normal men, less than 4% is free (not protein bound). We therefore assessed both the free 
(free androgen index & free testosterone) and the bound forms (total testosterone) of the 
hormone along with its binding protein (SHBG) and the gonadotrophins (FSH and LH) to 
fully characterise each individual. To avoid sampling error induced by diurnal variation in 
hormone levels all samples were drawn early morning after an overnight fast. To study the 
effects, if any, of the acute stress of fracture on levels of these hormones in the perioperative 
period, longitudinal follow-up of both groups was planned for one year. 
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With this background, the role of androgens in low trauma hip fracture in men were 
examined by evaluating the following: 
i) The androgen status of a randomly selected community population of elderly men 
ii) The effects of hip fracture on male sex hormones from the perioperative period upto 1- 
year 
iii) Difference in androgen levels between fracture cases and community controls 
iv) Androgens as risk factors for hip fracture 
6.3 METHODS 
6.3.1 Study Design 
100 consecutive men with low trauma hip fracture over a 14-month period were identified 
as cases. Simultaneously, an equal number of age matched controls were randomly recruited 
from the community. Details of study design and criteria used to recruit subjects in both 
arms of the study are given in Chapter 2. 
6.3.2 Male Sex Hormone Status 
Androgen status was assessed in both groups using 3 assays: serum testosterone, free 
androgen index (FAI) and free testosterone. In addition sex hormone binding globulin 
(SHBG) and the gonadotrophic hormones follicular stimulating (FSH) and luteinising 
hormone (LH) were also assayed. All measurements in both groups were performed at 
baseline, 6 and 12 months except for free testosterone, which was only measured at baseline, 
and 6 months due to the costs involved. Details of the assays used are outlined in Chapter 2. 
Timin : Baseline blood samples were collected from the controls at the time of their first 
visit and in the fracture cases within 48 hours of admission. In both groups blood was drawn 
early morning after an overnight fast. This was to avoid error induced by potential 
physiological diurnal variation in hormone levels. Follow-up samples were collected at 6 and 
12 months. 
Algorithm used to characterise type of hypogonadism: In subjects with abnormal sex 
hormone results further endocrine evaluation followed an algorithm. Patients with 
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laboratory results consistently showing either normal testosterone (>9nmol/1) and / or free 
androgen index (>30IU/1) or a "primary" hypogonadal pattern (low testosterone (<9nmol/1) / 
free androgen index (<30 IU/1) with raised LH (>10 IU/1) and or FSH (>10 IU/1)) did not 
have further assessment. Those patients with consistently low testosterone and low 
gonadotrophins (FSH & LH <10 IU/1) suggestive of "secondary" hypogonadism were 
further investigated with measurement of cortisol and prolactin at baseline and at 6 months 
to confirm the cause. Free thyroxine was measured only if thyroxine was less than 70 at 
baseline. Magnetic resonance imaging (MRI) and or computerised tomography (CT Scan) of 
the pituitary was performed if prolactin values were over 2500 mIU/l on at least 2 occasions 
after excluding diseases or medications that may be responsible for these results. Dynamic 
pituitary function tests were not considered appropriate in the subjects because of their age. 
6.3.3 Bone Markers 
Urinary deoxypyridinoline was measured as a marker of bone resorption using second 
morning void urine samples observing an overnight fast. Serum osteocalcin was used to 
assess bone formation using fasting blood sample. Measurements were performed both at 
baseline and at 6 months Details of the assays used are outlined in Chapter 2 and further 
description of bone markers is given in Chapter 9. 
6.3.4 Statistical Analysis 
Descriptive statistics were used to describe individual subject characteristics. Univariate 
statistics, both parametric and non-parametric where appropriate were used to compare 
baseline characteristics between groups. Paired tests were used to determine change over 
time between groups. Logistic regression was used to explore the relationship between hip 
fracture and the putative risk factor. All analyses were adjusted for age. 
6.4 RESULTS 
6.4.1 Androgens In Community Dwelling Elderly Controls 
Of the 100 community controls, 99,94 and 85 men had samples drawn for androgen assay 
at baseline, 6 months and 1 year respectively. The single missing observation in the control 
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group at baseline was a result of the sample being misplaced in the laboratory. Mean 
androgen levels (using either assay) and LH were within the normal reference range of the 
laboratory at all three time points (Table 6.1). However mean SHBG and FSH were above 
the laboratories reference range at baseline, 6 months and 1 year. This may either be a result 
of the small sample size of our study or the exclusion of the very elderly men when routine 
reference ranges are derived for a laboratory generally based on populations aged between 
20-50 years. 
Table 6.1 Androgen status in controls over one year 
Normal ranges Initial 6 months 12 months 
(n=99) (n=94) (n=85) 
Testosterone (nmol/1) 9-20 14.1 (5.3) 14.0 (5.0) 14.9 (5.2) 
Free androgen index (IU/1) 30-200 32.4 (12.4)* 28.6 (11.4) 28.1 (10.4)* 
Free Testosterone (pg/ml) 9-55 9.2 (3.4) 10.4 (4.0) NT 
SHBG (nmol/1) 10-40 47.5 (17.3)* 52.4 (17.2) 55.7 (17.6)* 
FSH (IU/1) 1.1-9.4 11.3 (14.6) 11.6 (14.6) 11.4 (14.0) 
LH (IU/1) 1.1-7.8 5.5 (5.8)* 6.0 (5.7) 6.0 (4.3) * 
Means and SDs are shown 
* Wilcoxon signed ranks test p<O. 0001 
A modest correlation was observed between the three assays, namely testosterone, free 
androgen index and free testosterone amongst controls. Correlation (Spearman's) between 
testosterone and FAI was r, =0.43 (p<0.01) and with free testosterone was r, =0.66 (p<0.01). 
The two measures of bio-available testosterone (free Al and free TT) correlated better with 
each other rs = 0.83 (p<0.01). Levels of FSH and LH were inversely related to androgen 
levels: FSH r, =-O. 3 0, LH r, =-0.55 p<O. 01, n=98 
Prospective follow-up of this cohort over a one year period showed a significant decline in 
bio-available testosterone assessed using free androgen index: 32.4 IU/I initially, 28.7 IU/l at 
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6 months, and 28.1 IU/l at 1 year (Table 6.1). Using Wilcoxon signed ranks test of the 85 
controls who had measurements both at baseline and at 1 year 61 (72%) showed a 
significant decrease in free androgen index; p<0.0001. This was accompanied by an increase 
in SHBG in 68 (80%) of the 85 controls; p<0.0001. An increase was also noticed in levels 
of both gonadotrophins (LH and FSH) although the increase in FSH did not reach statistical 
significance. Of the 85 controls who had measurement both at baseline and 1 year, an 
increase in LH was noted in 53 (62%) and in FSH in 40 (47%) men (Table 6.1). 
The proportion of men with hypogonadism defined as free androgen index less than 30 IU/l 
increased with increasing age. The percentage (number) by decade was 0%(0), 6%(1), 
7%(3), 21%(6) and 33%(1) from the fifth to ninth decade of life. The percentage fulfilling 
the criteria of hypogonadism also increased during the one-year follow-up. Androgen 
deficiency defined as serum testosterone <9.0 nmol/l was noted in 11/99 (11.1%) at 
baseline. Deficiency of bio-available testosterone, defined as free androgen index < 30.0 
IU/l, was noted in 39/97 (40.2 %). At 6 months the numbers increased to 15/94 (16%) and 
51/92 (55.4%) respectively. By I year they were 11/85 (12.9%) and 51/83 (61.4%). 
Subjects with hypogonadism were further characterised into "primary" or "secondary" based 
on the algorithm described earlier (see section 6.3.2). At all time points the majority 
exhibited "primary" testicular failure as the cause of the hypogonadism. Initially 8 had low 
testosterone levels: 5 with primary gonadal failure (elevated LH/FSH) and with 3 secondary 
gonadal failure (depressed LH/FSH). At 6 months 13 had low androgen levels: 6 with 
elevated LH/FSH, 5 with depressed LH/FSH and 2 with isolated LH deficiency. Bilateral 
orchidectomies without testosterone replacement explained hypogonadism in 3 controls. 
6.4.2 Correlation With Age, BMD And Bone Markers 
Results from first visit were used to analyse correlation with other variables, as they were 
contemporary to BMD measurement. All 3 assays used to assess androgen status (serum 
testosterone, free androgen index and free testosterone) correlated well with each other 
r, =0.83, p<0.01, n=89. With increasing age there was a modest decline in testosterone and 
bio-available testosterone; r, =-0.44 and -0.64 p<0.01 respectively (Figure 6.1). By contrast, 
there was an increase with age in SHBG (rs=0.21 p<0.05); LH (r, =0.42 p<0.01) and FSH 
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(rs=0.53 p<0.01), most marked in the eighth decade of life. Table 6.2 shows the age-related 
changes in androgen levels amongst community living elderly men. 
A weak but positive relation was seen between androgens and BMD at all sites of the 
proximal femur: rs =0.25, p<0.05, n=97. No correlation was seen with lumbar spine BMD 
(Table 6.3). A modest inverse relation was seen with bone markers (urinary 
deoxypyridinoline r, =-0.28, p<0.01, n=93 and osteocalcin r, =-0.30, p<0.05, n=70). 
Table 6.2 Androgen status in community controls by decade 
Variable Age by decade 
50-59 60-69 70-79 80-89 90+ 
(n=8) (n=17) (n=43) (n=29) (n=3) 
Testosterone (nmoUl) 14.7 16.5 14.8 11.9 8.2 
Free Androgen Index (IU/1) 43.8 42.5 33.0 23.4 20.0 
Free Testosterone (pg/ml) 11.2 12.6 9.4 6.8 5.2 
SHBG (nmol/1) 37.4 41.6 47.4 54.3 44.0 
FSH (IU/1) 16.9 5.1 7.5 17.2 28.1 
LH (IU/11 3.6 3.9 4.0 7.6 20.7 
Means are shown 
Figure 6.1 Free Androgen Index by Decade in Cases and Controls 
(Mean &95%CI are shown) 
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6.4.3 Androgen Levels At The Time Of The Fracture And Subsequent 12 Months 
Androgen status was assessed within 48 hours of the fracture in 91 of the 100 hip fracture 
patients. Missing observations were due to death or difficulty in sampling. Mean 
testosterone, free testosterone and free androgen index were significantly below the normal 
range quoted in the laboratory (Table 6.4). Mean LH was within the range but mean SHBG 
and FSH were above the reference range. This discrepancy can be explained on the basis 
that normal laboratory ranges are derived from populations aged between 20-50 years. 
At 6 months, of the 65 survivors, hormone measurements were possible in 51 cases (78.5%) 
following the strict early morning sampling technique after an overnight fast. The mean 
testosterone, free testosterone and free androgen index showed a significant increase from 
the perioperative period (almost doubling- refer Figure 6.2). They increased from an initial 
level of 4.1ng. ml, 3.8 pg/ml and 10.4 IU/1 to 9.7ng/ml, 6.4pg/ml and 19.5IU/l respectively. 
Of the survivors (n=65), 51 cases had measurements carried out both at the time of the 
fracture and at 6 months. Compared to baseline 40 of the 51 (78%) showed an increase in 
testosterone, 39 (80%) an increase in free androgen index and 34 (76%) an increase in free 
testosterone (Wilcoxon signed ranks test p<0.0001). There was a concomitant but non- 
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significant increase in serum levels of SHBG, FSH and LH; they were 54.4nmol/l, 13.0IU/l 
and 7.5IU/l respectively compared to 44.8nmol/l, 9.8IU/l and 5.1IU1 at baseline. 
At one year of the 56 survivors repeat samples were possible in 41 cases (73.2%). No 
significant change was seen in mean testosterone and free androgen index between 6 months 
and 1 year; at 1 year they were 10.7ng/ml and 19.4IU/l respectively compared to 9.7ng/ml 
and 19.5IU/l at 6 months (see Figure 6.2). Free testosterone was not measured at 1 year due 
to expense of the assay. Using the Wilcoxon signed ranks test the mean ranks of the 36 
cases that had measurements both at 6 months and 1 year were not significantly different. 
Similarly, there were no further changes seen in levels of SHBG, FSH and LH between 6 
months and 1 year (Table 6.4). 
Table 6.4 Androgen status in hip fracture cases 
Normal ranges Initial 6 months 12 months 
(n=91) (n=51) (n=41) 
Testosterone (nmol/l) 9-20 4.1(3.4) 9.7(5.2) 10.7(5.5) 
Free androgen index (IU/1) 30-200 10.4(10.9) 19.5(11.2) 19.4(9.9) 
Free Testosterone (pg/ml) 9-55 3.8(2.7) 6.4(3.6) NT 
SHBG (nmol/1) 10-40 44.8(19.2) 54.4(23.7) 59.0(24.6) 
FSH (I1J/1) 1.1-9.4 9.8(10.2) 13.0(11.9) 13.9(15.1) 
LH (IU/1) 11-78 5.2(4.8) 7.5(12.3) 7.1(7.0) 
Means and SDs are shown 










Months of follow up 
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6.4.4 Correlation With Age And Bone Markers 
Androgen levels changed significantly from time of fracture upto 6 months and subsequently 
stabilised. Therefore, levels at 6 month represent the best conservative pre-fracture estimate 
for an individual. However, due to the high mortality and hence reduced number of cases 
with repeat measurements at 6 months a selection bias may confound the association 
between androgen levels and the variables under study. Unlike controls it was therefore 
considered inappropriate to examine correlation between androgens and other variables in 
the fracture group. 
6.4.5 Androgen Status In Hip Fracture Cases Compared To Community Controls 
Androgen levels were available in 91 cases within 48 hours of the fracture and in 99 controls 
at the time of their first visit. At 6 months 51 of the 65 fracture survivors and 94 of the 99 
controls underwent repeat hormone measurements. At 1 year, the figures were 41 of 56 and 
85 of 94 respectively. 
Significantly lower levels of testosterone, free androgen index and free testosterone were 
observed in cases at the time of the hip fracture, at 6 and 12 months compared to controls 
(p<0.001). These differences persist even after adjusting for age and body mass index 
(Figure 6.3 & Table 6.5). No differences were seen in levels of SHBG, FSH and LH 
between the two groups at any time point. 
Figure 6.3: Change in total serum testosterone in cases and controls over 1 year 
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This was also true when repeat analysis was performed comparing the two groups by 
decade. Comparing the number (%) of subjects with hypogonadism a significantly higher 
proportion fulfilled the criteria amongst cases as opposed to controls. Androgen deficiency 
defined as serum testosterone <9.0ng/ml was noted in 81/91 (89%) of fracture cases versus 
only 11/99 (11.1%) of the controls (OR 64.8,95%CI 26.1,160.7) at outset. Deficiency of 
bio-available testosterone, defined as free androgen index < 30.0IU/1, was noted in 85/90 
(86.7 %) of fracture cases versus only 39/97 (40.2 %) of the controls (OR 25.3,95%CI 9.4, 
68.0). At 6 months, low testosterone was present in 25/51 (49%) cases compared to 15/94 
(16%) controls (OR 5.1,95%CI 2.3,11.0). Similarly, low bio-available testosterone was 
present in 44/50 (88%) cases compared to 51/92 (55.4%) controls (OR 5.9,95%CI 2.3, 
15.2). 
Detailed work-up of individuals based on their androgen status and the gonadotrophin 
response revealed a mixed picture of "primary" and "secondary" hypogonadism in both 
groups, significantly more in hip fracture cases than controls. Initially 78 fracture cases had 
low androgen levels (testosterone<9nmol/l and free AI<30IU/I): 14 with primary gonadal 
failure (LH/FSH elevated), 48 secondary gonadal failure (LH/FSH depressed), 12 mixed 
abnormalities and 4 indeterminate. Of the survivors, at 6 months 22 cases had low androgen 
levels: 7 with elevated LH/FSH and 8 depressed LH/FSH levels. Bilateral orchidectomies 
explained primary hypogonadism in 3 fracture cases. Two cases had hyperprolactinaemia 
(levels > 1500mIU/I) suggesting secondary hypogonadism both at the time of the fracture 
and at 6 months. CT Scan head of the only survivor did not show any pituitary abnormality. 
Dynamic pituitary function tests were not considered ethical in view of the patients' age and 
poor general health status. 
In the controls 8 had initial low testosterone levels: 5 with elevated LH/FSH, 3 depressed 
LH/FSH and none had mixed pattern. At 6 months 13 controls had low androgen levels: 6 
with elevated LH/FSH and 5 depressed LH/FSH and 2 isolated LH deficiency. Bilateral 
orchidectomies explained hypogonadism in 3 controls 
Prospective follow-up of both groups over 1 year showed a significant increase in androgen 
and gonadotrophin levels in cases from time of fracture upto 6 months with no further 
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change at I year. In contrast there was a significant reduction in bio-available testosterone 
with accompanying rise in SHBG, FSH and LH in the controls. This increase reached 
significance for SHBG and LH (Wilcoxon signed ranks test p<0.001). 
Table 6.5 Sex hormone levels at baseline, 6 and 12 months in controls and cases 
Variable Normal Range Controls 
Initial 6 months 12 months 
(n=99) (n=94) (n=85) 
Testosterone 9-20 14.1(5.3) 14.0(5.0) 14.9(5.2) 
Free Al 30-200 32.4(12.4) 28.6(11.4) 28.1(10.4) 
Free testos 9-55 9.2(3.4) 10.4(4.0) NT 
SHBG 10-40 47.5(17.3) 52.4(17.2) 55.7(17.6) 
FSH 1.1-9.4 11.3(14.6) 11.6(14.6) 11.4(14.0) 
LH 1.1-7.8 5.5(5.8) 6.0(5.7) 6.0(4.3) 
Variable Normal Range Fracture Cases 
Initial 6 months 12 months 
(n=91) (n=51) (n=41) 
Testosterone 9-20 4.1(3.4) 9.7(5.2) 10.7(5.5) 
Free Al 30-200 10.4(10.9) 19.5(11.2) 19.4(9.9) 
Free testos 9-55 3.8(2.7) 6.4(3.6) NT 
SHBG 10-40 44.8(19.2) 54.4(23.7) 59.0(24.6) 
FSH 1.1-9.4 9.8(10.2) 13.0(11.9) 13.9(15.1) 
LH 1.1-7.8 5.2(4.8) 7.5(12.3) 7.1(7.0) 
Mean values (SD) are shown 
Statistical notes 
Differences on Mann-Whitney U test 
Controls vs. Cases at 0,6 and 12 months p<0.0001 
Differences on Wilcoxon Signed Rank test 
Cases at 0 vs. at 6 and 12 months p<0.0001 
Cases at 6 vs. at 12 months NS 
Controls at 0 vs. 6 and 12 months NS 
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6.4.6 Testosterone As A Risk Factor For Hip Fracture 
Logistic regression was used to assess androgens as risk factors for hip fracture. The 6- 
month data were used since, from the earlier analysis it is clear that androgen levels are 
altered when measurements are performed at the time of the fracture and that they stabilise 
by 6 months. 
Table 6.6 shows the reduction in risk of fracture per unit increase in male sex hormone level. 
After adjusting for age and body mass index the risk of hip fracture decreased by 16% per 1 
unit increase in androgen levels: testosterone- OR=0.84,95%CI 0.77,0.92 and free 
androgen index- OR=0.93,95%CI 0.89,0.98. No difference was noted in the amount of 
risk conferred by low androgen levels when repeat analysis was performed using age alone 
or both age and body mass index in the regression equation. 
Table 6.6: Estimates of risk from logistic regression 
Per unit change in androgens 
Unadjusted Adjusted for age Adjusted for age and BMI 
Testosterone (/nmol/l) 0.85 (0.79,0.92) 0.85 (0.78,0.92) 0.84 (0.77,0.92) 
Free Al (/IU/1) 0.92 (0.89,0.96) 0.91 (0.87,0.95) 0.93 (0.89,0.98) 
By presence/absence of hypogonadism 
Unadjusted Adjusted for age Adjusted for age and BMI 
Testosterone < 9. Onmo1/I 5.06 (2.32,11.03) 4.91 (2.21,10.94) 4.44 (1.72,11.44) 
Free Al < 30.0 IU/I 5.90 (2.29,15.20) 6.34 (2.32,17.30) 3.61 (1.23,10.60) 
Odds ratio with 95% confidence interval are shown 
The analyses are based on measurements at 6 months. Results show raw data; after adjusting for age 
and for both age and body mass index. 
"Hypogonadism" was defined as serum levels less than the lower limit of the normal 
reference range for the assay in question at 6 months (i. e. testosterone <9ng/ml and Free Al 
< 30IU/1). Using logistic regression after adjusting for age and body mass index, presence of 
hypogonadism increased the risk of hip fracture over 4 fold. OR range: 3.6 (95 %CI 1.2, 
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10.6) to 4.4 (95%CI 1.7,11.4) Table 6.6. When free Al was evaluated as a risk factor for 
fracture a reduction in risk was observed when adjustment for BMI was made (OR 6.9-3.6). 
This may be explained on the basis that free Al is dependent on SHBG levels, which in turn 
correlates with BMI. 
6.5 CONCLUSIONS 
A number of conclusions can be drawn from the analysis carried out in this chapter. All 
three assays used to assess androgen status correlate well with each other although assays 
for the unbound (free) form of the hormone correlate better with each other; rs=0.83; 
p<0.01. 
In men living in community there is a gradual decline of male sex hormones with advancing 
age. Free hormone (free testosterone and free Al) is more sensitive to change (r., =-0.64; 
p<0.01) due to increase with age in the sex hormone binding globulin. It may therefore be 
argued that in this age group, measurement of free hormone might be superior in assessing 
individuals' sex hormone status. 40% of elderly men in the community exhibit biochemical 
evidence of hypogonadism. In the majority "primary" gonadal failure is the cause of this 
hypogonadism. 
A significantly higher proportion of men with low trauma hip fracture have biochemical 
evidence of hypogonadism; this varies from 80% if measurements are performed at the time 
of fracture to 53% (22/51) amongst survivors at 6 months. In the majority (46/78) the 
biochemical profile points towards "secondary" or hypogonadotrophic hypogonadism as the 
cause of the low hormone. The latter is known to be associated with chronic ill health. 
Tracing the androgen levels upto a year following the hip fracture raises the possibility of an 
acute inhibitory effect of fracture per se on hormone levels which normalises by 6 months. 
Hence, in the setting of an acute illness, timing of the samples is very crucial for accurate 
hormone assessment. 
Cases showed consistently lower levels of androgens compared to controls at baseline, 6 
months, 1 year, as a group, by decade and even after controlling for age and BMI. Results 
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from multiple logistic regression confirm low androgen levels to be a risk factor for hip 
fracture in men; the risk decreasing by 15-18% per unit increase in androgen levels. As a 
corollary, presence of biochemical hypogonadism increases the risk of hip fracture by 4-6 
fold in men aged 50 years and over. 
Androgens also show a small but significant positive correlation with BMD (rs =0.25, 
p<0.05) and an inverse relation with both urinary deoxypyridinoline and osteocalcin. It may 
therefore be conjectured that by regulating the rate of bone turnover androgens affect bone 
strength & quality and influence fracture risk. 
Some of the inherent constraints imposed by using a case-control design have been 
overcome by prospective follow-up of both groups for one year. Results clearly show a 
strong association between low male sex hormones and low trauma hip fracture in men. The 
factors underlying the development of hypogonadism and the mechanism by which it 






This chapter initially examines total serum oestradiol levels in a randomly selected 
community population of elderly men and compares the findings with a matched hip fracture 
population. It then studies the effect of hip fracture on levels of oestradiol over a 6-month 
period and examines the relationship between oestradiol, bone density and risk of hip 
fracture. 
Total oestradiol levels in the community controls were within the reference range for healthy 
younger men (aged 20-50 yrs) and correlated with CRP (r, =0.24; p<0.01, n=98), serum 
albumin (rs--0.23; p<0.01, n=97) and BMD (femoral neck rS-0.25; p<0.01, n=98). No 
correlations were seen with age, BMI or testosterone. These associations were stronger 
with free oestradiol calculated from a ratio of serum total oestrogen and sex hormone 
binding globulin. In order of importance, free androgen index, testosterone, age and serum 
albumin influenced free oestradiol levels in the controls. Together they explained 40% of the 
variance in free oestradiol levels. Free oestradiol was the most important sex steroid in 
predicting BMD. As an example, together with free androgen index, family history of 
osteoporosis and past history of fracture, it explained 27% of the variance in BMD at the 
femoral neck. 
Cases had significantly higher total oestradiol and free oestradiol levels compared to 
controls (p<0.001) at the time of the fracture, although they were still within the reference 
range. Level of both forms of the hormone reduced significantly 6 months post fracture 
(p<O. 01 by Wilcoxon signed rank test), such that free oestradiol reached values comparable 
to those in the controls. Concomitantly, significant alterations in the acute phase reactants 
namely C-reactive protein and serum albumin was noted. 
The role of oestradiol as a risk factor for hip fracture is not certain from this study. After 
adjusting for C-reactive protein and using the data at 6 months both total oestradiol (Odds 
ratio 0.98,95%CI 0.97,0.99) and free oestradiol (Odds ratio 0.34,95%CI 0.02,6.1) 
conferred protection although the values did not attain significance when free oestradiol was 
used in the analysis. 
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7.2 BACKGROUND 
Recent studies on osteoporosis in men have suggested that oestrogens may play a key role 
as in women (Khosla et al, 1998). Mutations in the oestrogen receptor gene and genes 
coding for the enzyme aromatase, which is responsible for the conversion of androgens to 
oestrogen's, have been reported in case reports of men with severe osteoporosis (Morishima 
et al, 1995). Treatment with oestrogen but not testosterone markedly increased BMD in 
these individuals (Carani et al, 1997). In a recent open trial of testosterone administered to 
eugonadal men with vertebral crush fractures, increase in BMD was significantly correlated 
with change in oestradiol but not testosterone levels (Anderson et al, 1997). The recent 
prospective study found that serum oestradiol but not testosterone was positively associated 
with BMD in men over age 65 years (Slemenda et al, 1997). Furthermore a recent 
epidemiological study (Khosla et al, 1998) showed correlation of BMD with bioavailable 
not total testosterone and with both total and bioavailable oestradiol. The authors also 
demonstrated that bioavailable oestradiol was the more important sex steroid in predicting 
femoral neck BMD supporting the hypothesis that oestrogen's play a key role in influencing 
BMD in men as in women. 
However, except for the study by Khosla et al previous studies are limited in studying 
subjects in a narrow age range and have failed to measure levels of free sex steroids. The 
latter is the fraction that is available to tissues and unaffected with increasing SHBG with 
age. Most studies have addressed the issue with testosterone or oestradiol but not with both. 
There have been no studies looking at men with osteoporotic fractures, nor have there been 
any case control studies. 
With this background this chapter examines the role of oestradiol in low trauma hip fracture 
in men by evaluating the following: 
i) Oestradiol levels in a randomly selected community population of elderly men 
ii) Comparison of oestradiol levels between community controls and hip fracture cases 
iii) The effects of hip fracture on levels of oestradiol from the time of the event to one year 
iv) Oestradiol levels as risk factors for low trauma hip fracture 
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7.3 MATERIAL & METHODS 
7.3.1 Study Design 
100 consecutive men with low trauma hip fracture were recruited as cases over a 14-month 
period. Simultaneously, an equal number of men were randomly recruited from the 
community as controls. Details of the study design and criteria used are given in Chapter 2. 
7.3.2 Oestradiol Assay 
Female sex-hormone status was evaluated in both groups by measuring serum oestradiol at 
baseline and at 6 months. Details of the competitive immunoassay used to measure 
oestradiol levels are given in Chapter 2. Free oestradiol was calculated as the ratio between 
oestradiol (in nmol/l) and sex hormone binding globulin. 
Initial samples were collected in the control population at the time of their first visit and in 
fracture cases within 48 hours of admission. Subsequent samples were collected in both 
groups at 6 months. Blood samples for the assay were collected early morning after an 
overnight fast to avoid error induced by physiological diurnal variation. This also ensured 
homogeneity in the sampling technique. 
7.3.3 Statistical Analysis 
Descriptive statistics were used to describe group characteristics in both cases and controls. 
Univariate statistics, both parametric and non-parametric where appropriate were used to 
compare baseline values between groups. Paired tests were used to determine change over 
time between groups. Logistic regression was used to explore the relationship between hip 
fracture and the putative risk factor i. e. oestradiol levels. Multiple linear regression using 
backward elimination with the probability of "F" to eliminate set at >0.1 and "T" to include 
set at p<0.05 was used to create models of BMD and oestradiol prediction. All analysis was 
adjusted for age. 
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7.4 RESULTS 
7.4.1 Oestradiol In Community Dwelling Men 
Total oestradiol levels in the controls (mean 106 pmol/l; SD 50) were within the reference 
range (<180 pmol/l) stated in the manufacturers kit for healthy younger men both at baseline 
and at 6 months (Table 7.1). 
Table 7.1 Oestradiol levels in controls at baseline and at 6M 
Variable N range Time No. Mean SD Signif* 
Age (years) Baseline 100 75.0 9.6 
BMI (kg/m2) 20-25 Baseline 97 26.7 5.5 
C-Reactive Protein (mg/1) 0-10 Baseline 100 3.0 5.4 
Oestradiol (pmol/I) <180 Baseline 98 106.2 50.4 
6M 90 121.5 37.9 <0.001 
SHBG (nmol/1) 10-40 Baseline 97 47.5 17.3 
6M 92 52.4 17.2 NS 
Free oestradiol Baseline 95 0.26 0.18 
6M 89 0.26 0.13 NS 
Means and SDs are shown 
* Wilcoxon signed ranks test between baseline and 6 months 
A significant increase in total oestradiol levels was noted at 6 months (p<0.001) compared 
to baseline (Table 7.1) using the Wilcoxon signed ranks tests. Fifty-six of the 88 subjects 
tested at both time points showed an increase. In contrast, free oestradiol levels (calculated 
as the ratio between oestradiol in nmol/l and SHBG) did not change. Of the 84 controls who 
had measurements at both time points, 44 showed an increase and 40 a decrease in free 
oestradiol levels (Wilcoxon signed ranks test p=NS). High total oestradiol levels defined as 
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more than 180 pmol/l were present in 8/98 (8.2%) controls at baseline and in 4/90 (4.4%) at 
6 months. 
The factors influencing free oestradiol levels were explored by multiple linear regression 
using backward elimination (Table 7.2). Serum levels of free androgen index (FAT); 
testosterone, albumin and age in combination explained 40% of the variance in free 
oestradiol levels. Male sex steroid levels (FAI and testosterone) were the principal 
determinants. 
Table 7.2 Factors influencing free oestradiol levels in controls 
Backwards linear multiple regression model 
Variable B 95% CI Significance 
Age 0.005 0.001,0.009 0.02 
Free androgen index 0.012 0.009,0.015 0.0001 
Testosterone -0.012 -0.018, -0.006 0.0002 
Serum albumin -0.004 -0.020,0.001 0.07 
Constant 0.09 -0.42,0.61 0.72 
Variables not in the equation: height, weight, C-reactive protein and serum globulin 
Multiple R=0.65; Adjusted R Square = 0.40 
Total oestradiol levels correlated with C-reactive protein and serum albumin (rs =0.24; 
p=0.017, n=98 and rs =-0.23; p<0.025, n=97 respectively) but not with age (rs 0.02), body 
mass index (r, =0.06), testosterone (rs =0.09) and bone markers (rs =0.02) as shown in Table 
7.3. By contrast, free oestradiol levels correlated with all [body mass index (r, =0.29, 
p=0.005); free androgen index (r5. =0.48; p<0.001); free testosterone (rs =0.42; p<0.001); C- 
reactive proteins (rs =0.33; p<0.001); albumin (r5 =-0.24; p=0.02)] except age (r, =-O. 15) and 
bone markers (rs =0.02) Table 7.3. 
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Table 7.3 Relationship with age, BMI, C-reactive protein and S Albumin in controls 
Variable Oestradiol Free Oestradiol 
rs Significance rs Significance 
Age(yrs) 0.02 NS -0.15 NS 
BMI(kg/m2) 0.06 NS 0.29 0.005 
C-reactive protein (mg/1) 0.24 0.02 0.33 0.001 
S Albumin (g/I) -0.23 0.03 -0.24 0.02 
Free androgen index (IU/1) 0.16 NS 0.48 0.01 
Free testosterone (pg/ml) 0.32 . 
01 0.42 0.01 
Urine Dpd 0.02 NS 0.02 NS 
Osteocalcin (ng/ml) -0.09 NS -0.16 NS 
rS = Spearman's Correlation Co-efficient 






Lumbar spine 0.28 0.007 0.33 0.001 
Femoral neck 0.40 0.001 0.43 0.001 
Inter-trochanteric 0.25 0.004 0.27 0.006 
Trochanteric 0.29 0.001 0.32 0.002 
Ward's triangle 0.37 0.001 0.43 0.001 
rs = Spearman's correlation coefficients 
After adjusting for age, both total and free oestradiol levels exhibited good correlation with 
BMD (Table 7.4). The correlation between free oestradiol and femoral neck BMD (r. 
=0.43) is shown in Fig 7.1. The correlations were better with all sites of the proximal femur 
than with the lumbar spine. The relationship was stronger with free oestradiol than with total 
oestradiol. 
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The interactions between free oestradiol and other factors influencing BNM were explored 
using multiple linear regression using backward elimination (Table 7.5 & 7.6). Free 
oestradiol levels were the most important sex steroid predicting BMD at all sites. Together 
with weight, free androgen index, family history of osteoporosis and past history of fracture 
they explained 27% of the variance in femoral neck BMD (Table 7.5). Similarly, with age, 
weight and past history of fractures they explained 25% of the variance in BMD at the 
lumbar spine (Table 7.6). 
Table 7.5 Factors influencing femoral neck BMD in controls. 
Backwards linear multiple regression model 
Variable B 95% CI Significance 
Weight 0.002 0.000,0.004 0.02 
Free androgen index 0.002 0.000,0.005 0.04 
Free oestradiol 0.222 0.06,0.39 0.009 
Sex hormone binding globulin 0.002 0.001,0.004 0.01 
Past history of fracture 0.05 -0.004,0.09 0.07 
Family history of osteoporosis 0.09 0.02,0.16 0.01 
Constant 0.07 -0.19 0.334 0.59 
Variables not in the equation: age, height, C-reactive protein, haemoglobin, calcium, serum 
albumin, serum globulin, vitamin D, family history of fracture 
Multiple R= 0.56; Adjusted R Square = 0.27 
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Table 7.6 Factors influencing lumbar spine BMD in controls. 
Backwards linear multiple regression model 
Variable B 95% CI Significance 
Age 0.002 0.002,0.01 0.004 
Weight 0.002 0.002,0.008 0.002 
Free oestradiol 0.113 0.06,0.51 0.01 
Past history of fracture 0.04 -0.01,0.16 0.07 
Constant 0.23 -0.45,0.479 0.97 
Variables not in the equation: height, C-reactive protein, haemoglobin, calcium, serum albumin, serum 
globulin, sex-hormone binding globulin, vitamin D, free androgen index, family history of fracture and 
osteoporosis 
Multiple R= 0.53; Adjusted R Square = 0.25 
7.4.2 Oestradiol Levels In Men With A Hip Fracture 
Total oestradiol levels were within the manufacturers normal reference range for healthy 
younger men both at the time of the hip fracture and at 6 months. In the immediate post- 
fracture period total oestradiol levels were significantly raised compared to those at 6 
months (p<0.001). This observation remained true even after adjusting for SHBG and 
analysing levels of free oestradiol (Wilcoxon signed ranks test p<0.001- Table 7.7). Of the 
45 survivors who had measurements both at the time of the hip fracture and at 6 months, 30 
showed a decrease in total oestradiol levels from the time of the incident event (p<0.01 by 
Wilcoxon signed rank test) Table 7.7. Similar changes were seen in free oestradiol. Elevated 
total oestradiol, defined as levels above 180 pmol/l, were seen in 27/90 (30%) cases around 
the time of the fracture and in only 3/49 (6.1 %) at 6 months. 
There was a modest correlation between total oestradiol, C-reactive protein and serum 
albumin (r, =0.25; p=0.027, n=77 and rs =-0.28; p=0.007, n=89 respectively). Similar 
correlation's were seen with free oestradiol (rs =0.23; p=0.048, n=74 and rS =-0.27; 
p=0.013, n=83 respectively). The correlation between free oestradiol and C-reactive protein 
is shown in Figure 7.2. 
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Table 7.7 Oestradiol levels in cases following hip fracture and at 6M 
Variable N range Time No. Mean SD Signif* 
Age (years) Baseline 100 79.9 9.4 
BMI (kg/m2) 20-25 Baseline 72 23.4 3.3 
SHBG (nmol/1) 10-40 Baseline 90 44.8 19.2 
6M 50 54.4 23.7 <0.001 
Oestradiol (pmol/1) <180 Baseline 90 160.6 104.5 
6M 49 102.2 47.0 <0.04 
Free Oestradiol Baseline 84 0.46 0.48 
6M 48 0.24 0.18 <0.02 
Means and SDs are shown 
*Wilcoxon signed ranks test between baseline and 6 months 
Figure 7.2 Free Oestradiol and C-reactive protein in fracture cases 
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rr = 0.23; p=0.05 
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7.4.3 Comparison of Oestradiol Levels Between Hip Fracture Cases And Controls 
The hip fracture cases were significantly older and had lower mean BMI compared to the 
controls (Table 7.8). There was no significant difference in mean SHBG values between 
cases and controls despite a significant increase in serum levels within the fracture group 
between time of fracture and 6 months (Wilcoxon signed rank test p<0.05). 
Table 7.8 Differences between cases and controls 
Variable N range Time Cases Controls Sig 
No. Mean (SD) No. Mean (SD) Mann Whitn 
Age (years) Baseline 100 79.9 (9.4) 100 75.1 (9.6) <0.01 
BMI (kg/m2) 20-25 Baseline 72 23.4 (3.3) 97 26.7 (5.5) <0.0001 
C-reactive protein(mg/1) 0-10 Baseline 82 120.5 (76.4) 100 3.0 (5.4) <0.0001 
6months 49 10.9 (19.4) 92 1.5 (4.5) <0.0001 
SHBG (nmol/l) 10-40 Baseline 90 44.8 (19.2) 97 47.5 (17.2) NS 
6months 50 54.4 (23.7) 92 52.4 (17.2) NS 
Oestradiol (pmol/1) <180 Baseline 90 160.6 (104.5) 98 106.2 (50.4) <0.0001 
6months 49 102.2 (47) 90 121.5 (37.9) <0.005 
Free Oestradiol Baseline 84 0.46 (0.48) 95 0.26 (0.18) <0.0001 
6months 48 0.24 (0.18) 89 0.26 (0.13) NS 
Means and SDs are shown 
Levels of both total and free oestradiol were significantly higher in cases compared to 
controls at the time of the fracture when analysed per se and after adjusting for age and BMI 
(data not shown). Differences in total but not free oestradiol persisted upto 6 months (Table 
7.8). A significant reduction was observed in both total and free oestradiol levels within the 
fracture group from the time of the fracture to 6 months (Wilcoxon signed rank test 
p<0.05). Concomitantly, levels of C-reactive proteins were significantly higher in cases 
compared to controls both at the time of the fracture and at 6 months despite a significant 
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reduction in CRP levels within the fracture cohort between the two time points (Wilcoxon 
signed rank test p<0.01). 
7.4.4 Oestradiol Levels As A Risk Factor For Hip Fracture 
Due to significant changes noted in serum levels of both total and free oestradiol from the 
time of fracture to 6 months and their correlation with the acute phase reactants (C-reactive 
proteins and serum albumin) the 6 month data was considered appropriate for evaluating 
oestradiol as a risk factor for hip fracture. 
Using multiple logistic regression, one picomol increase in total oestradiol levels reduces the 
risk of low trauma hip fracture by 1%. This is unchanged after controlling for age, body 
mass index and C-reactive protein. (Table 7.9). However, although there is a similar 
protective effect conferred by free oestradiol the values do not reach significance when 
examined per se, or after controlling for age, BMI and C-reactive protein. 
Table 7.9 Estimates of risk from logistic regression 
Hormone 
Time 
Odds ratio (95%CI) 
unadjusted adjusted for age adjusted for C- 
reactive protein 
Oestradiol (per pmolIl) Initial 1.01 (1.0,1.01) 1.01 (1.0,1.02) 1.0 (0.99,1.02) 
6 months 0.99 (0.98,0.99) 0.99 (0.98,0.99) 0.98 (0.97,0.99) 
Free oestradiol (per nmoUl) Initial 11.6 (2.71,49.7) 10.6 (2.3,47.9) 1.8 (0.03,122.3) 
6 months 0.42 (0.04,5.00) 0.43 (0.04,5.20) 0.34 (0.02,6.1) 
Odds ratio and 95% confidence intervals are shown 
The analysis is based on measurements both at baseline and at 6 months. Results show raw data; 
after adjusting for age and C-reactive protein 
7.5 CONCLUSION 
Both total and free oestradiol are present in measurable quantities in the serum of elderly 
men using conventional immunoassays. Levels are within the normal range established for 
younger healthy men aged between 20-50 years. Levels of both the total and free form of 
the hormone correlate well with acute phase reactants namely C-reactive protein and serum 
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albumin. Levels of male sex hormones (free androgen index and testosterone) account for 
40% of the variance in free oestradiol levels in addition to age and serum albumin 
Immediately after fracture a significant elevation in levels of both total and free oestradiol is 
seen. A reduction is seen at 6 months with levels of free oestradiol equalling those in the 
controls. This is accompanied by significant alterations in levels of acute phase reactants 
namely C-reactive protein and albumin. Similar findings have been reported after stress 
conditions like burns and may explain our observations. 
Serum oestradiol plays a significant role in determining bone mineral density at all sites. Its 
influence on BNID is stronger than male sex hormones. Together with free androgen index, 
past history of fractures and family history of osteoporosis, free oestradiol accounts for 27% 
of variation in BMD at the femoral neck. Similarly with age, weight and past history of 
fractures free oestradiol account for 25% of variance in BMD at the lumbar spine. 
This study was not designed to explore the relationship between serum oestradiol and risk of 
hip fracture in men. However, using data at 6 months both total and free oestradiol confer 
protection although the level of protection conferred by free oestradiol does not reach 
statistical significance. 
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8. BONE PROFILE AND CALCIOTROPIC HORMONES 
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8.1 Summary 
This chapter initially evaluates calciotropic hormones (vitamin D and parathyroid) in a 
randomly selected population of elderly men. It then compares the findings with a matched 
hip fracture population. Finally, it studies the effects of hip fracture on the bone (calcium, 
phosphate, and alkaline phosphatase) and calciotropic hormone profile over 6 months and 
examines their role as risk factors for hip fracture. 
In fracture cases and community controls 25-OH-D deficiency was subclinical and existed in 
the presence of a normal bone profile. No subject had biochemical evidence of osteomalacia. 
Sixty-five percent cases and 14% controls were confirmed to have 25-OH-D deficiency 
when first seen. Subjects at most risk of 25-OH-D deficiency were the very elderly, those 
living alone or in institutions, dependant for basic activities of daily living and spending little 
time out of doors. It was commoner in men with a cervical fracture than those with an inter- 
trochanteric fracture. 25-OH-D deficiency persisted 6 months after the fracture despite 
hospitalisation and being cared for post-operatively in residential and nursing homes. As 
expected, following fracture alkaline phosphatase levels were significantly raised. They 
normalised by 6 months. 
Using logistic regression and after correcting for age, presence of vitamin D deficiency 
(<lOng/ml) increased the risk of hip fracture over 10 fold (OR 10.23,95%CI 5.01,20.92). 
Parathyroid hormone levels and urine calcium/creatinine neither conferred risk nor 
protection to occurrence of hip fracture. 
This chapter raises awareness about the magnitude of 25-OH-D deficiency that is prevalent 
in an elderly Caucasian male community and amongst those presenting with a hip fracture. 
Therapeutic intervention should be targeted towards the "high risk group" namely, the very 
elderly who live alone or in institutions and are dependant for normal activities of daily 
living. This will help reduce the burden of this potentially preventable condition. Persistence 
of the deficiency state upto 6 months after the fracture furthermore highlights our ignorance 
and the absence of risk management strategies to identify these potentially reversible 
deficiency states even amongst hospitalised elderly. 
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8.2 Background 
Long lasting and severe vitamin D deficiency leads to osteomalacia, characterised by typical 
biochemical abnormalities of low calcium and phosphate and increased activity of alkaline 
phosphatase. In contrast, patients with primary osteoporosis usually have serum 
concentrations of calcium and phosphate within the normal range, and alkaline phosphatase 
rarely elevated. Therefore, in the opinion of many vitamin D deficiency is not an important 
pathogenetic factor in the development of osteoporosis. 
While osteomalacia appears to be uncommon in the majority of patients with hip fracture, 
subclinical vitamin D deficiency may often promote hip fracture by leading to secondary 
hyperparathyroidism which in turn increases bone turnover and accelerates bone loss 
(Chapuy et al, 1992, Lips et al, 1987). Contrary to the wealth of information on women 
with hip fractures, the relative importance of vitamin D deficiency as a risk factor for low 
trauma hip fractures is men is under-recognised. Among the mechanism of bone loss in 
elderly women, particularly many years after menopause, vitamin D deficiency is probably 
the most important (Alevizaki et al, 1973). Published reports concerning parathyroid levels 
in patients with hip fracture compared with controls groups are also conflicting (Benhamou 
et al, 1995; MacDonald et al, 1992; Cooper et al, 1989; Compston et al, 1989). However, 
growing evidence demonstrates that moderately low levels of vitamin D can have 
unfavourable effects on calcium homeostasis leading to bone loss, even if osteomalacia is 
not present. Furthermore, supplementation studies with calcium and vitamin D have shown 
reduction in hip fracture risk in elderly women (Chapuy et al, 1992). 
The relative importance of vitamin D deficiency, secondary hyperparathyroidism and bone 
mineral density as risk factors for hip fracture in men is not definitely established. In the 
framework of a case-control study of risk factors for hip fractures this study aimed to 
i) Determine the bone and calciotropic hormone profile of a group of elderly community 
dwelling men 
ii) Compare the findings amongst controls to matched cases with a low trauma hip fracture 
iii) Determine effects of hip fracture on serum levels of these hormones, and 




Study design, criteria for inclusion and method of recruitment of cases and controls is 
detailed in chapter 2. Details of assays used are also given. All laboratory work-up was 
carried out on blood and urine samples collected early morning after an overnight fast. 
Timing: In cases, all samples were collected within 48 hours of fracture. In both groups 25- 
hydroxyvitamin D, parathyroid hormone, corrected calcium, phosphate and alkaline 
phosphatase were measured at baseline and at 6 months. 
Assays used: 25-hydroxyvitamin D (25-OH D) was measured using the radioimmunoassay 
(RIA) method with a sensitivity of less than 3ng/ml and coefficient of variation (CV) less 
than 10%. Parathyroid hormone was assayed using the Nichols Institute Diagnostics intact 
PTH immunoassay with a CV of <3.4%. Second morning urine after an overnight fast was 
collected to measure urine calcium. Blood was drawn at the same time to estimate serum 
creatinine. The urine calcium creatinine ratio was calculated based on these observations. 
Vitamin D "deficiency" was defined as serum 25-OH-D levels less than lOng/ml; vitamin D 
"insufficiency" was defined as levels less than 20ng/rnl. Hyperparathyroidism was defined as 
serum parathyroid levels greater than 65pg/ml. 
Statistical analysis: Descriptive statistics were used to describe individual subject 
characteristics in both cases and controls. Univariate statistics, both parametric and non- 
parametric where appropriate were used to compare baseline characteristics between 
groups. Paired tests were used to determine change in subject characteristics with time 
between groups. Logistic regression was used to explore the relationship between hip 
fracture and the putative risk factor. Analysis was adjusted for age, where indicated. 
8.4 Results 
8.4.1 Calciotropic hormones in community dwelling controls 
Subject characteristics and details of laboratory parameters are shown in Table 8.1. Samples 
of one subject were accidentally discarded in the laboratory before bone profile and urine 
calcium / creatinine were assayed. Mean levels for all variables were within the normal 
reference range of the laboratory. 
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Table 8.1 Bone profile and calciotropic hormones in controls 
Variable Normal values No Mean S Dev 
Age (yrs) - 100 75.1 9.6 
S Albumin (g/1) 36-52 99 43.5 2.9 
Corrected Calcium(mmol/1) 2.1-2.6 99 2.3 0.08 
Inorg Phosphate(mmol/1) 0.6-1.5 99 1.0 0.20 
Alkaline Phosphatase (IU/1) 50-120 99 95.9 38.3 
Vitamin D (ng/ml) 10-42 100 18.3 7.1 
Parathyroid (pg/ml) 10-65 100 40.8 21.2 
U calcium / creatinine 100-450 99 336.4 213.3 
At 6 months (n=92): Vitamin D 20.8 ng/ml, Parathyroid 38.1 pg/ml 
Sixty percent of the controls had 25-hydroxyvitamin D "insufficiency" (levels <20ng/ml) at 
baseline. "Deficiency" of 25-hydroxyvitamin D (levels <10ng/ml) was present in 14% (Table 
8.2). Seventy nine percent (11/14) of those found 25-hydroxyvitamin D deficient were aged 
over 70 years. None of the subjects had biochemical features suggestive of osteomalacia. 
Table 8.2 Number (%) of controls with low 25-OH-D by decade 
Age in decade 50-59 60-69 70-79 80-89 90+ 
No per decade n=8 n=17 n=43 n=29 n=3 
Levels Total n (%) 
Vitamin D <1Ong/ml 14 
Vitamin D <20ng/ml 60 
Parathyroid >65 pg/ml 8 
Urine Ca/Cr <100 24 
Urine Ca/Cr >100 7 
1 (12.5) 2 (11.8) 4 (9.3) 6(20.7) 1 (33.3) 
4(50) 10 (58.8) 28 (65.1) 16 (55.2) 2(66.7) 
- -3 (7) 4 (13.8) 1 (33.3) 
1 (12.5) 5 (29.4) 13 (30.2) 5 (17.2) - 
2(25) - 4(9.3) 1 (3.4) - 
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25-OH-D deficiency was significantly more common in those institutionalised (living in 
nursing and residential homes) than those living in their own home: 75% versus 12% 
respectively, x2 =15.6, df--3, p<0.001. Amongst those living at home, it was commoner in 
those living alone [3/16 (18.8%)] than those with family [8/78 (10.3%)]. In addition, it was 
significantly more common in those single or widowed [6/21 (28.6%)] than those married 
living with spouse [8/79 (10.1%), x2 =4.7, df=1, p<0.03]. It was commoner in those less 
ambulant and spending less than one hour walking out of doors each day compared to those 
who walked one hour or more (12/ 59 (20.3%) & 2/41 (4.9%) respectively xz = 4.8, dgl, 
p<0.03). 
25-OH-D insufficiency (levels <20ng/ml) was commoner in those who walked less than an 
hour out of doors [38/59 (64.4%)] compared to those who spent more than an hour each 
day [22/41 (53.7%)]. The latter did not reach statistical significance. All 4 (100%) living in 
care had 25-hydroxyvitamin D insufficiency (levels <20ng/ml). 
Hyperparathyroidism was present in 8(8%) of controls; all were aged 70 years and over. 
Only 3% had both low vitamin D (<10ng/ml) and elevated PTH (>65ng/ml). Low urine 
calcium creatinine ratio (<100mmol/mmol) was present in 7/99 (7.1%). Nine (9%) had a 
combination of low 25-OH-D, raised parathyroid and low urine calcium / creatinine. 
Table 8.3 shows the change in bone and calciotropic hormone profile with age. There was a 
modest correlation between age and parathyroid hormone (r, =0.41; p<0.01; n=100); a small 
but significant correlation with corrected calcium (r, =0.25; p<0.05; n=99) but none with 25- 
OH-D levels. There was no correlation between age and serum albumin, alkaline 
phosphatase, inorganic phosphate and urine calcium creatinine ratio. 
There was no correlation between 25-hydroxyvitamin D levels, body mass index, 
parathyroid hormones, bone markers and BMD at any site (data not shown). A weak but 
significant correlation was seen between 25-OH-D levels and urine calcium creatinine ratio 
rs=0.21; p<0.05; n=99. 
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Table 8.3 Change in bone profile with age amongst controls (mean &S Dev) 
Age in decade 50-59 60-69 70-79 80-89 90+ 
No per decade n=8 n=17 n=43 n=29 n=3 
Age (yrs) 54.1 (3.3) 67.5 (1.6) 74.1 (2.7) 84.8 (2.3) 95 (2) 
S Albumin (g/1) 42.1 (3.8) 44.9 (2.7) 43.1 (2.8) 43.4(3) 43.7 (0.6) 
Corrected Calcium(mmol/1) 2.3 (. 05) 2.3 (. 08) 2.3 (. 09) 2.3 (. 07) 2.4 (. 05) 
Inorganic phosphate(mmol/1) 1.1 (0.2) 1.1 (0.3) 1.0 (0.2) 1.0 (0.1) 1.2 (0.2) 
Alkaline Phosphatase (IU/1) 80.4 (25.5) 94.4 (36.6) 89 (22) 116 (55.8) 98 (33.90 
Vitamin D (ng/ml) 21.5 (8.4) 18.0 (6.1) 18.4 (7.1) 18(7.3) 15 (8.4) 
Parathyroid Hormone (pg/ml) 25.6 (11.3) 35.5 (10.40 38.1 (16.6) 49.4 (28.2) 66.7 (26.3) 
U calcium / creatinine 264.6 (260.8) 400.1 (227.7) 361.5 (238.7) 293.1 (134.8) 171.5 (71.4) 
An increase in 25-hydroxyvitamin D levels was noted at 6 months (Figure 8.1). Fifty six of 
the 92 controls tested at both time points showed an increase (Wilcoxon Signed Ranks test 
p<0.003). This was statistically but not clinically significant. (25-hydroxyvitamin D level 
18.3 ng/ml at baseline; 20.7 ng/ml at 6 months). No significant change was observed in other 
laboratory variables including parathyroid hormone over the 6-month period. 
Figure 8.1 25-hydroxyvitamin D in cases and controls at baseline and at 6 month 
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8.4.2 Bone profile and calciotropic hormones in men with hip fracture 
It was possible to collect fasting early morning blood samples in 95 cases within 48 hours of 
the fracture. Catheterization made it difficult to collect appropriate urine samples for 
calcium estimation in all cases. 
Within 48 hours of the fracture, serum albumin and 25-OH-D level were low while alkaline 
phosphatase was near the upper limit of the reference range of the laboratory (Table 8.4). A 
significant increase in 25-hydroxyvitamin D levels was noted at 6 months (see footnote table 
8.4). Thirty six of the 50 cases who had measurements at both time points showed an 
increase (Wilcoxon Signed Ranks paired t test p<0.01). This rise (9.7ng/ml at baseline; 14.4 
ng/ml at 6 month) was clinically significant. 
A significant increase was also seen in levels of urine calcium/creatinine 6 months after the 
fracture. Twenty-seven of the 40 cases tested at both time points showed an increase 
(Wilcoxon Signed Ranks paired t test, p<0.02). The decrease in parathyroid hormone levels 
from 47.1 pg/ml at baseline to 43.2 pg/ml at 6 months was not significant (Wilcoxon Signed 
Ranks paired t test, p=NS). There was no significant change in other variables namely 
albumin, alkaline phosphate, phosphate and calcium. 
Table 8.4 Bone profile and calciotropic hormones in men with hip fracture 
(Mean & SDev are shown) 
Variable No 
Age(yrs) 100 
S Albumin(g/1) 95 
Co Calcium(mmol/1) 94 
In Phosphate(mmol/1) 90 
Alk Phosphatase(IU/1) 94 
25-OH-D(ng/ml) 94 
Parathyroid(pg/1) 95 
U calcium / creatinine 81 







10-65 47.1 (31) 
100-450 278.4(226.1) 
At 6 months (n=51): Vitamin D 14.4 ng/ml; Parathyroid hormone 43.2 pg/ml 
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25-OH-D levels were similar in cases with a cervical fracture and those with an inter - 
trochanteric fracture [mean (SD) cervical fracture: 9.2(4.2) ng/ml; inter trochanteric: 
10.4(5.3) ng/ml; p=NS]. However, 25-OH-D deficiency (< lOng/ml) was commoner in 
subjects with a cervical fracture (70.6%) than those with an inter trochanteric fracture 
(58.1%) 2=1.6; p=NS). 25-OH-D deficiency was commoner in those who were either 
single, widowed or divorced compared to those married [30/43 (69.8%) Vs 31/51(60.8%) 
x2=0.83; p=NS]. No difference were seen in their residential status (home versus in care) 
and degree of mobility (walking less than or more than an hour out of doors most days). 
Elevated PTH (>65pg/ml) was present in 17(17.9%) fracture cases; 16(94%) were aged 
over 70 and 14(82%) had additional low 25-OH-D. Low urine calcium/creatinine (<100 
mmol/mmol) was seen in 23 (28.4%) cases. 
8.4.3 Comparison between hip fracture cases and community controls 
Hip fracture cases were significantly older compared to community controls (p<0.01) Table 
8.5. Of the variables under study only age correlated to parathyroid hormone (r, =0.41, - 
p<0.01). Hence, age adjustment (see "*" Table 8.5) was carried when comparing 
parathyroid levels between the two groups. Albumin, inorganic phosphate and 25-OH-D 
were significantly lower in cases compared to controls (Table 8.5). Alkaline phosphatase 
was significantly elevated in cases compared to controls (p<O. 01). 
Table 8.5 Differences in cases and controls at baseline (mean & SD are shown) 
Variable Normal values 
Age(yrs) - 
Albumin(g/1) 36-52 
Co Calcium(mmol/1) 2.1-2.6 
Phosphate(mmol/1) 0.6-1.5 




U calcium / creatinine 100-450 
Cases Controls Significance 
79.9(9.4) 75.1(9.6) 0.01 
33.8(4.8) 43.5(2.9) 0.01 
2.3(0.1) 2.3(0.1) NS 
1.1(0.3) 1.0(0.2) 0.04 
116.9(69.6) 95.9(38.3) 0.01 
9.7(4.7) 18.3(7.1) 0.01 
47.1 (31) 40.8 (21.2) NS 
42.0 929) 40.8 (21.2) NS 
278.4(226.1) 336.4 (213.3) NS 
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Using the definitions described earlier 65% cases had vitamin D "deficiency" compared to 
14% controls (OR 11.4; 95%CI 5.6,23) see Table 8.6. Vitamin D "insufficiency" was seen 
in 97% cases compared to 60% controls (OR 20.2; 95%CI 5.9,68.3). Hyperparathyroidism 
was found in 18% cases compared to 8% controls (OR 2.5; 95%CI 1.0,6.1). 14.9% of 
cases had both 25-hydroxyvitamin D deficiency and hyperparathyroidism compared to only 
3% of controls. Low urine calcium/creatinine was seen in 23/81 (28.4%) cases compared to 
7/99 (7.1%) controls (OR 5.2; 95%CI 2.1,12.9) 
Table 8.6 Odds ratios for low 25-OH-D, raised PTH and low U Ca/Cr at baseline 
Cases Controls 
Abnormal values No (%) No (%) Odds ratio Chi-square Sig 
Vit D <20 ng/ml 91 (96.8) 60(60) 20.2 38.1 <0.01 
Vit D <10 ng/ml 61 (64.9) 14(14) 11.4 52.9 <0.01 
PTH >65 ng/ml 17 (17.8) 8 (8) 2.5 4.3 <0.04 
U Ca/Cr <100 23 (28.4) 7(7.1) 2.1 14.6 <0.01 
8.4.4 Calciotropic hormones as risk factors for hip fracture 
After correcting for age and using logistic regression analysis, per nanogram (ng) increase in 
vitamin D reduced the risk of hip fracture by 20% (OR 0.79,95%CI 0.73,0.85). Vitamin D 
sufficiency (>10ng/ml) reduced the risk by more than 90% (OR 0.1; 95% Cl 0.05,0.20). 
Parathyroid hormone levels and urine calcium/creatinine neither conferred risk nor 
protection to occurrence of hip fracture. 
8.5 Conclusion 
Low 25-OH vitamin D was common in hip fracture patients, who in addition were old, 
living alone at home or in institutions, incapable of independent daily life and spent 
insufficient time out of doors. Low 25-OH-D levels were present in the presence of a normal 
bone profile absence of raised parathyroid levels and, biochemical picture suggestive of 
osteomalacia. The 25-OH-D deficiency state was subclinical and emphasises the frailer 
condition of hospitalised patients with hip fracture. Low 25-OH-D levels have previously 
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been reported in hip fracture patients when compared with healthy controls (Chapuy et al, 
1992, Lips et al, 1987; Cooper et al, 1989). 
A significant increase in 25-OH-D levels were noted 6 months after the hip fracture 
compared to measurements in the immediate post fracture state. An explanation for this 
observation may be the timing of sampling after fracture (Ng et al, 1994) and/or nutrition 
supplements in hospital and in institutions following admission. 
Hyperparathyroidism was present in 18% of men with hip fracture compared to 8% of men 
living in community. The presence of secondary hyperparathyroidism in elderly people has 
previously been suggested, especially in patients with hip fracture (Benhamou et al, 1994; 
Compston et al, 1989). In this study parathyroid levels were similar in the two groups 
throughout the study duration. Published literature is conflicting with some studies even 
reporting lower levels of parathyroid hormone in the face of low 25-OH-D levels in both 
men and women with hip fracture compared to controls (Thieuband et al, 1997). Alteration 
in serum chemistry following fracture may be account for these differences. This calls for 
caution in interpreting biochemical data in elderly patients who have recently sustained a hip 
fracture. 
14% of the elderly Cornish men living in community also exhibited 25-OH-D deficiency. 
This was most marked in those in institutions or living alone at home and less ambulant. 
Similar results have been reported in recent years from the continent - 14% in an adult urban 
French population (Chapuy et al, 1992) and 6% among Swiss adults (Burnand et al, 1992). 
The authors relate vitamin D levels to latitude of residence and hours of sunshine. In 
contrast, men in North America have been shown to have a very low prevalence of vitamin 
D deficiency (Gallagher et al, 1998). An explanation for this difference is better sunlight 
exposure coupled with supplementation of dairy produce in the USA. 
Results from this study in combination with those published earlier highlight the common 
problem of vitamin D deficiency with resultant sub-optimal calcium absorption in the 
"healthy" elderly men living in community. It also underlines the even higher prevalence of 
vitamin D deficiency in men with hip fracture. Simple measures to replenish the deficiency 
status in these men will go a long way in fracture prevention. 
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9. BONE MARKERS 
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9.1 SUMMARY 
This chapter addresses a number of issues. Firstly, it looks into the question whether elderly 
men with hip fracture have a different bone turnover as compared to healthy men of the 
same age. Subsequently, it looks into differences in bone metabolism between men with 
cervical and inter-trochanteric hip fracture. Finally, it throws insight into the process of bone 
remodelling in a group of elderly men living in the community over a 6-month period. 
The subjects studied are those detailed in chapter 2. Baseline blood and second-morning 
void urine samples were collected shortly after fracture (maximum 48 hours) and, at the 
time of the first visit in controls. Repeat samples, in both groups, were collected at 6 
months. 
In men with hip fracture there was impairment of bone turnover evident by reduced bone 
formation with elevated bone resorption. This may account for net bone loss and 
susceptibility to fracture. There was no correlation between levels of bone markers and 
acute phase reactants (albumin, CRP, cortisol), suggesting this uncoupling to be antedating 
the fracture event. At 6 months both markers were elevated suggesting increased bone 
turnover associated with fracture healing. No measurable differences were noted in bone 
markers between men with cervical and inter-trochanteric hip fracture. 
In contrast, amongst controls, both osteocalcin and urinary deoxypyridinoline were within 
the normal reference range, suggesting normal bone remodelling. This was seen both at the 
time of the first visit and at 6 months. However, rate of bone turnover significantly declined 
within the group over this 6-month period. This was evident by significant reduction in both 
bone markers over this period. One explanation may be change in lifestyle and diet 
secondary to education as a result of participation in the study. 
The study was not designed to address the role of bone markers as risk factors for hip 
fracture. Within this constraint, this study shows a 40% increase in the risk of hip fracture 
(OR 1.41,95%CI 1.3,1.6) per unit increase in urinary deoxypyridinoline, and, an 18% 
reduction in risk of hip fracture per ng/ml increase in serum osteocalcin (OR 0.82,95%CI 
0.73,0.92). This risk / protection conferred is not altered after adjusting for age or BMD. 
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9.2 BACKGROUND 
Bone loss and increased bone turnover are recognised local changes after a fracture, but the 
exact pattern of these changes after different types of fracture is unclear. The availability of 
biochemical markers of bone metabolism enables us to study the different states of bone 
turnover. 
Biochemical markers of bone turnover are increased after fracture in some studies (Ingle et 
al, 1999; Bowles et al, 1997; Nyman et al, 1991) but not all (Lauritzen et al, 1987). In 
elderly osteoporotic subjects sustaining hip fracture, both increased (Slovik et al, 1984) and 
decreased (Cooper et al, 1989, Akesson et al, 1993) osteocalcin levels have been noted. 
The variations in the levels of bone markers may reflect, either the general underlying bone 
metabolic alterations caused by the disease, or post-traumatically induced changes related to 
the fracture event or the callus formation. Except for the study by Akesson in women with 
hip fracture (Akesson et al, 1993), measurements have been performed in a limited number 
of patients, and, in most cases, several days to weeks after the hip fracture. 
Abnormalities of bone turnover responsible for bone loss in men with osteoporotic fractures 
have not been clearly defined. With the increasing use of biochemical markers of bone 
turnover in the study of osteoporosis, it is important that the effects of fracture and fracture 
healing on levels of these markers are better understood. 
The aim of this study was to analyse potential abnormalities of bone turnover in elderly men 
shortly after hip fracture. To evaluate the bone metabolism status of these men, serum 
osteocalcin was used as a marker of bone formation and urinary deoxypyridinoline to reflect 
bone resorption. Subsequently, comparisons were made with matched controls without hip 
fracture. In order to avoid the confounding effects of fracture per se on bone turnover, 
samples were drawn as close to occurrence of hip fracture as possible (usually within 24 
hours, maximum 48 hours). Furthermore, levels of bone markers in serum were correlated 
with acute phase proteins and repeat measurements carried out at 6 months. Follow-up at 6 
months also helped evaluate bone metabolic properties during the phase of fracture healing. 
In addition, an attempt was made to address differences in bone metabolism between men 
with cervical and intertrochanteric hip fracture. 
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9.3 PATIENTS AND METHODS 
9.3.1 Study Design 
100 men, admitted consecutively with a low trauma hip fracture over a 14-month period 
were identified as cases. An equal number of men were randomly recruited as controls from 
a local general practice register. Details of the study design are given in chapter 2. 
9.3.2 Measurement Of Biochemical Markers Of Bone Turnover 
Bone markers were assayed at baseline (within 48 hours in men with hip fracture and at the 
time of the first visit in controls) and at 6 months. Majority of the initial measurements were 
made prior to fluid substitution and surgery. An early morning fasting blood sample and a 2- 
hour second morning urine sample were collected, for serum osteocalcin and urinary 
deoxypyridinoline, respectively. Blood samples were centrifuged immediately after 
collection and serum separated. Aliquots of serum and urine were stored at -800 C until 
assay. Samples collected from individual subjects were measured within a single analytical 
batch. The within batch CV was calculated from analytical duplicates for each analyte, 
details of which are in chapter 2. 
Osteocalcin was used as the marker for bone formation and urine deoxypyridinoline for bone 
resorption. Intact osteocalcin was assayed in serum using NovoCalcinTM kit. The assay has 
a minimum detection limit of 0.45 ng/ml. The intra assay and inter assay CVs over the range 
6.2-16.5 ng/ml were <10 and <9.8% respectively. Deoxypyridinoline cross-links were 
measured in the second-morning void urine using Pyrilinks-D immunoassay by Metra 
Biosystems. The assay is sensitive to detect a minimum value of 1.1 nmolIl. The within and 
between -run CV of the assay at the range <5.4 Dpd values is 8.4% and 4.8%, respectively. 
9.3.3 Analysis 
Descriptive statistics were used to describe group characteristics in both cases and controls. 
Univariate statistics, both parametric and non-parametric where appropriate, were used to 
compare baseline values between groups. Paired tests were used to determine change over 
time. Logistic regression was used to explore the relationship between hip fracture and the 




9.4.1 Bone markers in controls 
The number of subjects where measurements of various bone markers was possible at the 
two time intervals is given in Table 9.1. Osteocalcin was measured in only 71 men at 
baseline and in 92 at 6 months. The large number of missing observations, at baseline, was a 
result of the samples being misplaced in the laboratory. 
Table 9.1 Bone markers in controls at baseline and at 6M 
(Mean & SD are shown) 
Variable N range Time No. Mean SD P* 
Age (years) Baseline 100 75.1 9.6 
Osteocalcin (ng/ml) 3.4-9.1 Baseline 71 8.3 6.2 
6M 92 6.2 4.1 <0.0001 
U D-Pyr(nM/nM) 2.3-5.4 Baseline 96 5.5 3.5 
6M 90 5.1 2.6 <0.04 
Alkaline Phos (IU/1) 50-120 Baseline 99 95.9 38.3 NS 
6M 90 98.4 41.3 
* Wilcoxon signed rank test between baseline and 6 months 
Serum osteocalcin and urinary deoxypyridinoline were within the normal range of the 
laboratory both at baseline and at 6 months (Table 9.1). A decrease in levels of both bone 
markers was seen at 6 months. Of the 86 controls who had measurements both at baseline 
and at 6 months, 50 showed a decrease in urinary deoxypyridinoline. Similarly, of the 68 
controls, 54 showed a decrease in serum osteocalcin. This decrease in both markers over the 
6 month period was statistically significant (Wilcoxon signed ranks test, p<0.04 & p<0.0001 
respectively (Table 9.1). 
Osteocalcin and urinary deoxypyridinoline had a modest correlation with each other (r5 
=0.36, n=69, p<0.01), but not with alkaline phosphatase. Osteocalcin also correlated with 
age (OC: r5. =0.24, n=71, p<0.05; Udpd: rs =0.18, n=96, p=NS; AlkPhos: rs =0.13, n=99, 
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p=NS). In the very elderly (over 80 years) both osteocalcin and urinary deoxypyridinoline 
were above the laboratories normal range suggesting high bone turnover (Table 9.2). 
Urinary deoxypyridinoline had a small but significant inverse relationship with femoral neck 
BMD (rs =-0.21, n=96, p<0.05). There was no correlation with BMD at any other site. No 
correlation was found between BND, osteocalcin and alkaline phosphatase. Only alkaline 
phosphatase correlated with CRP (rs = 0.20, n=99, p<0.04). 
Table 9.2 Change in bone markers in controls with age 
(Mean & SD are shown) 
Variable N range 50-59 60-69 70-79 80-89 90+ 
No. 8 17 43 29 3 
Age (years) 54.1 (3.3) 67.5 (1.6) 74.1 (2.7) 84.8 (2.3) 95 (2) 
Osteocalcin (ng/ml) 3.4-9.1 6 (1.4) 7.4 (3.3) 6.3 (2.1) 11.4 (9.6) 14.2 (8.9) 
U D-Pyr(nM/nM) 2.3-5.4 5.3 (2.2) 5.2 (2.1) 4.5 (1.7) 6.6 (5) 11.6 (5.6) 
Alkaline Phos (IU/1) 50-120 80.4 (25.5) 94.4 (36.6) 89 (21.9) 111.6 (55.8) 98(33.9) 
High urinary deoxypyridinoline defined as levels more than 5.4 nM/nM was present in 38/96 
(39.6%) controls at baseline and in 25/90 (27.8%) at 6 months (Table 9.3). 20 of the 38 men 
(52.6%) at baseline and 15 of the 25 (60%) at 6 months were over the age of 80. 
Table 9.3 Subjects with abnormal bone markers at baseline and at 6 months 
Number (%) are shown 
Cases Controls 
Abnormal values No (%) No (%) 
U. D-Pyridinoline >5.4 Baseline 78 (86.7) 38 (39.6) 
6 Months 38 (77.6) 25 (27.8) 
S Osteocalcin <3.4 Baseline 16 (16.8) 3 (4.2) 
6 Months 4 (7.8) 21 (22.8) 
U dpd>5.4 & Osteo >9.1 Baseline 8 (8.9) 10 (14.4) 
6 Months 17 (34.6) 7(7.8) 
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9.4.2 Bone markers in men with hip fracture 
Serum osteocalcin was measured in 95 cases within 48 hours of the hip fracture and in 51 of 
the survivors at 6 months. 52 fractures were cervical and 43 were inter-trochanteric. Urine 
for deoxypyridinoline was collected in 90 and 49 cases at baseline and 6 months, 
respectively. Similarly, serum alkaline phosphatase was measured in 94 and 51 cases 
respectively (Table 9.4). 
Following fracture, C-reactive protein showed a significant increase in hip fracture patients 
compared to controls (Cases: 120.5 mg/l; controls: 3.0 mg/I; p<0.01). Concomitantly, serum 
albumin levels were 22.3% lower in men with hip fracture as compared to controls. Serum 
cortisol levels were markedly raised [mean (SD): 630.8mIU/l (266.1)]. Co-morbid diseases 
were significantly more common in cases compared to controls (for details see chapter 3). 
Serum osteocalcin levels on admission were 32.5% lower in men with hip fracture as 
compared to healthy controls (cases: 5.6 ng/ml; controls: 8.3 ng/ml; p<0.01). In men with 
hip fracture, at follow-up 6 months later, serum osteocalcin levels had significantly increased 
(46.4%) and reached levels 32.2% higher than the controls (cases: 8.2 ng/ml; controls: 6.2 
ng/ml; p<0.04). Of the 50 fracture cases that had measurements both at baseline and at 6 
months, 31 (62%) showed an increase in serum levels of osteocalcin compared to baseline. 
This increase was statistically significant (Wilcoxon signed ranks test; p<0.009). 
Soon after the hip fracture (within 48 hours), alkaline phosphatase was significantly elevated 
in cases compared to controls (cases: 116.9 IU/I; controls: 95.9 IU/l; p<0.01). In parallel to 
the changes observed in serum osteocalcin, the further rise in serum alkaline phosphatase 
levels, 6 months later, was significant but less marked (6.9%). 33 of the 51 cases who had 
measurements carried out at both time points showed an increase (Wilcoxon signed ranks 
test p<0.009) see Table 9.4. 
At the time of the hip fracture, urinary deoxypyridinoline was more than two times the value 
in the controls (cases: 11.2, controls: 5.5; p<0.01). These elevated levels persisted amongst 
the survivors' 6 months after the fracture (Table 9.4). Of the 47 fracture cases who had 
measurements both at the time of the hip fracture and at 6 months, 27 (57.4%) showed a 
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further increase in urinary deoxypyridinoline at 6 months. This did not reach statistical 
significance. 
Table 9.4 Differences between cases and controls: baseline & at 6 months 
(Mean & SD are shown) 
Variable N range Time Cases Controls Sig 
No. Mean (SD) No. Mean (SD) Mann 
Whitney 
Age (years) 
C-reactive protein (mg/1) 









100 79.9 (9.4) 100 75.1 (9.6) <0.01 
82 120.5 (76.4) 100 3.0 (5.4) <0.0001 
Baseline 95 33.8 (5.0) 99 43.5 (2.9) <0.0001 
Baseline 89 630.8 (266) NT* 
Baseline 95 5.6 (2.7) 71 8.3 (6.2) <0.0001 
6M 51 8.2 (5.3) 92 6,2 (4.1) <0.04 
Baseline 90 11.2 (6.1) 96 5.5 (3.5) <0.0001 
6M 49 10.2 (5.7) 90 5.1 (2.6) <0.0001 
Baseline 94 116.9 (69.6) 99 95.9 (38.3) <0.01 
6M 51 125 (52.6) 90 98.4 (41.3) <0.01 
Alkaline Phosphatase (IU/1) 50-120 
* NT: Not tested 
Men with hip fracture exhibited an imbalance of bone turnover with depressed bone 
formation and higher bone resorption. At the time of the hip fracture, poor bone formation 
exemplified by low serum osteocalcin (<3.4 ng/ml) was present in 16/95 (16.8%) cases. In 
contrast, increased bone loss suggested by high urinary deoxypyridinoline, defined as levels 
more than 5.4 nM/nM, was present in 78/90 (86.7%) cases (Table 9.3). Six months after 
fracture, bone turnover was increased with 17 (34.6%) cases exhibiting elevated levels of 
both serum osteocalcin and urinary deoxypyridinoline (Table 9.3). 
Men with cervical fracture were two years older compared to those with fracture at the 
inter-trochanteric site. There was no measurable difference in bone markers between the two 
groups (Table 9.5). Similarly, although men with 3 or more co-morbid diseases were older 
than those not diseased, there were no quantifiable differences in levels of bone marker 
between the two groups (Table 9.6). 
188 
Table 9.5 Bone markers in men with cervical versus inter-trochanteric fracture 
Cervical Inter-trochanteric 
Variable n Mean (SD) n Mean (SD) p 
Age (yrs) 55 80.8 (8.9) 45 78.9 (9.8) NS 
S Osteocalcin (ng/ml) 52 5.8 (3) 43 5.3 (2.4) NS 
UD Pyr (nM/nM) SD 11.3 (5.5) 40 11(6.8) NS 
Alkaline Phos (IU/1) SI 113.6 (57.3) 43 120.7 (82.4) NS 
Table 9.6 Bone markers in relation to presence of co-morbidity 
No co-morbidity 3 or more co-morbidities 
Variable n Mean (SD) n Mean (SD) P 
Age (yrs) 21 78.3 (13.6) 75 80.4 (7.9) NS 
C-reactive protein 18 103.5 (76.8) 64 125.3 (76.2) NS 
S Osteocalcin (ng/ml) 20 5.9 (3.4) 75 5.5 (2.5) NS 
UD Pyr (nM/nM) 18 12.4 (8.0) 72 10.9 (5.5) NS 
Alkaline Phos (IU/1) 20 126.1 (40.4) 74 114.4 (75.6) NS 
As expected, osteocalcin correlated to alkaline phosphatase rS = 0.23 (p<0.05). To evaluate 
whether or not the serum osteocalcin level was only a direct reaction to the sustained 
fracture, the study addressed the correlation to the acute phase response namely serum 
albumin, C-reactive protein and cortisol. No correlation was seen between bone markers, 
and any of the acute phase reactants measured at the same time (Table 9.7). No correlation 
was seen between bone markers and age or BMD at baseline and at 6 months amongst 
fracture cases. 
Table 9.7 Correlation with age, acute phase reactants and BMD 
Age Serum C-Reactive Cortisol BMD BMD 
Albumin Protein (Femoral neck) (L Spine) 
Osteocalcin 0.15 0.01 0.03 -0.02 -0.16 -0.05 
UD Pyr -0.06 -0.24* 0.08 0.15 0.02 -0.13 
Alkaline Phos 0.25* -0.04 -0.04 0.21 -0.26* -0.12 
* p<0.01 
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9.4.3 Bone markers as a risk factor for low trauma hip fracture 
Using baseline data, obtained within 48 hours of the event in cases, urinary 
deoxypyridinoline was a significant risk factor for low trauma hip fracture. There was a 40% 
increase in the risk of hip fracture (OR 1.41,95%CI 1.3,1.6) per unit increase in urinary 
deoxypyridinoline using multiple logistic regression. This risk was unchanged after adjusting 
for age (OR 1.38,95%CI 1.2,1.6) and or BMD (OR 1.34,95%CI 1.2,1.5). Elevated 
urinary deoxypyridinoline (>5.4) increased the risk of hip fracture 10 fold (OR 9.9) see 
Table 9.8, The risk associated was unchanged on repeating the analysis using the 6-month 
data. 
Table 9.8 Odds ratios for abnormal bone markers at baseline 
Odds ratio (95%CI) 
Abnormal values unadjusted adjusted for age 
U D-Pyridinoline (nM/nM) 1.41 (1.25,1.58) 1.39 (1.23,1.56) 
S Osteocalcin (ng/ml) 0.82 (0.73,0.92) 0.77 (0.68,0.88) 
U. D-Pyridinoline >5.4 (nM/nM) 9.92 (4.77,20.64) 8.95 (4.26,18.81) 
S Osteocalcin >9.1 ng/ml 0.35 (0.15,0.81) 0.21 (0.08,0.53) 
S Osteocalcin <3.4 ng/ml 4.59 (1.28,16.43) 4.67 (1.27,17.16) 
Serum osteocalcin is associated with a decreased risk of hip fracture. There was a reduction 
in risk of hip fracture by 18% per ng/ml increase in serum osteocalcin (OR 0.82,95%CI 
0.73,0.92). The protection conferred was not altered after adjusting for age (OR 0.77, 
95%CI 0.68,0.88) or BMD (OR 0.76,95%CI 0.64,0.90). Serum osteocalcin levels greater 
than 9.1 ng/ml reduced the risk of hip fracture by two third (OR 0.35) see Table 9.8. 
9.5 CONCLUSION 
As expected, men aged 50 and over, living in the community exhibit normal bone 
remodelling. Finding normal levels of serum osteocalcin and urinary deoxypyridinoline in 
this cohort of men over a 6-month period supports this. However, in the very elderly (over 
80 years) there is evidence to suggest a state of increased bone turnover. This is illustrated 
by significantly elevated levels of both serum osteocalcin and urinary deoxypyridinoline in 
men in this age group. In addition, one is able to demonstrate a good correlation between 
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age and osteocalcin. However, this result needs to be interpreted with caution, as the study 
was limited in the number of subjects studied in this age range. 
A statistically significant decrease in both bone markers, implying reduced bone turnover, 
was observed amongst the controls over the 6-month period. One explanation may be 
changes in lifestyle habits associated with increased calcium intake by diet or supplements as 
a result of participation in the study. 
This study failed to provide evidence to suggest that the rate of bone turnover determines 
BMD in elderly men. No relationship was found between BMD and osteocalcin and only a 
weak relation (r, =-0.21) with urinary deoxypyridinoline. 
It has been proposed that intertrochanteric fractures are the consequence of more severe 
osteoporosis than cervical hip fractures. In this study, bone markers have not pointed to any 
difference between these fracture types. On the contrary, similar levels have been found in 
patients with either fracture type. 
The data acquired suggests that bone turnover is disturbed in elderly men sustaining a hip 
fracture. In contrast to the expected age-related increase of osteocalcin, men with hip 
fracture instead have reduced osteocalcin level, reflecting decreased bone formation. The 
lower osteocalcin level in the fracture patients may indicate that this population of elderly 
men has impaired osteoblast function. 
Elderly men with hip fracture have an uncoupling of bone formation and resorption, changes 
that may contribute to net loss of bone. Significantly elevated levels of urinary 
deoxypyridinoline at the time of the fracture along with reduced serum osteocalcin supports 
this hypothesis. The increased resorptive activity seems unrelated to metabolic alterations 
induced by trauma and surgery. Absence of correlation between both bone markers and 
acute phase reactants, including cortisol levels at the time of initial sampling, indicates that 
reduced osteocalcin and urinary deoxypyridinoline are unrelated to the trauma-induced 
cortisol surge in these patients. Neither does it seem likely that cortisol should have a 
momentary effect on the osteoblasts and the higher urinary deoxypyridinoline level is not 
related to cortisol in the study. Furthermore, renal function was not significantly different 
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between the two groups. Therefore, an impaired kidney function or alteration in crea. tinine 
clearance cannot explain the increased urinary deoxypyridinoline. 
It has been shown that elderly patients in the presence of co-morbid diseases and poor 
mobility have increased bone resorption. Fracture patients were more disabled and had 
significantly more diseases compared to controls. Differences observed in this cohort of 
patients did not reach statistical significance. 
These data suggest that, the abnormal levels of osteocalcin and urinary deoxypyridinoline 
are unrelated to traumatically induced changes, but reflect abnormal bone turnover prior to 
fracture. These abnormalities may play a role in the decrease of bone mass and consequently 
the increased bone fragility that characterises osteoporotic hip fractures in the elderly, 
Men with hip fracture are capable of responding adequately to the fracture and initiate the 
healing process, which is reflected as an increase of both osteocalcin and alkaline 
phosphatase levels at 6 months. Whether the post fracture metabolic response reflects a 
general reactive increase of the bone turnover caused by the fracture itself or whether it is 
explained by fracture healing is debatable. 
Within the constraints of the study design, elevated urinary deoxypyridinoline is a risk factor 
and raised osteocalcin is protective for low trauma hip fracture in men. The risk / protection 
conferred is independent of age and bone mineral density. High levels of osteocalcin reduce 
the risk of hip fracture by two third (OR 0.35). Conversely, elevated urinary 
deoxypyridinoline increase the risk by 10 fold (OR 9.9). 
The study has limitations. Ideally, the first samples should be taken before occurrence of the 
fracture. In this study baseline samples were taken within 48 hours of the event when some 
changes may have already taken place affecting the true levels of the markers. This would 
not only alter the strength of the association between bone markers and risk of hip fracture 
but also raise doubt on the degree of uncoupling observed in these men following the 
fracture. There are little published data on the response to fracture using biochemical 
markers, and comparison with other studies is difficult because of different baseline sampling 
times, a variety of fractures and a number of markers measured by different methods. 
Another drawback of this study is the accidental loss of a small proportion of samples in the 
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laboratory. It may be argued that samples lost may have been different from those that were 
assayed. This is extremely unlikely, as there was no systematic selection bias. 
Fracture patients were ill and had significantly more concomitant illnesses like Parkinson's 
and stroke, which impaired mobility significantly more than the controls. However, no 
differences in bone markers were found in men with or without co-morbid disease. 
The study is limited in allowing us to identify the reasons for the increased bone resorption 
and its precise relation to occurrence of the fracture. Whatever the temporal profile of the 
bone resorption process in relation to fracture occurrence, it is evident that bone resorption 
continues unabated in as high as 77.6% of survivors at 6 months. Translating this in clinical 
terms, there may be an argument to initiate anti resorptive agents in individuals who sustain 
a fracture to reduce risk of further fractures. 
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10. QUALITY OF LIFE AND FUNCTIONAL IMPAIRMENT 
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10.1 SUMMARY 
This chapter addresses the quality of life and functional ability of a group of randomly 
selected elderly men living in community and compares their health to the standard norms 
published for the US general population. Using the same "generic" and "specific" health 
assessment tools it then evaluates the health status of a comparable group of men 4 weeks 
prior and 24 months after, a hip fracture. 
The populations studied (hip fracture cases and community controls) are those detailed in 
chapter 2. The Short Form-36 (SF-36) was used as the "generic" health assessment 
questionnaire and a modification of the (Health Assessment Questionnaires) HAQ termed 
"HAS" was used for assessing functional ability. A single interviewer administered the 
questionnaires within 48 hours of the fracture in cases and at the time of the first visit in the 
controls. They were re-administered at 6,12 and 24 months. 
In all 8 domains of the SF-36, quality of life amongst community controls was comparable 
to standard US norms. The physical component score (PCS) was 0.5SD below and the 
mental component score (MCS) 0.7SD above the published US scores. Cases scored poorly 
in all domains of the SF-36 except pain compared to controls both before and upto 24 
months after the hip fracture (p<0.001). The magnitude of difference observed between the 
two groups using the PCS, MCS and after adjustment for the confounding effects of age and 
co-morbidity remained unchanged. Fracture resulted in reduction of the PCS from 40.5 at 
baseline to 35.6,35.4 and 33.3 at 6,12 and 24 months respectively. After adjusting for 
group differences in age, co-morbidity and baseline physical function, presence of fracture 
reduced PCS by approximately 0.5SD at each assessment interval. The effect on the MCS 
was less dramatic. 
A good correlation was seen between the PCS and the health assessment score (HAS); x-- 
0.76, p<0.001. Cases scored higher (worse) compared to controls, at first visit (0.83 Vs 
0.27, p<0.001). Similar differences were observed at 6,12 and 24 months. Hip fracture had 
an immediate and pronounced effect on the HAS with an increase (worsening) of the score 
from 0.83 at baseline to 1.2 at 6 months. 
Overall the health status of our control population was comparable to the standards laid out 
for the US general population. Poor general health is a characteristic feature of men who 
sustain a low trauma hip fracture, and is evident at least 4 weeks prior to the episode. Hip 
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fracture results in an immediate decline in physical function, which continues to deteriorate 
steadily over 2 years; the effect on mental functions is less marked. After adjusting for 
differences in age, co-morbidities and "pre-fracture" functional dependence between the two 
populations at baseline, this study shows that fracture status independently influences an 
individuals quality of life for upto 2 years. 
10.2 BACKGROUND 
Over recent years there has been an explosion in the utilisation of health related quality of 
life instruments for a wide variety of diseases. Various generic instruments to measure 
quality of life have been developed with one, the Short Form-36 (SF-36), being widely 
adopted by many researchers. The SF-36 has been well validated for use in many countries 
and for many diseases. 
Disease specific instruments have been developed with the aim of evaluating specific quality 
of life issues relevant to patients with a particular disease. In the absence of any well 
accepted "specific" quality of life instrument for osteoporotic hip fracture patients the 
questionnaire used by the Mediterranean osteoporosis study (MEDOS) was considered 
suitable as a prototype. To simplify analysis and interpretation it was scored similar to the 
health assessment questionnaire (HAQ) used in rheumatoid arthritis. The validity and 
responsiveness of this questionnaire over time has yet to be established. 
There have been several studies addressing impact of osteoporotic fractures on quality of 
life and function of individual subjects. Most of these studies are focused at women. In 
addition, few have directly compared with age matched normal subjects without fracture. 
There are also no studies looking at both pre and post fracture health status. 
An evaluation of the specific impact of hip fracture on quality of life and function is 
important in determining the nature and magnitude of the health deficits associated with hip 
fracture. 
This section compares the quality of life and function in 100 men with hip fracture to 100 
comparable controls living in community who have not had a hip fracture. Due to the 
inherent properties of the SF-36 questionnaire, baseline assessment is the best possible 
estimate of the "pre-fracture" quality of life of the individual using such a study design. The 
modified MEDOS questionnaire termed the health assessment score "HAS" allowed 
assessment of many of the simpler tasks of daily life including eating, grooming and toileting 
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(Appendix 2.3). The combination of these tools with prospective assessment over 24 months 
gave the best possible estimate of health related quality of life following a hip fracture in 
elderly men. 
10.3 MATERIAL AND METHODS 
10.3.1 Recruitment of subjects 
The study used a case control design with simultaneous and prospective recruitment of hip 
fracture cases and community controls over 14 months. Details of inclusion and exclusion 
criteria and study design are described in chapter 2. 
10.3.2 Assessment of quality of life using generic SF-36 
The SF-36 (see Appendix 2.3) was administered in the standardised manner, with no 
interpretation of the questions by the interviewer. This instrument measures quality of life in 
eight domains: physical functioning (PF), role physical (RP), bodily pain (BP), general health 
(GH), vitality (V), social functioning (SF), role emotional (RE) and mental health (MH) (for 
a definition of terms see Table 1 under Appendices). From these eight domains two 
summary scores were calculated: these were the physical and mental component summary 
indexes (PCS and MCS) respectively (see Figure 1 under Appendices). 
The SF-36 was administered to all controls at the time of the first visit and to cases within 
48 hours of the hip fracture. Baseline questionnaire assessed quality of life 4 weeks prior to 
the event. The SF-36 questionnaire was re-administered amongst consenting survivors in 
both groups at 6,12 and 24 months. Where subjects were incapable of completing the 
questionnaire proxy members were not considered appropriate. These subjects were 
excluded from the analysis. Missing observations were largely due to death and dementia. 
Since the questionnaire was administered in the hospital setting, the form was checked for 
its completeness before the subject completed his visit. As a result problems in handling 
missing data were avoided. 
10.3.3 Assessment of functional capacity using HAS 
Functional capacity related to activities of daily living was assessed using another 
questionnaire (see Appendix 2.3) that was co-administered with the SF-36 in both cases and 
controls. This questionnaire was based on one used by the MEDOS (Mediterranean 
Osteoporosis Study) group and assessed degree of functional limitation in eight activities: 
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ability to dress/ undress, ability to eat, perform household chores, get up from a chair, climb 
stairs, wash and dry, walk indoors and outdoors. The response was graded: without 
difficulty = 0; with some difficulty =1, with much difficulty =2 and unable to do = 3. Use of 
an aid/ device or help from another person in performing any activity was scored as 2. 
Similar to the Health Assessment Questionnaire (HAQ) used in rheumatoid arthritis subjects 
the sum of all the eight individual scores gave a score ranging between 0 (independent) to 
24 (totally dependent). All the eight activities were equally weighted as in HAQ and the 
total score was then divided by 8 to give a composite health assessment score (HAS) 
ranging between 0-3 where 0 equals the best score and 3 the worst. 
Similar, to the SF-36 the HAS was evaluated at baseline, 6,12 and 24 months in both cases 
and controls. Missing observations were due to death and dementia. 
10.3.4 Assessment of co-morbidity 
Interviewer assisted questionnaire (see Appendix 2.2) also captured details of co-morbidity 
and concomitant medication from the information supplied by the subject and review of 
medical records. The co-morbidity score for each subject was calculated by adding the 
number of co-morbid diseases. List of medications specially those likely to affect bone 
metabolism namely calcium, corticosteroids, antiepileptics, bisphosphonates, vitamin D were 
noted. 
10.4 STATISTICAL ANALYSIS 
All data was entered in EXCEL and then transferred for analysis to SPSS and STATA. 
Descriptive statistics were used to characterise the study subjects. In addition to deriving 
original scores for all the 8 domains of the SF-36, two quality of life summary statistics- the 
physical and mental component summary scores (PCS and MCS)- were calculated from the 
physical and mental health domains of the SF-36 using previously established methods. The 
correlation coefficient estimates were made using Spearman Rho. Independent sample t test 
were used to compare SF-36 and HAS between groups and paired t test was used to assess 
longitudinal change within groups over the 24 month follow-up. The PCS and MCS scores 
of our study cohort were also compared to the standardised scores published for the US 
general population. Linear regression was used to analyse the independent effects of fracture 
status on PCS and MCS during different stages of the study period. 
198 
10.5 RESULTS 
Fracture cases were older and had significantly more co-morbidities than the control 
population (Table10.1). A greater proportion of cases consumed antipsychotics, 
antiepileptics and diuretics. The number of controls reporting intake of over the counter 
"health tablets" like multivitamins, calcium, vitamin D, cod liver oil etc. were significantly 
higher than cases (17% Vs 1%, =x2=14.9, df=1, p<0.001). 
Within group correlation analysis of both fracture and control subjects showed the SF-36 
physical component score was related to the HAS. rs=-0.76; p<0.0001, n=81 for cases and 
rs. =-0.71, p<O. 0001, n=99 for controls. 
Table 10.1 Descriptive characteristics of cases and controls 
Cases (%) Controls 
(%) 
Significance 
Mean age (years) 79.9 75.1 <0.01 
Cerebrovascular diseases 25.4 8.4 x2=9.4, df=1, p<0.001 
Parkinson's 14.6 1.1 2=12.1, df=1, p<O. 001 
Dementia 27.1 2.1 x2=23.5, dgl, p<0.0001 
Reduced mobility 26.0 4.2 x2= 17.6, df=1, p<0.0001 
Poor vision 21.9 7.4 x2=8.0, df=1, p<0.005 
Antipsychotics 8.3 0 2=18.3, dgl, p<0.004 
Antiepileptics 6.3 0 x2=6.1, df=1, p<O. 01 
Diuretics 30.2 15.8 2=5.6, df=1, p<0.02 
Presence of co-morbidity 79.9 64.1 2=5.5, df=1, p<0.02 
10.5.1 Quality of life assessed using SF-36 in controls 
The SF 36 questionnaire was completed by all controls at baseline but only 97,87 and 84 
men at 6,12 and 24 months respectively. The mean scores in the 8 domains at first visit are 
shown in fig 10.1b. The results are comparable to the means standardised for the general US 
population fig 10.1 a. 
The summary indices i. e. physical and mental component scores (PCS & MCS) are shown in 
figures 10.2. Both scores showed a decline, although the change in physical score (-0.5 SD) 
was greater than the reduction in the mental score (-0.3 SD) over the 24 month follow-up 
period. The physical scores were 0.5SD below the mean US standard at baseline and 
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deteriorated to 0.9SD below the US mean by 2 years. In contrast, controls consistently 
scored higher on the mental scores compared to the US standards. They scored +0.6SD 
higher at first visit and remained high by +0.4SD above the US mean at 2 years. 
Figure 10.3 illustrates the paired changes in PCS and MCS between baseline- 6 months, 
baseline-1 year and baseline-2 years. The observed decline in scores at all time points was 
significant (paired t test p<0.05 for all pairs 0-6,0-12 and 0-24 months). 
10.5.2 Functional capacity using Health Assessment Score (HAS) in controls 
Questionnaire used to calculate the health assessment score (HAS) was completed by 99, 
97,87 and 84 controls at baseline, 6,12 and 24 months respectively. The score ranged from 
0 to 3 with zero representing the best score implying functional independence. The mean 
HAS at first visit was 0.27. The score increased to 0.40 at 6 months and then remained at 
0.36 and 0.39 at 1 and 2 years respectively (fig 10.4). HAS showed an increase (worsening) 
in 31 of the 96 controls reassessed at 6 months compared to baseline (Wilcoxon signed 
ranks test p<0.001). Further change in the score was observed at 12 and 24 months with 34 
of the 86 and 30 of the 83 exhibiting a further increase (Wilcoxon signed ranks test 
p<O. 001). 
Detailed analysis of the 8 activities assessed (ability to eat, dress, perform household chores, 
get up from a chair, do stairs, wash and dry, walk indoors and outdoors) at the four time 
scales (baseline, 6,12 and 24 months) is attached in appendix 3. At first visit 87% could 
walk unaided, 77% get up from a chair without difficulty and 64% climb stairs. Only 1 
subject was unable to walk. At 1 year these figures had changed to 84%, 59% and 67% and 
by 2 years they were 85%, 62% and 56% respectively. 
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Figure 10.1a Mean SF-36 scores of the standard US general population 
PF: physical functioning, RP: role-physical, BP: bodily pain, GH: general health, VT: 
vitality, SF: social functioning, RE: role-emotional, MH: mental health 








PF RP BP GH VT SF RE MH 
Domains 
= Controls - U. S population 
Figure 10.1b SF-36 scores at baseline in controls standardised to US general 
population 
PF: physical functioning, RP: role-physical, BP: bodily pain, GH: general health, VT: 
vitality, SF: social functioning, RE: role-emotional, MH: mental health 
Domains of the SF-36 
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Figure 10.2a Physical component score (PCS) in controls over 2 years 
Mean (SD) PCS for the US population: 50 (10) 
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Figure 10.2b: Mental component score (MCS) in controls over 2 years 
Mean (SD) MCS for the US population: 50 (10) 
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Figure 10.3a: Changes in Physical component score in Controls over 2 years 
Paired data are shown as individual lines 
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Figure 10.3b: Changes in Mental component score in Controls over 2 years 
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Figure 10.4: Health Assessment Score (HAS) in cases and controls over 2 years 
10.5.3 Quality of life in hip fracture cases 
Only 81 cases completed the SF 36 questionnaire within 48 hours of the hip fracture. 
Follow-up scores at 6,12 and 24 months were available in 51,47 and 34 cases respectively. 
Baseline SF-36 scores reflected the "pre-fracture" health status. The pre-fracture mean 
scores in the 8 domains and their comparison with the controls are shown in figure 10.5. 
Cases scored significantly worse in all domains except pain (BP). The results of the 
composite physical and mental component scores are shown in figure 10.6. Even before the 
fracture cases scored significantly lower in both the PCS and MCS compared to controls. 
Pre-fracture mean physical score in the cases was more than 1 SD below the standard US 
mean. Pre-fracture mental scores although significantly less than the controls were normal 
by US standards. The immediate effect of fracture was seen on the physical but not on the 
mental component summary index see fig 10.5. Following the fracture the physical scores 
deteriorated steadily to more than 1.7 SD below the US mean at 2 years. The fracture event 
did not have an immediate effect on the mental scores (p=NS at 1 year). However, a 
significant later decline in MCS was observed at 2 years (p<0.04). 
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Figure 10.7a illustrates the paired changes in PCS between baseline- 6 months, baseline -1 
year and baseline-2 years. The decline in PCS was significant (paired t test p<0.05 for all 
pairs 0-6,0-12 and 0-24 months). The change in MCS (fig 10.7b) was significant only 
between baseline and 2 years (mean 50.1 at baseline, 45.1 at 2 years; paired t test p<0.035). 
Baseline SF-36 Scale Scores (original) 
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Q Controls Cases 
Figure 10.5: Mean SF-36 scores at baseline in cases and controls 
PF: physical functioning, RP: role-physical, BP: bodily pain, GH: general health, VT: 
vitality, SF: social functioning, RE: role-emotional, MH: mental health 
PF RP BP GH VT SF RE MH 
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Figure 10.6a: Physical component score (PCS) in cases and controls over 2 years 
Mean (SD) PCS for the US population: 50 (10) 
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Figure 10.6b: Mental component score (MCS) in cases and controls over 2 years 
Mean (SD) MCS for the US population: 50 (10) 
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Figure 10.7a: Changes in Physical component score in Cases over 2 years 
Paired data are shown as individual lines 
Mental Component Score in Cases 







-+-0-6 -t-0-12 -ý0-24 
Figure 10.7b: Changes in Mental component score in Cases over 2 years 
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10.5.4 Functional capacity in cases 
Questionnaire used to calculate the health assessment score were completed by 91,50,47 
and 35 cases at baseline, 6,12 and 24 months respectively The mean HAS at baseline was 
0.84. Fracture raised the HAS of the 50 survivors at 6 months to 1.2. The score stabilised at 
1.2 amongst survivors reassessed at 12 and 24 months (fig 10.4). 
Paired t test was used to analyse change in the score between two time points i. e. baseline-6 
months, baseline-12 months and baseline-24 months. 31 of the 47 cases assessed both at 
baseline and 6 months, 34 of the 45 assessed at baseline and at 12 months and 27 of the 34 
assessed at baseline and at 24 months scored higher than their initial values; paired t test 
p<0.001. 
Detailed analysis of the 8 activities assessed in the HAS at the four time scales (baseline, 6, 
12 and 24 months) is attached in appendix 3. Before fracture 59% could walk unaided, 51% 
could get up from a chair without difficulty and 40% could climb stairs without difficulty. 
Only 4% subjects were unable to walk. At 1 year these figures had changed to 36%, 37% 
and 15% and by 2 years they were 34%, 26% and 20% respectively. A significant 
proportion (15% & 20% respectively) were unable to walk at 12 and 24 months post 
fracture. 
10.5.5 Quality of life in cases compared to controls 
Fracture cases had worse scores in all domains except pain compared to controls both 
before and upto 24 months after the hip fracture. This was also true using the physical and 
mental component score. These differences in SF-36 physical and mental component scores 
persisted even when baseline differences in age and co-morbidities were allowed for in the 
multiple regression analysis (Table 10.2). This indicates that fracture status was a significant 
and independent determinant of quality of life. 
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Table 10.2 Determinants of the SF-36 physical component score at 6 months as the dependent 
variable 
Model Unstandardized Coefficients Standardized Significance 
coefficients level 
B Standard Error Beta 
Constant 65.29 7.03 0.001 
Age -0.24 0.09 -0.19 0.01 
Co-morbidities -8.02 1.96 -0.31 0.001 
Fracture status -5.30 1.85 -0.21 0.001 
Regression analysis was undertaken entering the independent variables age, presence of co- 
morbidities and fracture status into the analysis. The overall correlation coefficient was 
r=0.48, p<0.0001. 
Determinants of the SF-36 physical component score at 12 months as the dependent variable 
Model Unstandardized Coefficients Standardized Significance 
coefficients level 
B Standard Error Beta 
Constant 30.03 7.52 0.001 
Age -0.17 0.08 -0.14 0.04 
Co-morbidities -3.27 1.78 -0.13 0.07 
PCS (baseline) 0.60 0.08 0.51 0.001 
Fracture status -4.50 1.71 -0.18 0.01 
Regression analysis was undertaken entering the independent variables age, presence of co- 
morbidities, physical component scores at first visit and fracture status into the analysis. The 
overall correlation coefficient was r=0.67, p<0.0001. 
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Determinants of the SF-36 physical component score at 12 months as the dependent variable 




B Standard Error Beta 
Constant 57.43 6.75 0.001 
Age -0.13 0.09 -0.10 0.17 
Co-morbidities -4.35 1.88 -0.17 0.02 
HAS (baseline) -8.14 1.50 -0.42 0.001 
Fracture status -4.96 1.79 -0.42 0.001 
Regression analysis was undertaken entering the independent variables age, presence of co-morbidities, 
health assessment scores at first visit and fracture status into the analysis. The overall correlation coefficient 
was r=0.61, p<0.0001. 
Determinants of the SF-36 physical component score at 24 months as the dependent variable 
Model Unstandardized Coefficients Standardized Significance 
coefficients level 
B Standard Error Beta 
Constant 47.11 8.06 0.001 
Age -0.37 0.09 -0.29 0.00 
Co-morbidities -4.04 1.81 -0.16 0.03 
PCS (baseline) 0.52 0.09 0.45 0.001 
Fracture status -6.27 1.84 -0.24 0.00 
Regression analysis was undertaken entering the independent variables age, presence of co-morbidities, 
physical component scores at first visit and fracture status into the analysis. The overall correlation 
coefficient was r=0.69, p<0.0001. 
Determinants of the SF-36 mental component score at 6 months as the dependent variable 




B Standard Error Beta 
Constant 58.53 7.16 0.001 
Age -0.04 0.10 -0.03 0.68 
Co-morbidities -1.68 2.00 -0.07 0.40 
PCS (baseline) 
Fracture status -5.49 1.88 -0.24 0.001 
Regression analysis was undertaken entering the independent variables age, presence of co-morbidities, visit 
and fracture status into the analysis. The overall correlation coefficient was r=0.27, p<0.01 
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10.5.6 Functional capacity in cases compared to controls 
Cases consistently scored higher (worse) than controls at all time points (p<0.001) see 
figure 10.8. The rate of change in the HAS was significantly greater in cases compared to 
controls between any two assessment points. The change in the scores over time period 
varied between -0.12 and -0.17 in the controls compared to -0.49 and -0.63 in cases (figure 
10.8) 
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Figure 10.8: Health Assessment Score in cases and controls over 2 years 
10.5.7 Fracture status as a determinant of quality of life 
There were significant differences in age, number of co-morbidities and baseline physical 
functional status between the two study groups. To assess the independent effect of hip 
fracture on "quality of life" linear regression was used with the dependent variable as the 
physical or mental component score at a time point and independent variable age, presence 
of co-morbidities, baseline PCS or HAS and fracture status. At each assessment (6,12 and 
24 months) occurrence of hip fracture was associated with a significant reduction in the 
physical scores see Table 2. Presence of hip fracture decreased the PCS at any assessment 
interval by approximately -5.0 (-5.3, -4.5, -6.3 at 6,12 and 24 months respectively). This is 
equal to 0.5SD reduction by published US norms. The effects on mental functions were less 
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obvious. This indicates that fracture status was a significant determinant in the reduction of 
quality of life in the fracture subjects, which was not fully accounted for by poor physical 
and health assessment scores. Furthermore it was not primarily due to group differences in 
age, co-morbidity, PCS and HAS scores. 
10.6 CONCLUSIONS 
Controls, chosen at random from the same community population as the fracture subjects, 
are a good representative of the "general population" as their quality of life is comparable to 
published standards. Poor health status is characteristic of men who present with a low 
trauma hip fracture and is measurable/ quantifiable 4 weeks prior to the episode. Two of the 
SF-36 domains, physical health and mental health, illustrate the magnitude of the reduction 
in quality of life measures between the hip fracture and controls group. Poorer health status 
remains the hallmark of this population even 2 years after the fracture. Hip fracture has a 
detrimental effect on physical function, which is immediate and exhibits a continuos decline 
upto 2 years. The effect on mental function is less marked and only reached significance at 
2-years. 
The health assessment score (HAS) developed for this study is a good measure of the 
subjects' physical function. It correlated with the physical component score derived from the 
SF-36. The within group correlation analysis was rs =-0.76; p<0.0001, n=81 for cases and rs 
=-0.71, p<0.0001, n=99 for controls. Similar to the results obtained using the SF-36, the 
HAS was significantly higher (worse) in cases compared to control and remained so till 2 
years after fracture. 
SF-36 scores and HAS were not available in a significant number of subjects in both groups. 
Missing observations in the majority were due to mortality, dementia, frailty and refusal. It is 
likely that these individuals were less healthy and more debilitated. If true, the effect of this 
would be to underestimate the poor health associated with hip fracture and the strength of 
the association between fracture and quality of life. 
In the absence of a population based longitudinal study SF36 scores obtained within 48 
hours of admission are the best pre-fracture estimates for the individual. However, bias 
towards documenting poor health as a result of hospitalisation cannot be completely ruled 
out. Finding no differences in the pain score between the two groups at baseline despite a 
recent fracture gives reason to believe that this was not the case. 
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Group differences in age, number of co-morbidities, baseline dependency level as measured 
using both PCS and HAS may be responsible for the poor quality of life in fracture cases 
compared to controls over the 2 year follow-up. However, even when these differences 
were allowed for, the presence of hip fracture still had a significant effect on both the 
physical and mental spheres of quality of life until 2 years. This suggests that hip fracture 
had global and severe effects on the affected individual until 2 years that were only partly 
dependent on their reduction in functionality prior to fracture. 
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11. MORTALITY AND PROGNOSTIC FACTORS 
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11.1 SUMMARY 
This chapter addresses the mortality and causes thereof, associated with low trauma hip 
fracture in men. A comparison is made to a control population. Factors that influence the 
mortality associated with fracture are examined. 
The study population is the same as outlined in chapter 2.100 men with hip fracture and 
100 controls from the community were followed for a mean of 661 days (1.8 years) 
range 2-1128 days. The follow-up was 100% in both groups. Mortality was 60% in the 
hip fracture population against 10% amongst controls. After adjusting for age 
differences between the two study populations, presence of hip fracture increased the 
risk of death 8 fold (HR=8.1 95%CI 4.1,16.0). Causes of death were similar in the two 
groups: chest infections and heart disease being the commonest. 
Age was the single dominant factor influencing death (HR=1.1 for each year increase in 
age) following hip fracture. Men over 70 were more likely to die (HR=5.8) than those 
younger. Of the various factors influencing mortality (low body mass index, being single, 
presence of one or more co-morbid disease, occurrence of cervical hip fracture and low 
mental score (<8.0)) only residence in institutional care prior to admission, presence of a 
co-morbid condition and poor "pre-fracture" functional status attained statistical 
significance. The hazards ratio associated with nursing and residential home residence 
were 2.1 and 1.7 respectively. Presence of one or more co-morbid disease increased the 
risk of death nearly 3-fold (HR=2.8). Similarly, one unit increase in health assessment 
score (i. e. poorer score) was associated with a 60% increased risk of death HR=1.6, 
(95%CI 1.2,2.1). A higher physical component score (i. e. better quality of life) was 
protective HR=0.95 (95%CI 0.93,0.98). Multiple regression analysis confirmed the 
importance of age at the time of hip fracture and physical function before fracture as the 
most important determinants of outcome in this group of elderly men (HR 1.1 and 1.5 
respectively). 
In conclusion, mortality after hip fracture is high. The cause of death is unrelated to the 
fracture. The most important determinants of outcome are age and the individuals 
functional abilities at the time of fracture. Identification of this high mortality group on 




Hip fractures are a major public health problem. In the UK, the lifetime risk for 
sustaining hip fracture from age 50- years is 18% in women and 6% in men. Excess 
mortality varies after hip fracture with 12-month rates varying from 12%-35% (Keene et 
al, 1993). 
The incidence of hip fracture in men is about one third that in women, however, the 
available evidence would suggest the sequelae of hip fracture may be more serious in 
men. In particular several studies have suggested that mortality is greater than that 
observed in women. The reason for this excess in men is unclear. In part it may be 
related to co-morbid factors which both increase the risk of death and hip fracture (Poor 
et al, 1995). 
There are few studies that have specifically looked at the effect of pre-fracture health 
status on the observed excess mortality of these patients. The role of co-morbid factors 
in predicting death is unclear (Poor et at, 1995; Myers et at, 1991; Jencks et at, 1988). 
The majority of studies report mortality in total not separately by gender. 
The aim of this section is to examine mortality in a group of men with hip fracture, 
compare it with a comparable group of elderly men without a hip fracture living in the 
community and to determine factors which predict death post fracture including pre- 
morbid factors. Such data may help in identifying high-risk groups and help target 
specific preventive interventions. 
11.3 PATIENTS AND METHOD 
A case-control study with prospective follow-up of both groups for 2 years was 
designed. During the period 1995-97,100 men aged 50 years and over consecutively 
admitted with a low trauma hip fracture were recruited as cases. In parallel, 100 men 
living in the community were randomly selected from a local general practice register as 
controls. 
All 100 men with hip fracture consented to take part. To recruit 100 controls 185 men 
were invited to take part - participation rate 54%. All study subjects completed an 
interviewer-administered questionnaire. Where information could not be obtained 
directly from the subject it was obtained from a proxy relative or carer. First assessment 
was carried out at the time of the first visit in controls and within 48 hours of admission 
216 
in fracture cases. Information collected included demographic profile, residence prior to 
fracture (response set: own home / residential home / nursing home), mini-mental status, 
various co-morbid factors (including dementia, Parkinson's', heart disease, arthritis, 
diabetes, stroke, dementia, gut disorders, and osteoarthritis) and functional capacity 
using an 8 item questionnaire derived from the MEDOS and scored based on the health 
assessment questionnaire, termed health assessment score (for details see chapter 10). In 
addition quality of life 4 weeks prior to fracture was ascertained using the SF-36. The 
"physical component score" and " mental component score" were calculated in a 
standardised manner as described in the previous chapter. 
All subjects were reassessed at 6 months, 12 months and 24 months. Vital status, 
information about their current place of residence and current functional ability was 
collected by direct contact with the patient, relative or carer using similar questionnaires. 
The cause of death was confirmed using death certificates or post-mortem reports 
obtained using the vital registration system from the registrar general office. 
Statistical analysis: The pre and post fracture events at various time intervals were 
analysed using cross-tabulation procedures. The impact of various predictors of hip 
fracture on outcome was assessed using Kaplan Meier curves with log rank tests. Cox 
regression analysis was used to assess the predictive risk of the various confounding 
factors. In each case adjustment for age was carried out. Multiple cox regression analysis 
was used to assess the individual contribution of each risk factor identified. Analysis for 
hazards ratio was undertaken using STATA. 
11.4 RESULTS 
100 men with hip fracture, mean age 79.9 years (SD=9.4), and 100 controls, mean age 
75.1 (SD=9.6) were studied. The baseline characteristics of both cases and controls are 
outlined in Table 11.1. Men with a hip fracture were more likely to be older, living in 
institutional care, have co-morbid diseases and greater functional impairment on 
admission than those without a hip fracture. 
11.4.1 Differences in mortality between Cases and Controls 
Subjects were followed for a mean of 661 days (1.8 years) (range 2-1128 days). Follow- 
up was 100% in both groups. In total there were 60 deaths among the fracture cases and 
10 deaths among the controls (Table 11.2). Amongst cases early mortality (90 days) was 
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25%, more deaths occurred in the first year (45%) than in the second year (15%). Only 
one death was observed amongst controls in the first year, 9 more died by the end of the 
follow-up period. 
Table 11.1 Baseline characteristics of Cases and Controls 
At Baseline No. Cases No. Controls Significance 
Age (years) 100 79.9 (9.4) 100 75.1 (9.6) <0.001 
Residence Own Home 100 71 100 96 x2=22.7, d2, 
Residential H 14 2 p<0.000 
Nursing Home 15 2 
Co-morbidity None 96 17 (18%) 94 40 (43%) x2=22.4, d2, 
Less than 3 32 (33%) 36 (38%) p<0.000 
3 or more 47 (49%) 18 (19%) 
Physical Component Score Baseline 81 38.9 (11.8) 100 46(10) <0.000 
Health Assessment Score Baseline 91 0.83 (0.85) 99 0.27 (0.51) <0.000 
Mental Component Score Baseline 81 50.1 (12.6) 100 56.6 (8.1) <0.000 
Table 11.2 Outcome over 2 years in cases and controls 
Outcome Initially 3 months 6 months 12 months 24 months 
Dead Cases - 25 31 45 60 
Controls - --1 10 
In hospital/nursing H Cases 15 - 20 14 8 
Controls 2 -22 2 
In residential home Cases 14 -76 4 
Controls 2 -33 2 
In own home Cases 71 - 38 36 30 
Controls 96 - 94 89 87 
11.4.2 Factors influencing mortality in men with hip fracture 
Figure 11.1 presents the Kaplan Meier survival curve for the two groups. Deaths 
amongst hip fracture cases were more frequent than in the controls, and the rate was 
most marked in the first 3 months following fracture, with rates declining subsequent to 
this. The overall survival amongst the cases was 36.5% compared to 87.7% amongst 
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controls (log rank test 62.6, df=1, p=0.000). Using cox regression analysis mortality was 
significantly higher in men with a hip fracture compared to the controls [Hazards ratio 
(HR) 9.3 (95%CI 4.8,16.3); p<0.000] see Table 11.3. The excess mortality persisted 
after adjusting for age [HR (95%CI): 8.1(4.1,16.0)]; and subsequently for body mass 
index [HR (95%CI): 7.8(3.6,16.9)]. Similarly, despite controlling for "pre-fracture" 
quality of life (using either the physical component or health assessment scores) men 
with hip fracture continued to exhibit a 6-7 fold excess risk of dying compared to the 
controls (HR 6.2-7.2). 
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Figure 11.1 Kaplan-Meier Survival Curves amongst cases and controls 
Cases -; Controls ---- 
Table 11.3 Cox regression analysis for risk of death: cases versus controls 
Presence of hip fracture 
Adjusted for age 
Adjusted for age and BMI 
Adjusted for age & baseline functional capacity (HAS) 
Hazards Ratio Significance 
(95%CI) 
9.3 (4.8,16.3) 0.000 
8.1 (4.1,16.0) 0.000 
7.8 (3.6,16.9) 0.000 
6.7 (3.4,13.4) 0.000 
Adjusted for age & baseline physical component score (PCS) 6.2 (3.1,12.4) 0.000 
Adjusted for age & baseline mental component score (MCS) 7.2 (3.5,14.7) 0.000 
200 400 600 800 1000 1200 
219 
Figures 11.2-11.10 present Kaplan Meier curves looking at survival among hip fracture 
cases, according to their age (by decade), fracture type, residence on admission, marital 
status, presence or absence of co-morbidity body mass index, mental score and also their 
functional status. Detailed analysis of the survival curves is given as footnotes under 
each figure. Age was the single most important determinant of mortality. For each year 
increase in age the risk of dying increased by 10% (HR 1.1,95%CI 1.0,1.1) see Table 
11.4. Compared to men aged less than 70 years those older were at 6 fold higher risk of 
dying simply due to age (HR 5.8,95%CI 1.8,18.4). 
Table 11.4 Cox regression analysis for factors influencing mortality amongst cases 
Age (for each year increase in age) 
Age (>70 years) 
Body mass index (per kg/m2) 
Marital status: single Vs married 
Presence of one or more co-morbidity 
Fracture type: cervical Vs trochanteric 
Mental score: <8.0 Vs 8 and above 
Residence: Residential Vs Own home 
Residence: Nursing Vs Own home 
Hazards Ratio Hazards Ratio* Significance 
(95%CI) (95%CI) 
1.1 (1.0,1.1) 0.000 
5.8 (1.8,18.4) - 0.003 
0.98 (0.89,1.1) 1.0 (0.9,1.1) NS 
1.3 (0.8,2.1) 1.2 (0.7,1.9) NS 
4.2 (1.5,11.7). º 2.8 (1.0,7.7) 0.05 
1.3 (0.8,2.2) 1.1 (0.7,1.9) NS 
1.8 (1.0,3.2)+ 1.5 (0.9,2.6) NS 
2.1 (1.1,4.1)9 1.7 (0.8,3.3) NS 
2.0 (1.1,3.9) 2.1 (1.1,4.0) 0.03 
Physical Component Score (per unit change) 0.95 (0.93,0.98) 0.95 (0.93,0.98) 0.002 
Functional Capacity (per unit change in HAS) 1.5 (1.1,2.1) 1.6 (1.2,2.1) 0.004 
Mental Component Score (per unit change) 1.0 (0.98,1.0) 1.0 (0.98,1.0) NS 
* After adjusting for age; A both unadjusted and after adjusting for age; 
.6 p<0.005; + p<0.04; " p<0.03 
Of the various factors evaluated, after adjusting for age (using cox regression analysis) 
only institutional care at the time of hip fracture, presence of a co-morbidity and poor 
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"pre-fracture" physical function were found to be significantly predictive of mortality 
(Table 11.4). Presence of one or more co-morbid disease at the time of the hip fracture 
more than doubled the risk of dying (HR=2.8). There was a gradient effect with hazards 
ratio paralleling the number of co-morbid diseases present (HR=2.7 if number of co- 
morbidities <3; HR=2.8 if no. of co-morbidities >3- data not shown). Mental score of 
less than 8.0 on admission was associated with a 50% increase in risk of death (HR=1.5) 
but did not reach statistical significance. Similarly, a 30% increase in mortality was seen 
in those single (versus married) or with a cervical fracture (compared to inter- 
trochanteric hip fracture) with hazards ratio of 1.3 each (Table 11.4). A higher physical 
component score was protective HR=0.95 (95%CI 0.93,0.98); p<0.002. Men in the 
highest tertile of physical component score had 70% reduced chance of death (HR=0.30 
95%CI 0.14,0.65; p<0.002); those in the middle tertile 60% reduction (HR 0.39 95%CI 
0.19,0.80; p<O. 01) compared to men in the lowest tertile (Table 11.5a). Repeat analysis 
was carried out in a similar manner assessing risk associated with poor "prefracture" 
functional capacity assessed using the health assessment score. A similar gradient effect 
was seen with a higher hazard ratio associated with a poorer score (score range 0-3; 
0=best and 3=worst) see Table 11.5b. 
Table 11.5a Cox regression analysis: Baseline Physical Component Score as a 
factor influencing mortality amongst Cases 
Hazards Ratio S. E Significance 95% CI 
Age 1.1 0.02 0.000 1.1,1.1 
PCS lowest tertile Referent - - - 
PCS middle tertile 0.39 0.14 0.01 0.19,0.80 
PCS highest tertile 0.30 0.12 0.002 0.14,0.65 
PCS: Physical Component Score (mean 33.4, minimum 14.9, maximum 63.3) 
Lowest tertile: 14.9-32.8; Middle tertile: 32.9-44.5; Highest tertile: 44.6-63.3 
Table 11.5b Cox regression analysis: Baseline Health Assessment Score as a factor 
influencing mortality amongst Cases 
Hazards Ratio S. E Significance 95% Cl 
Age 
Health Assessment Score 0-0.9 
1-1.9 
2-3 
1.1 0.02 0.000 1.1,1.1 
Referent --- 
1.97 0.65 0.04 1.0,3.8 
2.58 0.98 0.01 1.2,5.4 
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Using stepwise multiple regression with age, functional capacity and residence into the 
equation, the former two variables (i. e. age and functional capacity) were good 
predictors of the excess mortality with hazards ratios of 1.1 and 1.5 respectively (Table 
11.6a). On adding co-morbidity to the regression equation the only significant variable 
influencing mortality was age see foot note Table 11.6a. On substituting a cut-off of 70 
years for age into the above regression equation, the significance of age on mortality was 
even more apparent with HR=4.6 95%CI 1.4,15.0; p<0.01. As a result, baseline 
functional capacity no longer retained its significance [HR 1.3 (95%CI 0.9,1.8); p=NS) 
see foot note table 11.6a. Repeat analysis replacing functional capacity (Health 
Assessment Score) with the physical component score (PCS) did not alter the results 
(Table 11.6b). Age and baseline physical component score were the only two variables 
that significantly influenced mortality; age being the dominant of the two. 
Table 11.6a Multiple Cox regression analysis for factors found to significantly 
influence mortality amongst fracture cases 
Hazards Ratio S. E Significance 95% CI 
Age* 1.1 0.02 0.000 1.1,1.1 
Functional capacity at baseline 1.5 0.27 0.04 1.0,2.1 
Living in Residential Home 1.1 0.48 NS 0.5,2.6 
Living in Nursing Home 1.4 0.59 NS 0.6,3.2 
On adding co-morbidity to the equation: age HR=1.1 (95%CI 1.1,1.1) p<0.000; Functional 
capacity HR 1.4 (95%CI 0.97,2.0) p=NS; Residence p=NS 
* Age over 70 years: HR 4.6 (1.4,15.0), p<0.01; Functional capacity HR 1.3 (0.9,1.8), p=NS; 
Residence =NS 
Table 11.6b Multiple Cox regression analysis for factors found to significantly 
influence mortality amongst fracture cases 
Hazards Ratio S. E Significance 95% CI 
Age* 1.1 0.02 0.000 1.0,1.1 
Physical Component Score 0.96 0.02 0.006 0.93,0.99 
Living in Residential Home 1.5 0.71 NS 0.56,3.8 
Living in Nursing Home 1.2 0.55 NS 0.52,3.0 
On adding co-morbidity to the equation age p<0.000; PCS p<0.01, residence and 
Co-morbidity =NS 
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11.4.3 Causes of death in Cases and Controls 
A comparison between cause of death in both cases and control is shown in table 11.7. 
Common cause of death were chest infection amongst the controls (n=4) and both chest 
infection (n=21) and heart disease (n=17) in cases. Table 11.7b presents a cross 
tabulation of the cause of death amongst cases according to time of death since fracture. 
No differences were noted with bronchopneumonia and heart disease most common at 
all assessment intervals. 
Table 11.7a Cause of death amongst cases and controls 
Cause of death Cases Controls 
(n=60) (n=10) 
Bronchopneumonia 21 4 
Heart Failure 9 0 
Ischaemic heart disease 8 1 
Pulmonary embolism 2 0 
Cerebrovascular accident 4 0 
Malignancy 5* 1 
Old age/ dementia 2 1 
Infections 44. 0 
Others 5" 3.6 
*Malignancy (n=5): prostate (3), stomach (1), unknown (1) 
^Infections (n=4): septicaemia following gangrene heel (1), GI obstruction (1), gastric ulcer (1), 
pseudomembranous colitis (1) 
. Others (n=5): Small bowel ischaemia (2), GI bleed (1), Parkinson's (1), Carbon monoxide 
poisoning (1) 
*Others 9n=3): Respiratory arrest due to COAD (n=1), Spinal cord compression at C4 (n=1), 
rupture abdominal aortic aneurysm (n=1) 
Table 11.7b Cause of death in hip fracture cases 
Cause of death Early Intermediate Late 
(< 1 month) 
(1- 6 months) (>6 months) 
Bronchopneumonia 6 9 6 
Heart Failure 2 - 7 
Ischaemic heart disease 3 3 2 
Pulmonary embolism 1 1 - 
Cerebrovascular accident 1 - 3 
Infections 1 - 3 
Malignancy - 1 4 
Others 1 2 4 
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Figure 11.2 K-Meier Survival curves stratified by age group (in decade) 
50-59 ; 60-69 70-79 ; 
80-89 ; 90+ --- 
Survival was 100% amongst the 3 men who were in the 5th decade of life. Of the 13 
men in the 6th decade 3 died; 2 within 3 months of fracture and one after 18 months 
(603 days). Mortality was 50% amongst men in the 7th decade (13/26 died). Three of 
the 13 died within 1 month, 6/13 by 6 months and all but 3 by 1 year. All deaths 
occurred within 2 years (689 days). A progressive decline in probability of survival was 
seen in men in the 8th decade of life during the entire period of follow-up. Overall 35 of 
the 47 men died; all but two within 2 years of hip fracture. The survival was 80.9% at 1 
month, 72.3% in 2 months, 63.8% by 6 months, less than 50% (48.9%) in 1 year, 29.0% 
in 2 years and only 20% by the end of the study period (1098 days). All but one (9/10) 
aged over 90 died; all deaths occurring within 1 year of fracture (265 days). Survival 
was reduced to 70% in 30 days, 50% in 2 months, 30 % in 6 months and 10% at 1 year. 
These differences in survival in the different age groups were statistically significant (log 
rank test 24.8, df-- 1, p=0.0001). 
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Figure 11.3 K-Meier Survival stratified by type of fracture: Inter-trochanteric versus 
Cervical fracture 
Inter-trochanteric fracture -; Cervical fracture ----- 
The study comprised of 55 cervical and 45 intertrochanteric hip fractures. By the end of 
the follow-up (1128 days) there were 36 (65.5%) deaths in the cervical fracture group 
and 24 (53.3%) in those with an inter-trochanteric fracture. Overall there was no 
statistical difference in survival between the two groups (log rank test 1.2, df=1, 
p=0.31). There was no difference in mortality in the first 6 months; survival 67.3% in 
men with a cervical hip fracture and 68.9% in those with an inter-trochanteric fracture. 
However, by 1 year there were more deaths in men with a cervical fracture compared to 
fracture at the inter-trochanteric region (survival 49.1% and 62.2% respectively). This 
excess mortality in men with a cervical fracture persisted with survival figures being 
38.2% and 45.4% respectively at 2 years. Interestingly, no further deaths were seen 
amongst patients with an inter-trochanteric fracture after 2 years (727 days). By 3 years 
(1128 days) men with cervical fracture experienced approximately a 15% higher 
mortality compared to those with an inter-trochanteric hip fracture. 
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Figure 11.4 K-Meier Survival Curves according to place of residence on admission 
Own home -----; Residential Home ; Nursing Home 
Men living in their own homes before the hip fracture showed a gradually progressive 
down-hill course with cumulative survival of 84.5% at 1 month, 80.3% at 2 months, 
70.4% at 6 months, 59.2% at 1 year, 51.5 at 2 years and 45.1% at 3 years. In contrast, 
men admitted from a residential home exhibited a very high mortality immediately after 
the fracture (28.6%) in 31 days (survival 71.4%). Mortality increased to 50% in just 
over 6 months (200 days) and was 78.6% (survival 21.4% only) in less than 2 years (675 
days). Interestingly, men who fractured in a nursing home had the lowest mortality in the 
first month after the hip fracture (6.7% mortality i. e. survival 93.3% in 31 days). Their 
survival was better compared to men admitted from a residential home in the first 6 
months (survival 66.7% in men from nursing home compared to 57.1% in men from 
residential home). However, by 1 year a reversal was seen with survival 46.7% in men 
from nursing home and 50% in those from residential home. This difference in survival 
was more marked at the end of 2 years with survival figures being 13.3% and 21.4% 
respectively. By the end of the follow-up period overall mortality was 54.9% in men 
admitted from home, 78.6% in men in residential home and 86.7% in men from nursing 
home (log rank test 7.7, df 2, p=0.02). 
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Figure 11.5 K-Meier survival curve by marital status 
Married ----; Single (includes single, widowed, divorced, separated) 
Mortality was high in both groups (single and married) in the initial few days following 
the hip fracture (cumulative survival: 88.9% and 81.8% in 30 days; 82.2% and 74.5% in 
2 months amongst single and married cases respectively). Single men had a higher 
chance of survival compared to married men until 9 months when mortality in both 
groups became equal (mortality 40%, survival 60%). Thereafter single men continued to 
die at a steady rate but the death rate in married men declined such that a reversal was 
seen with the probability of survival amongst married men higher than those single. By 1 
year survival dropped to 48.9% in single men compared to 60% in married men. These 
differences persisted and the survival probabilities were 31.7% and 49.1% respectively at 
2 years. Despite continued deaths amongst married men and no further mortality in 
single men, the overall survival was lower (31.7%) in men who were single compared to 
41.1% amongst those who were married at the time of the hip fracture (log rank test 0.8, 
df-- 1, p=0.37). 
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Figure 11.6 K-Meier survival curves in the presence or absence of a co-morbid condition 
Absence of any co-morbidity ----; Presence of one or more co-morbid disease 
Men with one or more co-morbid condition showed a rapid and steady decline in 
survival from the time of hip fracture up to 14 months (427 days). Thereafter, mortality 
rate was less dramatic with cumulative survival by the end of the follow-up period of 
only 29.3%. For the initial 3 months, survival curves in men with hip fracture in the 
absence of any co-morbid condition were similar to those in men with a co-morbid 
disease (survival 76.2% versus 74.7% respectively). However, no further deaths were 
observed after 9 months (265 days) in men without a co-morbid disease. The overall 
mortality was over 70% (survival 29.3%) in the presence of any disease compared to 
less than 40% (survival 61.9%) in the absence of one (log rank test 3.3, df=l, p=0.07). 
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Figure 11.7 K-Meier Survival Curves according to Body Mass Index 
BMI: lowest tertile ------- ; middle tertile ---; highest tertile - 
Body mass index was divided into tertiles between the lowest and highest. Irrespective 
of body mass index mortality within first 2 months (61 days) was comparable in all 3 
groups: 25.8%, 30.5% and 28.6% respectively amongst those in the lowest to the 
highest tertile. After 2 months cumulative survival in men in the lowest tertile of BMI 
continued to decline at a steady rate until 33 months after hip fracture with overall 
survival of only 34.6%. In contrast no further deaths were seen amongst men in both the 
middle and the highest tertile of BMI after just over a year (377 and 375 days 
respectively). The cumulative survival at the end of the observation period was 34.6%, 
47.8% and 64.3% respectively in the lowest, middle and highest tertile (log rank test 1.4, 
df=2, p=0.50). 
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Figure 11.8 K-Meier Survival Curves based on Mental Scores 
Mental Score equal to or more than 8; less than 8---- 
Mental score assessment was possible in only 91 of the 100 hip fracture cases. 64 
(70.3%) scored 8 or more on a mental score scale of 0-10. Men with scores of less than 
8 showed a very high mortality within 60 days of the fracture. The survival was 70.4% in 
men with low scores compared to 89.1 % in men with higher scores (more than or equal 
to 8). A steady decline in survival was observed in both groups, although, at each time 
point men with low scores had a higher mortality compared to those with high scores. 
The survival figures were 59.3% versus 78.1% at 6 months, 48.2% versus 60.9% at 1 
year and 25.9% versus 51.6% at 2 years. By the end of the follow-up period only a 
quarter of men with low scores survived (mortality 74.1%) compared to over 50% 
(survival 51.6%) in those with high scores. This difference in mortality was statistically 
significant (log rank test 4.5, df=1, p=0.03). 
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Figure 11.9 K Meier Survival Curves stratified by PCS: Physical Component Score 
14.9-32.8----; 32.9-44.5 ; 44.6-63.3........ 
The Physical Component Score was derived from the SF-36 questionnaire using 
standard techniques. The mean PCS in the 81 cases where it was scored was 33.4 with a 
range between 14.9-63.3. Subjects were divided according to tertiles of PCS: lowest 
between 14.9-32.8; intermediate 32.9-44.5 and highest 44.6-63.3. A higher score 
signified better functional ability and independence. Interesting 27 subjects each fell into 
either group. 21 among the lowest tertile, 12 of the intermediate and 10 of the highest 
tertile died at the end of the observation period. Mortality amongst men with the lowest 
scores was evident from the immediate post fracture period with survival reduced to 
78% at 1 month, 44% by 1 year and 21.6% by 2 years. Men with the highest (best) 
scores exhibited no deaths within the first two months post-fracture. The survival at 1 
year was 74% with only one more death in the second year reducing the survival to 
70.4% at 2 years. Two further deaths reduced the final survival to 50.7% (mortality 
49.3%). Men with intermediate scores exhibited early mortality with survival reduced to 
81.5% in 2 months (47 days) and all but one death occurring in the first year with 
survival of 59.3% at 2 years. Due to only one extra death in the second year the 
cumulative survival at the end of the observation period amongst men in the intermediate 
tertile (55.6%) was better than men with the higher (better) scores (50.7%). The 
difference in survival between the three groups was statistically significant: log rank test 
11.6, df=2, p=0.003. 
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Survival Curve for Functional Capacity 











Figure 11.10 K Meier Survival Curve based on Health Assessment Score (Range 0-3) 
0-0.9 ----; 1-1.9 ; 2-3- --- 
Functional capacity was assessed using Health Assessment Score range 0-3, with 0= best 
and 3 worst functional ability. 91 of the 100 fracture cases completed the questionnaire: 
58 scored between 0-0.9,20 scored between 1-1.9 and 13 scored over 2. Survival was 
the best amongst men with the lowest score: 62% survival in the first year, 4 more 
deaths in the second year (survival 55%) and only two further deaths by the end of the 
follow-up with resultant survival of 46% (mortality 54%). Of the 20 men with 
intermediate scores 14 died, 8 within the first 3 months (98 days). There were no further 
deaths in the first year. The remaining 6 died in the second year of follow-up with overall 
survival of 30% (mortality 70%). All 13 men with the highest scores (range 2-3) died 
within the first year (298 days) with overall survival of only 23% (mortality 77%). The 
differences in survival seen between the 3 groups was statistically significant (log rank 
test 7.6, df2, p=0.02). 
11.5 CONCLUSION 
Our fracture cases had a very high mortality; 60% were dead after 24 months with 31 
deaths within 6 months of fracture. There were a wide variety of causes and most could 
not be directly related to the fracture. Bronchopneumonia and ischaemic heart disease 
were the commonest cause as would be expected in any elderly population. The 
previously reported mortality, with 16-37% of cases dying after fracture, probably 
under-estimates death by limiting follow-up to 12 months, excluding the very elderly by 
imposing upper age limits and excluding high risk cases who were admitted from 
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institutional care or have high dependency. This study has several advantages i) a case- 
control design, ii) controls representative of the community, iii) absence of an upper age 
limit, iv) inclusion of subjects irrespective of residence and degree of functional disability 
and v) complete follow-up of all study subjects in both groups over the entire study 
period. All contribute to the validity of the study results 
Presence of hip fracture was associated with over 9-fold increased risk of death 
compared to community controls. Our two study populations were not perfectly age 
matched. In addition there were significant differences in percentage requiring 
institutional care, number of co-morbidities and degree of functional disability at 
baseline. One could argue that the excess mortality noted amongst fracture cases is 
simply a reflection of these differences. However, the excess risk is still 6-8 fold after 
controlling for these variables. 
A number of factors were identified as predictors of mortality after fracture. In parallel 
to the observations by previous researchers increasing age, low body mass index, poor 
mental score on admission and presence of a co-morbidity were associated with 
increased risk; however only age and co-morbidity were statistically significantly. The 
single most important factor was age with 10% higher risk per year increase in age. The 
effect of age was significant even after adjusting for the other variables in a multivariate 
analysis (per year increase in age HR=1.1,95%CI 1.1,1.1, p<O. 000). 
Men with hip fracture are almost all elderly and many are frail. Most workers have found 
co-morbidities as risk factors for high mortality (Poor et at, 1995, Nettleman et at, 1996, 
Stavrou et at, 1997, Aharonoff et at, 1997, Myers et al, 1991). Presence of any co- 
morbidity was associated with an increased risk of mortality in this group of men 
(HR=4.2). A gradient effect was observed with a higher hazards ratio associated with 
increasing number of co-morbidities (HR=2.7 if no. of co-morbidities <3; HR=2.8 if no 
of co-morbidities >3). However, due to small numbers the effect of individual co-morbid 
conditions was not evaluated. Moreover, in a multivariate model the overall influence of 
co-morbidity remained insignificant after adjusting for other predictors of death. The 
cause of death in these patients reflects the co-morbidities; they were similar to those in 
the control population. The causes of death were likely to be chest infection, ischaemic 
heart disease, malignancies, stroke and gastrointestinal diseases similar to those reported 
by Poor et at, 1995. 
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Only two studies have addressed the relation of fracture type on mortality (Poor et al, 
1995 and Aharonoff et al, 1997) and both found no relation between the two. On the 
contrary, in this study, although statistically insignificant, men with a cervical hip fracture 
were at a higher risk with hazards ratio of 1.1-1.3 compared to men with an inter- 
trochanteric fracture. The number of fractures is small (55 and 45 respectively) and need 
caution before interpretation. Similarly the effect of marital status on outcome has not 
been addressed in previous studies in men. Men who were single were at greater risk of 
dying post fracture compared to their married counterparts. The only study addressing 
residence at the time of fracture as predictor of mortality (Poor et al, 1997) failed to 
show an association. On the contrary, in this study men living in institutional care at the 
time of the hip fracture had a 2-fold risk of dying compared to those living in their own 
homes. The difference in observation may be the small number of deaths (n=21) in the 
study by Poor and that data was collected from retrospective chart reviews and not by 
prospective follow-up. 
Previous researchers have not studied the effect of "pre-fracture" health status on 
mortality. This study addressed the role of both the physical and mental component 
scores derived using the SF-36 on mortality. A higher PCS was protective with risk of 
death reduced by 5% per unit increase in the score (HR=0.95). Along the same lines, a 
higher (poorer) functional capacity score (HAS) was a risk factor with hazards ratio of 
1.5. A higher pre-fracture PCS was protective with 70% reduction in risk of death 
(HR=0.30) amongst subjects in the highest tertile of the score. This finding was 
supported by observing over 2.5 fold increase in death amongst men in the highest tertile 
of functional capacity (poorer score) compared to those in the lowest (best) HR=2.58. 
The MCS had no influence (HR=1.0). After multivariate analysis in addition to age, pre- 
fracture physical functioning of the individual was the only significant predictor of 
mortality. 
Hip fractures represent a significant source of mortality for the elderly population. Many 
determinants of outcome are independent of the level of care given and are dependent on 
pre-fracture functional status. It is important to point out that neither the immediate not 
long term mortality rates after hip fracture are attributable solely to the hip fracture- the 
cause of death being what would be expected in any elderly population. Thus, hip 
fracture is often not the sole factor leading to death and functional decline; rather it is the 
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cumulative effect of the hip fracture in the setting of advancing age, co-morbidities, poor 
general health and physical disabilities. 
Patient's age, prefracture dependency in activities of daily living and presence of co- 
morbid conditions are all factors that are independent of treatment. This study provides 
prognostic information that can be shared with patients and their families. Knowledge of 
the probability of survival following hip fracture is of practical value when counselling 
patients and their families after the event. It also helps design measures to assess the 





Using a population based case-control study design with prospective follow-up for two 
years this study has shown that low trauma hip fractures are common amongst Caucasian 
men in Cornwall (incidence 140/100,000/year) and are the result of low bone mineral 
density coupled with an increased risk of falls. Some of the variables that seem likely to have 
contributed to this "high risk" status are frailty (low body mass index), poor milk intake in 
childhood, limited mobility in adult life, poor general health (low SF-36 scores), presence of 
co-morbid diseases (Parkinson's, dementia, poor mobility, poor vision, frequent falls) 
subclinical vitamin D deficiency, low sex steroids (androgens and oestrogen's) and impaired 
osteoblast function with uncoupling of bone turnover. 
The study also reveals that low trauma hip fracture in men is associated with significant 
morbidity and high mortality. Morbidity is evident by a high proportion in institutional care 
upto 2 years after the event, need for help with basic activities of daily living and poor 
scores using the SF36. The observed mortality of 45% and 60% at 1 and 2 years 
respectively, is unrelated to the fracture with chest infections and heart disease being the 
commonest cause. 
The main findings of this study have been described in detail under separate headings in the 
"results" section of this thesis. An attempt has also been made to discuss the strengths and 
limitations of each finding and comparisons made with published literature. In the 
subsequent section an attempt is made to draw the findings together in a larger format and 
conclude with recommendations for future research. The sequence in which risk factors are 
discussed follows the pattern in which they appear in the "results" section of the thesis. 
4.2 Incidence 
Low trauma first hip fractures in elderly Caucasian males is common with an incidence of 
140/100,000/year in Cornwall, which exceeds the only pre-existing UK incidence data on 
male hip fractures (114/100,000/year) from a 1985 study of 22 males in Oxford (Boyce and 
Vessey, 1985). The apparent rise in incidence reflects the rising world-wide incidence of hip 
fractures (Cooper et al, 1992; Kanis, 1993; Gullberg et al, 1997). 
237 
4.3 Risk Factors- Anthropometry, Lifestyle, BMD, Endocrine and Bone Markers 
4.3.1 Anthropometry 
In this study, men with hip fracture were lighter and had low body mass index. There were 
no differences in height. The relationship of height to risk of hip fracture has been studied by 
a number of workers (Meyer et al, 1993 & 1995; Hemenway et al, 1994; Poor et al, 1995; 
Nguyen et al, 1996; Grisso et al, 1997). Most studies have suggested taller height to be an 
independent risk factor for hip fracture (Meyer et al, 1993; Hemenway et al, 1994; Poor et 
al, 1995) with an odds ratio of 1.6 per 6 cm increase in height (Grisso et al, 1997). One 
possible explanation for this is the strong association of height with hip axis length, itself a 
risk factor for hip fracture. No difference was observed in hip axis length between the two 
groups in this study supporting the findings of similar height. Furthermore, it has been 
suggested that since height decreases with advancing age measurement of "current" height 
may not be as reliable as "peak" height in assessing the fracture risk of an individual. The 
cross sectional design of this study precluded such measurements. 
The relationship between weight and risk of hip fracture has been studied using "current 
weight", "weight gain" and "weight loss" over defined periods and linking these to risk of 
hip fracture. All studies confirm low weight to be a risk factor (Nguyen et al, 1996; Langlois 
et al, 1998; Mussolino et al, 1998) supporting the observations in this study. 
Although low BMI is a significant predictor of hip fracture risk in women it has not been 
consistently related to hip fracture risk in men. One reason for this discrepancy is the timing 
of the measurement in relation to the fracture. Studies using "current" anthropometric 
measurements have consistently shown low BMI to be a risk factor for hip fracture in men 
(Meyers et al, 1993; Grisso et al, 1997; Langlois et al, 1998; Burger et al, 1998). In 
contrast studies that have based calculations on "previous" weight (Felson et al, 1993; 
Hemenway et al, 1994) have failed to show the association. Findings from this study 
strengthen the importance of low body mass index as a potentially modifiable risk factor for 
low trauma hip fracture in men. 
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4.3.2 Lifestyle Risk Factors 
Due to the study design and setting, this study was limited in studying the effects of age and 
race on risk of hip fracture in men 
The study showed that fracture risk was increased sevenfold in single men and fivefold in 
men living alone or in care. This is in keeping with the only previous report on men by 
Meyer and colleagues (Meyer et al, 1993) that "unmarried" and "divorced" states were 
significant risk factors for fracture. 
The mother was the most common relative affected with osteoporosis in both groups. 
Maternal history of osteoporosis and or fracture is a well-recognised risk factor for 
osteoporosis in women. There is dearth of literature for men. The Rancho Bernado Study 
(Soroko et al, 1994) showed a significant relationship between maternal history of 
osteoporosis and lower BMD at the hip in men. The sample size of the current study may 
have meant small numbers of relatives to observe sizeable differences between the two study 
populations. 
Walking for one hour each day decreased fracture risk by 74%. A protective effect was 
noticed with increasing duration of walking ranging from less than half an hour to over an 
hour each day (Odds Ratio 0.37-0.26). This supports the observations of previous workers 
reporting inactivity as a risk factor (Poor et al, 1995) and exercise decreasing fracture risk 
(Paganini-Hill et al, 1991; Nguyen et al, 1996; Grisso et al, 1997). The degree of protection 
conferred has been shown to be irrespective of type of activity (Grisso et al, 1997). 
Lifestyle factors such as occupation, alcohol intake, and tea and coffee consumption were 
unrelated to fracture risk. Compared to never smokers, past versus current smokers were at 
increased risk of hip fracture but the results did not attain statistical significance (OR 1.35; 
95%CI 0.54,3.38 and OR 1.77 95%CI 0.58,5.45). The effect of smoking on hip fracture 
risk in men is less clear. The Leisure World Study (Paganini-Hill et al, 1991) showed that 
fracture risk was associated with current smoking and that the risk for past smokers was not 
different from that of lifetime non-smokers. A recent meta-analysis of cigarette smoking, 
BMD and risk of hip fractures (Law and Hacksaw, 1997) have concluded similar effects on 
BMD and risk of hip fracture in both sexes. Results for alcohol have been varied in previous 
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prospective studies in men. Moderate alcohol consumption has been suggested to be 
associated with increased BMD (Glynn et al, 1995) and alcohol abuse with osteoporosis and 
increased fracture risk (Slemenda et al, 1992). In contrast two case-control studies did not 
find an association between current or past alcohol intake and risk of fracture despite a 
relatively high prevalence of heavy use (Grisso et al, 1991, Poor et al, 1995). Varying 
results for both alcohol and smoking may be due to the differences in the way in which these 
variables were measured. Poor recall relating the duration and extent of consumption of 
both products in this group of elderly men may have affected the study results. 
Fracture risk was increased fourfold amongst those drinking less than one glass a week of 
milk in childhood. Studies in women have showed a relationship between low calcium intake 
and fractures (Cumming and Nevitt, 1997). However, the previous two studies addressing 
this in men did not show a significant relationship, probably due to the small number of hip 
fractures (21 & 31 respectively) in their study population (Nguyen et al, 1996; Mussolino et 
al, 1998). More recent studies addressing the relationship between diet, calcium and BMD 
in men have confirmed a positive correlation (Burger et al, 1998; Nguyen et al, 2000). 
Compared to controls, cases exhibited poor overall health at the time of the fracture as 
suggested by low mean body mass index, low scores in most of the SF-36 domains and 
frequent co-morbidities. Some co-morbidities (Parkinson's disease, dementia, reduced 
mobility, poor vision and history of falls) increased the risk of fracture, possibly by 
increasing the risk of falls. Others including heart disease, osteoarthritis and diabetes had no 
effect. Almost all studies confirm the presence of co-morbid diseases as risk factors for hip 
fracture (Mussolino et al, 98). Using a case-control study design Poor and colleagues 
demonstrated significantly increased risk of hip fracture in association with Parkinson's (OR 
8.0), dementia (OR 5.3), blindness (OR 5.5), vertigo (OR 6.0), hemiplegia (OR 2.6) or 
anaemia around the time of fracture (OR 2.6) (Poor et al, 1995). Similar results were 
obtained in another case-control study (Grisso et al, 1997). The authors demonstrated 
specific chronic illnesses (stroke, Parkinson's disease) as well as having two or more chronic 
illnesses to be associated with increased risk of fracture. An explanation for the association 
is the probable link between these disorders and secondary causes of osteoporosis or an 
increased likelihood of falling. The present and earlier studies focusing on fracture risks in 
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males underline the important links between ill health, concomitant co-morbidities, risk of 
falls and hip fracture. In the absence of any published data on quality of life in men with hip 
fracture this study is limited in making comparisons with other study populations. 
4.3.3 Bone Mineral Density 
This study identified several risk factors for fracture. The most obvious is low bone mineral 
density. Using the WHO definition of osteoporosis (t-score <2.5SD of young normal mean), 
and using the manufacturers (Hologic) normal value, 83% of fracture cases were 
osteoporotic at the femoral neck, and 36% at the lumbar spine (the corresponding figures 
for the controls were 39% and 5% respectively). After adjusting for age, height and weight, 
the risk of hip fracture increased for each standard deviation reduction in bone mass at all 
sites measured. The association was stronger for measurements at the proximal femur than 
the lumbar spine: lumbar spine (OR=1.8), femoral neck (OR=3.1). Bone mass, at all sites, 
was lower in those with an inter-trochanteric compared to those with cervical fractures, 
though the difference was significant for the trochanteric measurement site only. Although 
the link between bone mass and risk of hip fracture is well established in women (Marshall et 
al, 1996), there are few data in men and the number of study subjects is small (<40) 
(Karlsson et al, 1993; Greenspan et al, 1994 & 1998; Boonen et al, 1997; Nyquist et al, 
1998; De Laet et al, 1998). 
The magnitude of the risk of hip fracture associated with femoral neck BMD has been 
reported in several studies. Nguyen reported a 66% reduction in risk of hip fracture (n=31) 
per SD increase in BMD at the femoral neck (Nguyen et al, 1996), while De Laet (De Laet 
et al, 1998), reported a3 fold increase in risk of fracture (n=23) associated per SD decrease 
in BMD. These data are similar to the findings in this study of a 3.1 fold increase in risk per 
SD decrease in femoral neck BMD. 
In this study the strength of association between bone mass and fracture risk was greater for 
measurements at the hip than those at the spine. This may be in part due to the presence of 
concurrent degenerative disease which leads to an artifactual increase in spinal bone density 
(Masud et al, 1993; Jones et al, 1996). 
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Men with trochanteric fractures had lower bone mass at all skeletal sites compared to those 
who had sustained cervical fractures. The difference, however, was significant only for 
trochanteric BMD. Similar findings have been reported using the Singh Index in men 
(Sernbo et al, 1989) and DEXA in women (Karlsson et al, 1993; Greenspan et al, 1994). In 
contrast, however, to previous reports in women this study could not confirm a protective 
effect of femoral neck BMD (Greenspan et al, 1994). 
There are certain limitations that need to be considered in interpreting these findings. 
Fracture cases were recruited consecutively, and none of those invited to participate 
declined. Controls were recruited from a local general practice, and a proportion of those 
invited (46%) declined to participate. If this was because they were less healthy and 
therefore likely to have lower bone mass than those who took part, the observed differences 
in BMD between fracture cases and controls may have been overestimated. An alternative 
strategy would have been to select the controls from a hospital population, however, such a 
group, because of concurrent illness may not be representative and it may be difficult to 
extrapolate the findings to the general population. It has been suggested that community 
controls comprise the more appropriate control group in case-control studies of hip fracture 
in the elderly (Moritz et al, 1997). 
It is possible that observed differences are confounded with age. However, the use of a 
range of different analytic approaches suggests that this is not the case. Furthermore, all 
patients had BMD measurements within a maximum one week of the fracture (preferably 3- 
4 days). The observed low density cannot therefore be accounted for by immobilisation 
induced bone loss. 
The frailty and poor mobility of cases immediately after the hip fracture caused difficulties in 
obtaining data concerning bone mass in a significant proportion (38%). Individuals in whom 
BMD was not assessed were older and a greater proportion had co-morbidities than those 
who were assessed - factors again likely to be linked with lower BMD. The effect of such 
selection bias, if present, would be to underestimate the strength of the relationship between 
hip fracture and BMD. 
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This study was cross-sectional - one of the major limitations with such a design is that it is 
not possible to determine the temporal nature of the observed associations. Prospective 
studies are required to determine the predictive risk of BMD in determining future fracture 
risk. In addition this study looked at a group of UK Caucasians - these findings may not 
necessarily be applicable to other racial/ethnic groups and for in different study settings. 
4.3.4 Hip Axis Length 
Unlike previous published findings in women, this study did not find any association 
between hip axis length and hip fracture risk in men. In women an increase in hip axis length 
has been linked with hip fracture risk in several studies (Faulkner et al, 1993, Duboef et al, 
1997). To the best of my knowledge there are no previous reports concerning the influence 
of HAL on fracture risk in men. Two previous studies suggested no difference in femoral 
neck axis length (one of the component parameters of HAL) among fracture cases than 
controls (Peacock et al, 1995), however, the link between FNAL and hip fracture risk is less 
clear (Karlsson et al, 1996, Center et al, 1998). The mechanism by which an increase in 
HAL confers an increase in susceptibility to fracture in women is unknown. Studies suggest 
that the risk persists after adjustment for body height and weight indicating it is not a 
surrogate for body size (itself linked with an increased risk of hip fracture) (Faulkner et al, 
1993). It has been suggested that HAL is a marker for the ability of the femur or pelvis to 
absorb or avoid the impact of a fall (Faulkner, 1995). 
There are important gender differences in both the shape of the proximal femur and pelvis 
including the pelvic brim (Beck et al, 1992; Wahner et al, 1994) which may influence bone 
strength or resistance to fracture. It is possible that one or more of these shape parameters 
interact with HAL, and explain the discrepant findings in relation to fracture risk in men and 
women. 
In contrast to existing literature in women, results from this study show that hip axis length 
does not appear to be associated with the risk of hip fracture in Caucasian men and should 
not therefore be included in risk evaluation. There is therefore the need for caution in 
extrapolating the predictive risk of HAL observed in female Caucasians, to other population 
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groups. However, limitations of using a cross sectional study design in assessing predictive 
risk of the variable under study needs to be borne in mind. 
4.3.5 Androgen 
In this study there was also a clear and powerful association between the risk of fracture and 
male hormone levels. Hypogonadism was 5 times commoner in cases than controls and the 
risk of hip fracture associated with the presence of low free androgens was over 6 fold (OR 
6.34). Because all blood samples were collected early in the morning after overnight fast, the 
criticism of previous studies (Stanley et al, 1991; Jackson et al, 1992; Boonen et al, 1997), 
that measurements may reflect diurnal variation, does not apply to this study. 
Biochemical evidence of hypogonadism has been reported in upto 20% of men with 
vertebral fractures (Baillie et al, 1992) and upto 50% of men with hip fractures (Stanley et 
al, 1991; Jackson et al, 1992). However, these studies are limited by small numbers, 
heterogeneity in timing of sample collection (Jackson et al, 1992), selection of the control 
population (Stanley et al, 1991) and absence of BMD measurement (Stanley et al, 1991; 
Jackson et al, 1992; Abbasi et al, 1995). Assessment of hypogonadism based on chart 
reviews with their inherent problems of accuracy and completeness furthermore cast doubt 
on the results (Stanley et al, 1991; Abbasi et al, 1995). The recent case-control study 
reporting hypogonadism in men with an osteoporotic hip fracture (Boonen et al, 1997) is 
limited in controlling for the effects of trauma due to proximity in sample collection to the 
fracture event (18 hours) and its cross sectional design. Our observations of significantly 
reduced levels of androgens in the subjects immediately after the hip fracture which double 
at 6 months in the face of consistency of sampling time further support this criticism. 
Another limitation of published case control studies is in determining with certainty whether 
the hypogonadism noted preceded the fracture or was secondary to fracture -induced 
debilitation. This methodological limitation has been overcome by prospective follow-up of 
the survivors which confirms significantly low male sex hormones in the fracture population 
compared to community controls even one year after the event. There was a marked rise in 
hormone levels between the baseline measurement and six months, which then stabilised on 
subsequent sampling. Although the continuing low hormone level may reflect a hitherto 
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unobserved long term sequelae of trauma, it seems reasonable to suggest that measurements 
six months after the fracture provide fair estimates of pre-fracture hormone status 
The mixed aetiologies of hypogonadism found in both groups are consistent with previously 
described primary testicular failure and alterations in hypothalamic-gonadotrophin function 
in ageing men. The only prospective population based cohort study failed to find a link 
between hypogonadism and male hip fractures (Nyquist et al, 1998) but its small size (10 
hip fractures) means it was under-powered and must be interpreted with caution. 
It is possible that low male hormones are a risk factor for hip fracture in men. Previous 
studies that have shown an association between low hormones and the risk of fracture have 
tended to assume that the association is mediated by BMID. This study was not designed to 
investigate that hypothesis. However, amongst controls this study was able to detect a 
positive association between androgen levels and bone density at all sites of the proximal 
femur (rs=0.25, p<0.05) though not at the lumbar spine. In addition an inverse correlation 
was seen with bone markers (urinary deoxypyridinoline and osteocalcin rS =-0.27 and -0.30 
respectively). It may be conjectured that by regulating the rate of bone turnover androgens 
affect bone strength and quality and influence fracture risk. 
This study, then, suggests that explanations for the association between hormone levels and 
the risk of fracture either lie with the proximal effects of low male hormones or with the 
effects of other factors which carry a risk of fracture and which lead to low hormone levels. 
The relatively high prevalence of "hypogonadotrophic hypogonadism" 6-12 months post- 
fracture which is often the result of long-standing ill-health (Nachtigall et al, 1997) may 
provide a significant clue. It may be reasonable to hypothesise therefore, that in the 
appropriate setting low testosterone is a surrogate marker of chronic ill health and may be 
used as a screening tool to predict the group "at risk". 
Although this study has clearly demonstrated the powerful association between low 
androgens and male hip fracture the study has its limitations. This study suffered from the 
expected difficulty of recruiting healthy very elderly age-matched controls when studying a 
predominantly geriatric population/disease. This explains why earlier studies in men with hip 
fractures have not looked at the very elderly (90+ age group). To overcome this practical 
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problem different analytical approaches to address this issue are reported and it seems 
unlikely that the strong associations noted are substantially artefacts of age 
In common with other studies in literature addressing men with hip fractures this is a case 
control design and has inherent drawbacks. A major difficulty is getting good estimates of 
pre-fracture hormone status for cases -a problem that has not been addressed in previous 
studies. With the inherent limitations of a case control design, measurements at 6 months are 
our best possible estimates of the pre fracture androgen status of these individuals. It is still 
the case that a large prospective cohort study is needed to provide a definite account of the 
role of male sex hormones in bone health. 
4.3.6 Oestrogen 
In community controls, oestradiol levels exhibited good correlation with BMD (range 
r, =0.25-0.43). Correlations were better with BMD at all sites of the proximal femur than the 
lumbar spine and stronger with free oestradiol than total oestradiol. Similar observations 
have been reported by previous researchers using total oestradiol (Foresta et al, 1984; 
Slemenda et al, 1997; Anderson et at, 1998) and oestrogen / SHBG ratio (Greendale et al, 
1997; Khosla et al, 1998). Of the two sex hormones (androgen and oestrogen), results from 
this study suggest free oestradiol to be the more important sex steroid predicting BMD at all 
sites. This supports the observation of the only pre-existing cross sectional study involving 
37 healthy men that found BMD at all sites correlating more closely with oestradiol than 
with testosterone (Anderson et al, 1997). 
Levels of both total and free oestradiol were significantly elevated immediately after the 
fracture and returned to values comparable to controls at 6 months. After burn trauma, 
oestradiol levels in males are elevated, sometimes very much (Dolecek, 1989). It has been 
postulated that these elevated levels arise from adrenal precursors (Plymate et al, 1987) and 
promotes alteration of hypothalamic function. The latter results in markedly reduced 
secretion of bioactive LH and diminished Leydig cell function. Significant associations noted 
in this study between oestradiol and acute phase proteins (CRP rs =0.23 and serum albumin 
rS =-0.23) support the role of acute phase response to the marked endocrine changes noted 
after fracture in this study. 
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There is dearth of literature on the role of oestradiol in causation of an osteoporotic fracture 
in men. This study was not designed to answer this question. However, with this in mind 
and, after adjusting for changes in serum levels associated with acute phase response, low 
oestradiol and free oestradiol levels were found to be a risk factor for hip fracture in men 
(OR 0.98 and 0.34 respectively). The values for the latter did not reach statistical 
significance. Using similar case-control study design low oestradiol levels have been 
reported in men with vertebral fracture (Francis et al, 1989) but not hip fracture (Boonen et 
al, 1997). Discrepancy in results may be related to sample size of the populations under 
study and timing of samples in relation to the fracture event. It may also be conjectured that 
differences in the magnitude of stress accompanying hip fracture compared to vertebral 
fracture may have a bearing on the degree of alteration noted in serum oestradiol levels 
between the two fracture types. Prospective studies are needed to better delineate the true 
role of oestradiol in male osteoporosis. 
4.3.7 Vitamin D 
Immediately post fracture 20% of cases had undetectable vitamin D levels (<5nmol/1) and 
low vitamin D (<10nmol/1) was 10 times commoner in cases than controls. It is likely that 
other risk factors such as being single, living alone or in institutions and presence of co- 
morbid diseases reducing mobility and thereby outdoor activity contributed to these very 
low levels in this group of elderly men. Low vitamin D levels persisted 6 months post 
fracture confirming hypovitaminosis D as a risk factor for hip fracture in men (OR 10.2). 
Several recent reports of vitamin D levels in men with hip fracture have included small 
numbers (<43) (Boonen et al, 1997; Thieuband et al, 1997; Diamond et al, 1998); all 
suggest low vitamin D levels as a risk factor for hip fracture. The only randomised, placebo 
controlled trial of vitamin D supplementation in a significant number of men did not show 
any difference in incidence of hip or other fracture between the groups after a mean follow- 
up of 3.5 years (Lips et al, 1996). Critics suggest this may be due to the high mean diet 
calcium intake in both groups masking any significant differences. 
Fourteen percent of elderly Caucasian men living in the community in Cornwall were also 
found to be deficient in vitamin D. It was most common amongst those in institutions or 
living alone at home and less ambulant. Similar results have been reported in recent years 
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from the continent - 14% in an adult urban French population (Chapuy et al, 1992) and 6% 
among Swiss adults (Burnand et al, 1992). The authors relate vitamin D levels to latitude of 
residence and hours of sunshine. In contrast, men in North America have been shown to 
have a very low prevalence of vitamin D deficiency (Gallagher et al, 1998). An explanation 
for this difference is better sunlight exposure coupled with supplementation of dairy produce 
in the USA. Results from this study in combination with those published earlier highlight the 
common problem of vitamin D deficiency with resultant sub-optimal calcium absorption in 
elderly men living in community. Simple measures to replenish the deficiency status in these 
men will go a long way in fracture prevention. 
4.3.8 Bone Markers 
Men with hip fracture exhibit an imbalance of bone turnover with depressed bone formation 
(low osteocalcin) and higher bone resorption (high urinary deoxypyridinoline). Bone 
turnover has been studied after hip fracture in females (Akesson et al, 1993) but not in men. 
Similar findings were noted and, the authors suggested that this uncoupling of bone turnover 
might be an important determinant of low bone mass that characterise patients with hip 
fracture. 
Type of fracture does not seem to significantly alter the levels of bone markers. It has been 
proposed that intertrochanteric fractures are the consequence of more severe osteoporosis 
than cervical hip fractures. In this study, levels of bone markers were similar amongst 
patients with either fracture type. 
It has been shown that elderly patients in the presence of co-morbid diseases and poor 
mobility exhibit increased bone resorption. Fracture patients were more disabled and had 
more co-morbidities than the controls. However, no significant differences were observed 
between the two groups. 
A good correlation was seen between the bone markers amongst the controls; a finding 
supported by earlier publications (Gallagher et al, 1998; Kenny et al, 1998). The study also 
demonstrated a good correlation between age and osteocalcin. The effect of age on bone 
markers in men is still controversial. Some report a decrease (Wishart et al, 1995), some an 
increase (Orwoll et al, 1990) while others show no relationship of bone turnover with age 
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(Resch et al, 1994). Differences in study populations and the radioimmunoassays used may 
contribute to these differences 
This study failed to provide evidence to suggest that the rate of bone turnover determines 
BMD in elderly men. No correlation was seen between osteocalcin and BMD and only a 
weak correlation with urinary deoxypyridinoline. Results in literature are mixed. Most 
(Sherman et al, 1992; Krall et al, 1997; Kenny et at, 1998) but not all studies (Kelly et al, 
1990; Wishart et at, 1995) reveal an inverse relationship between bone markers and BMD 
most consistently at the femur. 
4.4 Outcome: Morbidity and Mortality 
4.4.1 Morbidity 
The 40 fracture cases that survived for 24 months had extensive morbidity and poor quality 
of life quantified using the SF-36. Twelve needed institutional care and only 11 could walk 
and 7 dress independently. Hip fracture subjects scored significantly lower than the controls 
in all domains of the SF-36 except pain. The mean physical component score was 38.9 
(compared to 46 in controls). The health assessment score was 0.83 (compared to 0.27 in 
controls) on a scale of 0-3 with zero implying functional independence. Two retrospective 
reviews of medical records (Poor et al, 1995, Diamond et al, 1997) have reported poor 
functional outcomes after male hip fractures. One study of 131 males reported that at 12 
months 29% survivors were bedfast or chair and bedridden and 45% needed institutional 
care (Poor et al, 1995). Another study of 51 males reported 50% were institutionalised and 
had significant (17%) post fracture functional decline (Diamond et al, 1997) by 12 months 
Pre-fracture the cases had poor overall health shown by low mean BMI, low SF-36 scores in 
most domains and frequent co-morbidities. The single report focusing exclusively on 
fracture risks in males (Poor et al, 1995) and more extensive studies in females (Cummings 
et al, 1995; Ensrud et al, 1997; Guo et al, 1998) underline the important links between ill 
health and hip fractures. 
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4.4.2 Mortality 
Presence of hip fracture increased the risk of death 8 fold (Hazards ratio 8.1). Mortality was 
60% at 2 years compared to 10% in the control population. Mortality rate was most marked 
in the first 3 months following fracture (25%), with rates declining subsequently. Residence 
in institutional care at the time of the fracture, poor functional status pre-fracture and 
presence of co-morbidity increased the risk of death. 
The previously reported mortality, with 16-37% (Poor et at, 1995; Aharonoff el at, 1997) of 
cases dying after fracture, probably under estimated mortality by limiting period of follow- 
up, excluding the very elderly and high risk cases residing in institutions and dependant on 
basic activities of daily living. Most workers have found co-morbidities as risk factor for 
high mortality (Jencks et at, 1988; Myers et at, 1991; Poor et at, 1995; Nettleman et al, 
1996, Stavrou et at, 1997, Aharonoff et at, 1997). It has been argued that the excess 
mortality noted in men may be related to co-morbid factors which both increase the risk of 
death and hip fracture (Poor et at, 1995). Cause of death was similar in the two groups: 
infections and heart disease being the commonest. These are similar to those reported by 
Poor and co-workers (1995). The only study addressing residence at the time of fracture as 
predictor of mortality (Poor et al, 1995) failed to show an association. The difference in 
observation may be the small number of deaths (n=21) in the study by Poor and that the data 
was collected from retrospective chart reviews. No data exist on the effect of pre-fracture 
health on mortality in men. 
4.5 Size of the problem and recommendations for the future 
Male hip fractures are a neglected and major health problem. Replicating the Cornish pattern 
throughout England and Wales gives 10,000 male hip fractures annually with 5800 deaths 
and 1200 cases needing long term care 2 years post fracture. In women hormonal risk 
factors related to menopause with resultant low BMD are dominant causes of osteoporotic 
fractures including hip fractures. This study confirms low BMD as an important risk factor 
for hip fracture in men as in women. However, in contrast to data in women, low androgen 
levels associated with male hip fractures may be related to chronic ill health and not only 
normal physiological ageing process. The substantial mortality and morbidity of male hip 
fracture together with the existence of several potentially reversible risk factors suggest 
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there is an urgent need to initiate simple preventative measures in males as well as females. 
The study identifies "high risk" individuals as single men, living alone or in care, with 
multiple diseases, a history of falls and low BMI. Preventive measures such as ensuring 
adequate calcium particularly during childhood, encouraging regular exercise throughout 
adult life particularly walking in the elderly; giving vitamin D supplements, preventing falls 
and importantly improving general health should all be beneficial in reducing the burden of 
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Impact and risk factors for hip fractures in men with special emphasis to bone density, 
biochemical and endocrine parameters. 
HYPOTHESIS 
Osteoporosis is a major risk factor for hip fractures in males leading to increased 
mortality and morbidity. 
Male osteoporosis leading to hip fracture is commonly associated with hypogonadism. 
The early detection and treatment of male hypogonadism may reduce the risk of 
osteoporosis and hip fractures. 
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RATIONALE 
Osteoporosis in men is a neglected and important clinical and public health problem. Hip 
fractures represent the most serious complication of osteoporosis in terms of morbidity, 
mortality, disability and medical costs. Hip fractures are the commonest fractures of the 
elderly. The current costs for care of people with such fractures is estimated as £940M. In 
1990, about 30% of 1.66 million hip fractures worldwide occurred in men. The respective 
risk at 50,70, and 90 years of age is 2.4,3.8, and 7.91/o in men; and 9,11.7, and 17.5% in 
women. Hip fractures in men account for one third of all hip fractures and have a higher 
mortality than in women. By the ninth decade of life, 4% of men will have sustained a 
forearm fracture, 7% a vertebral fracture and 5% a femoral neck fracture. The age specific 
incidence of hip fractures is increasing. Although the risk of hip fractures in men and its 
associated morbidity, mortality and cost is substantial, very few studies have been directed in 
this direction. Some of the recognised risk factors for hip fractures in men are pre-admission 
ambulatory problems, confusion, heavy alcohol intake and low body mass. It is not known 
whether the risk factors in men differ from those in women or whether there is a sex 
variation in the relative importance / contribution of these risk factors. 
Bone is lost with advancing age in men as in women. Bone mass correlates with strength 
and this bone loss leads to an increased incidence of osteoporotic fractures of the forearm, 
vertebral body and femoral neck. However, the relative contribution of low bone mass, that 
is osteoporosis, to fractures in men has not been fully established. Studies on osteoporosis 
have focussed largely on the enormity of the problem in women. More data is therefore 
needed on contribution of bone density to hip fractures in men. 
Sex hormone deficiency is a well-documented and important cause of bone loss in women 
and men. Men have a greater bone mass at all stages presumably because of a higher peak 
bone mass at skeletal maturity, and absence of a distinct phase of accelerated bone loss at 
mid life. Although in women, menopause is a dominant contributory factor to the latter, it 
does not exclude the gradual bone loss from midlife in men to be associated with hormonal 
factors. It is known that there is an age associated decline of sex hormones levels in men but 
its contribution, to risk of osteoporosis and or fractures in men has not been well 
established. Little data exists correlating sex hormone levels to bone mineral density and 
fracture risk in men. 
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It is with this idea, that we plan to look into the descriptive epidemiology of hip fractures in 
men aged 50 years or more with special emphasis to assess the remedial causes that may be 
targets for preventive strategies in future. 
OBJECTIVES 
1. To establish the descriptive epidemiology encompassing risk factors and outcome of hip 
fractures in men aged 50 years and above in Cornwall. 
2. To find a correlation, if any, of bone mineral density and sex hormone levels to risk of 
fracture, in men. 
STUDY DESIGN 
A prospective, case control study of men aged 50 years or more, residents of Cornwall, 
presenting to the Royal Cornwall Hospital with hip fracture in a one year duration. All cases 
will undergo detailed evaluation for possible risk factors for the fracture, bone mineral 
density, biochemical and endocrine studies and functional assessment. 
Equal number of healthy age matched men would be analysed for serum testosterone levels 
to determine the prevalence of hypogonadism in the general population, as this may be an 
important treatable cause of osteoporosis in this population. 
Functional assessment, outcome and development of any new fracture in all patients will be 
analysed at baseline and every 6 months for 2 years. 
INCLUSION CRITERIA 
Men aged 50 years or more, resident of Cornwall, consecutively admitted with a hip fracture 
following fall from standing height or less. 
EXCLUSION CRITERIA 
1. Men with hip fracture NOT residents of Cornwall. 
2. Hip fractures due to "major trauma" will be included when counting for insight into the 




At First Visit 
Clinical: "risk factor" questionnaire 
Functional: "functional assessment" questionnaire- includes SF 36 plus disease specific 
questions of the MEDOS questionnaire. 
Radiological: Xray thoraco-lumbar spine (lateral view) 
Bone mineral density (lumbar spine and femoral neck); in patients with 
bilateral hip fracture/ replacement and/or multiple spinal fractures making 
analysis at 2 sites technically difficult forearm densitometry will be added. 
Hip axis length measurement 
Laboratory: Full blood count 
Routine biochemistry 
Thyroid function tests 
Cholesterol and triglycerides 
Serumurine electrophoresis 
Parathyroid, 25 OH Vit D 
S Prolactin, 
S Cortisol 
S Testosterone, SHBG, FSH, LH 
Prostate specific antigen 
S Osteocalcin, Bone Alk Phos 
24 hour urinary calcium 
Urinary Calcium/creatinine ratio 
Urinary crosslinks 
? Cytokines IL1, IL6 
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At follow up visits 
Postal/ Clinical review to assess outcome and to identify any further fracture. 
Functional assessment questionnaire every 6 months 
BNID every 6 months in patients requiring active intervention 
Serum chemistry individualised to each patient depending on his risk factor 
S Testosterone, lipid profile and PSA every 6 month of patients on hormone replacement. 
TREATMENT 
All patients will be advised to lead an active healthy lifestyle, spend time walking out of 
doors for at least half an hour each day and ensure adequate Calcium and Vitamin D by diet 
or supplements. In men, with low androgen levels testosterone replacement therapy will be 
administered. Blood for PSA, lipid profile, FBC and androgen levels will be monitored every 
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A 1 ,J_........ 
Appendix 2.1 
CR No: ............................................ 
Ward: ............................................ 
t'1U U1 CJ J. .................................................................................................................................. 
.................................................................................................................................. 
Post Code: ................................................................ 
Tel No: ............................................ 
Date of Birth: .......................................................... 
Marital Status: Single/Married/Divorced/Separated/Widowed 
Ethnic Origin: Caucasian/Asian/Other 
Date of Interview/Scan: ............................................ 
CONDITION DURING HOSPITAL STAY 
Date of fracture: ...................................... Date of admission: ...................................... 
Date of operation: ...................................... 
*Nature of operation: ................................................................... 
*Site of fracture: Right/Left *Type of fracture: ...................................... 
*Any concomitant fracture (please specify): ......................................................................... 
I Iip-mcn. clot 
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SOCIODEMOGRAPHIC DATA 
Education - Years in school from aged 5: .......... years 
Years of higher education (after `A' Levels): .......... years 
Admitted from: own home: Q 
another's home: Q 
residential home: Q 
nursing home/long term hospital care: tM, 
Q 
hospital: Q 
nthPr (n1r>aca ct i' .,.. _..,. \N ......... ........ ý. ................................................... 
Where did you live in the past? during childhood: rural / urban 
in young adulthood: rural / urban 
in the recent past: rural / urban 
Do you live? alone: Q 
together with wife/children/relative: Q 
together with person/s NOT your relative: Q 
What kind of work have you done for the longest period of your life? 
agriculture/farming/forestry/fishing: 
industrial/mining/construction/similar: 
office work/other white collared work: 
domestic work: 
other (please state): ...................... 
n 
How heavy is or was your main activity? 
during childhood: sedentary / light physical / heavy physical 
during young adulthood: sedentary / light physical / heavy physical 
during recent past: sedentary / light physical / heavy physical 
312 
OTHER FINDINGS 
Are you able to read a newspaper with or without glasses? 
Which glasses do you use? distance: Q 
reading: Q 
bifocal: Q 
YES / NO 
What is the colour of your skin? light complexion: Q 
dark complexion: Q 
other (please specify): ..................... 
What was the colour of your hair 




What is the colour of your eyes? blue/green/grey: Q 
brown/black/mix ed: Q 
Mental Score 
Correct Slightly Wrong False 
What is your age? Q Q Q 
What is your name? Q Q Q 
What is your home address? Q Q Q 
What day of the week is it? Q Q Q 




How much time do you typically spend walking out of doors each day? 
none / some, but less than half an hour / half to one hour / more than one hour 
I am interested in the amount of physical activity you undertook both at work and at 
home at different stages of your life. 
in childhood in adulthood in recent past 
light: Q Q Q 
moderate: Q Q Q 
heavy: Q Q Q 
very heavy: Q Q Q 
Immobilisation 
Have you ever been confined to bed for a period of greater than 2 months? YES / NO 
If YES, at what age? .......... years 
for how long? .......... months 
Smoking Have you ever smoked? YES / NO 
If YES, how old were you when you first started smoking: .......... years 
How many did/do you smoke a day: .................... 
If you have now stopped, how old were you when you stopped: .......... years 
Alcohol On average how many units of alcohol do you drink in a week: .................... units 
Have you ever drunk more regularly in the past? YES / NO 
If YES, how many units per week and for how many years? 
.................... units per week 
for 
.................... years (average) 
314 
Caffeine How many cups of coffee do/did you usually have a day? 
in childhood in adulthood in recent past 
never: Q Q Q 
sometimes: Q Q Q 
I-2 cups per day: Q Q Q 
3 or more cups per day: Q Q Q 
How many cups of tea do/did you usually have a day? 
in childhood in adulthood in recent past 
never: Q Q Q 
sometimes: Q Q Q 
1-2 cups per day: Q Q Q 
3 or more cups per day: Q Q Q 
Calcium Intake 
How many days in the past week did you eat each of the following milk products? 
days per week amount 
hard cheese: .................. .................. 
soft cheese: .................. .................. 
yoghurt: .................. .................. 
milk: .................. .................. 
others (ice cream): .................. .................. 
For the period indicated below, mark the words that best describe how often you drank milk (include 
whole, low fat, skimmed). 
in childhood in adulthood in recent past 
3 glasses or more per day: QQQ 
1-2 glasses per day: QQQ 
every week but not every day: QQQ 
less than once a week: QQQ 
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PAST FRACTURE HISTORY 
Have you ever suffered from a broken bone (fracture)? YES / NO 
If YES, please state bone broken (site), age at time (years) 
and cause (level of trauma) - spontaneous 
minor trauma (fall from standing height or less) 
major trauma (fall from greater than standing heigh or external injury 
eg. RTA/falling down stairs) 
Site Age Cause 
Have any of your parents, brothers or sisters sustained a broken bone (fracture)? YES / NO 
If YES, please state bone broken (site), age at time (years) and cause (level of trauma). 
Relative Site Age at time Cause 
Does any member of your family suffer from osteoporosis? YES / NO 
If YES, please state which relative, their age at the time of diagnosis and how the diagnosis was made. 
Relative Age at time How diagnosis was made (please delete) 
posture / loss of height / clinical examination / x-ray / BMD 
posture / loss of height / clinical examination / x-ray / BMD 
posture / loss of height / clinical examination / x-ray / BMD 
posture / loss of height / clinical examination / x-ray / BMD 
316 
CIRCUMSTANCES AROUND PRESENT FRACTURE 
Site: outdoors / indoors 
Time of Day: morning / midday / afternoon / evening / night 
Light Conditions: in daylight / in twilight / in darkness 
Physical Circumstances Around the Fall 
Did the fracture follow a fall? YES / NO 
If YES, was the fall: 
on the same level? YES / NO 
from one level to another? YES / NO 
during change of posture - rising from bed? YES / NO 
transferring from bed? YES / NO 
transferring from chair? YES / NO 
other/unknown? YES / NO 
due to tripping or slipping - on a pavement? YES / NO 
on the floor? YES / NO 
on a rug? YES / NO 
on a stairway? YES / NO 
other/unknown YES / NO 
in a traffic accident? YES / NO 
if YES, were you: the driver/passenger of a car YES / NO 
a motorcyclist? YES / NO 
a cyclist? YES / NO 
a pedestrian? YES / NO 
other? YES / NO 
any other accident? (please specify): 
Comments about cause of fracture: 





*Body Mass Index: 






............... right ............... left 
............... weight (kg)/height (m2) 
............... C ill 
LUMBAR SPINE - Measurement Reference No: 
T- youn normals Z- age-matched normals 
Site /cm2 SD % SD % 
FEMUR - Measurement Reference No: 
T- you normals Z- - age-matched nomials 





FOREARM - Measurement Reference No: 
T- youn normals Z- age-matched normals 
Site cmz SD % SD % 
Forearm 
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HIP FRACTURES IN MEN 
MEDICAL QUESTIONNAIRE 
FRACTURE HISTORY 
Site of fracture: Right Left 
Type of fracture: Cervical Trochanteric 
Nature of operation: ........................................................................... 
Any concomitant fracture: ............................................................... 
ANY CONTRIBUTING MEDICAL CONDITIONS TO FALL 
Past history of falls? YES / NO 
If YES, how frequent? ............................................ 
current stroke/paresis: Q 
cardiac disease: Q 
poor vision: Q 
dizziness: Q 




on any medications causing drowsiness: Q 






Previous diseases and medical conditions, along with operations, if any: - 




01, Marfans, Ehler Danlos, homocystinuria: Q 
thyroid diseases - hypo/hyper: 
Q 




milk intolerance (lactose intolerance): Q 
gastrectomy/intestinal resection: Q 
malabsorption/Crohn's/steatorrhoea/ 
prolonged obstructive jaundice/ 
chronic liver disease/cirrhosis: Q 
chronic renal disease: 
Q 
haemochromatosis - skin pigmentation/DM/ 
cardiomegaly, hepatomegaly/hypogonadal: Q 
hypogonadism: Q 







DRUG HISTORY - PAST/CURRENT 
Which of the following medications have you used or are currently using? 















Have you taken or are you taking any of the following medications for osteoporotic bone 
disease? 
Calcium: Q 






Others (specify): ......................................................................... 
320 
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The following questions ask you for your views about your health, 
how you feel and how well you are able to do your usual activities. If 
you are unsure about how to answer any questions, please give the 
best answer You can and make any of your own comments if You like. 
In general, would you say your health is: Excellent 
Q 




Compared to one year ago, how would you rate your general health now? 
Much better now than one year ago Q 
Somewhat better now than one year ago Q 
About the same Q 
Somewhat worse now than one year ago Q 




3. HEALTH AND DAILY ACTIVITIES 
The following questions are about activities you might do during a typical day. 
Does your health limit you in these activities? If so, how much? 
Yes, Yes, 
limited limited 
a lot a little 
a) Vigorous activities, such as running, lifting QQ 
heavy objects, participating in strenuous sports 
b) Moderate activities, such as moving a table pushing 
a vacuum cleaner, bowling or playing golf 
c) Lifting or carrying groceries 
d) Climbing several flights of stairs 
e) Climbing one flight of stairs 
f) Bending, kneeling or stooping 
g) 
Walking more than a mile 
h) Walking half a mile 
i) Walking 100 yards 




Q Q Q 
Q Q Q 
Q Q Q 
Q Q Q 
Q Q Q 
Q Q Q 
Q Q Q 
Q Q Q 
Q Q Q 
4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health? 
Yes No 
a) Cut down on the amount of time you spent on work or Q Q 
other activities 
b) Accomplished less than you would like Q Q 
c) Were limited in the kind of work or other activities Q Q 
d) Had difficulty performing the work or other activities Q Q 
(ie. it took extra effort) 
33 
S. During the past 4 weeks, have you h: id any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
Yes No 
a) Cut down on the amount of time you spent on work QQ 
or other activities 
b) Accomplished less than you would like Q 
c) Didn't do work or other activities as carefully as usual QQ 
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbours or groups? 
Not at all Q 
Slightly Q 
Moderately Q 
Quite a bit Q 
Extremely Q 
7. How much bodily pain have you had during the past 4 weeks? 
None Q 




Very severe Q 
8. During the past 4 weeks, how much did pain interfere with your normal work (including work 
both outside the home and housework)? 
Not at all Q 
A little bit Q 
Moderately Q 
Quite a bit Q 
Extremely Q 
24 
These questions are about how you feel and how things have been 
with you during the past month. (For each question, please indicate 
the one answer that comes closest to the way You have been feeling. ) 
9. How much time during the past month: 
a) Did you feel full of life? 
b) Have you been a very nervous 
person? 
c) Have you felt so down in the dumps 
that nothing could cheer you up? 
d) Have you felt calm and peaceful? 
e) Did you have a lot of energy? 
f) Have you felt downhearted and 
low? 
g) Did you feel worn out? 
h) Have you been a happy person? 
i) Did you feel tired? 
j) Has you health limited your social 
activities (like visiting friends or 
close relatives). 
Please tick one box on each line 
All of Most of A good Some of A little None of 
the time the time bit of the time of the the time 
the time time 
Q Q Q Q Q Q 
Q Q Q Q Q Q 
Q Q Q Q Q Q 
Q Q Q Q Q Q 
Q Q Q Q Q Q 
Q Q Q Q Q Q 
Q Q Q Q Q Q 
Q Q Q Q Q Q 
Q Q Q Q Q Q 
Q Q Q Q Q Q 
10. Please choose the answer that best describes how true or false each of the following statements is 
for you. 
Please tick one box on each line 
Definitely Mostly Not Mostly Definitely 
True True Sure False False 
a) I seem to get ill more easily than 11 F1 7 F] 
other people 
b) I am as healthy as anybody I know 
c) I expect my health to get worse 
d) My health is excellent 
Q Q Q Q Q 
Q Q Q Q Q 
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FUNCTIONAL CAPACITY BEFORE AND AFTER THIS FRACTURE 
Able to dress/undress: before fracture after fracture 
without any difficulty F1 7 
with some difficulty F1 
with much difficulty F 
unable to do F 
Able to eat: before fracture after fracture 
without any difficulty F1 F1 
with some difficulty F1 F1 
with much difficulty F 
unable to do 17 
Able to perform household chores: before fracture after fracture 
without any difficulty F1 F 
with some difficulty F1 F1 
with much difficulty F1 F] 
unable to do F1 F1 
Able to get up from a chair: before fracture after fracture 
without any difficulty F1 F1 
with some difficulty F1 F1 
with much difficulty F1 P 
unable to do F1 F1 
Able to climb stairs: before fracture after fracture 
without any difficulty F1 F 
with some difficulty F1 F1 
with much difficulty F1 F1 
unable to do p Li 
ýý) 
Able to wash and dry your entire body: 
without any difficulty 
with some difficulty 
with much difficulty 
unable to do 
Can walk: 





before fracture after fracture 
independently F 
with sticks/crutches F 
with Zimmer frame F1 F1 
with the help of others F1 F1 
unable to do RR 
Able to walk indoors: before fracture after fracture 
without any difficulty F1 
with some difficulty El 
with much difficulty F1 
unable to do F 
Able to walk outdoors: before fracture after fracture 
without any difficulty 11 11 
with some difficulty F1 5 
with much difficulty F1 El 
unable to do F1 F] 
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HIP FRACTURES IN MEN 
FOLLOW UP ASSESSMENT 
6 months from fracture 
Appendix 2.4 
Surname: ................................................... CR No: ............................................ 
Forename(s): ................................................... 
Address: .................................................................................................................................. 
Post Code: ................................................................ Tel No: ............................................ 
Date of Interview/Scan: ............................................ 
Please list any fractures you have sustained since your last visit/scan. 
Bone Broken Age Cause 
Please list all medications that you are taking at present. 
Name of drug Dose Date started Reason for medication 
6tü-ass. doc 
328 
Outcome of previous surgery for broken hip? 
None: Q 
Wound infection: Q 
Fracture not yet healed: Q 
Further intervention required: Q 
Other (please specify if possible): 
When you left the hospital, did you got to: 
your own home: Q 
relatives or friends: Q 
long term hospital bed: Q 
nursing home: Q 
residential home: Q 
other (please specify: ...................................................................... 
How many times have you seen your doctor (GP) for any reason during the last six months? ... 
Are you still being reviewed at hospital for your hip fracture? YES / NO 
Do you need help with any of the following and, if so, what help do you receive? 
Friend/Relative Social Paid 
Washing: F F1 F1 
Dressing: F1 F1 
Cooking El 
Cleaning 
Shopping: LI LI 
Walking: LI LI LI 
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MALE OSTEOPOROSIS STUDY 
PATIENT IDENTIFICATION 
Appendix 2.5 
Surname: ................................................... CR No: ............................................ 
Forename(s): ................................................... Ward: ............................................ 
Address: .................................................................................................................................. 
Post Code: ................................................................ Tel No: ............................................ 
Date of Birth: .......................................................... 
Marital Status: Single/Married/Divorced/Separated/W id owed 
Ethnic Origin: Caucasian/Asian/Other 




Education - Years in school from aged 5: 
Years of higher education (after `A' Levels): 
Admitted from: own home: Q 
another's home: Q 
residential home: Q 
nursing home/long term hospital care: Q 
hospital: Q 
other (please state): ............................. ......... 
Where did you live in the past? during childhood: 
in young adulthood: 
in the recent past: 
Do you live? alone: 
together with wife/children/relative: 
together with person/s NOT your relative: 
years 
years 
rural / urban 
rural / urban 
rural / urban 
El 
What kind of work have you done for the longest period of your life? 
agriculture/farming/forestry/fishing: Q 
industrial/mining/construction/similar: Q 
office worklother white collared work: Q 
domestic work: Q 
other (please state): .............................................. 
How heavy is or was your main activity? 
during childhood: sedentary / light physical / heavy physical 
during young adulthood: sedentary / light physical / heavy physical 
during recent past: sedentary / light physical / heavy physical 
331 
OTHER FINDINGS 
Are you able to read a newspaper with or without glasses? 
Which glasses do you use? distance: Q 
reading: Q 
bifocal: Q 
YES / NO 
What is the colour of your skin? light complexion: Q 
dark complexion: Q 
other (please specify): ....................... 
What was the colour of your hair 




What is the colour of your eyes? blue/green/grey: Q 
brown/black/mix ed: Q 
Mental Score 
Correct Slightly Wrong False 
What is your age? Q Q Q 
What is your name? Q Q Q 
What is your home address? Q Q Q 
What day of the week is it? Q Q Q 




How much time do you typically spend walking out of doors each day? 
none / some, but less than half an hour / half to one hour / more than one hour 
I am interested in the amount of physical activity you undertook both at work and at 
home at different stages of your life. 
in childhood in adulthood in recent past 
light: Q Q Q 
moderate: Q Q 
Q 
heavy: Q Q Q 
very heavy: 
Q Q Q 
Immobilisation 
Have you ever been confined to bed for a period of greater than 2 months? YES / NO 
If YES, at what age? .......... years 
for how long? .......... months 
Smoking Have you ever smoked? YES / NO 
If YES, how old were you when you first started smoking: .......... years 
How many did/do you smoke a day: .................... 
If you have now stopped, how old were you when you stopped: .......... years 
Alcohol On average how many units of alcohol do you drink in a week: .................... units 
Have you ever drunk more regularly in the past? YES / NO 
If YES, how many units per week and for how many years? 
.................... units per week 
for 
.................... years (average) 
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Caffeine How mane cups of coffee do/did you usually have a day? 
in childhood in adulthood in recent past 
never: 
Q Q Q 
sometimes: Q Q Q 
1-2 cups per day: Q Q Q 
3 or more cups per day: Q Q Q 
How many cups of tea do/did you usually have a day? 
in childhood in adulthood in recent past 
never: 
Q Q Q 
sometimes: Q Q Q 
1-2 cups per day: Q Q Q 
3 or more cups per day: Q Q Q 
Calcium Intake 
How many days in the past week did you eat each of the following milk products? 
days per week amount 
hard cheese: .................. .................. 
soft cheese: .................. .................. 
yoghurt: .................. .................. 
milk: .................. .................. 
others (ice cream): .................. .................. 
For the period indicated below, mark the words that best describe how often you drank milk (include 
whole, low fat, skimmed). 
in childhood in adulthood in recent past 
3 glasses or more per day: QQQ 
1-2 glasses per day: QQQ 
every week but not every day: QQQ 
less than once a week: QQQ 
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PAST FRACTURE HISTORY 
Have you ever suffered from a broken bone (fracture)? YES / NO 
If YES, please state bone broken (site), age at time (years) 
and cause (level of trauma) - spontaneous 
- minor trauma (fall from standing heigif, ht or less) 
- major trauma (fall from greater than standing heigh or external injury 
eg. RTA/falling down stairs) 
Site Age Cause 
Have any of your parents, brothers or sisters sustained a broken bone (fracture)? YES / NO 
If YES, please state bone broken (site), age at time (years) and cause (level of trauma). 
Relative Site Age at time Cause 
Does any member of your family suffer from osteoporosis? YES / NO 
If YES, please state which relative, their age at the time of diagnosis and how the diagnosis was made. 
Relative Age at time How diagnosis was made (please delete) 
posture / loss of height / clinical examination / x-ray / BMD 
posture / loss of height / clinical examination / x-ray / BMD 
posture / loss of height / clinical examination / x-ray / BMD 
posture / loss of height / clinical examination / x-ray / BMD 
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CIRCUMSTANCES AROUND PRESENT FRACTURE 
Site: outdoors / indoors 
Time of Day: morning / midday / afternoon / evening / night 
Light Conditions: in daylight / in twilight / in darkness 
Physical Circumstances Around the Fall 
Did the fracture follow a fall? YES / NO 
If YES, was the fall: 
on the same level? YES / NO 
from one level to another? YES / NO 
during change of posture - rising from bed? YES / NO 
transferring from bed? YES / NO 
transferring from chair? YES / NO 
other/unknown? YES / NO 
due to tripping or slipping - on a pavement? YES / NO 
on the floor? YES / NO 
on a rug? YES / NO 
on a stairway? YES / NO 
other/unknown YES / NO 
in a traffic accident? YES / NO 
if YES, were you: the driver/passenger of a car YES / NO 
a motorcyclist? YES / NO 
a cyclist? YES / NO 
a pedestrian? YES / NO 
other? YES / NO 
any other accident? (please specify): ....................... ..................................................... 






*Body Mass Index: 











LUMBAR SPINE - Measurement Reference No' 
T- youn normals Z- age-matched normals 
Site Q/em2 SD % SD 
FEMUR - Measurement Reference No: 
T- "oun normals Z- - age-matched normals 





FOREARM - Measurement Reference No: 
T- your g normals Z- age-matched normals 
Site /cm2 SD % SD % 
Forearm 
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MALE OSTEOPOROSIS STUDY 
6 mth - FOLLOW UP ASSESSMENT 
At)t)endix 2.6 
Surname: ................................................... CR No: ............................................ 
Forename(s): ................................................... GP: ................................................. 
Address: .................................................................................................................................. 
.................................................................................................................................. 
Post Code: ................................................................ 
Tel No: ............................................ 
Date of Interview/Scan: ............................................ 
Please list any fractures you have sustained since your last visit/scan. 
Bone Broken Age Cause 
Please list all medications that you are taking at present. 
Name of drug Dose Date started Reason for medication 
6fü-ass. doc 
I318 
Where are you now living? 
in your own home: Q 
with relatives or friends: Q 
in a long term hospital bed: Q 
in a nursing home: Q 
in a residential home: Q 
other (please specify: ......... ............................................................. 
How many times have you seen your doctor (GP) for any reason during the last six months? .... 
Are you being reviewed in hospital for any medical condition? YES / NO 
Do you need help with any of the following and, if so, what help do you receive? 
Friend/Relative Social Paid 
Washing: 0 LI 
Dressing: LI LI LI 
Cooking LI LI LI 
Cleaning LI LI LI 
Shopping: LI LI LI 
Walking: LI E LI 
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HIP FRACTURES IN MEN 
FOLLOW UP ASSESSMENT 
12 months from fracture 
Appendix 2.7 
Surname: ................................................... CR No: ............................................ 
Forename(s): ................................................... 
Address: .................................................................................................................................. 
Post Code: ................................................................ Tel No: ............................................ 
Date of Interview/Scan: ............................................ 
Please list any fractures you have sustained since your last visit/scan. 
Bone Broken Age Cause 
Please list all medications that you are taking at present. 
Name of drug Dose Date started Reason for medication 
12fio-as. doc 
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Where are you now living? 
in your own home: 
Q 
with relatives or friends: Q 
in a long term hospital bed: Q 
in a nursing home: 
Q 
in a residential home: Q 
other (please specify: .......... ............................. 
How many times have you seen your doctor (GP) for any reason during the last six months? ............... 
Are you still being reviewed at hospital for your hip fracture? YES / NO 
Do you need help with any of the following and, if so, what help do you receive? 
Friend/Relative Social Paid 
Washing: F1 F1 F1 
Dressing: F1 F1 n 
Cooking F1 R F1 
Cleaning F] F1 F1 
Shopping: LI LI LI 
Walking: LI LI LI 
'11 
MALE OSTEOPOROSIS STUDY 
12 mth - FOLLOW UP ASSESSMENT 
Appendix 2.8 
Surname: ................................................... 





Post Code: ................................................................ 
Tel No: ............................................ 
Date of Interview/Scan: ............................................ 
Please list any fractures you have sustained since your last visit/scan. 
Bone Broken Age Cause 
Please list all medications that you are taking at present. 
Name of drug Dose Date started Reason for medication 
12fii-as. doc 
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Where are you now living? 
in your own home: Q 
with relatives or friends: Q 
in a long term hospital bed: Q 
in a nursing home: Q 
in a residential home: Q 
other (please specify: .......... .......................................... 
How many times have you seen your doctor (GP) for any reason during the last six months? 
Are you being reviewed at hospital for any medical condition? YES/NO 
Do you need help with any of the following and, if so, what help do you receive? 
Friend/Relative Social Paid 
Washing: Q Q Q 
Dressing: Q Q Q 
Cooking Q Q Q 
Cleaning Q Q Q 
Shopping: Q Q Q 
Walking: Q Q Q 
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HIP FRACTURES IN MEN 
FOLLOW UP ASSESSMENT 
24 months from fracture 
Demographic data: 
Appendix 2.9 
Tel No: ............................................ 
Date . ........................................... 
Please list any fractures you have sustained since your hip fracture/ in the last 2years. 
Bone Broken Age Date/ year Cause 
Where are you now living? 
in your own home: Q 
with relatives or friends: Q 
in a long term hospital bed: Q 
in a nursing home: Q 
in a residential home: Q 
other (please specify: .......... ............................. 
Do you need help with any of the following and, if so, what help do you receive? 
Friend/Relative Social 
Washing: F1 F1 
Dressing: p El 
Cooking F 
Cleaning 11 El 
Shopping: 1-1 El 
Walking: Fý El 
Have you had any falls in the last year? Yes 




MALE OSTEOPOROSIS STUDY 
Appendix 2.10 
24 mth - FOLLOW UP ASSESSMENT 
Demographic data: Tel No: ............................................ 
Date 
. ............................................ 
Please list any fractures you have sustained since your last scan / in the previous 2 years. 
Bone Broken Age Date/ Year Cause 
Where are you now living? 
in your own home: Q 
with relatives or friends: Q 
in a long term hospital bed: Q 
in a nursing home: Q 
in a residential home: Q 
other (please specify: .......... ....................................................... 








Have you had any falls in the last year? Yes 







SF 36 IN CASES AND CONTROLS 
Pre-fracture quality of life assessed by SF-36 in cases and controls 
Domain Cases Controls Significance 
Namther Median (IQ Number . Median (10 . Mann-rt`hitnev ii 
range) range) test 
Energy and Vitality 81 60 (38-73) 100 70 (55-80) <0.01 
Physical function 83 40 (10-80) 100 85 (45-90) <0.01 
Physical Role Limitation 83 50(0-100) 100 100 (50-100) <0.01 
Social function 85 78 (33-100) 100 100 (89-100) <0.01 
Mental Health 81 76(60-92) 100 88(80-92) <0.01 
Mental Role Limitation 83 100 (0-100) 100 100 (100-100) <0.01 
Health Perception 81 60(40-80) 100 70(65-90) <0.01 
Pain 81 89 (56-100) 100 83 (67-100) NS 
Quality of life over 24 months assessed b y SF-36 in cases and controls 
(med ian and interquartile ranges) 
Domain Time Cases Controls Difference 
between groups 
Numb Median (IQ Nitnib Median (10 Mann-Whitney 
range) range) U test 
Energy 0 81 60 (38-73) 100 70 (55-80) <0.01 
6 51 55 (35-75) 97 65 (50-80) <0.01 
12 47 45 (35-60) 87 65 (50-80) <0.01 
24 34 43 (30-51) 84 65 (46-80) <0.01 
Pain 0 81 89 (56-100) 100 83 (67-100) NS 
6 51 89(44-100) 97 78(50-100) NS 
12 47 78 (33-100) 87 89 (67-100) NS 
24 34 56 (44-81) 84 78 (56-100) <0.01 
Physical function 0 83 40(10-80) 100 85 (45-90) <0.01 
6 51 20 (0-40) 97 75 (35-90) <0.01 
12 47 15 (0-45) 87 75 (45-90) <0.01 
24 34 20 (5-55) 84 73 (38-90) <0.01 
Social function 0 85 78 (33-100) 100 100 (89-100) <0.01 
6 51 56 (11-89) 97 100 (72-100) <0.01 
12 47 56 (22-100) 87 100 (67-100) <0.01 
24 34 56 (22-78) 84 94(56-100) <0.01 
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Functional status at first visit in cases and controls 
Activities of daily living No. Without With some With much Unable x2 
difficulty difficulty difficulty to do 
Able to dress/undress Cases 91 58.2 16.5 15.4 9.9 72 =22.2, ff- -3 
Controls 100 84 13 1 2 p<0.000 
Able to eat Cases 91 81.3 12.1 4.4 2.2 72 =11.7, d f--3 
Controls 100 96 4 0 0 p<0.008 
Able to perform household chores Cases 91 33 29.7 7.7 29.7 x2 =37.6, df=3 
Controls 100 76 15 2 7 p<0.000 
Able to get up from a chair Cases 91 50.5 33 14.3 2.2 2 7 =20.4, df=3 
Controls 100 77 19 1 3 p<0.000 
Able to climb stairs Cases 91 39.6 27.5 13.2 19.8 72 =16.1, df=3 
Controls 100 64 24 7 5 p<0.000 
Able to wash & dry their body Cases 91 54.9 18.7 7.7 18.7 72 =24.6, df=3 
Controls 100 85 11 2 2 p<0.000 
Able to walk indoors Cases 91 59.3 26.4 9.9 4.4 X2 =22.1, df 3 
Controls 100 87 12 0 1 p<0.000 
Able to walk outdoors Cases 91 46.2 26.4 11 16.5 y2 =24.9, df=3 
Controls 100 80 13 3 4 u<0.000 
Functional status at 6 months in cases and controls 
Activities of daily living No. Without With some With much Unable x2 
difficulty difficulty difficulty to do 
Able to dress/undress Cases 50 34 34 12 20 72=27.9, df=3 
Controls 98 75.5 18.4 3.1 3.1 p<0.000 
Able to eat Cases 50 74 20 4 2 y2=16.6. df=3 
Controls 98 95.9 4.1 0 0 p<0.001 
Able to perform household chores Cases 50 14 26 10 50 72=44.7, df=3 
Controls 98 66.3 15.3 9.2 9.2 p <0.000 
Able to get no from a chair Cases 50 44 32 6 18 y2=14.4, df=3 
Controls 98 70.4 21.4 5.1 3.1 p <0.002 
Able to climb stairs Cases 50 18 40 2 40 72=40.9, df=3 
Controls 98 63.3 20.4 9.2 7.1 p <0.000 
Able to wash & dry their body Cases 50 40 24 6 30 /2=23.1, df=3 
Controls 98 74.5 17.3 3.1 5.1 p <0.000 
Able to walk indoors Cases 50 32 40 10 18 72=33.2, df=3 
Controls 98 78.6 15.3 4.1 2 p <0.000 
Able to walk outdoors Cases 50 24 36 18 22 72=28.1, df=3 
Controls 98 67 22.7 5.2 5.2 0 <0.000 
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Functional status at 1 year in cases and controls 
Activities of daily living No. Without With some With much Unable x2 
difficulty difficulty difficulty to do 
Able to dress/undress Cases 47 36.2 31.9 6.4 25.5 X2 =27.4, df--3 
Controls 87 77 17.2 3.4 2.3 p <0.000 
Able to eat Cases 47 83 8.5 8.5 0 x2=6.1, df=3 
Controls 87 93.1 4.6 1.1 1.1 NS 
Able to perform household chores Cases 47 19.1 21.3 14.9 44.7 y2 =36.6, df=3 
Controls 87 62.1 25.3 5.7 6.9 p <0.000 
Able to get up from a chair Cases 47 36.2 44.7 8.5 10.6 x2 =14.7, df=3 
Controls 87 66.7 27.6 4.6 1.1 p <0.002 
Able to climb stairs Cases 47 14.9 38.3 17 29.8 x2 =32.4, df=3 
Controls 87 58.6 27.6 10.3 3.4 p <0.000 
Able to wash & dry their body Cases 47 38.3 29.8 0 31.9 x2 =27.9, df=3 
Controls 87 77 18.4 1.1 3.4 p <0.000 
Able to walk indoors Cases 47 36.2 383 10.6 14.9 x2 =343, df=3 
Controls 87 83.9 13.8 1.1 1.1 p <0.000 
Able to walk outdoors Cases 47 23.4 44.7 8.5 23.4 X2 =34.8, df 3 
Controls 87 69 20.7 9.2 1.1 p <0.000 
Functional status at 2 years in cases and controls 
Activities of daily living Without With some With much Unable x2 
difficulty difficulty difficulty to do 
Able to dress/undress Cases 35 31.4 37.1 11.4 20 72=25.5, df=3 
Controls 84 75 19 4.8 1.2 p <0.000 
Able to eat Cases 35 77.1 20 0 2.9 y2=7.4, df=3 
Controls 84 94 4.8 0 1.2 p <0.03 
Able to perform household chores Cases 35 20 34.3 11.4 34.3 X2=30.7, df=3 
Controls 84 71.4 14.3 8.3 6 p <0.000 
Able to get up from a chair cases 35 25.7 40 20 14.3 y2=24.8, df=3 
Controls 84 61.9 33.3 4.8 0 p <0.000 
Able to climb stairs Cases 35 20 31.4 11.4 37.1 x2=21.5, df=3 
Controls 84 56 29.8 7.1 7.1 p <0.000 
Able to wash & dry their body Cases 35 31.4 28.6 8.6 31.4 y2=27.1. df=3 
Controls 84 71.4 17.9 8.3 2.4 p <0.000 
Able to walk indoors Cases 35 34.3 40 5.7 20 '2=35.7, df=3 
Controls 84 84.5 11.9 3.6 0 p <0.000 
Able to walk outdoors cases 35 25.7 31.4 11.4 31.4 72=24.0, df=3 
Controls 84 67.9 17.9 9.5 4.8 p <0.000 
34 
Functional capacity (mean HAQ scores) in cases and controls 
Baseline 6 months 12 months 24 months Paired t test* 
HAQ score Cases 0.83 1.2 1.2 1.2 <0.001 
Controls 0.27 0.40 0.36 0.39 <0.001 
* Paired t test p<0.00 1 between baseline-6months, 6-12 mo nths and 12-24 mont hs 
Cases versus controls: t test at baseline , 
6,12 and 24 months p<0.001 
Social impact at 6 months 
No help Relative Social Paid X2 
Help with washing Cases 52 32.7 17.3 3.8 46.2 -42=50.24, df--3 
Controls 98 87.8 6.1 0 6.1 P <0.000 
Help with cooking Cases 52 17.3 34.6 1.9 46.2 y2=61.3, df--3 
Controls 98 82.7 9.2 0 8.2 P <0.000 
Help with cleaning Cases 52 11.5 25 3.8 59.6 x2=60.1, df--3 
Controls 98 76.5 10.2 0 13.3 P <0.000 
Help with shopping Cases 52 173 32.7 3.8 46.2 2=56.5 df=3 
Controls 98 79.6 11.2 2 7.1 p <0.000 
Social im pact at 12 months 
No help Relative Social Paid X2 
Help with washing Cases 48.3 24.1 6.9 20.7 x2=25.02, df=3 
Controls 90.7 3.5 2.3 3.5 p <0.000 
Help with cooking Cases 17.2 41.4 10.3 31 x2=56.7, df=3 
Controls 89.5 5.8 0 4.7 p <0.000 
Help with cleaning Cases 17.2 37.9 10.3 34.5 x2=46.9, df--3 
Controls 83.7 5.8 0 10.5 p <0.000 
Help with shopping Cases 27.6 37.9 10.3 24.1 x2=45.6, df--3 
Controls 89.5 4.7 0 p <0.000 
Social impact at 24 months 
No help Relative Social Paid X2 
Help with washing Cases 51.4 25.7 0 22.9 x2=23.4, df3 
Controls 89.4 5.9 1.2 3.5 p <0.000 
Help with cooking Cases 37.1 37.1 0 25.7 /2=24.8, df=3 
Controls 81.2 12.9 1.2 4.7 p <0.000 
Help with cleaning Cases 31.4 37.1 2.9 28.6 2=23.1, df=3 
Controls 77.6 11.8 1.2 9.4 p <0.000 
Help with shopping Cases 28.6 42.9 0 28.6 42=30.9, df3 
Controls 80 12.9 1.2 5.9 p <0.000 
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Lift, Carry, Groceries - 
Climb Several Flights 
Climb One Fliaht- 
Bend, Kneel 
WaIMMile---ýý 
MIK Several Blo. ok5 




Physical Functioning, (PF) 




Role-Rhyýsical RIR N eaIth 
Had Difficulty X/ICI/- Cý \ 
i-. Pain-Magnitude 
a. Pain-Interfere - 
/ krý.. 0, ) 
Bodily, Pain (BP) 
1. EVIGFF Rating 
11a. Sick Easier 
11 b. A Healthy General Health (GH) 
11C. Health To Get Wbrse 
11d. Health Excellent 
9. a. Plep/Life 
9. g. Wbrn Out 
Vitality (VT) 
9: i. Tired 
6.. Social-Extent 
16. Social-Time. - 
5a. Gut Down Time- 
5b. Aiooomplished Less 
50. Not Careful---- 
9: b.. Nervo. us 
9o. Down in Dumps 
ad. Peaceful Mental Health (MH) 
9f. Blue/Sad 
9h. Happy 
Social Functioning (SF)r' 
Mental 
Role-Emotional (RE) Health 
(MCS) 
Significant correlation with othle. r. summary measure. 
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